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 ABSTRACT
Osteoarthritis (OA) is a chronic, painful condition and is of major concern to both human and 
veterinary medicine. This degenerative joint disorder is characterised by pathological changes in 
articular cartilage, the underlying subchondral bone and synovial membrane. To date, treatment 
modalities are generally limited to ‘symptom-modifying’ therapies that only address joint pain. The 
primary aim of this project was to develop a targeted, ‘structure-modifying’ gene-based therapy for the 
future treatment of OA in the dog, with the prospect of developing an animal model for human disease.
To modify disease progression at the molecular level therapeutic genes can be introduced into 
arthritic joints to regulate those enzymes responsible for extra-cellular matrix (ECM) turnover. Since 
the matrix metalloproteinases (MMPs) play a central role in the development of OA, gene-based 
therapeutics should include mediators for controlling the synthesis and activity of these enzymes at the 
transcriptional and/or post-translational levels. Candidate proteins that may be of therapeutic benefit in 
treating OA include interleukin-1 receptor antagonist (IL-lRa), soluble tumour necrosis factor 
receptors (sTNFR) and various tissue inhibitors of MMPs (TIMPs). The cDNA encoding the canine 
homologue of IL-lRa was isolated using reverse transcription polymerase chain reaction (RT-PCR) 
and RNA harvested from canine peripheral blood mononuclear cells (PBMCs) as a template. Sequence 
analysis of the canine IL-lRa demonstrated an open reading frame of 531 base pairs (bp) encoding a 
protein of 177 amino acids showing considerable sequence similarity with the homologous sequences 
published for other species. The canine-specific therapeutic proteins including IL-lRa (19.5 kDa), 
TIMP-1 (22.8 kDa) and TIMP-2 9(24.3 kDa) were expressed using the in vitro transcription and 
translation techniques, however, sTNFRI (23.2 kDa) was unable to be expressed using this system.
Levels of therapeutic gene expression are strictly controlled at the transcriptional level by promoter 
regions of DNA. Candidate promoters that have potential for driving disease-specific expression in 
arthritic joints include those that are upregulated by pro-inflammatory cytokines and growth factors 
associated with the pathogenesis of OA. The canine homologues of MMP-9 and -13 promoters were 
cloned for use in a homologous species-specific targeted gene transfer study for canine disease. The 5'
untranslated regions (UTRs) were obtained by genome walking upstream of the canine MMP-9 and -13 
translation start sites using genomic DNA (gDNA) as template. DNA fragments of 1894 and 1494 bp 
were isolated and on analysis demonstrated regions of sequence homology with the equivalent 
promoter sequences already determined for other species. In general, conserved regions correlated with 
numerous putative DNA binding motifs including Activator Protein-1 (AP-1) sites and a Nuclear 
Factor (NF)-kB binding domain. A consensus TATA-(like) box was identified in each case and shown 
to direct transcription initiation from specific positions upstream of the translation start site. The 
promoters were then characterised using various cell lines analysed for endogenous MMP-9 and -13 
gene transcription using relative semi-quantitative reverse transcription PCR (RT-PCR). The canine 
MMP-9 and MMP-13 promoter fragments were sufficient to drive basal expression of a luciferase 
reporter gene in both Madin Darby canine kidney cells (MDCK) and primary rat eardiocytes. Basal 
activity of the MMP-13 promoter fragment (1494 bp) could be significantly enhanced by the treatment 
of transfected primary rat eardiocytes with interleukin-1 (IL-1[3) and basic fibroblastic growth factor 
(bFGF), with some induction also observed with tumour necrosis factor (TNFa). However, no 
induction of this promoter was observed in the MDCK cells. In comparison the canine MMP-9 
promoter fragment was enhanced by TNFca in the MDCK cells and bFGF in the rat eardiocytes. Five 
MMP-9 promoter deletion vectors were also analysed in MDCK cells and feline embryonic fibroblast 
(FEA) cells. The MMP-9 promoter deletion constructs were selectively enhanced by treatment of 
transfected MDCK cells with phorbol 12-myristate 13-acetate (PMA) suggesting that specific regions 
of the promoter were necessary for reporter gene expression. However, no effect was observed in the 
FEA cells. '
The potential for undesirable systemic effects 'related to constitutive over-expression of certain 
therapeutic transgene products may be limited through, the development of both ‘disease and cell type 
specific’ DNA targeting vectors that restricts therapeutic gene expression to diseased cell types of the 
joint through transcriptional regulation. To enable the incorporation of both disease and cell type 
specific promoter elements into one vector a novel dual-targeting vector system was designed. Two 
parameters were addressed during the development of this vector. Firstly, the promoters incorporated
 into this system for driving gene expression required strategic manipulation to enhance promoter 
activity while maintaining both disease and cell type specificity. Secondly, the utilisation of Cre-lox 
technology was necessary to enable both disease and cell type targeting systems to be incorporated into 
a single vector system. Canine MMP-9 promoter luciferase reporter, pGL3/cMMP-9(1894) and 
deletion constructs, pGL3/cMMP-9(984), (628) and (534) were analysed in response to both pro­
inflammatory cytokines, interleukin-1 (1L-1(3) and tumour necrosis factor (TNFa) in human 
chondrosarcoma cells (SW1353). These deletion studies, in combination with mutagenesis analysis, 
guided the manipulation of the MMP-9 promoter with the incorporation of multiple NF-kB sites into 
the 5' end to enhance activity while maintaining disease-specificity. The mouse collagen type XI 
(mColXI) promoter (1.2 kb) was also cloned from murine genomic DNA (gDNA) and analysed for cell 
type specific promoter activity in the chondrocyte-specific cells (SW1353) and undifferentiated 
chondroprogenitor cells (ATDC5). The mColXl promoter was manipulated with the incorporation of 
S0X9 enhancer sites into the vector to increase activity while maintaining cell type specificity. 
Attempts were then made to strategically sub-clone the canine MMP-9 and mouse ColXl promoters, 
manipulated with NF-kB and SOX9 sites respectively, into one plasmid vector containing the gene for 
‘Cre recombinase' and loxH sites to create a novel dual-targeting system. The aim of this vector system 
was to restrict therapeutic gene expression to diseased cell types of the osteoarthritic joint.
The introduction of DNA into target cells both in vitro and in vivo is a challenge in the development 
of efficient gene-based therapeutics. Although many chemical, biological and physical transfection 
delivery systems are routinely used, problems associated with cell type specificity, transfection 
efficiency and safety have encouraged the development of new transfer technologies such as particle- 
mediated bombardment using a gene gun. A relatively new physical approach for mammalian gene 
transfer is particle mediated bombardment using a gene gun where microscopic particles, coated with 
the gene of interest, are accelerated into cells by a motive force such as helium pressure discharge. Two 
reporter genes, (i-Galactosidase ((3-Gal) and Enhanced Green Fluorescent Protein (EGFP), were 
delivered to MDCK cells and rabbit synovial fibroblasts (HIG-82) respectively using gold particle (1,0 
pm) bombardment to evaluate transfection efficiency at different helium pressures (100 and 150 psi). 
Transfection of both cell types was evident at these pressures despite some cell death. The in vitro
delivery of gold particles into synovial tissue samples tissues taken from a freshly euthanatised dog at 
post-mortem examination (PME) was then analysed to evaluate the penetration depth of gold particles 
(1.0 pm) at helium pressures of 250 and 500 psi. Darkfield microscopy, used to evaluate 
histopathologic synovial specimens, demonstrated that particle-mediated bombardment could 
potentially be used to transfect the lining cells of the synovial membrane.
This thesis addresses some of the challenges in the development of gene-based therapeutics for 
canine OA. The aim of this study was to perform preliminary studies for the future development of a 
homologous gene transfer system for canine disease. The main focus of the project was to develop a 
targeted therapy using canine disease-specific promoters combined with a cell type specific promoter 
and Cre-lox technology to restrict therapeutic gene expression to diseased cell types of the 
osteoarthritic joint.
ii
  
 
LIST OF CONTENTS
Abstract...................................................................    i
List of contents..................................................................................................................................... iii
List of figures.......................................................................................................................................xiv
List of tables...................................................................................................................................... xvii
Acknowledgements.........................................................................................................................xviii
Authors declaration..........................................................................................................................xix
Publications..........................................................................................................................................xx
Chapter I
General Introduction and review of the hterature
1.1 ABSTRACT............................................................................................................................. 1
1.2 PATHOGENESIS OF OSTEOARTHRITIS ..........................................................................2
1.2 .1 Definition and classification of osteoarthritis.....................................................................................2
1.2.2 Prevalence of osteoarthritis........................................................................................................................2
1.2.3 The molecular structure of cartilage......................................................................................................4
1.2.4 Structural organisation of articular cartilage....................................................................................... 7
1.2.5 Dynamic structure of the joint................................................................................................................. 7
1.2.6 Aetiology of osteoarthritis..........................................................................................................................8
1.2.7 Pathological changes in osieoarthritis.................................................................................................10
1.2.8 Diagnosis of osteoarthriris....................................................................................................................... 13
1.2.9 Enzyme-mediated degradation of the articular cartilage matrix............................................... 15
1.2.9.1 The matrixmetalioproteinases ........................................................................................ 17
1.2.9.2 Aggrecanases.................................................................................................................... 21
1.2.10 Regulation of the matrix metalloproteinase activity through the TIMPs............................. 23
1.2.11 Regulation of the matrix metalioproteinases through cell signalling molecules................24
1.2.11.1 Pro-inflammatory mediators........................................................................................... 26
1.2.11.2 Anti-inflammatory mediators.......................................................................................... 28
1.3 THERAPIES FOR CANINE OSTEOARTHRITIS.......................................................... 30
1.3.1 Symptom modifying therapies............................................................................................................. 30
1.3.2 Structure-modifying therapiis..............................................................................................................31
1.3.2.1 Matrix supplements  .......................................................................................................... . .. 32
1.3.2.1.1 Pentosan polysulphates...........................................................................................................................32
1.3.2.1.2 Glucosamine, chondrotin sulphate and collagen preparations ................................................32
1 .3.2.1.3 Hyaluronan................................................................................................................................................33
1.3.2.2 Anti matrix metalloproteinase drugs............................................................................... 33
1.3.2.3 Inhibition of intra-cellular signalling mechanisms......................................................... 34
1.3.2.4 Recombinant protein technology and Immunotherapy................................................. 34
1.4 GENE THERAPY............................................................................................................................... 36
1.4.1 Elements of gene therapy.......................................................................................................................36
1.4.1.1 Selection ofappropria te therapeutic genes..................................................................... 36
1.4.1.2 Selection of appropriate gene organisation..................................................................... 38
1.4.1.3 Selection ofappropriate vector vehicles.......................................................................... 38
1.4.1.3.1 Viral vectors................................................................................................................................................ 38
1.4.1.3.2 Non-viral vectors.......................................................................................................................................41
1.4.1.4 Selection of an efficient gene transfer system................................................................. 42
1 4.1.4 .1 In vivo or c\ vivo for gene delivery.................................................................................................... 42
1.4.1.4.2 Systemic or local gene delivery...........................................................................................................42
1.4.1.5 Selection of appropriate methods for regulating gene expression.................................. 43
iii
 1.4.2 Construction of the gene therapy transcriptional unit.................................................................44
1.5 SUMMARY.............................................................................................................................................. 46
Chnpier II
Materials nnd Meihodt
2.1 TMATERIALS.......................................................................................................................47
2 .1.1 Cell cuCture materials............................................................................ .................................................. 47
2.1.1.1 CeU lines....................................................................................................................... 47
2.1.1.2 Plasticwasa...................................................................................................................... 47
2.1.1.3 Solutions, media sndsupplements................................................................................. 47
2.1 1 .3.1 Media.......................................................................... .................................................................................47
2. 1 1 3.2 Supptemenir......................................................................................................... ....................................48
2.1.2 Radioohhmicals......................................................................................................................................... 48
2.1.2.1 JSS Methionine................................................................................................................ 48
2.1.3 General chemicals.................................................................................................................................... 48
2.1.4 Comptere tdtr.............................................................................................................................................48
2.1.5 Bacterial strains.......................................................................................................................... ............. 49
2.1.3.1 E.coli One Sho® TOP1O....................................................................................................................... 49
2.1.5.2 E.ccUU/Mto................................................................................................................................................49
2.1.5.3 XLl-Blue Supercompetem ceUi...................................................................................... 49
2.1. 6 DNA.............................................................................................................................................................. 49
2.1.6.1 Plasemd vectooc. .................................................. .....................................................................................49
2.1.6.1.1 pCR 2.1-TOPQ .......................................................................................................................................49
2.1.6.1.2 pTlagei™ Mammalian Exprassion Vcctoo..................................................................................... 50
2.1.6.1.3 pGL3-basic Vector ...................................................................................................................................50
2.1.6.1.4 pGL3-eontrol Vector................................................................................................................................50
2.1.6.1.5 pRL-CMV Vecior" ..................................................................................................................................50
2.1.6.1.6 pCAGGS-ni8Cra2.1.6.L7 pUCI8.......................................................................................................... 50
2 .1.6.1.7 pUC18........................................................................    50
2.1.6.2 Molecidas Sice Standasds......... ............ ............. ............. ...............................................................51
2.1.6.3 Oligonucleotide primers.........................................................................................................................51
2.1.7 Enzyme r....................................................................................................................................................... 51
2.1.7.1 Restriction enzymee................................................................................................................................51
2.1.7.2 T4DNA Ligase ..ll.....lll...l......l....ll.ll..l....l..ll....ll.....l.....l...l..lll.....ll....l.l....lll.....l....ll..lll..51
2.1.7.3 Tag DNA polymerase ............................................................................................................................  52
2.1.7.4 Platinum Phc DNA Pofymerase.......................................................................................................... 52
2.1.7.5 Ac^-vsnasge Genome Polyme.rcse Mice............................................................................................ 52
2.1.7.6 Resdy-To-Go™PCR beads................................................................................................................... 52
2.1.7.7 Murine Mo/ojn^ey Virus Reverse Transcriptase Enzyme ............................................................ 52
2.1.7.8 Avian Myeloblastoses Vicus Reverse Tranncriptase .................................................................... 53
2.1.7.9 RNseeOUT™ Recombinsnt Ribonuclesse Inhibitor..................................................................53
2.1.7.10 Alkatinc Phosphnanet,.............................................................................................................................  53
2.1.7.11 DNsee 1: DNA-faee ™............................................................................................................................. 53
2.1 .8 Prorein SDS-PAGE standardi.............................................................................................................. 53
2.19 Equcpme ni..................................................................................................................................................53
2.1.9.1 Msjor Equipment......................................................................................................................................53
2.1.9.2 Consumsbles...............................................................................................................................................54
2.1.10 Buffers, solutions and growth media.................................................................................................54
2.1.10.1 Wstec..............................................................................................................................................................54
2.1.10.2 Antabioticc....................................................................................................................................................54
2.1.10.3 Buffers snd solutions................................................................................................................................54
2.1.10.4 BacaeriologicnMecda.........................................................................................................................  56
iv
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 METHODS............................................................................................................57
2.2.1 Growth and manipulation of mammalian cells............................................................................... 57
2.2.1.1 Basic technique..........................................................................................................................................57
2.2.1. U Crvopresen’ation of cells............................. . . ............................................................................... . 57
2.2.1.1.2 (]cII Counting.......... ................... ............... .............................................. ...............................................57
2.2.1.2 Cell ines57
2.2.1.2.1 Madin Darbv canine kitincv (MDCK) cells.................................................................................. 57
2.2.1.2.2 Feline embnonie libroblasis ( F FA)........................................ ....................................... .................58
2.2.1.2.3 Primary rat cardiocvtcs . ................................. ................ .......... . ............................................. ........58
2.2.1.2.4 Human chondrosarcoma cells (SW 1333i................................................................ -......................58
2.2.1.2.5 Mouse undifferentiated chondroprogenitor cells (A FDC5)............................................ . ......58
2.2.1.2.6 Rabbit svnox - ial fibroblasts (! HG-82)............... ................................... ...................................... .....59
2.2.2 Recombinant DNA techniques............................................................................................................ 59
2.2.2.1 Storage and growth of bacteria ....................................................................................... 59
2.2.2.2 Extraction and purification of plasmid DNA ................................................................. 59
2.2.2.2.1 Large Scale Plasmid Preparations........... ......................................................................................... 59
1.1.1.22 Small Scale Plasmid Preparations............................... .................................... .................................60
2.2.2.3 Determination of (ribo)nucleic acid concentration........................................................ 60
2.2.2.3.1 Determination by spec tro photo metry...................................................... .......................................60
2.2.2.3.2 Estimation of double stranded DNA concentration via gel electrophoresis..........  ......... 60
2.2.2. A Restriction endonuclease digestion................................................................................ 60
2.2.2.5 Electrophoresis of DNA  .....................................................................................61
2.2.2.6 Purification of restriction enzyme fragments...................................................................61
2.2.2.7. Dephosphorylation...........................................................................................................61
2.2.2.8 Ligation of vector and insert DNA ..................................................................................61
2.2.2.8.1 Ligation of restriction digested DNA fragments..........................................................................61
2.2.2.8.2 Ligation using TA cloning methods.......... ...................................................................................... 62
2.2.2.9 Transformation of bacteria with plasmid DNA.............................................................. 62
2.2.2.9.1 Transformation of TOPIC celts;...........................................................................................................62
2.2.2.9.2 Transform ation of JM109 cells*...................... .  ....................................................................................62
2.2.2.9.3 Transformation of XLl-Bluc Supercompetent cells.................................................................... 63
2.2.2.10 Screening of transformants for desired recombinant plasmids...................................... 63
2.2.2.10.1 (/ - complementation................................................................................................................................ 63
2.2.2.10.2 Restriction analysis of small-scale plasmid preparations................. -....................................... 63
2.2.2.10.3 PCR amplification of broth or small-scale plasmid preparations....................................  63
2.2.3 Preparation of total RNA....................................................................................................................... 63
2.2.3.2 RNA extraction usingRNAzoFMBsolution....................................................................... ...........64
2.2.3.3 Assessment of RNA using agarose gel electrophoresis.................................................. 64
2.2.3.4 DNase Treatment of RNA.............................................................................................. 64
2.2.4 First strand cDNA synthesis................................................................................................................. 65
2.2.5 Amplification of DNA by the polymerase chain reaction...........................................................65
2.2.5.1 Primer design..................................................................................................................  66
2.2.5.2 Preparation of PCR reactions....................................................................................................... ........ 66
2.2.5.3 Reaction conditions........................................................................................................ 67
2.2.5.4 Purification and assessment of PCR products................................................................ 67
2.2.6 DNA sequence analysis..........................................................................................................................67
2.2.6.1 Automated sequencing................................................................................................... 67
2.2.6.1.1 Sample preparation...................................................................................................................................68
2.2.6. 1.2 Sample sequencing...................................................................................................................................68
2.2.6 .1 .3 Sequence evaluation.......................................................................    68
2.2.7 Transient transfection of mammalian cells......................................................................................69
2.2.8 Genetic reporter systems.........................................................................................................................69
2.2.9 Analysis of recombinant proteins...........................      70
v
 Chapter III
Cloning and expression of canine IL-lRa cDNA
3.1 ABSTRACT.............................................................................................................................................. 72
3.2 INTRODUCTION...............................................................................................................................73
3.2.1 Candidate therapeutic proteins.............................................................................................................73
3.2.1.1 Inteilculdn-1 and receptor antagonist............................................................................. 75
3.2.1.2 Tumour necrosis factor and receptors............................................................................ 76
3.2.1.3 Tissue inhibibrss of metalloproteinase............................................................................ 77
3.2.2 Construction of anti-arthritic therapeutic vectors..........................................................................78
3.2.2.1 The coding .region of the gene ....................................................................................... 78
3.2.2.2 The immedtate 5' unnanslated region............................................................................ 79
3.2.2.3 The immedtate 5' untranslatedregion............................................................................ 80
3.2.2.4 Therapeuticpmteui saabllity........................................................................................... 80
3.3 MATERIALS AND METHODS.................................................................................................. 81
3.3.1 Preparation of RNA from canine peripheral blood mononuclear cells.................................83
3.3.1.1 Isolation ofiipopolysaccharide-stimulaisd canine PBMCs............................................ 83
3.3.1.2 Isolation of total RNA..................................................................................................... 83
3.3.2 Reverse Transcription Polymerase Chain Reaction (RT-PCR)................................................ 83
3.3.2.1 First strand cDNA synthesis........................................................................................... 83
3.3.2.2 PCR amp/itication .......................................................................................................... 84
3 .3.2.2 1 Primer design..................................................... ...................... .. 84
3.3.2.2.2 PCR conditions......................................... .............................................................................................. 84
3. 3.3 . Cloning. into pCR®2. 1-TOPO.................................................................................................................85
3. 3 .4 Sequence evaluation of constructs.......................................................................................................85
3.3.5 Sub-cloning of therapeutic cDNAs into pTarget™ mammalian expression vectors ....... 86
3.3.5.1 Primer design.................................................................................................................. 86
3.3.5.2 PCR. conditions .............................................................................................................. 86
3.3.5.3 Purification of PCRpooducts andaddition of dATPs.................................................................87
3.3.5.4 Ligation and transformation canine therapeutic cDNAs............................................... 87
3.3.5.5 Isolation and screening ofrecombinantpaasmids........................................................................ 87
3.3.5.6 Sequence evaluation of constructs ................................................................................. 87
3.3.5.7 Plasmid vector maps....................................................................................................... 88
3.3.6 Expression of cDNAs................................................................................................................................88
3.3.6.1. In vino nanscription and translation.............................................................................. 88
3.3.6.2 SDS-PAGE...................................................................................................................... 88
3.3.6.3 Protein Visualisation....................................................................................................... 89
3.4 RESULTS................................................................................................................................................... 90
3.4.1 RNA quantity and quality.......................................................................    90
3.4.2 PCR amplification and cloning of the canine IL-lRa cDNA.................................................... 90
3.4.3 DNA sequence analysis of the canine IL-lRa gene.......................................................................92
3.4.3.1 Searching database wi'tii sequence ................................................................................. 92
3.4.3.2 Nucleotide and deduced amino acid sequence of canine IL~lRa cDNA....................... 92
3.4.3.3 Comparison ofcanme IL-lRa nucleotide andjratom. sequences to other species......... 92
3.4.4 Sub-cloning of cDNAs into pTartget expression vector............................................................. 96
3.4.5 Expression of cDNAs...............................................................................................................................96
3.5 DISCUSSION
3.5.1 Prediction of canine IL-iRa biological function based on sequence homology............. 101
3.5.2 In v.tto?taanscription/translation of the canine IL-lRa, sTNFRI. LIMPT. TIMP-2 ... 1^01
3.6 SUMMARY^............................................................................................................................................. 103
vi
  
Chapter IV
Cloning of canine matrix metalloproteinase -9 and -13 gene promoters
4.1 ABSTRACT................................................................................................................................... 104
4.2 I INTRODUCTION.....................................................................................................................105
4.2.1 Targetinggenetherapy.......................................................................................................................... 105
4.2.2 Candidate disease-specific proi-noteer..............................................................................................105
4.2.2.1 Matrix meetaUoproeeinase-9..................................................................................................................106
4.2.2.2 MafflxmietaUoproeeitiase-13 ...........................................................................................106
4.2.3 Construction of anti-arthritic therapeutic vectorr.........................................................................107
4.2.3.1 5' Untrannlatedregion (UTR)........................................................................................ 109
4.2.3.2 Transcription factors......................................................................................................111
4.2.3.3 Gene transcriptton ......................................................................................................... Ill
4.3 MATERIALS AND METHODS...................................................................................112
4.3.1 Amplification of canine MMP-9 & -13 gene promoters, 5Z UTRs using
GenomeWalker™ techniques............................................................................................................. 116
4.3.1.1 Primer design................................................................................................................. 116
4 .3.1.1.1 MMP-9 promoter specific primerr................................................................................................... 116
4.3.1.1. 2 MMP-13 promoter specific pi'mierr......................................... .  ...................... .............................116
4.3.1 .1.3 GcnomcWalkcr Adaptor primets............................................... ..................................................... 117
4.3.1.2 Preparation of canine genomic DNA from peripheral blood mononuclear ceUl.......... 117
4.3.1.3 Digestion and purification ofcanine genomic DNA..................................................... 117
4.3.1.4 Ligation of digested canine gDNA to Genome WOker Adaptors.................................. 118
4.3.1.5 PCR-based DNA Waring in GenomicWalker Libraries............................................... 118
4.3.2 Cloning of canine MMP-9 and MMP-13 promoter fragmentt............................................... 119
4.3.2.1. Purification, ligation and transfoomarion ...................................................................... 119
4.3.2.2 Isolation and screening of recombinant plasmids......................................................... 119
4.3.3 Sequence evaluation <^tf constructt....................................................................................................119
4.3.4 Isolation and sequence analysis of tHe canine MMP-9 & -13 promoter frapgnente........120
4.3.4.1 Primer design................................................................................................................. 120
4 . .3.4 .1.1 MMP-9 promoter specific primers...................................................................................................120
4.3.4.1.2 MMP-13 promoter specific primerr................................................................................................ 120
4.3.4.2 Amplification and cloning of canine MMP-9 and MMP-13 pronloies fragments......... 120
4.3.4.3 Sequence evaluation of constructs containing MMP-9 & -13 promoter fragments........121
4.3 .4 .3 1 Primer design for sequencing............................................................................................................121
4.3.4 .3.2 Sample preparation and data analysis.............................................................................................121
4.3.4.3.3 Alignment of the canine sequence with homologous sequences... .... ................................. 122
4.3.5 Determination of transcription initiation sites using GeneRaces™ techniquee..............122
4.3.5.1 Primer design................................................................................................................. 123
4.3.5.1 .1 MMP-9 gene specific primers............................................................................................................123
4 .3 .5.1.2 MMP-13 gene specific primers.......................................................................................................... 123
4.3.5 .1 .3 Firefly lucifesaie gene specific primers........................................................................................123
4.3.5 .1 .4 GeneRaaet's| primers........................................................................................................................... 123
4.3.5.2 Cell line and transfections.............................................................................................. 124
4.3.5.3 Isolation of total RNA.................................................................................................... 124
4.3.5.4 DNase Treatment and removal ofreagents................................................................... 124
4.3.5.5 Dephosphorylation of RNA........................................................................................... 125
4.3.5.6 Purification of RNA ....................................................................................................... 125
4.3.5.7 Removal of the mRNA cap structure............................................................................. 125
4.3.5.5 Ligation of the GeneRacer™ RNA Oligonucleotide to the decapped mRNA................ 125
4.3.5.9 First strand cDNA synthesis.......................................................................................... 126
4.3.5.10 PCR amplification ......................................................................................................... 126
vii
 4.3.5.11 Cloning intopCRf2.1-TOPO vector „... . .. .....n... .. . . .n.."............ ,, n..."........... .....l.... . .... 12
4.3.5.12 Sequence evnluntiln o^the transcription initistion sites......................................................... .121
4.4 RESULTS
4.4.1 Isolation of canine MMP-9 & -13 promoter sequences using
GenomeWnUdng™ iechniqcet...........................................................................................................128
4.4.1.1 DNA qusntityasnd qualitys..".........................................".................".."..".."..""......... 128
4.4.1.2 PCR Amplsftcaaton of the pclmlatc fragments.............................................................................128
4.4.1.2.1 MMP-9 promoter sgenoec walk......................... .................................................................. ............128
4.4.1.2.2 MMP-13 promoter genome walk.............................................................. .................................... ...128
4H3 Cloning and screening for positive clones containing the canine MMP promoters 132
4.4.2 DNA sequence evaluation of the csnine MMP promoters..................................................... 132
4.4.2.I. Blast Search ofNCBI dntsbnst with sequences.......................................................................... 132
4.4.2.2 Sequence dsta snsysec........................................................................................................................ 132
4.4.2.3 1dentiftcst:ion of putstsvt DNA binding domsins........n. .....n...... „. .„. .m. m.."...... „.. n... 132
4.4.2.3.1 Canine MMP-9 promoter alignment............. ............ .................................................................... 132
4.4.2.3.2 Canine MMP-13 promo ter alignmeni.............................................................................................133
4.4.3 Transcription initiation sites.............................................................................................................133
4.4.3.1 Analysis of RNA qusn tity and quality.............................................................................................  133
4.4.3.2 PCR amplification and cloning of the MMP transcription initiation sites........................133
4.4.3.3 DNA sequence an nays is of the canine transcriittion iniatnailn sites....................................134
4.4.3.3.1 Canine MMP-9 transcriptioul suri sites..................................................................................... 134
4.4.3.3.2 (kmine MMP-13 transeriptioimi stnit siti^et....................................................................................134
4.5 DISCUSSION
4.5.1 ASlalysts of the 5' regulatory regron of canine MMP-9 and MMP-13.....................................139
4.5.1.1 rn^a^^iSs of the 5' tegunatoly eegi.>n ofcanwie MMP-9......................    139
4.5.1.2 ArnaSysss of the 3' teguaatOJys eegoon of canrine MMP-13..............................................................139
4.5.2 Analysis of the MMP9S aidi MMP-13 rranscripiion iniilarion sites........................................140
4.5.2.1 Determination of the MMP-9 transcriptional start site..............................................................140
4.5.2.2 Determination of the MMP-13 transcriptions start site............................................................141
4.6 SUMMARY..........................................................................................................................142
Chlpier V
Chnracterisntion of cmme MMP -9 md -13 gem promoters
5.1 ABSTRACT........................................................................................................................143
5.2 INTRODUCTION............................................................................................................144
5.2.1 Regulation of matrix metalloproreinnse gene trnnscription......................................................144
5.2.1.1 ReguSation of MMP-9 (Gelatinase B) transcription......................................................................144
5.2.1.2 ReguSation of MMP-13 (Collagenase-3) transcription............................................................... 145
5. 2.2 Pro-inflnmmatory sigsla^Cng iJlitwlys............................................................................................. 145
5.2.2.1 Nuclear Factor (NF)-kB signalling pathway.................................................................................. 146
5.2.2.2 Mitogen-activatedplotenn kinase (MAPS) pathway..................................................................148
5.3 MATERIALSAND METHODS...................................................................................150
5.3.1 Cloning of MMP-9 promoter deletion cosisaructs into pCR®2. 1-TOPO................................152
5.3.1.1 Primer design..............................................................................................................................................152
5.3.1.2 PCR ampiification of the canine MMP-9plomoter deletions................................................ 154
5.3.1.3 Cloning into pCR2.®!<) TOPO vector..................................................................................................154
5. 3.2 Sub-clonmg of the MMP-9 (deletions) & -^1^3 promoters into pGL1-Bntic...........................154
viii
  
5.3.2.1 Resfriction enzyme digestlon of vectors........................................................................ 155
S.3.2.2. Purification, ligation and transformation....................................................................... 155
5.3.2.3 Isoaation and screening of recombinant paasmids......................................................... 155
5.3.2.4 Sequence evaluation....................................................................................................... 156
5.3.2.5 Paas/nid vector maps...................................................................................................... 156
5.3.3 Endogenous MMP-9 &1I3 gene transcription using RT-PCR..............................................156
5.3.3.1 Cell fines andeeagcms .................................................................................................. 156
5.3.3.2 Stimutation of ceils......................................................................................................... 157
5.3.3.3 Ilotation ofiotolFNA.................................................................................................... 157
5.3.3.4 First sttand cDNA synthesis.......................................................................................... 157
5.3.3.5 Primer design................................................................................................................. 157
5.3.3.6 PCR ampfification of MMPregions using PCR ........................................................... 158
5.3 .4 Analysis of canine MMP-9 & -13 using Dual-Lucfferase^Reporter Assays........................159
5.3.4.1 Taenofeitiee of eeUs with lucifeaiis espoiirssonitructs............................................... 159
5.3.4.2 Stimutation of cells......................................................................................................... 160
5.3.4.3 LucHerase assays............................................................................................................ 160
5.4 RESULTS
5.4.1 Cloning of the canine MMP1I3 and MMP-9 promoters into the pGL3-Basic................. 161
5.4.2 Characterisations off. the camne M^MP9((8^!^')r and MMP1l3(4494S promoters................. 166
5.4.2.1 Endogenous basal and induced MMP-13 and MMP-9 gene ........................................ 166
5.4.2.2 Analysis of cloned canine gGL3/MMP-919844S and
promoter constructs using DuafPLuciferase Reporter assays....................................... 166
5.4.3 Identification of PMA responsive dements m the canine MMP-9 promoter................... 172
5.4.3.1 Endogenous expediton of camne MMP-9 in MDCK cels........................................... 172
5.4.3.2 Analysis of cloned canine MMP-9 ptoJnoter fragments using lucfferase reporters....... 172
5.5 DISCUSSION
5.5.1 Characterisation of the doned camne MMP9(11894. and MMP11311494)
promoter fragments................................................................................................................................176
5.5.1.1 Assessment of basal and induced endogenous transcription of .MMP-9 Sc-13genes... A76
5.5.1.2 Comparison of basaS and induce activity ofGGE3/MMP-9 & -13 (^(^r^^mict^s............... 177
5.5.2 Amalysis of canine MMP-9 promoter for the identification of PMA responsible
elements using deletion constructs..................................................................................................178
5.5.2.1 Assessment of basal and PMA induced endogenous transcription levels of MMP-9. ..T78
5.5.2.2 Gharacterisatoon of the camne MMP9S promotes usmg (^(leti^t^is analysis............................ 178
5.5.3 Rdevance of MMP promoters o gene-based therapy................................................................179
5.6 SUMMARY....................................................................................................................180
Chapter
Targeting therapeutic gene expression to the diseased cell types of the
canine osteoarthri^c joint
6.1 ABSTRACT........................................................................................................... 1M
6.2 INTRODUCTION...........................................................................................................182
6.2.1 TranscriptionaS regulation of transgenes.........................................................................................182
6.2.1.1 MenSpuSation ofpsomoters for targeting gene therapy.................................................. 182
6.2.1.2 TSslce sfecifisfsomoifes Ore tfrfiting enee tieraapy.................................................................183
6.2 .1.2.1 Cliondroryte specific gene expression......................................................................................184
6.2.1.3 A dual-promoter syseern firs targeting gene therapy...................................................... 185
ix
  
 
 
 
 
6.3 MATERIALS AND METHODS............................................................................................... 187
6.3.1 Cloning of all promoters into pCR2 .1®TOPO vector.................................................................. 191
6.3.1.1 Primer design ................................................................................................................ 191
6.3.1.11 Canine MMP-9 ysomoter manipulation with NI‘-KB sites.......................................................191
6.3. !.1.2 Mouse collagen type XI promoter . + /- manipulation wiihSOXO slice)..........................  191
6.3.1.1.3 Mouse collagen type XIiniron 1 ( + /- manipulation wiih SOX9 sues) ...............................192
6.3.1.2 PCR amplification.......................................................................................................... 193
6. .1. 1.2.1 MMP-9 manipulation with multiple NE-kB sues.,. ...................... ....... .................................. ..193
6.3.12.2 Mouse collagen type XI pl•omoteramplii1e.uion and manipulation ........... ................... 193
6.3.1.2.3 Mouse collagen type XI intronic amplication and manipulatinn.......... .............................193
6.3.1.3 Cloning into pCR®2.1-TOPO vector.............. 193
6.3.1.4 Sequence evaluation....................................................................................................... 194
6.3.2 Sub-cloning canine manipulated MMP-9 promoter & mouse collagen type XI
promoter/intronic fragments into yGL3-Baiic luciferase seyosies vectors.......................194
6.3.2.1 Restriction enzyme digestion.........................................................................................194
6.3.2.1.1 (amine MMP-9(muliiyie NF-KB sites) and mouse collagen type XI promoter + /-
(multiple SOX9 sites)................................................................... ........................................................ 194
6.3.2.11 Mouse collagen type XI [3SOX9(inison)3SOX9| sites...................... ............... ..................... 195
6.3.2.2. Purification, ligation and transformation....................................................................... 195
6.3.2.3 Isolation and screening ofrecombinant plasmids......................................................... 195
6.3.2.4 Plasmid vector maps  .......................................................................................................... 196
6.3.3 Mutagensis.................................................................................................................................................196
6.3.3.1 Primer design................................................................................................................. 198
6.3.3.2 PCR amplifocaiion of mutated vectors........................................................................... 198
6.3.3.3 Endonuclease Digestion................................................................................................ 198
6.3.3.4 Transformation and plasmid preparation................ ................................................................. 198
6.3.33 Sequence evaluation....................................................................................................... 199
6.3.3.6 Plasmid vector maps...................................................................................................... 199
6.3.4 RT-PCR for endogenous transcription of MMP-9 and collagen type XI genes..............199
6.3.4.1 Cell lines and reagents .................................................................................................. 199
6.3.4.2 Isolation (^^putificed total DNA......................................................................................200
6.3.4.3 Forst strand cDNA synthesis..........................................................................................200
6.3.4.4 Primer design.................................................................................................................200
6.3.4.5 PCR amplification ofMMP-9 and collagen cDNA fragments using PCR.................... 201
6.3.5 Lu^erase seyosier assays to analyse the basal and induced activity of the
manipulated canine MMP-9 promoter fragments and the mouse collagen type XI 
ysomoter/inironic fragments.............................................................................................................201
6.3.5.1 Transfection of cells ......................................................................................................202
6.3.5.2 Stimulation of cells...... . ......................................................................................................202
6.31.5.3 Luciferase assays............................................................................................................202
6.3.6 Preparation of components required for the dual-targeting vector coniisuciion ..........202
6.3.6.1 The incorporation ofloxH sites into the dual targeting vector.....................................203
6.3.6.2 Primer design for cloning intopCR®2.1-TOPO vector..................................................203
6.3.6.2.1 Mouse collagen type XI gene p^amoter phis /o.vH site:................................................203
6.3.6.2.2 Mouse collagen type XI uurannsox9 shus plus /w.yH siit........................................................ 203
6.3.6.3 PCR amplification .........................................................................................................204
6.3.6.31 Mouse collagen type XX promotcr/AzyH........................................................................................ 204
6.3.6.3.2 Mouse collagen type XX tntrannSOX9/1ovH.................................................................................204
6.3.6.4 Cloning of PCR products into pCR~2.1-TOPO vectors.................................................205
6.3.6.5 Sequence evaluation......................................................................................... ..............................205
6.3.7 Construction of dual targeting vector..............................................................................................205
6.3.7.1 Restriction enzyme (RE) digestion  ....................................... 205
6.3.7.1.1 RE digestion for cIis consisuciion of vector (A): pGl^/mCoIXIlo\I 1 .......................... ....205
6.3.7.1.2 RE digesion for the construction of vector B; yGL3/mColXl/^tAH-Cre............................206
6.3.7.1.3. RE digestion for the construction of
x
  
 
 
vecior C; pG! J/rnCoIX!lov! ^-Cie~t•MMP-9(3NFli’B)....... ............................. ........................ 206
6.3.71.4 RE digc'ttioi for eonstrcction of
vector D: pGE3/mColX! Aj.^k1 i-Cte-cMMIM(3NFl<B)|SOX9(itttroit)SOX9j................... 207
6.3.7.2 Pudification, ligation and transformation......................................................................................207
6.3.7.3 Isolation and screening ofrecombinant plasmids......................................................................207
6.3.7.4 Sequence evaluation...............................................................................................................................208
6.3.7.5 Plasmid vector maps...............................................................................................................................208
6.3.8 Westein bloi rnllysis of Cre expression.......................................................................................... 208
6.3.8.1 Sample preparation................................................................................................................................208
6.3.8.2 SDS-PAGE................................................................................................................................................ 209
6.3.8.3 Blotting snd blocking the membrane............................................................................................. 209
631.8.4 Antibody binding and detection usingECL ™ techniques.......................................................209
6.4 RESULTS................................................................................................................................................210
6.4.1 Cloning of ihe cmme MMP-9 promoier deleiions, NF-kB murnrion
md multiple NF-kB siies mio ihe pGL3-Bnsic lcicif'emse reporier vector.......................210
6.4.1.1 Vector maps............................................................................................................................................... 210
6.4.2 Chnaacterisntion of ihe cmme pGL3/cMMP-9 promoier delciions,
NF-kB murnrion md multiple NF-KB siies m humrn chondaosnrcomn cells................213
6.4.2.1 Analysis of endogenous basal and induced transcription of MMP-9 genes in
SW1353 cells............................................................................................................................................. 213
6.4.2.2 Analysis of all cloned canine MMP-9 palmoter constructs using
Dusl-Luciferase®Reporter assays............................................................................................. ........215
6.4.2.2.1 Ailiysit of cmme pGI3/cMMP-9(1984), (984), (628~), (534) .......................... ......................215
6.4.2.2.2 Ailirtit of miiilied clime pGL3/cMMP-9(628)(NFK'Bmut") ........................................... 215
6.4.2.2.3 Aillysis of mtiipcinted clime pGLJ/cMMP-911894((5NKKB; 3NFkB; INFkB)........215
6.4.3 Cloning of ihe mouse collngen Type XI promoier, 3&5SOX9 promoters,
miron/SOX9 mio ihe pGL3-Bntic luciferlse reporier vecior.................................................219
6.4.3.1 Vector maps...............................................................................................................................................219
6.4.4 Chnrlcterisntion of mouse conlgeii type XI promoier md inrronic contrrucis
mmipullted wiih SOX9 sites m SW1353 md ATDC5 cells................................................... 222
6.4.4.1 Analysis of endogenous transcription of collagen type XI genes ........................................222
6.4.4.2 Analysis of mouse collagen type XIpromo ter and inarlnsc sequences
manipulated with SOX9 sites using Dual-Luciferasc Reporter Assays............................224
6.4.4.2.1 Mouse coillgen iype XI promoter +/- (3SOX9) lid (5SOX9) ii pGL3............................ .224
6.4.4.2.2 Mouse colllgei iype XI promoter lid inlion(SOX9) ii pGL3............................................. 224
6.4.5 Cloning of ihe dull ilrgeting vecior consirucrion 6.4.5. Vector maps..................................227
6.4.6 Western bloi rnllysis of Cre recombinnrion durmg ^^^006100........................................ 230
6.5 DISCUSSSON.................................................................................................................  231
6.5.1 Cm ihe cmme MMP-9 promoier be mmipullted io enhmce lciivity
while mlinilining diselse-specificity?...........................................................................................232
6.5.1.1 Analysis of endogenous basal and induced transcription of MMP-9............................... 232
6.5.1.2 Analysis of all canine MMP-9 pclmoafc constructs using luclffcasf reporters..............232
6.5.2 Cm ihe mouse collngen type XI promoier be mmipullted io mEmce
nciiviiy while mlininining cell-type specificity?........................................................................ 234
6.5.2.1 Analysis of endogenous transcription of collagen type XI genes ......................................... 234
6.5.2.2 Analysis of all mouse collagen type XIpromoter fragments using lucsferaee assays....2MM
6.5.3 Cm l dunl-rnageting vecior system be developed io resirici iherlpeuiic gem
expression io disused cell types of ihe cmme osieolrihritic jomi?.................................... 236
6.5.3.1 Construction of the dual targeting vector.......................................................................................236
65.3.2 Western blot analysis of Cre recombination during construction........................................ 237
6.5.4 Future direction for the dual targeting vector.............................................................................. 237
6.6 SUMMARY..............................................................................................................................................239
xi
 
 
Chapter VII
Delivery of genes to synovial cells using particle-mediated bombardment
transfection techniques
7.1 ABSTTR1CT............................................................................................................................................240
72 INTRODUCTION.......................................................................................................... 241
7.2.1 Gene ddivery systems............................................................................................................................241
7.2.1.1 LIposetnes-ncddltedgene dcnveey.................................................................................241
7.2.1.2 Viraa vector mediaSedgene dedveiy...............................................................................241
7.2.1.2 Partied: bombardmeni mediated gene deRiver........................................................................... 241
7.2.12.1 fn \ Steo and ex ^r/rtr^t^ml ^08101-.. . .... ..............................................................................................242
7.2.1.2.2 In vivo and 7/j s’/u gene 1^10811.'r......................................................................................  242
7.2.1.2.3 Mechanical and functional parameters of partide bombartlmenn..........................................243
7.2.1.2.4 Limication8 of partide bombardment.........................  243
7.2.2 Therapeutic gem rIellvely to types of the Sourt................................. .................................. 244
7.3 MATERIALS s\ND METHODS..................................................................................246
7.3.1 Preparation of components for gene rgm systym........................................................................ 248
7.3.1.1 Preparation of cartridges................................................................................................248
7.3.1 .1.1 Prcdpitation of DNA onto micocarriers (gold pai'lidls) ...................................................248
7.3.1.1.2 Loading the DNA/Microcarrier suspension into Gokl-Coat Tubing ............................248
7.3.1.2 Preparation of gene gun.................................................................................................251
7.3.2 DcUvcry sf reporter plaamid vectors So cdls Sn .^sue cullure
using particle bombardment and liposome-mediated techniques .  ................................254
7.3.2.1 Ced tines and reagents ..................................................................................................254
7.3.2.2 Reporter plasmid redoor................................................... ....................... .....................254
7.3.2.2.1 Beta-Galaelosidase reporter plasmid (pCMV|3).........................................................................254
7.3.2.2.2 Enhanced Greein Fluorescent Protein reporter plasmid (EGFP)....... . ................................254
7.3.2.3 Transient transfection of tissue culture monolayer ceds with reporter construds....... 254
7.3.23 1 Parriele bombardment method of sransSeciion........................................... ................................254
7.32.32 Liposome-mediated transseetion..............  ....   .................256
7.3.2.4 Reporter Assayss............ ..................... ............................................................................ 256
7.3.2.-4.1 X-gal staunngassav . ......................................................... ............. ................................... - 256
7.3.2.4.2 Enhanced Green Fluorescent Protein (EGFP) Assay................................................................256
7.3.3 Denvery of gold, p»laicils so tiiisue sampEs taken aa post-mortem sxamination
using particle bombardment.............................................................................................................. 257
7.3.3.1 Samplepreparation........................................................................................................257
7.3.3.2 Particle bombardment oftissues....................................................................................257
7.4 RESULTS...........................................................................................................................260
7.4.1 Companion of liposome-mediated and parricCllbombardmeniimediated
transfection of monolayer cells in tissue culture.........................................................................258
7.4.1.1 The jf-galadosidase assay..     ............................................ 258
7.4.1.1 The EGFP assay.............................................................................................................258
7.4.2 Gold partide delivery to cell .types of She jourt............................................................... 261
7.5 DISCUSSION................................................................................................................... 265
7.5.1 Liposome-media ted and particle bombardmentinlediated methods
of gene transfection into monolayer cells in tissue culture..................................................... 265
7.5.2 Gold particle deKve^ to ceh t^pes of the canine jotclt..............................................................266
7.5.3 Optimisation of Srannfection parameter...................................................................................... 267
7.6 SUMMARY................................................................................................................................................... 269
XU
 Chayits VIII
General Discussion
8.1 ABSTRACT.................................................................................................................. 270
8.2 DISCUSSION................................................................. . ................................................271
8.2.1 Work described in thesss...............................................................................................271
8.2.2 Future studies........................................................................................................................273
8.2.2.1 Details ofproposed future research project................................................................... 273
8.2.2,11 Expression and biological characterisation of the canine specific
therapeutic proteins using a tissue culture explant system....................................................273
8.2.2.1.2 Local and systemic assessment of inducible disease specific promoters
in vivo using Adeno Associated Viral (AAV) vectors in rats....................................................274
8.2.2.1.3 In vivo study using the canine model of osteoarthritis.............................................................274
8.3 SUMMARY...................................................................................................................... 275
GLOSSARY................................................................................................................ 276
REFERENCES.........................................................................................................278
APPENDIX................................................................................................................311
xill
LIST OF FIGURES
Figure 1-1 Schematic drawing of a j oint..................................................................................................................5
Figure 1-2 Moleeular structure of articular cartilage..............................................................................................6
Figure 1-3 AeticOogy of osteoarthritis......................................................................................................................9
Figure 1-4 Palhololgcd dimgee sn she ccrnne olteoarihritic joint...................................................................11
Figure 1-5 Ah^ltololeict^l section of osteoarthritic synovial tiisue ..................................................................12
Figure 1-6 DeYcC()pmcnt of oleeophytes iit ccrnne c^l;tt;c^£lritll■ilrl.....................................................................12
Figure 1-7 Ragiographicd aseecement of camne oltecaarthrsi■tc iolnts.............................................................14
Figure 1-8 Enzymee-mediated degradation of articuler ccrtiiage matox .........................................................16
Figure 1-9 Domain structure of ihe matox meldloprotelnasee........................................................................19
Figure 1-10 Scntiieeii and aativation of the matnx meldleprolelnasee............................................................ 20
Figure 1-11 Schematic cepresentation of the domain olgrntletivn end siructure of ccrst1ege aggraecn.... 222
Figure 1-12 A cimpKflcd overvteev of the caguletivn of ccrst1agr iurnovee...................................................... 25
Figure 1-13 The gme therapy iranteriptivnal umt................................................................................................ 45
Figure 3-1 Candidate shecilpeclttc protoum............................................................................................................74
Figure 3-2 Oventiiw of c.epee'ilnentrg procedures cased to done and express c^arell^ spectifc
therapeutic cDNAs.................................................................................................................................82
Figure 3-3 Aseecement of FEN A qudiiy slsing TAE agrrole sgl electrophooeetd............................................ 91
Figure 3-4 PCR ampliCicctidn of IL-HRa from ccnine cDINtA.............................................................................91
Figure 3-5 Rectriction enzyme andysss of jaCdR^.1 /cl I l-ivi foo positive donee..............................................91
Figure 3-6 The cDNA sequence of carnne IL-lra............................................................................................... 93
Figure 3-7 The deduced amino arcd esq^^e of camne iI—llIa....................................................................... 93
Figure 3-8 7Aignment of the II- dra nudeotide sequences of diCfeeant surdce.............................................94
Figure 3-9 Alignmeni of the II —- m amino add sequences of diffeeann suedee.............................................95
Figure 3-10 PCR amplefication of the carnne homologues of ILdra, sTNFRIi TIMP-1, TIMP-2 for
eubdaleieg into the pTaaget Mammalian expression vector..........................................................97
Figure 3-11 Vector map foo pTARGETTcH-dRa................................................................................................ 98
Figure 3-12 Veetoo s^ip for pTARGET/csTNFRI............................................................................................. 98
Figure 3-13 Veetoo map for pTARGET/cTlMP-1.............................................................................................. 99
Figure 3-14 Vectoa map for pTARGET/cTIMP-2.............................................................................................. 99
Figure 3-15 Expresskm of ctaene IL-TRa, sTNFRI, TIMP-1 and TUMD-T ffom pTargee veetoo............ 100
Figure 4-1 Tram sapPon.........................................................................................................................................108
Figure 4-2 Mechamim of action of she LCR......................................................................................................110
Figure 4-3 Overview of dae experimentd procedure sased to done camne MMP-9 & s'13 promoters...! 13
Figure 4-4 Summary of Genome Wdking...........................................................................................................114
Figure 4-5 Summary of GeneRacer™ protoed..................................................................................................115
Figure 4-6 Purifed genomic DNA samphe........................................................................................................129
Figure 4-7 Digeeted genomic DNA samples pre (a) and poss sb) puri0.cction........................................... 129
Figure 4-8 Fil'st genome svdk for she MMP-9 promoter sequence................................................................130
Figure 4-9 Seeond genome wdk for tite MMP-9 promoter sequence....................................................... ...130
Figure 4-10 First genome wdk for MMP-13 promote!......................................................................................131
Figure 4-11 Seeond genome wdk for MMP-13 promotee.................................................................................131
Figure 4-12 Nudeotide sequence of camne MMP-9 promoter .......................................................................135
Figure 4-13 Nucleotide sequence of camne MMP-9 partid cDINA..................................................................135
Figure 4-14 Nucleotide sequence of camne MMP--13 promotee......................................................................136
Figure 4-15 Nucleotide sequence of camne MMP-13 partid cDNA...............................................................136
Figure 4-16 Allgnmeni of camne MMP--9 promoter sequence sviih other spedes........................................137
Figure 4-17 Aleldl'nnent of camne SMIMP-13 promoter sequence \Wih other speccd.....................................138
Figure 5-1 Nuclear Faccor (NF)-kB sicr'tdeing pathway...................................................................................147
Figure 5-2 IMtogen activated protein ltinase pathway (MAPK).....................................................................149
Figure 5-3 Overview of the experiment'd procedures used to clone the canine
MMP-9 &-13 promoters..................................................................................................................... 151
Figure 5-4 Mti^MlP-^ pm^mol^^c^^r deletion eralrnentr................................................................................................ 153
Figure 5-5 Vector map for pCLS/cMM-^^^..............................................................................................162
Figure 5-6 Vector maps for pGL3/cMMP-9(984)..............................................................................................162
xiv
Figure 5-7 Vector map for pGL3/cMMP-9(628)..............................................................................................163
Figure 5-8 Vector map for pGL3/cMMP-9(534)..............................................................................................163
Figure 5-9 Vector map for pGL3/cMMP-9(176)..............................................................................................164
Figure 5-10 Vector map for pGL3/cMMP-9(102)..............................................................................................164
Figure 5-11 Vector map for pGL3/cMMP-13(1494).........................................................................................165
Figure5-12 Basal and induced levels of endogenous MMP-13 transcription in MDCK cells................... 168
Figure 5-13 Basal and induced levels of endogenous MMP-13 transcription in primary rat eardiocytes. 168
Figure 5-14 Basal and induced levels of endogenous MMP-9 transcription in MDCK cells..................... 169
Figure 5-15 Basal and induced levels of endogenous MMP-9 transcription in primary rat eardiocytes... 169
Figure 5-16 pGL3/cMMP-13(1494) promoter construct activity in MDCK cells.......................................170
Figure 5-17 pGL3/cMMP-13(1494) promoter activity in primary rat eardiocytes.......................................170
Figure 5-18 pGL3 / cM Ml P-9 (1894) promoter construct activity in MDCK cells..........................................171
Figure 5-19 pGL3/cMMP-9 (1894) promoter construct activity in primary rat eardiocytes.......................171
Figure 5-20 Basal and PMA induced levels of endogenous MMP-9 transcription in MDCK cells.........474
Figure 5-21 pGL3/MMP-9 promoter deletion construct activity in MDCK cells ......................................175
Figure 5-22 pGL3/MMP-9 promoter deletion construct activity in FEA cells ...........................................175
Figure 6-1 Targeting therapeutic gene expression to diseased ceU types of the join..................................186
Figure 6-2 Overview of experimental procedures used to manipulate and analyse the canine
MMP-9 promoter.................................................................................................................................. 188
Figure 6-3 Overview of the experimental procedures used to clone and analyse the mouse
collagen type XI promoter..................................................................................................................189
Figure 6-4 Overview of the experimental procedures used to clone the dual-targeting vector...............190
Figure 6-5 Simplified diagram of mutagenesis.................................................................................................... 197
Figure 6-6 Vector map for pGL3/cMMP-9(628)(NFKBmufl)...................................................................... 211
Figure 6-7 Vector map for pGL3/cMMP9(1 894)(5NF-KB)...........................................................................211
Figure 6-8 Vector map for pGL3/canine MMP-9/1894(3NF-kB)...............................................................212
Figure 6-9 Vector map for pGL3/cMMP-9(1894)(1 NF-kB)..........................................................................212
Figure 6-10 Endogenous levels of MMP-9 transcription in SW1353 ceUs using RT-PCR.........................214
Figure 6-11 Deletion and mutational analysis of the canine MMP-9 promoter............................................217
Figure 6-12 Manipulation of the canine MMP-9 promoter fragment with multiple NFKB sites................ 218
Figure 6-13 Vector map for pGL3/mColXI........................................................................................................220
Figure 6-14 Vector map for pGL3/mColXI(3SOX9)........................................................................................220
Figure 6-15 Vector map for pGL3/mColKI(5SOX9)........................................................................................221
Figure 6-16 Vector map for pGL3/mCoXII[3SOX9(intron)3SOX9j.............................................................221
Figure 6-17 Endogenous levels of coUagen type XI (mColXl) transcription in SW1353 ceUs using
relative semi-quantitative RT-PCR................................................................................................... 223
Figure 6-18 Endogenous levels of coUagen type XI (Col XI) transcription in ATDC5 ceUs using
relative semi-quantitative RT-PCR................................................................................................... 223
Figure 6-19 Analysis of the mouse collagen type XI promoter +/- 3 and 5 SOX9 sites...........................225
Figure 6-20 Analysis of the mouse collagen type XI promoter with intronicSOX9 sites..........................226
Figure 6-21 Vector map for Vector A construct: pGL3/mColXIAvH..........................................................228
Figure 6-22 Vector map for Vector B construct: pGL3/mColXIA\TI-Cre..................................................228
Figure 6-23 Vector map for Vector C construct: pGL3/mCoKI/0xH-Cre-cMMP-9(3NFKB)................229
Figure 6-24 Vector map for Vector D: pGL3/mCoKI/<:yHT-Cre-cMMT-9(3NFKB)-
OX9(iintr-oT)^^<OX(9S..................................................................................................................... 229
Figure 6-25 Western blot analysis of the CRE gene expression in the TOP1O bacterial cells................... 231
Figure 7-1 Histological structure of the synovial membrane...........................................................................245
Figure 7-2 Overview of experimental procedures for particle-mediated bombardment
transfection of cells..............................................................................................................................247
Figure 7-3 The Tubing Prep Station...................................................................................................................... 250
Figure 7-4 The gene gun...........................................................................................................................................252
Figure 7-5 Mechanics of the gene gun...................................................................................................................253
Figure 7-6 Transfection using the gene gun apparatus...................................................................................... 255
Figure 7-7 Liposome-mediated method of gene delivery ((J-GM)................................................................... 259
Figure 7-8 Particle bombardment-mediated method of gene delivery (p-Gall...............................................259
XV
Figure 7-9 Untransfected MDCK ctLeiss (fi-Gal)..................................................................................................259
Figure 7-10 Liposomer-nedialed gene delivery (EGFP)....................................................................................260
Figure 7-11 Particle bombardment-mediated gene del)cerryEGFP)...............................................................260
Figure 7-12 Gold particle penetration off canine fibrous synovium witii particle bombardment ............ 262
Figure 7-1- Gold particle penetration of canine fibrous synovium tissue with particle bombnrrlrnent ..262
Figure 7-14 Untransfected canine fibrous synovium ........................................................................................262
Figure 7-15 Gold particle penetration of canine fibroareolar synovium witii particle bombardment 263
Figure 7-16 Untransfected canine fibroareoiar synovium................................................................................263
Figure 7-17 Gold panicle penetration of canine adipose synovial Iissuc witii particle bombardment 264
xvi
LIST OF TABLES
Table 1-1 Classification of arthritis............................................................................................................................3
Table 1-2 Categosies of canine osteoarthritis..........................................................................................................4
Table 1-3 Classification of the matrix metaUoproteiiiases................................................................................. 18
Table 1-4 Tissue mhibitors ofmeta^vprotcinase................................................................................................23
Table 1-5 Potential therapeutic genes.................................................................................................................... 37
Table 1-6 Viral vectors for gene therapy............................................................................................................... 39
Table 2-1 Restriction enzymes..................................................................................................................................51
Table 2-2 Commonly used sequencing primers....................................................................................................68
Table 3-1 Primer sequences for amptification of canine IL-lRa...................................................................... 84
Table 3-2 Primer sequences for amptification ofcanine i^L^^-^Rsii sTNFRI. TTMP-l.TIMP-2.................. 86
Table 3-3 Primers for sequencing pTarget/cDNAs............................................................................................88
Table 3-4 Percentage of sequence h^omoOgyi between the canine ILlra nucleotide and emioo ccid
sequeiices aid other species.............................................................................................................. 96
Table 4-1 Primer sequences for gcnome walksog..................................................................................................117
Table 4-2 Primers to l^mp)ii^^ the canine MMP-9 and -13 promoter sequeocer.........................................................120
Table 4-3 Ptmeess for the internal sequencing of the canine MMP-9 and -13 plemoter sequeie'es .... 121
Table 4-4 Primer sequences for RACE techniques..................................................................................... l... 124
Table 4-5 PCR conditions for RACE protocols................................................................................................ 127
Table 5-1. Primer sequences for the PCR amptification of the canine MMP-9 promoted deleOni
coo.structs...............................................................................................................................................152
Table 5-2 Prmier for RT-PCR 9(MMP-9. MMP-13. cyclophitin)...............................................158
Table 6-1 Primer sequences for manipulating the canine MMP-9 sequence wiih NT'-K'B sites
aid the clooiog md maoipu)atson of the mouse ColXi promoter aid eohanccd
with SOX9 sites.................................................................................................................................. 192
Table 6-2 Primer sequences for N PKB mutageness ....................................................................................... 198
Table 6-3 Primer sequences for RT-PCR (MMP-9. ColXI and cyclophifio)...............................................201
Table 6-4 Primer seqences for the cloning of the dual-targe ting vector......................................................204
Table 6-5 Primer's for sequencing the dual targeting vector............................................................................208
xvii
ACKNOWLEDGMENTS
I would firstly like to thank my supervisor, Professor David Bennett, for giving me the opportunity to 
conduct this research and for his support over the past few years. I would also like to thank Dr. David 
Argyle for his inspiration and encouragement throughout the project. In addition I would like to thank 
Dr. Lubna Nasir for her technical support in all aspects of this thesis. Finally, I would like to thank 
Elizabeth Gault for her general assistance in the laboratory, particularly with the sequencing of DNA 
constructs.
I would like to acknowledge BSAVA Petsavers for funding this work.
XVlll
DECLARATION
Apart from the help acknowledged, I declare that work described was carried out by me and is 
not that of any other person, and further has not been submitted in full or in part, for 
consideration for any other degree or qualification.
Sarah Elizabeth Campbell, August 2002
XiX
PUBLICATIONS
Refereed Journals
Campbel! SIC Sood A. Argyle DJ. Nasir L. Argyle SA. Bennett D. The cloning and functional 
analysis of canine matrix metall/pt•oteltiase-I- gene promoter. Gene. 286(2):2—-240, 2002 
(see appendix 3)
Campbell SIC Nasir L. Argyle DJ. Bennett D. Molecular cloning and characterisation of canine matrix 
metalloproteinase^ (MMP-9) gene promoter. Gene. 273:81-87, 2001 (see appendix 2)
Campbell SIC Nasir L. Argyle DJ. Gault EA. Duthie S. Bennett D. Cloning of canine IL-lra, TNFR 
and TIMP-2. Veterinary Immunology and immun/path/l/gy. 78(2);207-214, 2001 (see 
appendix 1)
Abstracts
Campbell SIC Argyle DJ. Nasir L. Bennett D. Targeting therapeutic gene expression to diseased cell 
types of the canine osteoarthritic joint. British Society for Rheumatology (BSR) conference. 
Brighton, UK, 2002
Campbell SIC Argyle DJ. Nasir L. Bennett D. Applying gene therapy to canine osteoarthritis using a 
novel dual promoter targeting system. British Small Animal Veterinary Association 
(BSAVA) conference. Birmingham, UK, 2002. Awarded BVOA Leslie Vaughan prize 
2002.
Campbell SIC Argyle DJ. Nasir L. Bennett D. Gene therapy for canine osteoarthritis. A novel dual 
promoter targeting system. Advances in Tissue and Genetic Engineering for the Treatment of 
Arthritic Diseases annual conference. Providence RI, USA, 2001 (Invited speaker).
Campbell SIC Nasir L. Argyle DJ. Gault EA. Bennett D. A novel gene therapy approach for canine 
osteoarthritis. British Society for Rheumatology (BSR) conference. Edinburgh, UK, 2001
Campbell SIC Nasir L. Argyle DJ. Gault EA. Bennett D. Gene therapy and canine osteoarthritis. A 
novel targeting system for disease control. British Small Animal Veterinary Association 
(BSAVA) conference. Birmingham, UK, 2001
XX
 Campbeil CIC Nae1s L, Argyle DJ. Gault EA. Bennett D. A novel gene therapy treatment for aaeiee 
aeteaartbrit1e. Annual Veres1egsy Tegheere Rceegste Aeeaa1gtiae (AVTRW) meet1er. 
Cagsbarough, UK, 2001
Campbell CIC Nasir L. Argyle DJ. Gault EA. Beeeetr D. Canine Oeteaartbs1tie. A model Oor human 
gene therapy. Advances in T1eeue and Genetic Eeg1eeerieg Oos the Tregtmeer of Arthritic 
Dieegeee aeeugl aaefcreehe. Baerae, MA, 2000
Campbell CK, Nasir L. Argyle DJ. Gault EA. Beeeert D. Cgeiee Oeteaartbr1tie. Is gene therapy the 
gnewea? Aeeahigrian Vereriegry Teachers Research Workers (AVTRW) meeting. 
Chgsbasaugh, UK, 2000
Genbank database Submissions
Campbell CIC Nasir L. Gault EA. Argyle DJ. Bennett D. Canine interleukin-/ receptor aetggan1et (IL- 
lra) complete cDNA. 1999. Acheee1ae number; AF216526
Campbell CIC Ngeir L. Argyle DJ. Bennett D. Canine metgleaprateiegec-9 (MMP-9) psamatcs 5' UTR. 
2000. Aateee1ae number: AF280420
Campbell CIC Nasir L. Argyle DJ. Bennett D. Canine metgleapsateinase-/3 (MMP-13) promoter 5'
UTR. 2001. Atceseian number: AF384859
Additional conferences
Campbell CIC Nasir L. Argyle DJ. Bennett D. A novel gene bgeed therapy Oos hgeiee aercaartbritie. 
Celeue Autumn Meerier, Glasgow University, UK, 2001. Awarded prize for best 
prcecetation.
Campbell CE. Nasir L. Argyle DJ. Gault EA. Bennett D. Canine osreagrtbritie. A model for human 
gene therapy. The dieaavcsy oO new veterieasy media1eee ieternatianal symposium at Pfizer 
Canedw1ah, Kent, UK, 2000.
Campbell CIC Nasir L. Argyle DJ. Gault EA. Bennett D. Canine aereagstbririe. A model for human 
gene therapy. Cceeue Research Group Meeting, The Royal Iefirmary,Geaegaw, UK, 2000
xxI
 Chapter I
General Introduction and review of the literature
1.1 ABSTRACT
Osteoarthritis (OA) is a degenerative joint disorder characterised by pathological changes in 
articular cartilage, the underlying subchondral bone and synovial membrane. Although the 
aetiology of OA is still largely unknown, recent advances in molecular biology have determined 
the pathogenic processes which result in the net loss of cartilage components. This common 
condition can be very painful and is often associated with a chronic persistent lameness, yet current 
treatments are still limited to ‘symptom-modifying’ therapies. This chapter reviews the 
pathogenesis of OA, with particular reference to the canine disorder, which is relevant to the 
development of ‘structure-modifying’ therapies. Considerable attention is paid to the newly 
emerging technologies of ‘gene-based’ therapeutics on which this thesis is based, with particular 
focus on the technical problems that must be overcome in order to provide appropriately regulated 
expression of therapeutic genes.
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1.2 PATHOGENESIS OF OSTEOARTHRITIS
1.2.1 Dsfcnciion and classification of osteoarthritis
Arthritis, the term used to defioe joiot ioflammatioo, is used so a broad seise to describe oumcrour 
direarc eotitier affectiog my tissues of the joiot Arthritis cao be separated ioto two mam 
categories, the dcgeoerrtivc md the soflammatory arthropathies, md further sub-divided to defme 
specific disease types (Table 1-1). Although osteoarthritis (OA) is described as a degeoerriive 
cvodiiivo, there is also varymg degrees of mflammatory chmge withio the syovvium particularly 
cvideot io the caoioe rpccier where OA is a much more mflammatory cvodiiivo thm So other 
species. Three types of caoioe OA are oow recvgoised md have reeo described as primary 
(idiopathic), recvodrry md erosive (Table 1-2). Primary OA is relatively rare periaiosog to specific 
breeds such as the SpaoieL Goldeo Retriever, Boxer md Samoyed. Io comparisoo, OA secvodrrr to 
other causes such as hip dysplasia, elbow dysplasia, vsievchvndrosis aod cruciate disease is far 
more commoo (Beoocit, 1999) aod is particularly pfevaleot io the larger breeds of dog. Erosive OA 
is very rare aod is most ofteo seeo io the caosoe hip joiot where the OA, recvodary to dysplasia, is 
complicated by destructioo of the surchvndral booe. However, the true defimtioo of OA has yet to 
be resolved aod maoy modern day rheumatologists regard it mt so much as a disease, but as ao eod- 
pomt of joiot failure. Thus wheoever pathology affects a diarthrodial joiot, the ioeviiarle outcome 
will be OA. The idea that OA io mao is restricted to ooe joiot has teceot)r beeo challeoged by a 
oew hypothesis. It is mw coosidered that a geoeralised form of OA exists, directed by a primary 
metabolic disorder iovolviog systemic factors io which maoy jo^ts aod other tissues are affected, 
remote from the focal (Aspdeo et al., 2001).
1.2.2 Prevalence of osteoarthritis
OA is a chrooic, paioful cooditioo aod is of major coocem to both humao aod vcierioaty medicioe, 
affectiog me third of adults aged 25-74 years (Creamer aod Hochberg, 1997) aod 20% of the caosoe 
populatioo aged over ooe year of age (Beooett, 1980). The socideoce aod prevaleoce of OA is 
closely associated with the ageiog process aod it has receotly beeri hypothesised that in vivo
replicative seoe'ceoce may cause ao age-related declioe io the ability of choodrocytes to maiotaio 
articular cartilage, particularly through erorivo of telomere leogth aod seoesceoce (Martio aod 
Buckwalter, 2001). However, caoioe arthritis is ofteo iostiaied early so life but cliotcal disease is 
more likely io the older paiieot ssoce the disease is geoerady progressive aod thus the pathology 
worseis with age.
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Table 1-1 Classification of arthritis
Arthritis category Type Sub group
1) DEGENERATIVE a) Osteoarthritis
b) Traumatic arthritis
c) Haemophilic arthritis
d) Neuropathic arthritis
2) INFLAMMATORY a) Infective Bacterial
Dietoepaedneitie 
Eedahard1tie and gsrbritie 
Barreliae1e
Bacterial L forms
Tubercular
Mycoplasmal
Fungal
Protozoal
Viral
b) Immune-based Eroeiee
Rheumatoid
Pes1aeteae proliferative palyartbriris 
Palyarrbs1tie of Greyhounds 
Felty’s syndrome
Noeleraeivc
Cyetem1a lupus erythematosus 
Polngrthrit1s/polymyasitis 
Polngrtbritie/meniegitis 
Arthritis of Japanese Akitas 
Amyloidosis of Chinese Char Pei 
Polyarteritis nodosa 
Cjogsee’s syndrome 
Idiapatbih
Type I (no aeeaaiatians) 
Type II (‘reaatiec’)
Type III (eetesapatbit) 
TypellV (neaplgsr1h)
Druglieduaed 
Vgaa1earioe ‘reactiaee’ 
Plgsmacnt1h/eymphohnt1c gonitis
c) Crystal-induced Gout
Pseudagaut
Hydroxyapatitie
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Table 1-2 Categories of canine osteoarthritis
Osteoarthritis 
........ type.......
Aetiology Characteristics Breed predisposition
Primary
(idiopathic)
No identifiable cause but 
possibly some inherent 
metabolic abnormality of the 
cartilage predisposing to early 
degeneration.
Multiple joints in 
young adult dogs
Dalmatian, Chow,
Spaniel, Boxer, Golden 
Retriever, Samoyed
Secondary 2“ to identifiable joint diseases 
(e.g. hip dysplasia, cruciate 
disease, /ste/ch/nKl’/sis), 
repeated and/or excessive 
trauma
One or many joints 
involved
Breed predisposition 
often associated with the 
underlying cause
Erosive Generally of 2° type Destructive 
changes occur 
within the bone, 
mainly of the hip
No breed predisposition 
other than that 
associated with an 
underlying cause such as 
dysplasia
1.2.3 The molecular structure of cartilage
Cartilage tissue, lining the articular surface of joints, (Figure 1-1) consists of a small number of 
chondrocytes that produce and subsequently embed in an extra-cellular matrix (ECM) of water, 
proteoglycan and collagen (Figure 1-2). Proteoglycan monomers are large polyanions composed of 
polysaccharides, chondroitin sulphate (CS) and keratan sulphate (KS), bound by a core protein. 
Many of these proteoglycan sub-units are non-covalently bound to long filaments of hyaluronic acid 
forming a proteoglycan aggregate, also referred to as aggrecan, of highly negative charge 
(Hardingham and Fosang, 1992). Water molecules entrapped within this matrix containing 
negatively charged macromolecular complexes define the volume of the cartilage tissue, which in 
turn is prevented from unlimited expansion by the surrounding collagen network (Kuettner, 1992). 
Other molecules identified in the matrix such as decorin, fibromodulin and biglycan are currently 
under investigation and determination of their functions will enhance the understanding of cartilage 
metabolism (Knudson and Knuds on, 2001). Collagen, the most abundant protein in the body and 
found throughout the ECM, consists of fibres made up of fibrils with each fibril containing 
recurring polypeptide sub-units. The amino acids forming these polypeptide chains produce a poly- 
L-proline triple helical structure that is unique to collagen. There are a number of different collagen 
types, varying slightly in their amino acid sequence and structure, but in articular cartilage type II 
collagen is the most important forming the fibrillar network with the minor types IX and XI each of 
which facilitate fibril interaction with proteoglycan molecules and regulate fibril size (Cremer et al., 
1998).
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Figure 1-1 Schematic drawing of a joint
Aatihulgs surfaces of the joint are haecscd by bngliec cgitllgge tbgt is devoid of pcsitboedsium. The 
capsule is formed by two pgrte■ the external fibrous lgycs and the eneoeigl lgncs (sneaeigl 
membrane tbgt lieee the gstihulgs hgeity except Oos the hgitilggieaue gscge (Juequcisg et al.. 1992).
Marrow cavity
Periosteum
Synovial membrane
Spongy bone
Compact bone
Fibrous la yer o* 
capsu lc
Articular cavity 
Articular cm lilaqe
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Figure 1-2 Molecular structure of articular cartilage
The molecular structure of healthy articular cartilage consists of chondrocytes that produce and 
subsequently embed in an extra -cellular matrix (ECM) of water, proteoglycan and collagen. The 
proteoglycan component consists of eh/nKr/itin sulphate (CS) and keratan sulphate (KS) 
molecules attached to a core protein: these in turn are bound to hyaluronic acid via link proteins. 
The negatively charged sulphate groups attract water molecules and the entire structure is 
prevented from unlimited expansion by the presence of collagen type II fibres.
Chondroitin
sulphate
Core protein
Collagen 
Type II
Keratan sulphate
Link protein
t
Hyaluronic acid
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1.2.4 Structural organisation of articular cartilage
Normal articular cartilage is orgaoised mto dsffcrcnt layers each with a disiinct structure aod 
fuoctioo. The first layer, referred to as the superficial trogeoiirl zooe, is a thm regim with high 
collageo to proteoglycao ratio that serves as the glsdiog surface for articulatioo. Collageo fibres are 
aligoed io a patal)e) fashioo to the cartilage surface while chvndtocytes are eloogated aod quiesceot. 
The adjacmt layer, koowu as the ttrnsitivna) zooe, is much thicker, occupysog 40-60% of the 
cartilage depth where most of the cushiooiog aod load dirtributivo occurs. Io this tegion the mo- 
prra))e) collageo fibres are larger, ptotevglycan levels are higher aod chondrocytes more 
meiarolicr))y active. Io the deep zoom of the cartilage, collageo fibres are io a prra)le) aligomeot 
arraoged pcrpeodicu)af to the cartilage surface with chvodrvcyies arraoged io columos. Immediately 
beoeath this there is a trrnsitivo from cartilage to surchoodral boue where the collageo fibres 
exteud soto a zooe of calcified cartilage; these fibres are thought to mchor the cartilage layer to 
booe. Withm this orgaoised structure the compositioo of the cartilage also varies with respect to the 
choodroo, the choodrvcrie aod its susToundrng pericellular matrix. For example the zooe 
immediately surrouodiog the choodrvcries, the pericellular matrix, cvoiaios a high perceotage of 
proteoglycao whereas the regioo adjaceot to this, the territorial matrix, cooirios a liomg of thio 
collageo fibrils formsog a protective barfief to the chvodrocyie (Ghivzzaoi et al., 2000).
1.2.5 Dynamic structure of the joint
The uoique mechaoical property of articular cartilage relses oot ooly oi the structural properties of 
the proteoglycao md cartilage compvoents but also oo their specific threc-dsmensional rrrangemeot 
relative to choodrocytes. This critical structural arrangemeot is mediated by ceU adhesioo receptors 
that eoarle cell/cdl aod cell/ECM ioteractioos aod iotracellular plaques (peripheral membram 
protesos). The latter provides a functsonal liokage retweeo adherivn receptors aod fslameotr of the 
cytoskeletoo. These cell adhesioo complexes are mt static eotities but are dyoamic uoits that 
capture md iotegrate ssgoals from the extra-cellular envirvnmeot, regulated by biochemical evcois 
withio cells. Thus the cell adhesion complex provides a two-way sigoallmg retweeo the cell aod its 
external enviroomeot (Aplio et al., 1998). Type VI collageo immediately surrvuodiog the cells may 
also assist io cellular-matrix ioteracttoos with other ovn-co)lageoous pfvteios such as teoascio aod 
firroncctio (Aplio et al, 1998). It is therefore clear that the joiot is a dyoamsc structure with the oeed 
for the cootiouous remodelltig of the ECM to mamtaio health. Choodrocytes are respoossble for 
producmg the enzymes oecersary for the balamed ryothesis aod degradatioo of the ECM. However, 
io OA the dyiamics of this process are uocoupled with a chaoge so this steady state situatim, 
ferulisog io the oet degfadatioo of the ECM (Bullough aod Cawstoo, 1994).
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1.2.6 Aetiolo^gy of osteoarthritis
The cause of the uncauplieg process in cartilage tissue turnover seeuetinr in net degradation is 
unccsta1n but it is thought to be r combination of genetic, bia-metbgn1hal and merabalih fahtai■e 
(Kraus, 1997) all resulting in r common final pathway of hboedrahntc injury and ECM breakdown 
(Figure 1-3). It is becoming increasingly evident that abnormalities at the genetic level play an 
important role in both the initiation and maietcnaece oO OA within an iedividuge. However, this 
may glsa be complicated by the fact. that many initiating tausee of OA such as hip dysplasia and 
elbow dnsOuncrioe are also genetically influenced. A unique set of observations in Icelandic human 
families with a very high prevalence of hip OA suggests that there is a sige1O1hgnt genetic 
contribution to OA (Iegvasseon et al, 2000). Although genetic susceptibility has not been evaluated 
in the dog it is thought that the variation in disease severity observed within a group of dogs 
suffering from the same initiating cause, strongly eurgeers genetic variation. Altered genes 
predisposing an individual to OA may not only be inherited but can also be acquired through 
mutation. Cuch mutations have been found to occur in genes encoding important structural 
components of cartilage including many of the collagen types (Kuivaeiemi et al, 1997). A single 
base mutation in the gene encoding the human collagen type II gene has been shown to be 
responsible for the development of OA in man (Knowlton et al., 1990). Furthermore, hhgnres in the 
type II coeeagee gene in transgenic mice getered the collagenous network softening the articular 
cartilage (Hyrtinen et al, 2001) and haueed degenerative changes in the asticulas cartilage similar to 
OA (Helminen et al., 1993). More commonly OA develops through bio-metbaeihae fahtore sutb as 
joint instability as r result of anatomical abnormalities (hip and elbow dysplasia and cruciate 
failure), following neuropathy or even as a direct result of repeated or severe joint trauma (Bennett 
and May, 1994; Vaughan, 1990). Metabolic eaaross also aaerribure to the pathological abaeges 
observed in primary OA (Oddis, 1996), past1hulasly associated with the metabolic activity of the 
chondrocytes (Culzbachcs, 2000) influencing the turnover of collagens and proteoglycans 
(Faesbender, 1987). Whatever the cause, a similar process of degradation supervenes, with the only 
variation being the speed and severity of the disease process.
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Figure 1-3 Aetiology of osteoarthritis
The cause of vyicvarthriiiy (OA) is thought to be a combioatioo of geoetic. bio-mechaoical aod 
metabolic factors all dcyu)tiog io a commoo fmal pathway of chvodfvcyic mjudy. cxifa-cnllulaf 
matrix (ECM) breakdowo aod booe fcmvdclling. Chvodfvcytc iojury stimulates the ioflammatvfy 
process with 'yowlal nffuyivn. vascular chaogcy aod the release of cymkim'.
Crystal
Obesity Over use depvsiiion
1.2.7 Pathological changes in osteoarthritis
The first stage of OA is usually asymptomatic as the initial destruction of cartilage is balanced by 
an effective repair response mediated by growth factors, with the proliferation of chondrocytes and 
increased synthesis of the ECM. However, the biochemical changes that follow result in the net 
degradation of the ECM, partially resulting from the m.arked yet inadequate repair response failing 
to produce the normal balance of mature cartilage components. Instead the production of abnormal 
proteoglycan molecules within a disorganised collagen network results and is less able to counteract 
the osmotic pressure of the aggrecan, so influx of water occurs with associated swelling, fibrillation 
and cracking of the cartilage tissue (Figure l-4a). This early of OA is characterised by an increased 
thickness of the articular cartilage and dise/l/ur•ati/n (Figure l-4b). Only later does the cartilage 
slowly degrade progressing to a severely fibrillated and eroded tissue (Figure l-4c), with the 
eventual disappearance of the full thickness surface of the joint (Figure l-4d) (Dijkgraaf et al., 
1995). The release of breakdown products from the degraded articular cartilage into the surrounding 
environment instigates an inflammatory process within the synovium that is characterised by 
hyperplasia and hypertrophy of the synovial lining. At the histological level there is a mononuclear 
cellular infiltrate (Figure 1-5) with the involvement of a complex network of cytokines even at an 
early stage of disease (Smith et al., 1997).
Although OA is commonly considered a disease primarily involving cartilage, studies support a 
role for considerable bone involvement within the subchondral region and articular margins. 
Whether these changes are primary or secondary to the disease process have yet to be determined 
and they are likely to vary with the stage of disease (Lajeunesse et al, 1999). It is thought that 
cytokines are intimately involved in these bony changes with synoviocytes secreting prostaglandins 
(PG) and matrix metalloproteinases (MMPs) leading to the resorption and destincdon of the 
subchondral bone in some cases (Takahashi et al., 1998). Subchondral bone sehlerosis however is 
commonly seen in OA and may be an early response to trauma in cases of OA secondary to 
repeated trauma, or a secondary response to cartilage loss in advanced OA. Osteophytes are found 
at the articular margins occurring as early as three days after initiation of the arthritic process 
(Gilbertson, 1975) (Figure 1-6). The presence of these may play a compensatory role by altering 
joint shape through a sophisticated remodelling process to allow the redistribution of forces 
providing some articular cartilage protection (Moskowitz, 1999) and altering the joint such that it 
copes better with the abnormal forces placed upon it.
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Figure 1-4 Pathological changes in the canine osteoarthritfc joint.
Pathological changes to joint tissue showing a) fibrillation, b) discoloured and thickened synovium, 
c) early cartilage erosion and d) late stage full thickness cartilage ulceration
a) Histological 
section showing 
fibrillation and 
cracking of 
articular cartilage
Magnification x400
b)
Gross specimen of
stifle joint showing _
discoloured and 
thickened synovium 
compared to the 
normal joint. Marginal 
osteophytes can also 
be seen
Normal joint
c)
Gross specimen 
of stifle joint 
showing cartilage 
erosion
Gross specimen of the 
elbow joint. 
Disappearance of the 
full thickness articular 
cartilage with 
ebumation of the 
underlying 
subchondral bone
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 Figure 1-5: A histological section of synovial tissue taken from a canine osteoarthritfc
joint tissue.
A mananualcga cell infiltrgtian provides evidence o! ennavit1e.
Figure 1-6: Development of osteophytes in canine osteoarthritis
Bony outgrowths along the edge of the traahlcgr groove of the stifle joint arc evident on post­
mortem examination (PME).
Osteophytes
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1.2.8 Diagnosis of osteoarthritis
Jvini paio is usually the first cltoical 'tgii evideot io emioe paiieois sufferiog from OA. Usually this 
appears late m the disease wheo coosiderarlc joiot destructioo md temvde)liog have already 
occurred aod is probably due to a combtoatioo of factors. It may simply be the stretchiog of oetve 
eodiogs io the periosteum over osteophytes, microfractures io the surchoodral rooe, medullary 
hyperiensivn due to blood flow distorted by thickmed trabeculae, synoviiir or joiot iortarility. 
Reduced syoovial hyalurooao aod its destructim may also result io less efficseot lurricaiivo of the 
articular surfaces resultiog io further ioflammatioo aod paio. The preseoce of paio cao also be 
explaioed at the molecular level aod has beeo associated with the preseoce of crioktoes particularly 
soterleukio-1 (IL-1) aod tumour oecrvrir factor (TNF) (Takahashi et at., 1998; Emshoff et al., 
2000). Io the loog term, chrooic paio leads to yeosiiiraiivo where the threshold of paio receptors ts 
lowered aod the nvcivceptor uoit oot oormally respoosive becomes respoosive. As a result stimulus 
oot oormally paioful become paioful (allodyoia) with ao exaggerated paio respoose to a giveo 
stimuli (hyperalgesia). Muscle paio is ofteo aoother feature of OA aod may be due to ccotfal 
seositisatioo caused by the paioful joiot (Bajaj et al., 2001) or through ioflammatory mediators 
diffusiog from the jotot to sun,ouidiog muscles with the added effect of altered muscle fuoctioo to 
cope with the patoful jotot. Radiogfaphica) chaoges are evCdeot much later io the dtseased jotot with 
areas of iocreased deostiy to the surchoodral booe, joiot space oarrowiog (difficult to evaluate to 
the caoioe patteot), osteophyte formatioo aod booe remodelliog (Figure l-7a, b, c aod d).
Sioce OA is frequeotly dtagoosed late io the disease progresstoo, oumerous studies have 
attempted to ideottfy diagoosiic markers io syoovial fluid aod blood that may assist io the early 
ideotiftcatioo of diseased todivtdua)r. This may oot ooly assess the severity of disease but may also 
be used to moottor the effect of treatmeot (Rrirvik aod Gt0odahl, 1995). Markers cao be related to 
the mechaoisms of cartilage degradatioi such as the MMP eozymes tivolved ii jotot tissue 
dertruciioo (Lohmaoder et al., 1993) aod the cytoktoes TNF, IL-6 (Veoo et ah, 1993) aod IL-1 
(Shiomet er al., 1990) that modulate ECM turnover. Compooeots of cartilage aod booe cao also be 
used as markers of OA e.g. proteoglycaos (Heiiegard et al., 1985; Aricao et al., 1994a), hyalurooao 
(Aricao et al., 1994b), cartilage matrix glycoproteio (CMGP) (Fife aod Braidt, 1989), cartilage 
oltgometric matrix proteto (COMP) (Lohmaoder et al., 1994; Saxoe aod Heioegard, 1992), cross- 
liiks markers of booe tumours such as pyridtolotoe aod deoxypyrtdiidiie (Aricao, 1995), boie 
sialoproieio (BSP) (Peterssoi et al., 1998), osteocalcio (Aricao et al., 1996) aod fibroiectii (Lust et 
al, 1987). Aotirodies to some of the collageos (Bari et al., 1989) aod fragmeots of choodrocytes 
(Paroezai aod Nemeth-Crvka., 1988) have also beeo fouid. To date it ts reasooarle to cooclude that 
there is io reliable marker of OA that cao be used for early dtagoosis aid/or dtsease mooitoriog.
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Figure 1-7 Radiographical assessment of canine osteoarthritic joints
a)
Oeteapbytee 
are visible in 
thc right hip
A femoral head and 
ncck excision has been 
camed out on the left 
hip as a pain relieving 
procedure
h)
c)
Thc original 
tibial cosr1hee 
can still bc 
sccn
OA oO thc hock joint 
secondary to 
oetcochondaaeie 
dieecagns. There is 
groee remodelling of 
thc talocrural joint.
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1.2.9 Enzyme-mediated degradation of the articular cartilage matrix
Although the pathogenesis of OA is complex, involving many different tissue types and 
biochemical pathways, it is the proteolytic enzymes involved in the destruction of the cartilage 
tissue that have been the focus of considerable research. The biochemical changes in the ECM can 
largely be attributed to the activity of proteolytic enzymes made within and secreted by a number of 
cell types within the joint. These enzymes can be divided into four main groups according to the 
chemical group responsible for hydrolysis (Figure 1-8). The aspartate and cysteine proteases (the 
cathepsins) act at a low pH within the cell while the MMPs and serine proteases function within a 
neutral extra-cellular location (Elliott and Cawston, 2001). All of these enzymes play a role in 
matrix remodelling but the MMPs produced by both the chondrocytes and synovial cells are 
particularly important and are primarily associated with the normal turnover of connective tissue 
(Matrisian, 1992) and in the pathological destruction of cartilage matrix (Martel-Pelletier, 1999b).
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 Figure 1-8 Enzyme-mediated degradation of articular cartilage matrix
The eozyme' fnypvoyiblc for the dngdadaiivo of the ECM cao be segregated accvfdiog to their 
mtra- or extra-cellular locahoi. The aspartate aod cyyinioc proteases are dcypvoyiblc for the iotra- 
cellular turnover at low pH while the MMPs aod 'enie proteases are iovolved io the extra-cellular 
turnover at a ieutral pH (Modified from Elliott aod Cawstoo. 2001 ).
Msiallopaoisinatst (MMP)
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1.2,9.1 The matrix metalloproteinases
Over twenty different MMPs have been identified and classified into different groups according to 
their substrate specificity (Table 1-3), the collagenases (MMP-1, -8, -13, 18), gelatinases (MMP-2, - 
9), stromelysins (MMP-3, 10 -11,), the membrane type-MMP (MT-MMP-14. -15, -16, -17, -24, - 
25) and others such as Matrilysin (MMP-7), macrophage elastase (MMP-12) and MMP-19 (Elliot 
and Cawston, 2001; Nagase and Woessner, 1999). Many of these MMP's are elevated to varying 
degrees in osteoarthritic joint tissues including the collagenases MMP-1. 3, 13 (Bluteau et al., 2001) 
and MMP-8 (Chubinskaya et al., 1996), the gelatinases MMP-2 and 9 (Clegg et al., 1997; Coughlan 
et al., 1995) and MMP-7 (Ohta et ah, 1998). The unique properties of the individual MMPs are 
distinguished by structural variations which provides substrate specificity (Matrisian, 1992). For 
example the carboxy-terminal domain has been reported to contribute to the specificity of the 
interstitial collagenases and stromelysins (Sanchez-Lopez et ah, 1993). The gelatinases have an 
additional fibronectin-like gelatin-binding domain which contributes to the substrate specificity 
(Strongin et ah, 1993) and the MT-MMP have been shown to be membrane associated via a 
transmembrane domain at the carboxy-terminal end of the molecule (Sato et ah, 1994).
Despite their unique properties, the MMPs all belong to the same family sharing stmctural and 
functional domains (Figure 1-9), They vary slightly between different species but generally consist 
of regions encoding for a signal sequence, a prodomain, a zinc binding domain containing the 
catalytic site; a unique proline rich hinge region and a hemopexin-like carboxy-terminal domain. 
(Cawston, 1996). The MMPs are released from cells in a proenzyme state that requires activation 
(Figure 1-10). The latency of the MMPs is thought to be maintained by a bond between the 
unpaired cysteine residue in the prodomain and the zinc atom at the active site. Upon cleavage of 
this Cys-Zn bond, most of these enzymes undergo proteolysis, which irreversibly removes the 
propeptide domain; this mechanism of action is known as the ‘cysteine switch’ mechanism 
(Springman et al., 1990). This process of activation can be stimulated in vitro by physical 
(chaotrophic agents), chemical (HOCl, mercurials) and enzymatic (trypsin, plasmin) treatments that 
separate the cysteine residue from the zinc (Woessner, 1991). Many enzymes have since been 
implicated in the activation of the various MMPs and include the serine/cysteine dependent families 
such as the plasminogen activation / plasmin system and cathepsin B, stromelysin-1, collagenase-3, 
MT-MMP and gelatinase-A together forming an interactive web of regulation (Martel-Pelletier, 
1999).
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Table 1-3 Classification of the matrix metalloproteinases
Group Name Alternative names Suberrgree
Collagengse MMP1 Interstitial callggcngec Collagens I. 11 III. VII Vlll. X. gelatin. 
gggrecgn. link protein.
MMP-8 Neutrophil callggengse Collagens I. 1. III. V. VII. Vlll. X. gelatin, 
aggrecge. fibraecctle
MMP-13 Callggcngee-3 Collagens I. II. III IV. gelatin. gggrccge
MMP-18 Xenopue collggengse
Gclgtingecs MMP-2 Gclgtiegsc A Collagens IV. V. Vll. X. XI. gelatin, 
aggrecge. link protein. clastm. flbronchtin. 
laminin
MMP-9 Gclatingse B Callggeee IV. V. VII. X. gelatin. gggrecgn. 
link protein.
Stramelyeiee MMP-3 Stsomelysin-I Collagens 111. IV. IX. X. gelatin. gggreagn. 
link protein. elgstin. ribranchtin. lgmieie, 
ghtlvgtes MMP-1. -8. -13
MMP-10 Stromelyeie-2 Collagens III. IV. V. gelatin. gggrecgn. 
link protein. Oibronectin. elget1e, ghtivgtee 
MMP-1. -7. -8. -9
MMP-1 1 Stromclyeie-3
Mcmbrane-type MMP-14 Membrane typc-1 MMP Collagens I. II. III gelatin. gggrecgn.
MMP
MMP-15 MT2- MMP
fibranect1e. activates MMP-2. -13
Gelatin. Oibsancct1n. ght1egtce MMP-2
MMP-16 MT3-MMP Activates MMP-2
MMP-17 MT4-MMP
MMP-24 MT5-MMP Activates MMP-2
MMP-25 MT6-MMP Gelatin
9^™ MMP-7 Mgtailysie Collagens IV. X. gelatin. elgetin. gggaecge. 
link protein. Oibraneht1n. laminin. activates 
MMP-1
MMP-12 Metalloelgetgse Collagen IV. gelatin. fibsonectin. laminin. 
vitronectin
MMP-19 Aggrecgn
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Figure 1-9 Domain structure of the matrix metalloproteinases
The matrix metalloproteinas (MMP) family is represented schematically to demonstrate the relative 
size and conservation of sequences between members of this group. Each member of this family has 
at least four domains: i) the signal peptide sequence, ii) the propeptide domain that is lost during 
enzyme activation; iii) the catalytic domain that contains the conserved sequence 
VAAHEXGHXXGXXH in which the three histidine residues coordinate the active zinc site: iv) the 
carboxy-terminal domain that has homology to hemopexin and vitronectin, and contains a 
transmembrane domain in MT-MMP.
NH2
terminal
fransmembrane
domain COOH 
terminal
Eurin cleavage site: 
RXXR
Hinge
region
HEMOPEXINSIGNAL PRODOMAl CATALYTIC
Gelatin binding
Activation locus: Metal atom-binding domain:
PRCGXPD VAAHEXGHXXGXXH
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Figure 1-10 Synthesis and activation of the matrix metalioproteinases
The cysteine switch mechanism tor activation of the matrix metalioproteinases has been proposed 
(Springman et al.. 1990). Cysteine in the pro-enzyme domain contacts the zinc molecule to 
maintain latency of the enzyme. Physical agents such a sodium dodecyl sulfate (SDS) or chaotropic 
agents can unfold the structure to expose zinc. Reagents that react with sulfhydryl groups such as 
hypochlorous acid (HOCl) and organomercurials (aminophenylmercuric acetate. APMA) will 
inactivate the cysteine. Alternatively, proteolytic enzymes can initially cleave the pro-peptide, 
followed by autolytic cleavage by the activated MMP to remove the pro-peptide and confer 
permanent activity.
Cell surface Cytokine
Latent zymogen
Active
intermediate
Active enzyme
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1.2.9.2 Aggrecanoses
One of the centra! features of OA is the catabolism of the proteoglycan aggrecan component of 
cartilage tissue demonstrated by the increased loss of aggrecan metabolites from the cartilage 
matrix into the synovial fluid. Initial studies discovered two major sites of aggrecan proteolysis at 
the peptide bonds Asn341-Phe342 (DIPEN341-FFGVG) (Flannery et al., 1992) and Glu373-Ala374 
(Sandy et al., 1992) located within the highly conserved interglobular domain (IGD). Cleavage of 
the Asn^-Pha^ bond can be achieved in vitro by the action of MMPs while proteolysis of the 
G^aa-Aha™ and other specific Glu-Xaa peptide bonds has been associated with aggrecanse activity 
(Figure 1-11) (Caterson et al., 2000). The use of neoepitope antibodies specific for the newly 
generated N-terminal or C-terminal aggrecan sequences, cleaved by the MMP or aggrecanase, led 
to the purification and cloning of aggrecanase-1 and aggrecanase-2, two members of the ‘A 
Disintegrin And Metalloproteinase with Thrombospondin motifs’ (ADAMT) family (Abbaszade et 
al., 1999; Tortorella et al., 1999). Aggrecan fragments resulting from the in situ cleavage at the 
MMP-susceptible Asa^ APha"'1" bond and aggrecanase-susceptible dnaa-Akaa7'' bond have been 
detected in osteoarthritic articular cartilage (Lark et al., 1997). Furthermore studies have provided 
clear evidence that aggrecanase(s) are responsible for primary cleavage of the aggrecan IGD during 
cartilage degradation (Little et al., 1999).
21
 Figure 1-11 Schematic representation of the domain organisation and structure of
cartilage aggrecan
The agat1lggc gggaeagn bge been divided into domains represented by thc globular (G) 1.2.3 
domains. 1nteagIabulgr domain (IGD) kerr'an sulphate (KS) and abandaa1t1n sulphate (CS)-2 
regions. The alegegge e1tee Oor the matrix metgllaprate1ngeee (MMP) and gggreagngee enzymes 
have been identified on the gggreagn etauature located in the IGD and CS-2 regions.
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1.2.10 Regulation of the matrix metalloproteinase activity through the 
tissue inhibitors of metalloproteinase
Natural control mechanisms exist that regulate the process of MMP activation through the action of 
the tissue inhibitors of metalloproteinase (TIMPs) (Gomez et ah, 1997). These inhibitors are 
responsible for maintaining the balanced physiological turnover of the ECM, through non-covalent 
binding of the active form of MMP in a 1:1 ratio. An imbalance of MMP over the inhibitor has been 
shown to contribute to cartilage degradation in OA (Woessner and Gunja-Smith., 1991; Martel- 
Pelletier et al., 1994). The N-terminal domain of the TIMP is inhibitory and the C-terminal domain 
confers binding specificity (Yu et ah, 1996). So far four TIMPs have been identified, designated 
TlMP-1 (Murphy et al., 1977), TIMP-2 (Stetler-Stevenson et al., 1989), TlMP-3 (Silbiger et al.,
1994) and TIMP-1 (Greene et al., 1996) each with umque biological properttes (Ta)be L4). 
Although the TIMPs can all function in MMP inhibition, differences are observed in their tissue 
distribution and transcriptional control. The TIMPs also have specific abilities to bind pro-MMPs 
with TIM P-1 and TIMP-3 able to bind pro-MMP-9 whereas TlMP-2, -3 and -4 can all form 
complexes with pro-MMP-2 (Elliott and Cawston, 2001; Brew et al., 2000). The TIMPs in turn are 
regulated by a series of cytokines and growth factors including transforming growth factor (3 
(TOPP), epidermal growth factor (EGF), platelet derived growth factor (PDGF), basic fibroblastic 
growth factor (bFGF), interleukin-1 (IL-1) and prostaglandin E? (PGEi) (Borden and Heller, 1997). 
This strict regulation is essential since excessive production of TIMPs may have a detrimental effect 
on tissue degradation (Apparailly, 2001). A detailed discussion of TIMP-1 and TIMP-2 can be 
found in chapter III.
Table 1-4 Tissue inhibitors of metalloproteinase
Name MMP inhibition Mature
protein
size
(kDa)
Glycosylated Gene
regulation
Tissue specific
expression
Pro­
enzyme
binding
TIMP-1 All MMPs 20.2 yes inducible Bone and ovaries MMP-9
TIMP-2 All MMPs 21.7 no constitutive Lung, ovaries, 
brain, testes, heart 
and placenta
MMP-2
TIMP-3 All MMPs 21.7 yes inducible Kidney, brain, 
lung, heart, and 
ovary
MMP-2
MMP-9
TIMP-4 MMP-1, 2, 3,7, 9 22.6 no Kidney, placenta, 
colon, testes, 
brain, heart, ovary 
and skeletal 
muscle
MMP-2
23
 1.2.11 Regulation of the matrix metalioproteinases through cell signalling 
molecules
Although it is well established that multiple enzymes are responsible for the degradation of articular 
cartilage their gradual dys-regulation has yet to be fully defined. It is currently believed that 
articular cartilage integrity is maintained by the balance between a complex network of cytokine 
driven anabolic and catabolic processes with a disruption in this signalling network responsible for 
the pathological changes in OA. Signalling molecules are chemical, cellular messengers that are 
produced by all cells and referred to as cytokines and growth factors. Cytokines are released by 
cells in response to specific signals and influence the function of target cells by exerting a positive 
or negative effect on gene expression (Arend and Dayer, 1993). Many different signalling pathways 
are activated by cytokines each leading to the formation of multi-protein complexes and eventually 
to the binding of transcription factors to regulatory elements of DNA such as Activator protein-1 
(AP-1) and Nuclear Factor-KB (NF-kB) sites within promoters (Adcock, 1997). The details of 
specific signalling pathways associated with OA are detailed in chapter V.
In general terms cytokines within the joint are primarily involved in the processes of synovial 
inflammation and cartilage degeneration where they are secreted from synovial cells following 
phagocytosis of degraded ECM (Ruggeri, 1996). The release of these cytokines stimulates synovial 
proliferation and activates the release of MMPs leading to the destruction of the ECM (Kacena et 
al., 2001). This continuous production of degraded ECM, its up-take by synovial cells and the 
subsequent production of cytokines forms a positive feedback mechanism, which leads to increased 
levels of joint destruction. Many different signalling molecules are implicated in the disease process 
but the pro-inflammatory cytokines lL-1 and TNF are particularly important (Martel-Pelletier, 
1999a). However, these two cytokines form just a small part of a much more complex cell­
signalling network that involves molecules such as interferon y (IFNy), TGF3, leukaemia inhibitory 
factor (LIF), interlenkin-1 receptor antagonist (IL-lRa), leukotrienes, oxygen free radicals, PG and 
various other interleukins each with unique functions in enzyme regulation, acting independently 
and within the complex network. It is now clear that a cascade of cytokine activation occurs in OA 
with the potential for a functional hierarchy existing between them (Figure 1-12).
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Figure 1-12: A simplified overview of the regulation of cartilage turnover.
A complex network of pro-inflammatory mediators enables specific interactions between cartilage, 
bone and synovium and results in the synthesis of active enzymes responsible for degradation of 
the extra-cellular matrix (ECM). This in turn is controlled through a series of anti-inflammatory 
and anabolic mediators.
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1.2.11.1 Pro—nflarmnatory mediators
Both IL-1 and TNF have been intimately associated with the path/l/gieal changes in OA. Although 
these eyt/lKnes have overlapping and synergistic actions they have independent roles in cartilage 
destruction, with IL-1 thought to be responsible for cartilage degradation while TNF is thought to 
drive the inflammatory process (van den Berg et al, 1999a). However, it is evident that their roles 
are not exclusive but instead they have multiple functions dependent on the absolute levels and the 
presence of other ambient molecules. Previous studies suggested the importance of lL-1 as a 
mediator of joint damage in OA with high levels of lL-lo/3 secreting macrophages detected in 
synovial tissue removed from osteoarthritie joints (Westacott et al., 1992) and increased expression 
of the lL-1 type I receptor identified on OA chondrocytes (Martel-Pelletier et ah, 1992). It is now 
known that IL-1 is responsible for cartilage metabolism with its ability to suppress the synthesis of 
type II collagen while promoting the formation of type I collagen. IL-1 can also induce the 
production of enzymes involved in matrix degradation and suppress the ability of chondrocytes to 
synthesise new proteoglycan molecules (Pelletier et al., 1991). TNFa is also responsible for the 
degradation of articular cartilage albeit with a potency of approximately 10 fold lower than that of 
IL-1 (Campbell et ah, 1990). The involvement of TNF in OA was implicated following the 
identification of TNFa production in synovial explants (Brennan et ah, 1992) and synovial fluid 
samples (Hrycaj et ah, 1995; Hopkins and Meager, 1988) from osteoarthritie joints. The density of 
TNFa receptors is also significantly higher in chondrocytes isolated from OA lesions as compared 
to chondrocytes from non-affected areas (Westae/tt et ah, 1994). Synthesis of both IL-1 and TNF 
are up-regulated by a variety of cytokines including IL-17 which stimulates their production in 
macrophages (J/van/vic et ah, 1998a).
Recent studies have revealed that these two principal pro-inflammatory cytokines IL-1 { and 
TNFa may also be involved in the pathways responsible for the activation of osteoclast driven bone 
resorption (Lacey et al, 1998). They are thought to have an indirect effect through members of the 
TNF receptor-ligand super-family now known as the receptor activator of NK-kB ligand (RANKL) 
or osteoprotegerin ligand (OPGL). This ligand binds to the membrane-bound signalling receptor 
referred to as RANK leading to the resorption of bone (Suda et ah, 1999; Li et ah, 2000). Control of 
osteoclast resorption occurs through osteoprotegerin (OPG), an endogenous soluble antagonist of 
RANK ligand (Simonet et al, 1997). Although bone resorption is rare in OA, it is a feature of so- 
called erosive OA and the RANK ligand may be implicated in these cases.
Many different interleukins have been identified as important mediators of articular cartilage 
destruction. IL-6 is a multifunctional cytokine that has been identified in the canine osteoarthritic 
joint (Venn et al., 1993). Both IL-ip and TNFa can induce the production of IL-6 and its presence 
is required for IL-1-inKuceK inhibition of proteoglycan synthesis in human articular cartilage 
(Nietfeld et ah, 1990) suggesting its pro-inflammatory role in OA. However, IL-6 also induces the 
production of TIMPs rather than the MMPs and therefore had a dual function playing a part in the 
feedback mechanism and limiting enzyme damage (Lotz and Guerne, 1991). LIF has also been 
detected in synovial fluids from patients with OA and is secreted in the presence of IL-13 and 
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TNEEr from cultured synoviocytes (Hamilton et al.. 1993) and hboedrohytes (Campbell et al.. 1993). 
In the process of OA. LIE degrades human articular cartilage (Henrotie et al.. 1994) and stimulates 
the loss of proteoglycans (CissoII and Bell. 1993) whilst syecsg1sing with interleukIn-S (lL-8) to 
potentiate the TNEfz-PGE^ effects on synovial fibroblasts (Alraedine et rl.. 1999a; Martel-Pelletier 
1999r). However. LIE also has rn anri-ieflgmmarosy function simiegs to IL-6 and thereOare has a 
dual role in the progression of OA (Westatatt and Sbarif, 1996). Onhastgt1e M (OSM). a member oO 
the cytokine family that includes LIE. granulocyte holoen-stimuear1eg factor (GCSE) and IL-6 
(Rose and Bsuce. 1991). is another cytokine associated with thc pathogenesis oO gstbriris. OSM 
combines with IL-1 to promote release of collagen fragments from bovine eaegl cartilage in culture 
(Cawst^ et al.. 1995) and increases the production of MMP-1 in human choedrohytce and synovial 
fibrobegets (Cawst^ et al.. 1998).
Cbemak1ees which are regulated by IL-1 and TNE function to secruit leukocytes to sites oO 
inflammation and have also been implicated in the protcse oO cartilage degradation in OA 
(Pulsatelli et al.. 1999. Yuan et rl.. 2001. Alraeddine et al.. 2001). Chemokine subfamilies are 
dietieguiehed according to the arrangement of the Oisst two cysteines. which are separated by one 
amino acid (CXC) or are adjacent (CC). The CXC hhemokiees include IL-8 (CXCL8). and platelet 
Oactor 4 (CXCL4) and the CC cbcmokinee include RANTES. macrophage inflammatory protein-Lx 
(MIP-la. CCL3). MIP-lp (CCL4) and thc monocyte chemoattractant proteins (MCPs). Several of 
these hbemokines including IL-8. MCP-I. MIP-la and MIP--1 (3 are over produced in arthritic joints 
(Taub and Oppenheim. 1993).
Reactive oxygen species (ROS) ase yet another group of molecules thought to be involved in the 
degenerative changes associated with OA. ROS whiab include superoxide. hydrogen peroxide. the 
hydroxyl radical and nitric oxide (NO) are produced by chondrocytes. neutrophils and fibroblasts 
(Moulton. 1996). ROS affect the preservation oO thc cartilage matrix by mediating cytokinc and 
growth Oactor stimulated mtralteeluear signalling and concurrent gene activation (Lo and Cruz.
1995). Considerable research hrs focused on the Involvement of NO in thc pathogenesis of OA. NO 
is an inorganic. gaseous free radical synthesised from arginine in a reaction catalysed by NO 
synthase (NOS) from a variety of different heee types. Tbie enzyme exists as isozymes. an inducible 
(iNOS) and hanstitutiec (cNOS) form. The inducible form is up-rcgulated by IL-lp chondsocytes 
(Stadler et al.. 1991) acting to suppress the synthesis oO aggrocm (Taskiran et rl.. 1994) and type II 
collagen (Cao et al.. 1997). NO has now been implicated as an impartaer mediator of intra-artiaulgr 
pathophysiology (Evans et al.. 1995) with increased concentsrtioes oO nitrites. the stable breakdown 
products of NO observed within thc synovial fluid of osteoarthritic jaiere (Srcfaeov1a-Raaic et al.. 
1994; Errrell et al.. 1992). Eurthcrmorc. cxplants of human cartilage released large amounts of 
eitaire when stimulated with IL-Ip and TNEa (Murrell et al.. 1996). The effeate oO NO in OA arc 
likely to bc exested within cartilage. where NO promotes a number of catabolic effects on 
ahondrocntes leading to ECM loss. These effects include i) inhibition of matrix synthesis 
(Stefanovih-Rac1c et al.. 1995). ii) modulation of MMPs (MuiTell et al.. 1995). iii) iehreaeed 
susheptibleltn to other oxidants (Clancy et al., 1997) and iv) induction oO apoptosis (Blanco et al.,
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1995) . It has been reported that inhibitors of inducible NO synthase (iNOS) have therapeutic effects 
on the progression of lesions in the experimental OA dog model (Pelletier et ah, 1998).
1.2.11.2 .Ati-inflamma tors media tors
Activities of pro-inflammatory mediators are strictly regulated by a series of anti-inflammatory 
molecules. For example, the effects of IL-la/p are controlled by the endogenous interleukin-1 
receptor antagonist (IL-lRa) functioning as a competitive inhibitor to the type 1 receptor (Arend, 
1993) and shown to have chondroprotective effects in experimental OA (Caron et al., 1996). 
Soluble receptors that inhibit the binding of IL-ip have also been identified (Symons et al., 1991) 
and it has been suggested that IL-lRll, which binds 1L-13 with high avidity, may function as an 
inhibitory decoy receptor (Colotta et al., 1994, Attur et al., 2000). In a similar manner, the effects of 
TNF can be e/ntrolled by the soluble receptors that bind and inactivate TNF (Mageed et al., 1998).
Modulators of cytokine activity also exist; these include lL-4, IL-13 and IL-10 which reverse the 
TNF induced release of PGE2by OA synovial fibroblasts (AlaaeKKine, Di Battista, Pelletier, Kiansa, 
Cloutier, and Martel-Pelletier, 1999). Additional functions include the blocking of collagen release 
from IL-l/OSM stimulated cartilage tissue by lL-4 (Cawston et ah, 1996) and IL-13 (Cleaver et al., 
2001). IL-13 can also reduce the production of pro-inflammatory cytokines and MMPs, favouring 
the production of IL-lra (Jovanovie et al, 1998b). Furthermore, lL-10 inhibits production of TNFa 
and IL-1 stimulated progression of established eollagen-lnKueeK arthritis (Walmsley et al., 1996).
Numerous growth factors are also associated with the anabolic processes of cartilage matrix 
turnover. For example insulin-like growth faetor-1 (lGF-1) is a potent mediator of cartilage 
proteoglycan synthesis even in the presence of pro-inflammatory cytokines (Tyler, 1989) and serum 
levels of IGF-1 are found to be low in OA (Denko et al., 1990). However, IGF-1 is important in 
both cartilage and bone turnover with the development of abnormal subchondral bone sclerosis 
(Martel-Pelletier et al., 1998) and osteophyte formation (Schouten et al., 1993). TGF3 is also a 
powerful mitogen for inducing cartilage and bone turnover while reducing inflammation and 
stimulating matrix synthesis (Wahl et al., 1989). TGFp inhibits matrix degradation by stimulating 
protease inhibitor production, and blocking MMP release (Roberts and Sporn, 1990) and also 
promotes cartilage repair by stimulating production of collagen, fibronectin and inhibitors of 
plasminogen activators in the joint (Morales et al., 1988). TGFp up-regulates the levels of TIMP 
within the joint, specifically by transcriptionally up-regulating the levels of TIMP-3 (Su et al.,
1996) . TGF3 also suppresses cartilage degradation, stimulates production of proteoglycans in the 
repair of articular cartilage (Glansbeek et al., 1998) and is thought to be involved in the negative 
feedback regulation of TNF induced collagenase activity (Shlopov et al., 2000). However, TOF3 
has a dual role in OA since it can also induce IL-ip production (Wahl et al., 1993a) and excessive 
levels have been shown to induce OA after multiple intra-articular injections into murine joints (van 
Beuningen et al., 2000). All of these growth factors function together in a complex network, for 
example the insulin-like growth factor (IGF-1) and bone morphogenetic protein-2 (BMP-2)
stimulate proteoglycan synthesis while transforming growth factor (TGFpl) stimulates synthesis of 
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collagen (Smith et al., 2000) and fibroblast growth factor-2 (FGF-2) is important in the regeneration 
of articular cartilage (Otsuku et ah, 1997).
OA is clearly a very complex pathological event. The initial inflammatory response stimulates a 
cascade of cytokine activation that enhances the produetion of proteolytic enzymes within the joint. 
Understanding the strict regulation of the biochemical pathways involved requires further research 
at the molecular level and holds the key to the development of new structure-modifying therapies.
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1.3 THERAPIES FOR CANINE OSTEOARTHRITIS
The mainstay of treatment for OA in all species is drug based; however a variety of surgical 
treatments have been attempted in human and canine patients and include debridement, excision 
orthoplasts, lavage and mechanical penetration into the subchondral bone to promote cartilage 
resurfacing. Operative treatments to restore some of the funetional capacity of affected joints by 
soft tissue releases and osteotomies are currently in use and even transplants using osteochondral, 
periosteal and perichondrial tissues are under development (Ghivizzani et al., 2000). Joint 
replacement surgery is frequently used in man to provide a pain free articulation, total hip 
replacement is now regularly performed in the dog, usually for the treatment of end-stage disease 
(Bennett and May, 1994).
1.3.1 Symptom modifying therapies
The main treatment for OA in canine patients relies on a combination of medical and physical 
modalities. In general the medical compounds available are limited to ‘symptom-modifying’ 
therapies that suppress one or more of the cardinal signs of inflammation with the principal value of 
pain relief. As such, the standard treatment for the canine patient includes anti-inflammatory drugs 
(Johnston and Budsberg, 1997) in combination with weight control and physiotherapy.
The non-steroidal anti-inflammatory drugs (NSAIDs) are indicated for use in a variety of painful 
musculoskeletal conditions, including OA. Almost all NSAIDs are weak carboxylic or enolic acids 
possessing analgesic, antipyretic, peripheral anti-inflammatory and anti-thrombotie qualities acting 
primarily through the inhibition of cyclooxygenase (COX). The COXs catalyse the first two steps in 
the synthesis of PG from arachidonic acid in a pathway that is clearly implicated in the pathogenesis 
of OA. A series of cartilage-explant studies demonstrated osteoarthritic cartilage released fifty times 
more PGs than normal cartilage which coincided with the up-regulation of chondrocyte COX-2 
mRNA and protein (Amin et al., 1997). Furthermore, pro-inflammatory cytokines such as IL-1 have 
since been shown to be responsible for this increased production of PG in both chondrocytes and 
synovial cells (Knott et al., 1994).
There are at least two distinct isoforms of cyclooxygenase, COX-1 and COX-2. COX-1 is 
constitutively expressed in many tissues, where it plays a role in a range of physiological processes; 
COX-2 however, is an inducible fonn that is generally up-regulated in response to the inflammatory 
processes observed during disease progression. Although the NSAIDs are extremely efficacious 
drugs in the treatment of arthritis some of the original compounds developed were shown to have 
considerable side-effects within the joint causing further damage to the osteoarthritic cartilage 
(Huskisson et al., 1995) and to increase the risk of peptic ulcer disease and renal insufficiency. As 
such considerable research has been directed at developing selective COX-2 inhibitors that have 
anti-inflammatory properties without the adverse side-effects (Golden et al., 1999). The potency 
ratio for inhibition of COX-1: COX-2 can be determined and varies widely between the different 
NSAIDs, being high for Aspirin, Flunixin, Phenylbutazone and Piroxicam where the side-effects 
may be considerable and lower for Naproxen, Carprofen, Meloxicam and Nabumetone. However,
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this depends on the in vitro and in vivo experimental systems used to determine these values. 
Although these new COX-2 inhibitors are reposted to possese fewer e1de-eOfecte than thc non- 
sclective agents is it now believed that COX-2 is important in the sesaeut1ae of chraeih 
inflammation. wound healing and angiogenesis. The selective COX-2 inhibitors therefore have the 
capability oO reducing the resoeutiae of chronic 1eflammgrioe and fos example delaying the healing 
of fractures (Simon et al.. 2002). The NSAIDs can also seduce blood clotting. leading to excessive 
bleeding into the joint after injury. There is now inaseasieg concern that blood within the joint can 
1nasegse the risk oO OA with early studies showing that blood elements. such as iron. are toxic to 
chondrocytes and hge induce apoptosis in rabbits (Madhok et al.. 1988). Certain NSAIDs have been 
shown to inhibit cytokines such as lL-1 and as such taued theaserically have a structure modifying 
effect in addition to their symptom modifying effects (Herman et al.. 1991).
Castihosteso1de have also been used in the treatment oO canine OA. Prednisolone. 
mctbylpredeieoeaee and dcxamcthasone asc compounds that asc typically used and administered 
using standard protocols. Preparations are also available that contain combinations of NSAIDs. 
taaticastei•oids. opioid analgesics and non-opioid analgesics. The drugs included in each 
preparation may be additive in theis toxic as well as therapeutic effects and therefore case must be 
taken when dispensing. A typical combination therapy used in the dog is Psedeeuhotroph1n (PLT) 
which is a combination of Cincbapben and Prednisolone.
The rrearmcer regimen for canine OA not only selies on thc use of the gnril1nflgmmatory drugs 
but also on weight hontral to reduce the effects of weight-bearing on aampromised joints. It has 
been demonstrated that a decrease in body fat is an important parameter for symptomatic pain relief 
in knee OA (Toda et al.. 1998). Periods oO regular controlled exercise is also indicated Oor 
osteogsthritic joints since daily moderate exercise augments glycosaminoglycan psaductiae and 
tb1akeess of articular cartilage in the canine joint (Kieirantr et al.. 1988).
1.3.2 Structure-modifying therapies
With an increasing awareness oO the pgthaeogicge processes occurring in the disease process it is 
now possible to develop ‘structure-modifying’ therapies. The drugs included in this category may 
be defined as agents that reverse. retard or stabilise the underlying pathology of OA. thereby 
providing symptomatic relief in the long-term by altering the progression of the disease. Many 
different compounds are thought to affect the turnover oO thc ECM components oO the cartilage 
matsix. however their biological properties have not been fully determined and theis long-tcsm 
effects have yet to be established. Nevertheless almost all of these drugs do have ‘symptom- 
modiOying’ effects and also have the potential to be ‘srsucturc-madifying’. Much evidence of a 
ersuhture-modifying effect is based on in vitro tissue culture studies and these effects can not be 
directly translated to the whole animal.
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1.3.2.1 Matrix supplements
1..3.2.1.1 Pentosan polysulphates
Sodium pentosan polysulphate (NaPPS), more commonly known as Cartrophen, is a semi-synthetic 
polymer with a molecular weight of 2000. This relatively new e/mpounK, available on the 
veterinary market, is delivered subcutaneously once a week over a period of one month. This 
compound and calcium pentosan polysulphate (CaPPS), an orally bio-available preparation (Innes 
et al., 2000), exhibit a wide range of pharmacological activities that are relevant to the metabolic 
pathways implicated in the pathobiology of OA. Polysulphated glyeosaminoglycans (Adequan) is 
another simpler preparation which is used in the horse and dog, however there is no lisceiide for its 
use in the dog in the UK. The major effects of these drugs are i) preservation of cartilage integrity 
by supporting chondrocyte anabolic activities, including biosynthesis of aggrecan and 
K/wnregulating proteases responsible for matrix catabolism, ii) reducing synovial inflammation, 
iii) normalising the ability to produce hyaluronan, iv) improving intra-articular blood flow and v) 
increasing the threshold for platelet activation (Ghosh, 1999). Although alleviation of clinical signs 
is quite evident, the effect only appears to be transient and the long-term effects of these drugs 
require further investigation.
1.3.2.1.2 Glileosanrlne, ehonKrotin sulphate nod eolkijgen preparations
Glucosamine hydrochloride is a supplement that facilitates the manufacture of hyaluronan (HA), 
collagen and PGs necessary for the restoration of the healthy articular cartilage and synovial fluid. 
When administered orally to the dog, a large percentage of the unionised compound passes into the 
systemic circulation within one hour (Setnikar et al., 1991). Since glucosamine hydrochloride is not 
plasma protein bound, free glucosamine is widely distributed with active up-take into the liver, 
kidneys and cartilage tissues, and in the latter it can be found 48 hours after administration 
(Setnikar et al., 1986). Recently, it has been demonstrated that orally ingested glucosamine can be 
incorporated into chondroitin sulphate of canine cartilage (Dodge et al., 2001). A well controlled 
clinical trial in man has shown that glucosamine has a structure-modifying effect in knee OA 
(Reginster et al., 2001). Glucosamine also inhibits IL-1 induced catabolism of aggrecan (Sandy et 
al., 1998), inhibits the release of leucocyte elastase (Kamel et al., 1991), and prevents the 1L-13 
mediated activation of human chondrocytes (Shikhman et al., 2001).
Chondroitin sulphate, an oral supplement extracted from shark, whale or beef cartilage, is used to 
reduce the indices of inflammation in OA synovial fluid, including reduction in collagenase 
activity, phospholipase A2 and n-aeetyl-glucosamlniKase, as well as increasing the HA 
e/neentrati/n and synovial fluid viscosity (Ronca et al., 1998). Chondroitin sulphate is found in 
synovial fluid and cartilage within 24 hours of oral administration (Conte et al., 1995).
The term nutraeeutical is often used to describe these oral supplements which are supplied 
individually or in combination; collagen preparations are often included as well. Additional 
nutraeeuticals include minerals and vitamins such as zinc, vitamin C and the essential fatty acids.
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Zinc is a trace element involved in the enzymatic processes throughout the body, particularly 
implicated in growth plate function (Litchfield et ah. 1998) and in the assembly of cartilage matrix 
proteins (Rosenberg et al., 1998). Vitamin C is a scavenger of ROS which are released by 
inflammatory cells and degrade the glucuronic acid component of hyaluronic acid (Jahn et ah, 
1999) and cartilage proteoglycan aggregates. Vitamin C is destroyed in preference to the 
components of the synovial fluid, thereby maintaining the visco-elasticity of the fluid. Essential 
fatty acids, including omega-3 (/z-3) found in fish oils, have been shown to modulate the expression 
and aetivity of degradative and inflammatory factors that cause cartilage destruction during arthritis 
(Curtis et al., 2000). Furthermore, this omega-3 has been used to reduee inflammation in 
rheumatoid arthritis (RA) in human patients and lowered their requirements for NSAIDs (Belch et 
al., 1988). Diets are now available containing omega-3 for dogs but no studies have been 
performed to determine their clinical value.
Despite the widespread use of nutraceuticals in both human and veterinary medicine their 
application still remains controversial. The databases show a plethora of contradictory results taken 
from different clinical trials carried out world-wide and strictly controlled clinical trials need to be 
performed before their use can be fully justified.
1.3.2.1.3 Hyaluronan
Hyaluronan (HA) is widely distributed and an important component of the joint tissues where it 
plays an essential role in the formation of proteoglycan aggregates. Hyaluronidases are enzymes 
that degrade HA through the random cleavage of the P-N-acetyl-hexosamine-(l-4) glycosideic 
bonds. The low levels of HA associated with OA can be replaced by exogenous hyaluronan 
(sodium hyaluronate) which acts as a lubricant immediately post-injection and later functioning to 
reduce further destruction of cartilage and promote its repair (Niethard, 1999). HA also relieves 
pain and may provide damage-blocking effects associated with the ability of HA to block the 
penetration of fibronectin peptides mediating cartilage chondrolysis rather than by distinct effects 
on cartilage tissue itself (Menzel and Farr, 1998). HA is usually administered via an intra-articular 
injection where the joint compartment allows the introduced drugs to directly interact with its 
constituents. Chondroprotective drugs, such as hyaluronan, have been reported to favourably 
influence OA when administered intra-articulai'iy (Graf et al., 1993).
1.3.2.2 rAtt matrix metalloproteinase drugs
The antibiotic tetracycline and related compounds were the first major group of compounds 
identified to inhibit the MMPs. More specifically, doxycycline can reduce the severity of articular 
cartilage breakdown with structure modifying effects associated with reduction in the levels of 
MMPs in diseased articular cartilage extracts (Brandt, 1995). Initial attempts to develop synthetic 
MMP inhibitors used a zinc binding group attached to modified peptides that could bind to sub­
sites around the catalytic zinc component of the MMP (Beckett et al., 1995). Since then, alternative 
inhibitors have been developed containing carboxylic acid, thiol and phosphorous ligands that co­
33
ordinate with the zinc atom in the active site to block the action of the MMP on its substrate. More 
recently, the determination of crystal structures for the MMPs has enabled the design of selective 
inhibitors with good oral bioavailability (Bottomley et al., 1998). Although these drugs are 
currently in clinical trials they are not in general use.
1.3.2.3 Inhibition of intra-cellular signalling mechanisms
A number of inhibitors are proposed to function via inhibition of intra-cellular signalling 
mechanisms. Esculetin (EST) is a coumarin derivative which was found to protect rabbit articular 
cartilage from proteoglycan loss in response to lL-1 (Watanbe et al., 1999) and inhibit cartilage 
resorption induced by IL-l/OSM (Elliott et al., 2001). Tenidap which belongs to the oxindole class 
has a dual action inhibiting cyclooxygenases and blocking the zymosan-induced expression of IL- 
1, TNF, IL-6 and lipopolysaeeharlde (EPS) in synovial membranes (Ounissi-Benkalha et al., 1996). 
Tendiap can also reduce the level of IL-1 receptors and collagenase expression in human arthritic 
synovial fibroblasts (Martel-Pelletier et al., 1996). Furthermore, in vivo administration of tenidap to 
experimental dogs markedly reduced progression of cartilage lesions, osteophyte formation and 
synovial inflammation (Fernandes et al., 1995) in addition to decreasing collagenase, stromelysin 
and gelatinase activity (Fernandes et al., 1997).
1.3.2.4 Recombinant protein technology and Immunotherapy
The development of ‘structure-modifying’ therapeutics in the treatment of arthritis has evolved 
with advances in molecular biology and recombinant protein technology. Over the past ten years 
research has identified certain species of RNA and proteins with promising eh/nKroprotective and 
anti-inflammatory properties offering the prospect of disease modification for arthritis (Kang et al., 
1997a). Recently the US Food and Dmg Administration and regulatory bodies in the UK have 
approved a number of stmcture-modifying anti-rheumatic agents including infliximab, anakinra 
and etanercept (Fleischmann et al., 2002). Infliximab is a chimeric anti-tumour necrosis factord 
monoel/naI antibody used in combination with methotrexate for the treatment of RA. This 
monoclonal antibody reduces the inflammatory response and decreases MMP levels leading to a 
decreased joint Kestmetion in patients with RA (Brennan et al., 1997). Anakinra (Kineret), a 
recombinant form of human IL-lRa (Amgen) is used for the treatment of the signs and symptoms 
of RA either as a monotherapy or in combination with methotrexate. Significant improvement in 
both clinical signs and radiographleal changes have been observed (Garces, 2001). Etanercept 
(Amgen) is a low affinity p75 soluble TNF receptor shown to down regulate MMP-1 and MMP-3 
in RA (Catrina et al., 2002).
However, effective in vivo delivery of therapeutic RNA molecules and proteins is one of the 
major limitations of this therapy. Whether the therapeutic molecule is administered orally or 
parentally (subcutaneous, intraperitoneal, intramuscular or intravenous injection) its delivery to the 
joints relies upon the vascular perfusion of the synovium (Evans and Robbins, 1994). Since 
cartilage is avascular, drug delivery to this tissue relies on the inefficient passive diffusion from the
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synovial tgpillgr1es into the joint cavity. The rapid hleasgnhe oO psateiee from the joint space due to 
theis short intra-articular halO-eieee. means that even the use of direct iersg-astiaular 1njeht1oee. the 
most promising form of delivery. has limited application. These limitations require the repeated 
administration of large protein toehentratians in order to achieve stable therapeutic levels within 
joints. This results in the exposure of nae-trrget tissues and undesirable eide-effette. especially iO 
systemic delivery is employed. In addition. most proteins of ietcseet ase excluded fos serious 
coeeideratioe due to their large nan-diffusibIe properties (Evans and Robbins. 1994). There is rlso 
the potential for an immune sespaese even to hbimerih and humanised monahlonal antibodies.
Most of these problems can now be circumvented by the delivery of genes encoding therapeutic 
RNA os protein molecules. the basis oO gene therapy. By taking one step back along the molecular 
pathway the DNA encoding therapeutic molecules can be delivered to cells of diseased joints with 
many rdvgetagee (Kang et a.. 1997a). E1setly. delivery of DNA into cells is not sestrihted by the 
size and diOOusiblIlity of the molecule and therefore allows a broader range of potentially useful 
protein-based drugs to be investigated. Secondly. the need for repeated administration can be 
circumvented if the therapeutic gene is integsated into the genome os placed within a stable 
episamal vector. Thirdly. the ability to regulate gene expression in a tissue specific manner should 
seduce exposure oO non-target organs and limit side-effeare. However. the application of rhie 
powerful molecular technique must be thoroughly underetoad before being used in any celeicge 
trials.
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 1.4 GENE THERAPY
Gene therapy is defined as the delivery of genes into the cells of an individual for therapeutic 
purposes and is one of the newest areas of molecular medicine. It was initially proposed in the late 
1960’s as a means of compensating for heritable genetic diseases (Wolff and Lederberg, 1994). It 
was thought that these diseases such as cystic fibrosis, phenylketonuria and (--thalassemia, the 
result of a single gene defect, could be resolved by the introduction of the wild-type gene into the 
patient (Anderson, 1994). However, it is now reeognised that gene therapy can also be used in the 
treatment of acquired, multi-genic diseases such as cancer and arthritis with the transfer of 
appropriate genes as a type of drug delivery system. The potential for gene based therapeutics to 
become a leading therapy encouraged the Recombinant DNA Advisory Committee of the National 
Institute of Health to grant the first human gene transfer clinical trial in 1988. However, it wasn’t 
until 1994 that permission was given for its application to the treatment of musculoskeletal 
disorders with the transfer of genes into joints affected by RA. Research into gene based therapy 
for arthritis in human medicine (Evans and Robbins, 1995) is now complemented by studies in 
domestic animals which not only provide ideal models for analysing the therapeutic benefits to 
human patients but also enables the development of new veterinary treatments (Argyle, 1999). 
Gene therapy is a powerful therapeutic tool with tremendous potential for not only controlling the 
progression of a disease, but through the genetic alteration of the germ-line DNA, it also offers the 
potential of permanently eliminating genetic diseases. As such there are numerous ethical concerns 
associated with this new technology including the spectre of eugenics (Latchman, 1994) and every 
step in its development must be handled with care. Safety assessment data must be obtained for in
vivt clinical trials carefully evaluating every tissue for transgenic integration and for levels of 
foreign DNA and transgene expression. Although the idea of gene therapy is simple, the 
application of this new technology in vivt is much more complex with many technological 
problems that must be overcome before it can be accepted as a safe clinical practice.
1.4.1 Elements of gene therapy
1.4.1.1 Selection pf appropriate thtusptuticgents
The first step in developing a gene-based therapy is the selection of appropriate therapeutic genes, 
identified by understanding the disease pathogenesis. Two main pathologies afflict the joint 
affected by OA; one is inflammation, which occurs as a synovitis and the other is the breakdown of 
the ECM components of the articular cartilage. These two processes are ideal targets for gene 
therapy with the potential for arresting disease progression. However, repairing the damage already 
inflicted on the joint prior to therapy is also important, so there is also a need to introduce those 
genes that promote cartilage regeneration. A list of candidate proteins is shown in Table 1-5 with 
some of their effects on disease control. The stage and degree of the osteoarthritic process will also 
determine the selection of appropriate therapeutie genes, encoding for one or more anti­
inflammatory, chondroprotective or chondroreparative proteins as determined for each individual.
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The selection of iersa-hcllulrs os secreted rhcsapcuria proteins is mother important parameter and 
will be determined by the disease type. However. several problems rse associated with the use oO 
therapeutic gene psaducte that remain ietsa-eellular e1nae ae<te syetbeeieed they only benefit the 
transfected cell. Therefore to enable these proteins to be suhteeeful a large number oO teIle require 
to be transfected therefore limiting its use in the systemic rnd lnrl in vivo delivery techniques. It is 
therefore likely that most therapeutic gene products will be secreted proteins that rse compatible 
with both ex vivo and in vivo dclivesy systems.
Table 1-5 Potential therapeutic genes
Protein Effects
IL-lRa Antagonise IL-1. Aeti-1nflrmmrtory. chondroprotehtive
IL-1 soluble receptors Antagonise IL-1. Aeti-inflrmmrtory. chondroproteht1ve
TNF soluble receptors Antagonise TNF. Anti-inflammatoi'y, chondroprotehtiee
Il-4 Anti-1eflammatoi’y. induces IL-lra
IL-10 Anti-inflammatory. induces IL-lra
y-IFN Inhibits MMP induction in thondrocytee
TGF-p Antagonises responses of chondrocytes rnd synaviacytee to lL-1. 
Promotes cartilage matrix synthesis.
TIMPs Inhibit MMPs. chondropratective
Superoxide d1smutaee Antagonises oxygen-derived free radicals
Soluble ICAM-1 CD44 Blocks cell to tele. cell to matrix interactions
IGF-1 Promotes crrtilrge matrix synthesis, Antagonises catabolic effect of' 
IL-1
bFGF Psomotes cartilage matrix synthesis
Numerous cytokines have been identified rs potential medirrose of asticulas inflammation but IL-1 
and TNF have been pasticuerrln implicated in the proheseee oO ECM degradation stimulating 
cartilage breakdown whilst inhibiting repair (Asend and Dayer. 1990). Thus antagonists of these 
two cytokines hold prrticular promise as anti-rrthritic agents (Evans et al.. 1998). Agents that have 
suecessOully blocked the arthritic changes obsesved with lL-1 include IL-1Ra (Oligim et al.. 1999) 
and soluble forms of the lL-1 receptors (Ghivizzani et al.. 1998). Prevention of collagen-induced 
arthritis by the gene detieern of soluble TNFR receptors (slL-lR) has aeea shown great psomisc rs 
anrrgoeisrs oO TNF (Mageed et al.. 1998). An retesnrtiee approach f'os disease coerroe is to 
modulate the activity of lL-1 and TNR via other cytokines euhh as IL-4 (Jaostee et al.. 1999. Kim 
et al.. 2000. 2001) rnd IL-10 (Fellowes et al.. 2000. Lechman ct al.. 1999) both of which have 
demonstrated potential as effective treatments Oor collagen induced arthritis.
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Degradation of articular cartilage involves the extra-cellular digestion of the matrix by 
proteinases (Cawston, 1996) and perhaps, oxygen-derived free radicals such as superoxide, 
hydroxyl radical or NO and its derivatives (Stefanovie-Raeie et al., 1993). Antagonists of these 
mediators include TIMPs, plasminogen activator inhibitors (Hart and Fritzler, 1989) and inhibitors 
of cysteine proteinases. Free radical damage may be prevented by genes e/King for enzymes such 
as superoxide dismutase and other anti-oxidant proteins. Increasing evidence has also implicated 
various types of cell adhesion molecules in the arthritic process such as CD 18 (Jasin et al 1992), 
1CAM-1 (ligo et al., 1991) and CD44 (Galea-Laui'i et al., 1993). Genes encoding soluble forms of 
these molecules or other blocking proteins may be of future therapeutic use. Finally, cartilage 
repair through the increased synthesis of proteoglycans may be stimulated by growth factors such 
as IGF-1 (Mi et a.i., 2000), bFGF (Cuevas et al 1988) and TGF3 (Morales and Roberts, 1988).
L4.1.2 Selection of appropriate gene organisation
Selected therapeutic genes can be expressed from a cloned complementary DNA (cDNA) or 
genomic DNA (gDNA) sequence. The cDNA sequence is an exact copy of the mRNA transcript 
and is directly transcribed and translated to a functional protein without the need for complex post­
transcriptional processing such as splicing. cDNA is used for most standard applications due to size 
constraints of the current vector vehicles for transferring genes to cells, where most vectors have an 
upper gene size limit of 4-6 kb. In comparison gDNA not only contains intronic sequences 
spanning up to hundreds of kilobases presenting problems for gene delivery but also requires post­
transcriptional modifications for effective protein expression. However, for future gene therapy, 
once vector technology has advanced, it may be beneficial to include intronic sequences and 
important V and 5' regulatory regions present in the gDNA for strictly regulating tissue-specific 
gene expression.
1.4.1.3 Sslectioo of fpproprirta vector reviidcs
Appropriate vehicles are required to enable the efficient delivery of therapeutic genes to cells of the 
joint. These vectors are responsible for transferring DNA to the nuclei of cells where the 
transcriptional machinery is responsible for gene expression. Most DNA vectors may remain 
episomal and gene expression from these is usually transient. Some vectors however, become 
integrated into the host chromosome which not only provides long-tenn expression but also ensures 
that the introduced gene will be transmitted to daughter cells on replication. Numerous vector 
systems have been developed for gene transfer and have been divided into viral and non-viral 
vectors lOligin/ et al., 2000).
14.1.3.1 Vital vectors
Viruses are very efficient vectors for gene therapy since they take advantage of the natural ability 
of viruses to infect and deliver nucleic acids to specific cell types, whilst avoiding the host immune 
response. Viruses are made safe for use as gene transfer vectors by rendering them replication
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incompetent through the inactivation of one or more genes essential for viral replication, which are 
replaced by the genes of interest (Robbins and Ghivizzani, 1998). Propagation of these deficient 
viruses is then performed in specialised cell lines providing the missing essential viral functions in 
tusns (Krougliak and Graham, 1995). A number of vimses have been modified for vector 
application in gene transfer to joints as shown in Table 1-6.
Table 1-6 Viral vectors for gene therapy
Viral
vector
Insert
size
(kb)
Viral
genome
state
Infection of
non-dividing
cells
Infection
efficiency
Duration of
transgene
expression
Level of
trans gene
expression
MLV 4-6 Integrated No low Persistent high
Lenti virus 4-6 Integrated Yes Moderate Persistent Moderate
AV 7.5 Episome Yes high Transient Very high
AAV 4 Integrated Yes Moderate Persistent/
transient
Moderate
HSV 40 Episome Yes Very high Transient Very high
Retroviruses are RNA vimses that replicate through a double-stranded intermediate, integrating 
into the host cell chromosome for long-term viral RNA expression. Retrovirsuses are the most 
commonly used vector in tx vivt gene therapy clinical trials (Robbins et ah, 1994) particularly the 
MMLV (Kim et al., 1998). This virus is non-pathogenic to humans and has no regions of homology 
with human retroviruses. The DNA sequence encodes for three major proteins for replication and 
packaging; structural proteins (gag), reverse transcriptase (pol) and envelope proteins (env). 
Construction of gene therapy vectors requires the replacement of these sequences with therapeutic 
genes followed by propagation in packaging cell lines that supply the gag, pol and env proteins. 
These therapeutic constructs are then capable of infecting cells and integrating into the genome but 
are unable to propagate. Retrovimses have been used for in vivt gene delivery to the synovium of 
the rabbit knee (Ghivizzani et al., 1997) and tx vivt delivery of IL-lra to the synovium (Bandara et 
al., 1993). However, retroviral vectors have three limitations which has led to the development of 
other viral vectors. Firstly, the virus can only accept 8kb of foreign DNA, secondly the random 
insertion of DNA into the host genome has aroused the concern of mutagenesis and thirdly, their 
inability to transduce non-dividing cells, although their use in arthritis is possible since the 
synovium actively divides in OA.
Adeno-Associated Vimses (AAV) have the potential to circumvent some of the problems 
associated with retrovimses. AAVs belong to the Parvo vims family of single stranded small DNA 
viruses that require a helper virus such as Adeno Vims (AV) or Herpes Simplex Virus (HSV) for 
replication. Wild type virus is non-pathogenic, is not associated with any known disease and can 
infect a wide variety of dividing and non-dividing cells. Long-term expression is a possibility since
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they are capable of integration into the bost genome rt r single site. although tb1e feature is lost on 
geecrrt1oe of the sehambinant visus. However. thc main problem aesahirted with the AAV vectors 
is the limitation on inscst size (restricted to 4 kb) (Oligim ct ah. 2000).
Lentie1ruees are a class oO serroviruees that includes human immueo-defih1enhy virus (HIV). 
simim immunodeficiency virus (SIV). equine infectious anaemia (EIA) and hrpr1ee arthritis 
eehepbrlitis virus (CAE). All lentiviruses are associated with a slow progressive destruction of the 
immune system and since wild type viruses arc pathogenic these vectors rse intr1ne1aalln more 
dangerous to use. Manipulation of these viral vectors is difficult since the production of additional 
rcccesosy proteins through the alternative epliaing of the primary transhsipr is necessary. However. 
lentiv1rusee can integrate into the genome oO non-dividing telle and therefore show promise as a 
very useful vector system (Klimatcheva et al.. 1999). The first successful use oO leetiv1ruses as 
gene therapy vectors has been Oos in vivo gene delivery to the eyeoeium (Gouze et rh. 2002).
Adenoviruses (AV) have a double stranded DNA genome with invested terminal repeats at cither 
end; 47 serotypes exist but 2 and 5 arc the two most commonly used for gene transfer and rre 
excellent vehicles for gene delivery in a wide range of cell types (Bramson et al.. 1995). Thc DNA 
oO the adenovirus does not integrate into the host genome but remains as an episomal element with 
replication and packaging ohaurrieg in the nucleus. Several versions of repliaatiae-mtompetent 
adenoviral vectors have been developed (Robbins and Gh1eizzani, 1998) genesally with thc 
replacement oO the errly genes such as EIA and ElB genes with the tsrnegene. AV have potential 
as gene thcrrpy vectors since they crn infect a wide range of dividing and nae-dividing cells and 
are thus suited to in vivo gcne delivery. They are rlso capable oO producing high titse recombinant 
virus and can accept large amounts oO rdditional DNA (approx 30 kb). These advantages have lcd 
to their widc-spread application (Evans et ah. 2001) and examples used Oor orthopaedic application 
include the delivery of hlL-lRa to synoviocytes (Roessler ct ah. 1995) and IGF-I to the eyeavium 
(Saxes et al.. 2001).
Herpes Simplex Virus (HSV) contains r linear double-stranded DNA molecule (152 kb); tbis 
large genome has the potential to carry large amounts oO foreign DNA in excess oO 40 kb and has 
been used fos the development oO multigenc vectors (Krisky et al.. 1998). This virus crn ief'eat 
almost all known cell types including nae-dividing cells both in vitro and in vivo but is difficult to 
make and only supports transient expression (Gloriaso et al.. 1997). However. replication-defective 
HSV vectors have been analysed for gene transfer in vivo (Masconi ct al.. 1996). Other viruses such 
as Simian Virus 40 (SV40). Polyoma Virus. Papilloma Vims and Picornavirus are being explored 
as potential vector systems for gcne therapy (Evans and Robbine. 1995).
Although viral vector technology has alseady shown huge potential for genc delivery systems 
there is the honhem that reaambieatioe of defective virus with visal sequences present in the hast 
aele mry generate replication-competent vireses that can propagate in the patient. Additionally 
there is the potential for an immune response to visrl proteins. As r result considerable research has 
focused not only on refining these viral based vectors but aeeo on the development of alternative 
non-viral methods.
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1.4. i.3.2 Non-\ irail \cctors
Mammalian DNA expression plasmids are non-viral vectors that are widely used for standard gene 
el/ning techniques and in vitro transfer studies. These synthetic vectors have the advantage of 
being non-immunogenic since they do not introduce strongly antigenic materials and they are easy 
to produce with a greater chemical stability. Plasmids however have two major disadvantages, they 
usually remain episomal, providing transient gene expression and are generally less efficient in the 
transfer of nucleic acid to cells when compared with viral vectors. The low transfection efficiency 
of naked DNA plasmids has been addressed with the development of a variety of chemical methods 
for introducing DNA into cells.
The transfer of DNA to mammalian cells have utilised liposomes as carriers which make stable 
complexes with DNA that are small enough to enter cells. Liposomes are grouped into two 
categories based on their mode of DNA entrapment. Since DNA is negatively charged it can be 
held with positively charged liposomes (cationic liposomes) to make a complex or it can be 
entrapped in the aqueous interior of the liposome (pH-sensitive liposomes) (Singhal and Huang, 
1994). Cationic liposomes have been utilised to deliver DNA to articular chondrocytes (Madry and 
Trippel, 2000) despite the low transfeetion efficiency and transient expression. The use of 
conjugates between DNA, polylysine and specific antibodies or DNA conjugated to specific 
receptor binding proteins such as asialoglycoproteins as found on hepatocytes have also been 
developed (Perales et al, 1994). This DNA-ligand complex enables the DNA to be targeted to cells 
that express a cell-specific surface protein recognised by the antibody or protein. Plasmids can also 
be forced into cells by particle bombardment using a gene gun (Klein et al., 1987). A full 
description of particle bombardment is discussed in chapter VII. Briefly, particles of gold are 
coated with DNA and then accelerated at a high velocity using pressurised helium allowing the 
DNA to penetrate cells. In general plasmid vectors are designed for introducing DNA into cells in 
tissue culture and are therefore most applicable for ex-vivo gene delivery to cells.
Recent advances in technology have produced potential alternative vectors to plasmids for gene 
transfer studies. Mammalian artificial chromosomes (MAC) for example can now be constructed 
via two different methods (Grimes and Cook, 1998) and, although still in the early stages of 
development, have shown potential as gene transfer vectors for complementing genetic deficiencies 
(Mejia et al., 2001). This vector system offers the prospect of sustained therapeutic gene 
expression, important for the chronic condition of OA, as demonstrated by the stable expression of 
the hypoxanthine phosphoribosyltransferase locus (115 kb) for six months in vitro (Wade-Martins 
et al., 2000). The development of MACs began following the success of yeast artificial 
chromosomes (YACs) and bacterial and Pl artificial chromosomes (BACs) as large DNA cloning 
vectors (Monaco and Larin, 1994). Major efforts have aimed to define the vital chromosomal 
structures, alpha satellite and telomeric DNA, to enable these vectors to function as normal 
chromosomes and divide within the cell. MACs are fully functional autonomous vectors that do not 
integrate into the genome thus overcoming problems of gene silencing and oncogenesis from 
random integration into the host cell genome. Finally, the size of the vector enables the
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incorporation of large pieces of genomic DNA allowing important up-stream and down-stream 
regulatory regions to be included for accurate transgene expression and providing the potential of 
introducing multiple therapeutic genes (Warbuiton, 1999). Efficient transfer of artificial 
chromosomal DNA into cells confronts the same problems associated with plasmid vectors, 
although there have been reports that a 60-Mb MAC was transferred into a hamster cell line using 
cationic lipids (de Jong et al., 2001). However, these problems are enhanced by the sheer size of 
the chromosome component and efforts to improve transfection efficiency will enable these vectors 
to become a realistic alternative to plasmid vectors.
1.4.1.4 Setottion op an efficCentggnn ttunnfet syssctn
14.1.4.1 In vivt or tx vivo ftu gene dcOtvtn
There are currently two basic methods for gene transfer to joints referred to as the in vivt (direct) 
approach and the tx vivt (indirect) approach with selection based on the anatomy and physiology 
of the target tissues, the vectors employed and safety considerations. The direct delivery system 
involves the introduction of appropriate vectors into the joint cavity for transfer to target tissues of 
the joint. This technique is technically simpler but efficient delivery of vectors to target tissues such 
as the synovium is more difficult (Nita et al., 1996) and it may be difficult to regulate the efficiency 
of transduction and the level of gene expression. The indirect delivery system involves removal of 
joint cells from the patient followed by in vitut propagation and genetic modification before cells 
are screened for the therapeutic genes and re-introduced into the joint (Evans et al., 1992; Kang et 
al., 1997a). This is not only technically complex, expensive, time consuming and invasive but it is 
also currently very difficult for cells, especially chondrocytes, to re-establish themselves within the 
joint tissues. As an alternative to chondrocyte transduction, synovial cells are potentially easier to 
manipulate and can be used successfully in both the in vivt and tx vivt techniques for gene transfer 
to joints (Evans et al., 1999; Bandara et al., 1992). However, with the advent of new tissue 
engineering technologies the tx vivt technique may become a viable option with its advantages of 
regulating the efficiency of transduction and the level of gene expression.
14.1.4.2 Systemic or local jgetne delivery
Genes can be delivered locally to sites of disease, such as the joint space, or into the systemic 
circulation. Local delivery is used in preference to systemic delivery in order to restrict most of the 
gene expression to a small anatomical site and reduce undesirable side-effects. However, even 
using this technique it is likely that a small percentage of the DNA will enter the circulation 
through the inadvertent transduction of inflammatory cells; this has been demonstrated by the 
identification of a marker gene in the untreated contra-lateral joint (Evans et al., 1999). Systemic 
delivery may be desirable for RA where there is multiple joint involvement but side-effects are 
more likely.
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 1.4.1,5 Sslectiom erfappt•rnriatemethoOs fborregilatinngfein cepprssiao
The efficient transfer of genes to target cells does not necessarily ensure successful treatment of 
disease. Genes must be expressed for specified lengths of time at appropriate therapeutic levels, as 
determined by the disease type. Although gene expression is regulated at many levels the control of 
gene expression for gene based therapeutics has generally focused on the level of gene transcription 
with the application of promoters (Whalen, 1994). Promoters are regulatory regions of DNA 
located in the 5' untranslated region (UTR) of the gene; a full description of promoter function is 
described in chapter IV. Viral promoters are usually used in the development of gene therapy 
vectors and include the cytomegalovirus (CMV) and the SV40 both of which provide high levels of 
constitutive expression. However, gene expression from these promoters is often lost when cells 
stop dividing, possibly due to the methylation of cytosine residues, within the promoter, by cellular 
methylases (Hoeben et al., 1991; Challita, 1994). Eukaryotic promoters have been evaluated as 
alternatives to prolong gene expression and include those that drive constitutive expression of 
house-keeping genes within the cell such as the KihyKrofoIate reductase gene promoter 
(Scharfmann et ah, 1991). However, the level of gene expression from eukaryotic promoters is 
generally far lower than that from viral promoters so hybrid promoters are under development to 
achieve high long-term expression. Eukaryotic gene promoters can be used for driving tissue- 
specific gene expression which is particularly useful for reducing expression of the transgene in 
non-target cell types. However, the context of the vector is important since there have been reports 
that promoter interference from viral vector promoters may affect activity and specificity of the 
tissue specific promoter (Miller and Vile, 1995).
In many diseases, high-level gene expression from constitutive promoters is acceptable since the 
therapeutic effect of the expressed proteins is well tolerated over a wide range. However, this is not 
true for all disease types in which sustained high levels may not only be unnecessary but may be 
detrimental to tissues, OA is an example of a disease that should be tightly regulated to avoid 
complications arising from the persistent overproduction of anti-inflammatory and 
chondroproteetive molecules. The most efficient method for this is to use inducible promoters that 
regulate gene expression in response to the presence of exogenous or endogenous stimuli. 
Examples include those promoters that respond to exogenous stimuli such as the metallothionein 
promoter that responds to heavy metals (Mayo et al., 1982) and drug inducible promoters such as 
tetracycline (Ghersa et al., 1998) and rapamycin (Ye et ah, 1999). Even radiotherapy has been used 
to stimulate promoter activity (Marples et al., 2002). Endogenously stimulated promoters can be 
used to harness pathological changes to gene expression and include promoters such as those for 
metalloproteinase, aggrecanase and hyaluronidase all of which are up-regulated by the 
inflammatory cytokines present in the disease state. Although research has focused on the 
involvement of promoters in regulating gene expression other elements of the transcriptional 
machinery are equally important such as enhancers and silencers which effect the relative activity 
of the promoter. Locus Control Regions (LCR) are also important since a considerable number of 
gene therapy approaches involve the expression of genes integrated into an unnatural position in
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the host genome. Structural organisation of the chromatin is an important feature of gene regulation 
since minimal secondary structure associated with episomal locations may result in poor tissue 
specificity while integration into an area of highly complex secondary structure may result in gene 
silencing. Elements of the translational machinery are also important since the level of protein 
synthesis depends upon translational efficiency and the stability of the mRNA transcripts as 
discussed in chapter 111. Ultimately the aim will be to control the expression of multiple therapeutic 
genes simultaneously from one vector thereby strictly regulating disease progression.
1.4.2 Construction of the gene therapy transcriptional unit
The design of a gene therapy vector system requires a ‘transciptional unit’ that consists of a region 
of protein-coding DNA (Jacob and Monod, 1961) and includes all associated regulatory regions 
referred to as promoters and enhancers based in the 3' and 5' UTRs. The expression of a gene for 
gene-based therapeutics requires the correct assembly of this transcriptional unit, as illustrated in 
Figure 1-13, to enable the trsns-scting protein factors to specifically bind the regulatory regions of 
DNA and direct transcription. As discussed in detail in chapter 111 the transcriptional unit must 
include the gene sequence cloned either as cDNA (in frame) or gDNA with optimised translation 
start and stop sites tenninating at the polyadenylation site present in the 3' UTR. The 5' UTR 
corresponding to the regulatory promoter must contain the core promoter elements, activation 
sequences, enhances and locus control elements to regulate gene transcription. The function of the 
5' regulatory region, is primarily responsible for the binding of appropriate transcription factors and 
the recmitment of RNA polymerase to the transcription initiation site. Gene regulation is discussed 
further in chapter IV. The transcriptional unit may then be modified with the manipulation of 
promoter sequences to target gene expression to diseased cell types of the canine osteoarthritic joint 
as attempted in chapter VI. Finally the gene therapy constructs must be easily delivered to the cells 
of the joint using in vivt or tx vivt techniques. The application of particle bombardment mediated 
gene delivery is described in chapter VII.
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Figure 1-13 The gene therapy transcriptional unit
Thc ‘trgneaaiptiangl unit' aaneiete of paatcin-aad1ng DNA and includes all geeaa1gtcd regulatory 
regions referred to as paamatcre and enhancers based in thc 3' and 5' UTRs. Thc trgnear1tp1angl 
unit must include thc gcnc sequence alancd cither as genomic DNA (aaetg1n1ng black cxons and 
rcd introns) or complementary DNA (aaetg1n1eg only black cxons) with optimised trgnelgt1on start 
and stop e1tce terminating at thc palngdcnylatian site present in thc 3' UTR. Thc 5' UTR 
aaaacepand1ng to the rcgulgtarn promoter must contain thc aarc promoter elements. gat1vgt1an 
sequences. enhances and ^1^ aaetaal elements to regulate gcnc trgneaaipt1an. This region is 
primarily rcepane1blc for binding the appropriate tagneaa1pt1an fgatare and recruitment of RNA 
polymerase to thc trgeeaa1pt1an initiation site.
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1.5 SUMMARY
As the details of the molecular mechanisms involved in the pathogenesis of OA are unveiled new 
‘structure-modifying’ treatments such as gene therapy can evolve. Gene therapy is moving rapidly 
from the laboratory to the clinic with a number of clinical trials for orthopaedic disease already in 
progress. However current gene transfer studies have focused on the use of highly active 
constitutive promoters for driving high levels of gene expression in any cell type. This thesis 
identifies potential therapeutic genes and attempts to address the problems associated with non­
specific gene expression with the development of a dual-promoter vector system for the 
transcriptional targeting of therapeutic genes to the diseased cells of the canine osteoarthritic joint.
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 Chapter II
Materials and Methods
2.1 MATERIALS
Materials in regular use, such as equipment, general reagents and solutions are detailed in this 
section.
2.1.1 Cell culture materials
2.1.1A Ctll lints
MOCK cells were grown and maintained for use in transfection experiments by Mrs. Elizabeth 
Gault in the Molecular Therapeutics Research Group, University of Glasgow Veterinary School. 
TEA cells were kindly supplied by Mr Matthew Golder, Feline Virus Unit, University of Glasgow. 
Primary rat cardiocvtes were kindly supplied by Dr. Arvind Sood, Department of Biochemistry 
and Molecular Biology, University of Glasgow.
AiPDCS cells were kindly supplied by Dr. David Thomas, King’s College London, Guy’s Hospital. 
SWl 353 cells were supplied by The American Type Culture Collection (ATCC).
HIG-82 cells were supplied by The ATCC.
2A.1.2 PJisticwnrt
Tissue culture flasks, 6, 12, 24-well plates, Falcon conical centrifuge tubes (15 and 50ml) Pipettes 
(5, 10, 25, 50ml) were supplied by Greiner (Gloucestershire, UK). White, tissue culture treated 
ViewPlate™-96 were supplied by Packard (Berkshire, UK).
2.1.1.3 Sol^^^intn, metSa nndsupplimentn
All solutions and media for cell culture were supplied by Gibco BRL Life Technologies, unless 
otheiwise stated.
2,1.L3.1 Meddi
All media were supplied as sterile solutions and stored at 4°C
Dulbecco’s MEM with Glutamax-1 with sodium pyruvate, glucose and pyridoxine.
Dulbecco’s MEM/ Nutrient mix F-12 (1:1) without L-Glutamine and with pyridoxine.
Dulbecco’s MEM 25MM Hepes without sodium pyruvate, with glucose and pyridoxine.
Dulbecco’s modified Eagle’s medium with glucose and sodium bicarbonate, without L-Glutamine 
(Sigma).
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 Medium 199 with Earle’s salts, L-glutamine and sodium bicarbonate (Sigma). 
Nutrient Medium F-12(HAM) with L-Glutamine
2.1.1.3.2 Supplements
Foetal Cair Serum (FCS): virus and mycoplasma screened. FCS was heat inactivated at 56"C for 
30 minutes, then stored in 50ml aliquots at -20°C.
1 lorse serum (HS ); Heat inactivated at 56"C and stored at -20"C until use.
L-glulamine: supplied 200mM (IOOx) stock solution and was stored at -20"C in 5 ml aliquots. 
Penicillin/streptomyein (iVS): supplied as a IOOx stock solution of 10,000 units penicillin and 
10,000 units streptomycin per ml and stored in 5 ml aliquots at -20°C.
Fungizione; supplied as a lOOx stock solution and stored in 5 ml aliquots at -20“C.
Nystatin: supplied as a IOOx stock solution and stored in 1 ml aliquots at -20°C.
Try psin-EDTA: supplied as a lOOx stock solution and stored in 5 ml aliquots at -20°C.
Sodium py rin• ate: supplied as a lOOmM stock solution and stored at 4°C.
Non Essential Amino Acids (NEAA): supplied as a lOOx stock solution and stored at 4°C. 
Ciprofloxacin: Anti-mycoplasma antibiotic added to tissue culture medium as necessary to a final 
e/neentration of lOmg/ml (Miles, Bayer Diagnostics)
Insulin: (bovine pancreas) lyophilized powder reconstituted in sterile water to a concentration of 
lOmg/ml and stored at -20°C (Sigma-Aldrich Company Ltd, Dorset, UK).
Human apo-transferrin: powder reconstituted in sterile water to a concentration of lOmg/ml and 
stored at -20”C (Sigma-Aldrich Company Ltd, Dorset, UK).
Sodium selenite: lyophilized powder reconstituted in sterile water (lO’4M), stored at -20°C (Sigma- 
Aldrich Company Ltd, Dorset, UK).
2.1.2 Radio chemicals
2.1.2.1 35S Methionine
EasyTag™ Methionine, L-[35S], (specific activity of 43.5 TBq/mmol) was used in the in vitro
transcription/translation prot/c/l for labelling proteins. Supplied by PerkinElmer Life Sciences 
(NEN) and stored at 4°C.
2.1.3 General chemicals
Chemicals used were of analytic, ultrapure or molecular grade quality and were supplied by a range 
of biotech companies.
2.1.4 Complete kits
QIAquick® PCR Purification Kit (QIAGEN, UK)
QIAquick® Gel Extraction Kit (QIAGEN, UK)
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QIAprep® PCR Spin Miniprep Kit (QIAGEN, UK)
EndoFree® Plasmid Maxi Kit (QIAGEN, UK)
GeneRacer™ Kit (Invitrogen. UK)
Universal GenomeWalker Kit (Clontech, UK)
TOPO TA Cloning® (Invitrogen)
TNT® Quick Coupled Transcription/Translation Systems (Promega)
Dual-Luciferase® Reporter Assay System (Promega)
QuikChange™ Site-Directed Mutagenesis Kit (Stratgene)
ECL Western Botting Detection Reagents (Amersham Pharmacia Biotech)
DNA Sequencing Kit Big Dye™ Terminator Version 3.0 Cycle Sequencing Ready Reaction (ABI) 
X-Gal Staining Assay Kit (Gene Therapy Systems)
2.1.5 Bacterial strains
2.1.5.lE.coU Ont Oho® TOPO
Chemically Competent E.coIC Cells (>1 x 109 cfu/pg) (Invitrogen). Genotype; F mcrK A(mrr-
/?5<RMS-77cc‘BC)680 lacZAM15 AlacXJA dttR rtcAl araD139 A(ara-ltu)1691 galJJ galK rpsL
(SrrR) tndAl nppG
2.13.2 E.ctnjMm
High Efficiency JM109 Competent Cells (>108 cfu/gg) (Promega). Genotype: tndAl rtcAl
gyrA96 thi hscdRll (rC, mi*) rtlAl sppEAA A(lac-prtAB) [F', fraD36 pro AB /a#IqZAM15]
2.1.5.3 XLl-Blup nupclnrrmpeltnt celts
(>1 x 109 cfu/pg) (Stratgene, The Netherlands). Genotype; rtcAl tndAl gryA96 thi-l hsdRU
sppE44 rtlAl lac [F, prtAB /npEF^AlMl 5Tn 10 (Tet‘)]
2.1.6 DNA
Plasmid, molecular weight markers and oligonucleotide DNAs were stored at -20”C.
2.1.6.1 Plasmid vtcttrs
2.1.6.1.1 nCR '2T-TOPO
pCR®2.1-T0P0® (3900 bp) is supplied by Invitrogen and contains lacZ' Beta-lactamase gene 
(amp1) and Kanamycin resistance (Kad) genes. T7 promoter and M13 forward and reverse primer 
binding sites are also present. This plasmid is designed for directly cloning PCR products with 3' 
deoxyadenosine residues (A overhangs), generated by the non-template dependent activity of Taq
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polymerase. The vector is supplied as linearised DNA with single 3' KeoxythymlKine (T) residues 
and topoisomerase attached, allowing for efficient ligation of the target sequence to the vector,
2.1.6.1.2 pTurget™ MammaHaa Expeession Veci:or
pTarget™ Mammalian Expression Vector (5670 bp) is supplied by Promega and contains a T7 
promoter, CMV immediate early promoter and enhancer sequences and SV40 late poIyaKenyIati/n 
signal. A neomycin selectable marker (Neo11), lacZa, Beta-lactamase gene (aim)1) and T7 & 
pTarget primer binding sites are also present. A multiple cloning site (MCS) is available in addition 
to single 3' deoxythymidine (T) for TA cloning.
2.1.6.1.3 pGL3-basle Vector
pCL3-basic Vector (4818 bp), supplied by Promega, lacks a eukaryotic promoter and enhancer 
sequences, allowing cloning of putative regulatory sequences into the MCS. The coding region for 
firefly (Photinus pyralis) luciferase gene (/wc+) is followed by a SV40 poly(A) signal. This vector 
also contains Beta-lactamase gene (amp1) and RV3, RV4 and GL2 primer binding sites.
2.1.6.1.4 pGL3-eo^ilroI Vector
pCL3-controI Vector (5249 bp), supplied by Promega, contains a SV40 promoter, enhancer, late 
and up-stream poly(A) sequences resulting in strong expression of firefly (Photinus pyralis)
luciferase gene (luc+) in many types of mammalian cells. Beta-lactamase gene (amp1) and RV3, 
RV4 and GL2 primer binding sites are also present.
2.1.6.1.5 pRL-CMV Vector*0
pRL-CMV Vector1''''1 (4079 bp), supplied by Promega, contains the CMV immediate-early 
enhancer/promoter region providing strong constitutive expression of Renilla (Renilla renifonni^)
[sea pansy] luciferase in a variety of cell types. The Beta-lactamase gene (ampr) and SV40 late 
polyadenylation signal is also present.
2.1.6.1.6 pCAGGS-nlsCrc
pCACCS-nIsCre (5810 bp), supplied by Prof. Jun-ichi Miyazaki of Osaka University Medical 
Schoolm Japan, contains the CMV-immediate early/chicken (-Actin fusion promoter driving 
expression of nuclear localisation signal/Cre recombinase fusion protein. PoIyaKenylati/n signal 
and the Beta-lactamase gene (ampr) are also present.
2.1.6.1.7 pUCI8
pUC18 (Invitrogen): pBR322 based cloning vector contains the lacZo and amp* genes with a MCS 
and M13 forward and reverse primer annealing sites. This plasmid is supplied with TA cloning kit 
for use as positive control for verifying the transformation efficiency of competent bacteria at a 
concentration of 0.1 pg/ml. •
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 2.1.6.2 Molecular Size Standards
All maskers were supplied by GIBCOBRL Life Tehbealagiee rnd include I kb DNA Ladder (size 
range: 75- 12.216 bp). 1 Kb Plus DNA Ladder™ (size range: 100- 12,000 bp). 100 bp DNA Ladder 
(size range: 100-2072 bp). Low DNA Mass™ Lrddes (size range: 100-2000 bp rnd 5-400 ng).
2.1.6.3 Oligonucleotide primers
Oligonucleotides fos use in polymerase chain seahtions (PCR) and tnhle sequencing were 
synthesised by MWG Biotech rnd Sigmr-Genasye. Primers were either sevesse pbaee. desalted or 
Poly Acrylamide Gel elettsapbaresie (PAGE) purified and supplied as lyophilised DNA. Primers 
were setanetituted in dHiO rnd stosed rt -20"C in 20 |il aliquots at lOpM.
2.1.7 Enzymes
All enzymes were stored rt -20"C. being removed immediately before use.
2,1.71 Restriction ennyn^ee
All restriction enzymes rnd their aseaaiared buffess wcse supplied by Promega. Kramel and 
Qontehh.
Table 2-1 Restriction enzymes
Restriction enzyme Restriction site Buffer Incubation
Temp (°C)
EcnK 1 [G^AATTC] Buffer 6 (blue) 37
Stu 1 [AGG^CCT] Buffer B 37
Dra 1 [TTT^^AAA] Buffer B 37
Pvu II [CAG^CTG] Buffer B 37
EcnK V [GAT^ATC] Multi-Core™ 37
Xhn 1 [G^TCGAG] Buffer 6 (blue) 37
Kpn 1 [GGTAC*G] Mulii-Crre™ 37
Sma 1 [CCC^GGG] Mutii-Core™ 30
Hind II [aUgCTT] Buffer E 37
Xha 1 [T^CTAGA] Mutd-CoreeM 37
Nei 1 [ATGAA^T] Buffer D 37
2.1.7.2 T4 DNA Ligase
T4 DNA ligase was provided by Promega with ligation buffer (used at a Oinal coeceetrarioe of 30
mM Tris-HQ (pH 7.8). 10 mM MgCL. 10 mM DTT rnd 1 mM ATP) to catalyse thc joining of two 
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strands of DNA between the 5'-phosphate and the 399 hydroxyl groups of adjacent nucleotides in 
either a cohesive-ended or blunt-ended configuration.
2.1.7.3 Taq DNA po7ymtr^ssn
Taq DNA polymerase was provided by QIAGEN and has 5’ to 3’ exonuclease activity and non­
template dependant activity with the addition of 3' deoxyadenosine (A) residues to PCR products 
for TA cloning.
2.1.7.4Platinum PN DNA Ptlym^rast
Platinum Pfx DNA polymerase was provided by Invitrogen and has proofreading 3' to 5' 
exonuclease activity with high fidelity. This enzyme is provided in an inactive form with a 
specifically bound antibody to provide an automatic ‘hot-start’ for PCR, enabling increased 
specificity, sensitivity, and yield. Full activity of the enzyme is re-gained on denaturation at 94°C. 
PCR Enhancer Solution is provided with this enzyme as a novel PCR co-solvent to facilitate 
efficient amplification of GC sequences by offering higher primer specificity, broader magnesium 
concentrations and annealing temperatures and improved thermo-stabalisation of DNA 
polymerases.
kb2.1.7.5 Advantage Gtnomic Po7ymtrast Mix
Advantage® Genomic Polymerase was provided by Clontech and provides efficient and accurate 
amplification of genomic DNA templates using a combination of the primary Tth DNA polymerase 
(thermostable DNA polymerase from Thannus thtrintphips), a minor amount of a second DNA 
polymerase to provide 3 to 5 proof reading activity (VentiO and TthStart™ Antibody to provide 
automatic ‘hot-start’ PCR (Kellogg tt al., 1994). This antibody reduces or eliminates non-specific 
amplification products and primer-dimer artifacts created prior to the onset of thermal cycling. The 
antibody inhibits enzymatic activity during PCR reaction set-up at ambient temperatures. 
Polymerase activity is restored at the onset of thermo-cycling because the antibody is denatured at 
high temperatures. The loss of inhibition is complete and irreversible, so the polymerase regains 
full activity for PCR.
2.1.7.6Rfady-To-Go™PCR btads (Afmtrsham, Pharmacia)
Ready-To-Go™PCR beads (Amersham, Pharmacia) are designed as pre-mixed, pre-dispensed 
reactions for performing PCR amplifications. When brought to a final volume of 25 pi, each 
reaction contains Taq DNA Polymerase (1.5 units), 10 mM Tris-HCL, (pH 9.0 ), 50 mM KCl, 1.5 
mM MgCE, 200pM of each dNTP and Bovine Serum Albumin (BSA).
2.1.7.7 Muuine ^^MPjp^^ Viruu RRvetse Tranncripiase Ennyme
Murine Moloney Leukaemia Virus Reverse Transcriptase (MMLV-RT) enzyme, provided by
GIBCOBRL, uses single stranded RNA in the presence of a primer to synthesise a complementary 
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high temperatures. The loss of inhibition is complete and irreversible, so the polymerase regains 
full activity for PCR.
2.1.7.61Ready-To-Go™PCR beads (Ama-sham, Pharmacia)
Ready-TorC/™PCR beads (Amersham, Pharmacia) are designed as pre-mixed, pre-dispensed 
reactions for performing PCR amplifications. When brought to a final volume of 25 pi, each 
reaction contains Taq DNA Polymerase (1.5 units), 10 mM Tris-HCL, (pH 9.0 ), 50 mM KCl. 1.5 
mM MgCl], 200pM of each KNTP and Bovine Serum Albumin (BSA).
2.17.7Murine Moloney Virus Reverse Transcriptase Enzyme
Murine Moloney Leukaemia Virus Reverse Transcriptase (MMLV-RT) enzyme, provided by 
GIBCOBRL, uses single stranded RNA in the presence of a primer to synthesise a complementary 
DNA strand. This enzyme is isolated from E.Coli expressing a portion of the pol gene of the M­
MLV on a plasmid.
2.1.7.8 Avian Myeloblastosis Virus Reverse Transcriptase (AML-RT)
Avian Myeloblastosis Virus Reverse Transcriptase functions in a similar manner to MMLV-RT,
2.1.7.9 RJhiscOUTT0'Recojmbinant Ribonuclease Inhibitor
RNaseOUT™ Recombinant Ribonuclease Inhibitor, provided by Invitrogen, is an acidic protein 
with a very high binding affinity for ribonucleases such as RNase A, B, C and is a non-competitive 
inhibitor.
2.1.7.10 Alkaline Phosphatase,
Calf Intestinal alkaline phosphatase provided by Promega catalyses the hydrolysis of 5'- phosphate 
groups from DNA.
2.1.7.11 DNase I: DNA-free™
DNase I provided by Ambion is a deoxyribonuclease I enzyme that cleaves double-stranded or 
single stranded DNA. Cleavage preferentially occurs adjacent to pyrimidine (C or T) residues, and 
the enzyme is therefore an endonuclease. Major products are 5-phosphorylated di, tri and 
tetranueIeotiKes. In the presence of magnesium ions, DNase I hydrolyzes each strand of duplex 
DNA independently, generating random cleavages. In the presence of manganese ions, the enzyme 
cleaves both strands of DNA at approximately the same site, producing blunt ends or fragments 
with 1-2 base overhangs. DNase I does not cleave RNA.
2.1.8 Protein SDS-PAGE standards
Wide Range (6.5 to 205 kDa) Color Markers molecular weight standard (Sigma).
53
2.1.9 Equipment
2.L9.1 Major Equipment
Benhl^tap teerrirUge: CPR Centrifuge (Beckman)
Microcentrifuges: Centrifuge 5402. 5415R rnd Minispin (eppcndoie)
Water haths: Sub 36. and W6 (Gsrnt)
Spectrophotometer: GeneQuant pm RNA/DNA calculator
Automatic Sequencing Apparatus: ABI 3100
Gel dryer: Model 583 Gel Dryer (Biorad)
Pipettes: Finnipipette Techpette (0.5-10. 5-40. 40-200. 200-1000 pi)
Ultraviolet trans-illuminator: T2201 (Sigma Chemical Company)
(Jcl dohumentatian system: Uvi tec (Thistle Scientific)
Luminometea: Dynex MLX
Horizontal orbital shakes: 4628-ICE Labline Instruments inc (IL)
Incubator: B5042 (Hesaeus)
Gcl eyerems: Hoefer HE 33 Mini Horizontal Submarine Unit
Power packs: PAB 35-0.2 (Kikusui electronics corp)
Balance: Precisr 100A-300M (Precisa Balances Ltd. Buaks, UK)
Stirrer: Magnetic Stirrer Hotplate (Stuart Scientific. UK)
PCR Machines: GeneAmp PCR System 2400. 2700 and DNA Thermal Cycler 480 (Peskin Elmer)
2.1.9.2 Consieumbhs
Syringe top filters (0.2pm pore size) were supplied by Nalgenc™. (NY. USA) for sterilisation of 
ampicillin and tissue culture reagents.
EremlnO tubes: screw top 1.5ml and 0.5ml and 1.5ml flip top tubes were supplied by Thermo 
Life Sciences.
Pipette tips were supplied by Greincr.
Filter tip pipette tips (10. 100. 200. lOOOfPl) were supplied by Fieeitip (Thermo Lrb Systems)
Petri dishes were supplied by Sterieie (StaOOs, UK)
Bijoux were supplied by Grcines
Uni versa Is were supplied by Greiner
Scalpel blades were supplied by Swan-Morton (Sheffield)
Para film wrs supplied by Sigma
2.1.10 Buffers, solutions and growth media
2.1.10.1 Waste
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Sterile water for procedures involving recombinant DNA, PCR etc was supplied by Baxter. 
Vivendi Water systems (USF ELGA) was used to supply water for preparation of general solutions 
and media.
2.1.10.2 An ^hittics
Ampicillin; Reconstituted with dHjG to lOmg/ml, filter sterilised and stored in 1 ml aliquots at - 
209C until use.
2.1.10.3 Bufftrs and so7ptions
Ammonium persulphate: 10% (w/v) stock solution in dHoO
5t) x TAE Buffer Solution: Tris base 484.5g, NaOAc 272.15 g, NaCl 116.8 g, NaoEDTA 74.45 g. 
pH adjusted to 8.15 with glacial acetic acid and made up to 2 L volume.
THE Buffer Solution: 0.09M Tris Borate, and 0.002M EDTA
Lysis Buffer; 25mM Tris HCL pH 8,0 with glacial acetic acid and made up to 2 L volume 
1M Tris HCL: 121g Tris base, 800ml dHiO. Adjusted to the desired pH with concentrated HCL 
and made up to 1L.
TK Buffer: lOmM Tris-HCL (pH 8.0), ImM EDTA
1 x PBS: 140mM NaCl, 2.7mM KCL, lOmM Na2HPO4,1.8 mM KH2PO4 (pH 7.3)
0.2M (2x) Phosphate Buffered Saline (PBS): 0.2M Na2HPO4, 0.2M NaH2PO4, 1.8% w/v NaCl, 
pH 7.4
lOx DNA Gel Loading Buffer: 20% w/v Ficoll 400, O1M Na2EDTA, pH 8, 1.0% w/v sodium 
dodecyl sulphate, 0.25% bromophenol blue, 0.25% xylene cyanol. Stored at room temperature and 
used at a 1:10 dilution.
Ethidiiim bromide: made to a working dilution of lOmg/ml with dH2O in a fume cupboard. Stored 
away from light.
X-Gal solution: (5-bromo-4-chloro-3-indole-b-galactoside) prepared as 50 mg/ml stock in 
dimethylformamide; stored at -20°C in the dark.
Transfass"' Transfection Reagent: (Promega) Supplied as dried lipid film that forms multi­
lamellar vesicles upon hydration with nuclease-free water (400pl) and stored at -20°C.
OLPC water: 0.5ml of Diethylpyrocarbonate in 500ml water, overnight at room temperature in the 
fume cupboard and autoclaved.
Lysis mix: 0.32M sucrose, lOmM Tris, 5mM MgCl, 1% Triton X
Nuclei lysis mix: lOmM Tris, 0.4 NaCl, 2mM EDTA
TRIS-EDTA: (10/1 pH 7.4)
TRLS-EDTA: (10/0.1 pH7.5)
10 x SDS PAGE. Electrode (Running) Buffer: tris base 60g, glycine 288g, SDS 20g. Made up to 
2L by addition of dH2O
Transfer Buffer: 1.93 g Tris, 9 g glycine. Made up to IL by addition of dH2O
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10\ Ponceau's Red Stain: 2 g Paeheru S. 30 g Trihhloroahetih acid (TCA). 30 g Sulpbopalicnelt 
acid. Made up to 100 ml by rddition of dH°O
TBS-Tween: 150 mM NrCl (8.77 g). 50 mM Tris (6.06 g) rnd 0.05% Tween (0.5 ml). Made up to 
IL by addition of dHoO
Blocking Buffer: 1 g non-Oat skimmed milk powder in 20 ml TBS-Tween
.Aitihodv diluant: 0.2 g noeif’at skimmed milk powder in 20 ml TBS-Tween.
SDS Protein sample loading buffer• 95% loading buffer (Biomd pre-made) and 5% 2- 
meshrptoethreol added immediately prior to use.
Gei Fixing ealut1on Oos protein 5^0^: Methanol (50 %). glacial rhetic acid (10 %) rnd HoO 
(40%)
(All fixing solution for X-(Ld geeav: 4% w/v paraformaldehyde. O1M PBS9 0.12M eucraee. 
pH7.4. Dissolve sucrose (4.1g) in 50 ml oO 0.2 M PBS pH 7.4. cnll. hert 30 ml of dH2O (55“C to 
60°C) and rdd approximately 5 drops oO 10 M NaOH. Dissolve 4g of paraformaldehyde rnd filter 
through a Whatman qualitative size Oilter paper circle into ice cold PBS euhrase. Adjust pH to 7.4 
and make to 100 ml.
j-gal assay solution: potassium fesrocyreide (5mM). patreeium ferrihnanide (5mM). MgCL 
(2mM). X-gal (1 mg/ml). The potassium ferrocyanide and potrssium ferricyanide was prepared at 
100 mM in PBS and could bc stored at 4°C for up to a week. Thc x-gal was disealved in dimethyl 
sulphoxide (DMSO) fresh when required. The x-gal wrs added to the assay solution prior to the 
rssay.
2.1.10.4 BaaCeeiolooaccSMedia
Media was stesilised by autoclaving at 121°C for 15 minutes. unless stated otherwise
LB Medium: 20g tryptone. 20g NaCl. lOg Yeast Extract to 2L with dH2O. pH adjusted to 7.0 with 
NaOH.
SOC Medium: 2% tryptoee. 0.5% yeast extract. lOmM NaCl. 2.5 mM KCl. lOmM MgCL. lOmM 
MgSCL. 20mM glucose.
56
2.2 METHODS
Common methods used throughout the thesis are described in this chapter, whilst techniques 
specific to one area are described in later chapters. Many of the methods described are based on 
standard techniques, which are detailed in Current Pr/t/e/ls in Molecular Biology Volumes 1 & 2 
(Ausubel et al. 1994).
2.2.1 Growth and manipulation of mammalian cells
2.2.1.1 Basic technique
All procedures involving manipulation of mammalian cells were carried out using standard aseptic 
procedures. Where possible all procedures were performed in a laminar flow hood.
2.2.1.1.1 Cryopreservatioii of cells -
In order to preserve stocks of cell lines for long term use, cells were stored over liquid nitrogen. 
Cells to be frozen were grown to mid-log phase (as described below) and removed into a sterile 50 
ml centrifuge tube (using trypsin-EDTA as necessary). The cells were centrifuged at 1200g for 2 
minutes, the supernatant discarded and cells re-suspended in freezing medium (appropriate culture 
medium supplemented with DMSO at 5%) to a e/neentrati/n of approximately 2 x 10" cells/ml. 
The cell suspension was transferred in 1 ml aliquots, to labelled cryovials (NALGENE™) and 
brought to -70°C at a controlled rate (-rfC/min) using NALGENE™ Cryo 1°C Freezing Container 
(NALGENE, USA). The vials were then transferred to a liquid nitrogen freezer. Cell stocks were 
revived by rapid thawing in a 37”C water bath and subsequently used following standard 
techniques as described below.
2.2.1.1.2 Cell Counting
Cells were counted using a haemocytometer as follows. Cells were diluted ten fold in media and 
lntr/Kueed to the haemocytometer chamber and counted under an inverted microscope with 4x10 
objective. Cells lying on the top and right hand perimeter of each large (1 ml) square were 
included, those on the bottom and left hand perimeter were excluded. Cell concentrations (cells/ml) 
were calculated by multiplying the mean number of cells per large square by 10' and 10 to correct 
for the dilution factor. Where an estimation of live cell numbers was required 0.4% trypan blue 
(Sigma) was used to dilute the cell suspension and allowed to incubate for five minutes at room 
temperature prior to counting; dead cells take up the stain and therefore appear blue.
2.2.1.2 Cell lines
2.2.1.2.1 Madin Darby canine kidney (MDCKQ cells
The MDCK cell line was derived from a kidney of an apparently normal female cocker spaniel in
September 1958 by S.H. Madin and N.B. Darby. The cells grow as an adherent monolayer in 
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culture and were cultured in 20-30 ml Dulbecco’s MEM with gluatamax-1 medium supplemented 
with 10% FCS and ciprofloxacin at lOpg/ml, 100 lU/ml penicillin and lOOpg streptomycin and 
fungizone in 75 cm" tissue culture flasks at 37“C, 5% CO2. Cultures were split, typically 1:9 every 
three and a half days when sub-confluent and were trypsinised and seeded into new flasks as 
described above,
2.2,1.2.2 Feline embno^uic fibroblasts (FEA)
The FEA cell line is a fibroblast cell line derived from whole feline embryos (Jarrett et al., 1973). 
The cells grow as an adherent monolayer in culture and were cultured in 20-30 ml Dulbecco’s 
MEM containing 10% FCS, 10 mM HEPES, 2 mM L-glutamine, 100 IU/ml penicillin and lOOpg 
streptomycin in 75 cm" tissue culture flasks at 37°C. 5% CO2. Cultures were split, typically 1:3 to 
1:4 every three to four days, when sub-confluent. The medium was decanted from the cell 
monolayer; the cells washed twice with Hanks medium, then incubated in trypsin-EDTA (5ml) at 
37°C for approximately five minutes. The detached cells were then washed in fresh medium and 
pelleted by centrifugation at 1200 i'pm for 2 minutes, prior to re-suspending in fresh medium and 
seeding new tissue culture flasks.
2.2.L2.3 Primary rat cardlocytes
The primary rat cardiocytes (Iwaki, Sukhatme et al., 1990), a gift from Dr. Arvind Sood, were 
provided pre-plated on 96 well plates. Cells were maintained in a mix of Dulbecco’s modified 
Eagle’s medium and medium 199 (at a ratio of 4:1) supplemented with lOOunits/ml of penicillin 
and streptomycin, 4% horse serum and 5% FCS at 37°C, 5% CO2.
2.2.1.2.4 Human chondrosarcoma cells (SW1353)
The SW 1353 cell line was initiated by A. Leibovitz at the Scott and White Clinic, Texas in 1977 
from a primary grade II chondrosarcoma of the right humerus obtained from a 72 year old female 
Caucasian. Stock cultures of cells were cultured in Dulbecco’s MEM/F-12 supplemented with 10% 
foetal calf serum, 2mM Glutamine, Ix non-essential amino acids, 100 units/ml of penicillin and 
streptomycin, 20 U/ml nystatin in 75 cm" tissue culture flasks at 37°C, 5% CO2. The cells grow as 
an adherent monolayer in culture and were split typically 1:4 when sub-confluent every 3.5 days 
and were trypsinised and seeded into new flasks as described above.
2.2.1.2.5 Mouse .undifferentiated chondroprogcnitor cells (ATDC5)
The ATDC5 cell line was isolated from a differentiating culture of murine AT805 teratocarcinoma 
expressing a fibroblastic cell phenotype (Atsumi et al., 1990). Cells were maintained in Dulbecco’s 
MEM/F-12 supplemented with 5% FCS, 3x 10® M sodium selenite, lOpg/ml human apo- 
transferrin, lOpg/ml insulin in 75 cm" tissue culture flasks at 37°C, 5% CO2. The cells grow as an 
adherent monolayer in culture and were split typically 1:9 when sub-confluent every 3.5 days and 
were trypsinised and seeded into new flasks as described above.
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2.2.1.2.6 Rabbit s\n<>\ ial fibimblast s (HIG-S2)
The HIG-82 synovial fibroblast cell line was derived from the intra-articular soft tissue from the 
knee joint of a young female rabbit (Georgescu et al., 1988). The cells grow as an adherent 
monolayer in culture and were cultured in 20-30 ml Ham's F-12 medium supplemented with 10% 
FCS and 100 IU/ml penicillin and lOO|Pg streptomycin in 75 cm" tissue culture flasks at 37”C, 5% 
COi. Cultures were split, typically 1:4 every three and a half days, when sub-confluent and were 
trypsinised and seeded into new flasks as described above.
2.2.2 Recoimfoixnjant DNA techniques
2.2.2.1 Storage and growth of bacteria
Plasmids were maintained in E.coli strains One Shot® TOP 10 and JM109. To enable storage of 
these E.coli host strains and of transformants obtained during this work, glycerol stocks were 
prepared. The desired bacterial culture was streaked onto a 1.5% agar plate (1.5% agar in LB 
medium); in all cases where the bacterial stock contained a plasmid conferring ampicillin resistance 
the medium was supplemented with 50-100pg/ml ampicillin. The plate was incubated overnight at 
37°C and the following day single colonies were picked using a pipette tip into 3-4 ml LB medium 
(supplemented with 50-100pg/ml ampicillin) in a sterile universal. The cultures were incubated at 
37"C overnight in a horizontal orbital incubator (225 rpm). Confirmation that the overnight culture 
was derived from bacteria containing the desired recombinant plasmid was achieved by DNA 
extraction (see 2.2.2.2.1) and restriction digestion (see 2.2.2.4). Glycerol stocks (15%) were 
prepared by the addition of 90pl of glycerol (50%) to 210pl of culture and were stored at -20°C and 
-70°C. Bacterial stocks were revived for subsequent work by using a sterile pipette tip to scratch 
the surface of the stock, following which it was streaked onto an agar plate as outlined above.
2.2.2.2 Extraction and purification of plasmid DNA
Plasmid DNA was isolated using a modification of the alkali lysis technique (Bimboim and Doly, 
1979).
2.2.2.2.1 Large Scajc_ Plasmid Preparations
Large quantities of high quality endotoxin-free plasmid DNA, for sequencing purposes or 
transfections, were purified from 150ml of an exponentially growing overnight culture of 
recombinant bacteria using the EndoFree® Plasmid Maxi Kit (QIAGEN, UK). An overnight culture 
(3.5ml) of the desired transformant was grown and used to seed a 250 ml culture, which was then 
grown overnight at 37°C, with shaking. The remainder of the protocol was performed according to 
the manufacturer's instmctions. DNA was stored at -20°C.
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22.2.2.2 Smail Seale Plasmid Preparations
Smaller quantities of high quality plasmid DNA, for molecular manipulation or sequencing 
purposes was purified from 4ml of an exponentially growing overnight culture of recombinant 
bacteria using the QIAprep® PCR Spin Miniprep Kit (QIAGEN, UK). The culture was spun at 
3000 rpm for 10 minutes and the supernatant removed. DNA was purified from the cell pellet 
according to the manufacturer’s instructions. In this procedure the cells were lysed to release the 
DNA constructs which were then separated by centrifugation and attached to a filter and washed 
with a buffer before being eluted in sterile water (SOjpl). DNA was stored at -20°C.
2.2.2.3 Determination of (ribo)nucleic add concentration
222.3.1 Determination by spcctropholometT
(Ribo)nucleic acid samples were diluted 1:20 by addition of 5 pi of (ribo)nucleic acid to 95 pi of 
dHiO. The optical density was measured at 260 nm and 280 nm, in comparison to a blank of dH2O. 
An optical density (OD) reading of 1,0 at 260 nm corresponds to an approximate (ribo)nucleic acid 
concentration of 50 pg/ml for double stranded DNA, 40 pg/ml for RNA, or 33 pg/ml for single 
stranded oligonucleotides. The ratio of the OD readings at 260 nm and 280 nm (OD260/OD280) was 
used to estimate the purity of the (ribo)nucleic acid. Pure preparations of DNA and RNA have an 
OD260/OD280 of 1.8 and 2.0, respectively; a lower value suggests possible protein or phenol 
contamination.
2.2.2.3.2 Estimation of double stranded DNA concentration via pel electrophoresis 
In cases where there is insufficient sample to permit quantification via spectrophotometry or where 
it was desired to verify the purity of DNA fragments of a certain size the concentration of dsDNA 
was determined by running the sample on an agarose gel (see 2.2.2.5). The intensity of the 
fluorescence of the unknown DNA was compared to that of a known quantity of the appropriate 
size marker (Low DNA Mass™ Ladder) following staining with ethidium bromide and 
visualisation by UV transillumination.
2.2.2.4 IRetrii^tic^n endonudeese digestion
Typically, 1-2 pg of DNA were digested in a 20 pi reaction mix containing the appropriate buffer 
and 5 to 10 units of desired restriction enzyme. The reactions were incubated at the recommended 
temperature (typically 37°C) for a minimum of one hour. Where the isolation of restriction 
fragments was required, larger quantities of DNA, generally 5-10 pg, were digested, with the 
reaction volume and components being increased proportionally.
Recombinant plasmids contain a variety of restriction enzyme sites. One or more appropriate 
restriction enzymes can be incubated with DNA constructs at 37°C in the correct buffer, as
determined by the manufacturer’s recommendations, to cut at specific positions and produce 
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fragments of different sizes. The sizes of these fragments could be pre-determined and then viewed 
by gel electrophoresis.
2.2.2.5 E7fctrophortsis of DMA
DNA fragments of 0.1-10 kb were separated and identified by agarose gel electrophoresis using a 
Hoefer HE 33 Mini Submarine Electrophoresis Unit (Amersham Pharmacia Biotech, San 
Francisco, CA). Typically, 0.5 - 0.1 g of agarose was added to 50 ml of 0.5x TAE buffer, melted in 
the microwave (medium for 1.5 minutes), and mixed to produce a 1 to 2% gel. Once the gel mix 
had cooled to 55°C, 1.5pl of ethidium bromide (lOOmg/ml) was added and the gel poured into a gel 
support (100 x 65 mm) in its casting tray and an appropriate gel comb (twelve or twenty well) 
inserted. The gel was allowed to solidify before transferring to an electrophoresis tank; the gel was 
immersed 0.5x TAE buffer and the comb carefully removed. DNA samples were prepared by the 
addition of an appropriate volume of lOx gel loading buffer. Molecular size standard DNA was 
prepared similarly and the samples loaded into the wells using a micropipette. Gels were run at 100 
volts for 20 to 30 minutes depending on the agarose percentage, then removed from the gel 
apparatus and visualised on a UV transilluminator (UVi tec, Thistle Scientific) and photographed 
using a Mitsubishi P91 photographic unit.
2.2.2.6 Purification ofrtstriction tnyymt frsgmtnts
Where purification of DNA fragments was required for construction of recombinant plasmids, 
DNA was purified from agarose gels using the QIAquick® Gel Extraction Kit (QIAGEN). 
Following electrophoresis, DNA fragments of interest were excised from agarose gels using a clean 
scalpel and the remainder of the procedure was performed according to the manufacturer’s 
instmctions.
2.2.2.7. Dtphosphorylation
Vector DNA was linearised using an appropriate restriction enzyme(s). However, when cut with 
one enzyme, dephosphorylation steps were required to prevent re-circularisation of the vector. Both 
5' phosphate groups were hydrolysed with 0.05 units of calf intestinal alkaline phosphatase (CIAP, 
Promega) with 50 mM Tris-HCl (pH 9.3), 1 mM MgCB, 0.1 mM ZnCla and 1 mM spermidine in a 
total volume of 50 pi at 37°C for 2-3 hours.
2.2.2.8 Ligasion oPvetcot ann it^netr DNA
2.2.2.8.1 Ligation.of rcstriccion digested DNA fraagientts
Fragments of DNA generated by restriction digestion were ligated into approximately 50-100 ng of 
vector using T4 DNA ligase (Promega) according to the manufacturer’s instmctions. Quantities of 
vector and insert DNA were calculated using a molar ratio in the range of 1:1 to 1:5 in the 
following equation:
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 X ng vector x Y kb insert x insert ; vector molar ratio = ng of insert required 
Z kb vector
Vector and insert were mixed with ligation buffer (lx) and DNA ligase (1 unit), in a total volume 
of 10 pi. Ligation reactions were allowed to proceed at 16°C overnight.
2.2.2.8.2 IJigatton using 'TA doninjg methods
Ligations of DNA fragments generated by Taq Polymerase during PCR were carried out according 
to the manufacturer’s instructions with the pCR2.1®TOPO TA Cloning Kit (Invitrogen). Briefly, 
freshly purified PCR products (15 ng) were directly cloned into the pCR®2.1-TOPO plasmid vector 
(0,5pl), incubated for 5 minutes at room temperature. Topoisomerase 1 is covalently bound to the 
ends of the linearised vector to facilitate the cloning procedure.
All ligations were stored at -20°C if not used immediately. A negative control ligation, omitting the 
DNA insert, was generally set up in parallel to the above, in order to check for ‘background’ when 
performing subsequent transformations.
2.2.2.9 TTansfoomatiojn of bacteria with plasmid DNA
In addition to the transformation with recombinant plasmid, the bacteria were also transformed 
with a control plasmid (as a positive control) and a ligation reaction from which the insert DNA 
had been omitted (as a negative control).
2.2.2.9.1 Transformation ufTOPOO cells
Cells were thawed on wet ice, gently mixed and 25-50 pi of cells were transferred to chilled 
microcentrifuge tubes for each transformation as required. Ligation reaction (0.5-5pl) or control 
plasmid (pUClS) was added to cells (1-20 ng DNA), moving the pipette through the cells while 
dispensing in order to facilitate mixing. Cells were left on ice for 30 minutes, then heat shocked in 
a 42°C water bath for 30 seconds. After heat shocking, the cells were placed on ice for 2 minutes, 
200 pi of SOC medium was added and the tubes were incubated at 3TC for 1 hour with shaking at 
225 rpm. Variable volumes of cells were plated onto LB plates containing ampicillin (100 mg/ml) 
and X-Gal stock (35 pi) solution was spread on the plate one hour prior to use if blue-white colour 
selection was used and all plates incubated overnight at 37°C.
2.2.2.9.2 Transformation of JM1109 ceils
The transformation procedure for these cells was essentially as described for TOP 10 cells with 
minor modifications. Cells were left on ice for 20 minutes before being heat shocked in a 42°C
water bath for 45 seconds. A larger volume of SOC medium (450 pi) was necessary for cell 
recovery.
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2.2.2.93 Transformation of XLl-Bluc Supercompetent ceils
The transformation procedure for these cells was essentially as described for TOP 10 cells with 
minor modifications. Cells heat shocked in a water bath at 42"C for 45 seconds and SOC medium 
(500 pi) was added for cell recovery.
2.2.2.10 Scceening of transformants for desfieC rrccmbinant plaasnids
Most plasmids used in this project conferred ampicillin resistance upon the host bacteria, allowing 
selection and maintenance of transformed bacteria with ampicillin supplemented media.
2.2.2,10.1 g- complementation
The pCR2.1®TOPO plasmids contain genes encoding the lacZa fragment of the p-galactosidase 
and the lac promoter and are therefore capable of g-complementation with the (p fragment encoded 
by the E.coli host strains DH5g, JM109 and TOP 10 One Shot™ giving active p-galactosidase. The 
incorporation of X-gal into LB agar plates allows the selection of transformants based on blue- 
white screening. Disruption of the lacZa expression occurs with the cloning of fragments into the 
MCS of the vector, hence recombinants with plasmid containing insert DNA appear white whilst 
non-recombinants, expressing a functional p-galactosidase, appear blue.
2.2.2.10.2 Restriction analysis of small-scale plasmid preparations
Plasmid DNA, isolated as described in 2.2.2.2. was subjected to restriction digestion with the 
appropriate enzyme(s) (2.2.2.4), and the resulting products of digestion were run on an agarose gel. 
Bacteria with plasmids containing inserts of the desired size were stored as glycerol stocks as 
detailed in section 2.2.2.1.
2.2.2.10.3 PCR amplification of broth or small-scale plasmid preparations
A sample of bacterial culture (50 pi) was removed and heated at 95°C for 6 minutes and 
centrifuged at 12,000 rpm for 6 minutes. Aliquots of the supernatants (lOpl) were then used as 
template in PCR reactions.
2.2.3 Preparation of total RNA
Clean, full-length RNA is essential as the starting material for molecular techniques, hence when 
isolating the RNA it was necessary to ensure that all the preparation material is free from 
ribonuclease (RNAse) activity. This is a very stable, active and ubiquitous enzyme that degrades 
RNA requiring no cofactors for function. Inhibition of this enzyme was instigated by wiping all 
equipment with RNase ERASE (ICN Biomedicals, Inc, Ohio) followed by a thorough rinse with 
DEPC treated water. All plastic-ware was treated by soaking overnight in DEPC treated water 
followed by autoclaving and drying. All solutions were prepared using DEPC treated water. Gloves 
were worn and changed frequently.
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2.23.2 RNA entt^iation using gRNAAoff B soh-ition
Various methods have been used for the isolation of undegraded RNA (Chirgwin et ai., 1979; Cox, 
1968). Progress in this field has made it possible to convert RNA isolation into a single-step 
procedure (Chomczynski and Sacchi 1987). The RNAzolIM B methods promote formation of 
complexes of RNA with guanidinium and water molecules and abolishes hydrophilic interactions 
of DNA and proteins. In effect, the DNA and proteins are efficiently removed from the aqueous 
phase with the RNA remaining in this phase during the sample extraction.
RNAzol1”1 B solution (AMS Biotechnology) (25ml) was added directly to the cell monolayer 
and the RNA solubilised by passing the lysate a few times through the pipette. Aliquots of the 
homogenate and chloroform in a 10:1 ratio were shaken for 15 seconds and then placed on ice for 5 
minutes and centrifuged for 15 minutes at 2400 rpm and 4°C. At this point the homogenate formed 
two phases: the lower blue phenol-chloroform phase and the colourless upper aqueous phase; 
whereas DNA and proteins were in the interphase and organic phase. The upper aqueous phase was 
transferred to a clean ependorf tube containing an equal volume of isopropanol (750pl) and chilled 
at 4°C for 15 minutes. The samples were centrifuged again for 15 minutes at 13,000 rpm and 4”C, 
the supernatant discarded and the RNA pellet washed once with 75% ethanol by vortexing 
followed by a final centrifuge step for 8 minutes at 13,000 rpm and 4‘C. The RNA samples were 
stored in 70% ethanol at -20°C until required. When required for further applications the RNA was 
centrifuged for 8 minutes at 13,000 rpm and 4°C, the supernatant removed and the RNA pellet 
dried at room temperature for 2 minutes (it is important not to let the RNA pellet dry completely as 
it will greatly decrease its solubility). The RNA was then re-suspended in 40 |il of DEPC water.
2.2.33Asoosoment ooRNA usinn egeaooe gee eSentJtinhonisis
RNA samples were assessed by gel electrophoresis on a 1% agarose TAE gel by comparing the 
bands to a 100 bp molecular weight standard (GIBCO BRL). The quality of the RNA samples were 
assessed by examining the integrity of the 18S and 28S ribosomal RNA bands which migrated 
through the gel at a rate corresponding to their predicted molecular weights.
2.23.4 DNase TTraarmut of RNA
Contaminating DNA was removed from RNA samples using DNA-free™ (Ambion) methods. 
Briefly, 0.1 volume of lOx DNase I (final concentration of: 10 mM Tris-HCl pH7.5, 2.5 mM 
MgCla, 0.1 mM CaCB) and 2 units of DNase I were added directly to the RNA (35pi) samples, 
mixed and incubated at 37"C for variable lengths of time (generally > Ihr). The enzyme reaction 
was stopped by the addition of DNase Inactivation Reagent (5pi) for two minutes at room 
temperature. Samples were then centrifuged at 10,000g for one minute to pellet the Inactivation 
Reagent and the supernatant containing the pure RNA was then transferred to a clean ependorf tube.
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2.2.4 First strand cDNA synthesis
The synthesis of complementary DNA (cDNA) requires the enzyme ‘reverse transcriptase’, 
initially identified as the enzyme involved in the formation of DNA-RNA hybrids in retrovirus 
replication. Reverse transcriptase synthesises a DNA strand complementary to an RNA template 
when provided with a primer that is base-paired to the RNA, containing a free 3'-0H group. 
Random primers, gene specific primers (GSP) or oligo-dT primers (the latter pairs with the poly-A 
sequence at the 3' end of most eukaryotic mRNA molecules) can be used to instigate the synthesis 
of cDNA strands in the presence of the four dNTPs. The RNA-DNA hybrid is subsequently 
hydrolysed by raising the pH (unlike RNA, DNA is resistant to alkaline hydrolysis) or using a 
ribonuclease and the 3'- end of the newly-synthesised DNA strand forms a hairpin loop priming the 
synthesis of the opposite DNA strand. The hairpin loop is removed by digestion with SI nuclease, 
which recognises unpaired nucleotides.
More specifically, total RNA samples in 9pl of DEPC water were denatured to remove any 
RNA secondary stmcture for 5 minutes at 65°C and then quenched on ice. First strand synthesis 
reactions were performed using the heat-treated RNA in a reaction mix containing reverse 
transcription buffer (Ix), reverse transcriptase (units), DTT (mM), dNTPs (pM), RNAse inhibitor 
(units) and primers (random gene specific or oligo-dT) (pM). The reaction conditions vary slightly 
between protocols but always included incubation at 42°C for 60 minutes and were completed with 
incubation at 85-95°C for 5-15 minutes. A Perkin-Elmer (PE) thermal cycler 480 was used for the 
reaction. The reaction mix was stored at 4°C before immediate use or -20°C for long term storage.
MMLV reverse transcriptase and Avian Myeloblastosis Virus Reverse Transcriptase (AMV- 
RT) are commonly used possessing RNA- and DNA-directed polymerase activity, and ribonuclease 
H activity specific to RNA in RNA-DNA hybrids
2.2.5 Amplification of DNA by the polymerase chain reaction
The polymerase chain reaction (PCR) is a powerful technique for amplification of specific DNA 
sequences from a complex mixture of DNA. The procedure was developed by Mullis and co­
workers in the mid 1980’s (Mullis et al., 1986; Mullis and Faloona, 1987) enabling large amounts 
of a single copy gene to be generated from genomic (Saiki et al., 1985; 1986) or viral DNA (Kwok 
et al., 1987). The initial method used the Klenow fragment of DNA polymerase I, which had to be 
replenished during each cycle as it is readily denatured by the amplification conditions used. The 
substitution of the thermostable Tsq polymerase, isolated from Thtrmis aquaticus, circumvented 
this problem and allowed the automation of thermal cycling (Saiki et al., 1988).
PCR enables the amplification of any unknown DNA sequence by the simultaneous extension of 
primer pairs, flanking the unknown sequence, each complimentary to opposite strands of DNA. The 
uses of PCR are many although it has been superseded by more conventional molecular biological 
methods in many areas, including sequencing (Innis et al., 1988), cloning (Scharf, 1990) and 
detection and analysis of RNA (Veres et al., 1987). An extensive overview of PCR and its
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applications is available (Innis and Gelfand, 1990) but an overview of the procedure is given below, 
with more detail in the appropriate chapters.
2.2.5.1 Primer design
Primer design was aided by some basic guidelines (Innis and Gelfand, 1990). An optimal primer 
pair should hybridise efficiently to the sequence of interest with negligible hybridisation to other 
sequences present in the sample. The distance between primers is rather flexible, ranging up to 10 
kbp, however the PCR reaction is considerably less efficient with distances > 3kbp. (Jeffreys et al.. 
1988). Smaller distances between primers lessen the ability to obtain much sequence information 
and to reamplify with nested internal oligonucleotides, if required. For any given pair, the 
annealing temperatures (Tm) and GC % were balanced.
For many applications, primers are designed to be exactly complementary to the template. For 
others, however, such as engineering for mutagenesis or new restriction endonuclease sites or for 
efforts to clone or detect gene homologues where sequence information is lacking, base-pair 
mismatches will be intentionally or unavoidably created. It is best to have mismatches, such as in a 
restriction endonuclease linker, at the 5' end of the primer; the closer to the 3' end of the primer, the 
more likely a mismatch will prevent extension.
The annealing portion of primers should generally be 18-30 nucleotides in length; it is unlikely 
that longer primers will help to increase specificity significantly. Additional sequences such as 
restriction enzyme sites, epitope tags or other desired motifs can be added to the 5" end of the 
primer, and may effect specificity of primer binding at low temperatures on complex templates so 
these primers are successfully used when amplifying from a single template vector. Primers should 
be designed with a GC content similar to that of the template, avoiding unusual sequence 
distributions such as stretches of polypurines or polypyrimidines if possible. The formation of a 
secondary stmcture such as hairpin loops greatly effects efficiency of annealing.
Primer-dimers are a common artifact most frequently observed when small amounts of template 
are taken through many amplification cycles. They form when the 3' end of one primer anneals to 
the 3' end of the other primer and polymerase then extends each primer to the end of the other. 
Therefore, these can be avoided by using primers without complementary sequences, especially in 
the 3' end (this can be minimised by optimising the MgCb concentration).
2.2.5.2 Preparation of PCR reactions
As PCR is such a sensitive procedure it is essential to take stringent precautions to avoid PCR 
contamination from tube to tube or carry over of PCR products (Saiki et al., 1988). All PCR 
reactions were set up in a designated separate room, at the side of the main laboratory where PCR 
products were handled. A set of micropipettes was kept for the sole purpose of setting up PCR 
reactions. Filter tip pipette tips were used to decrease the risk of reaction components passing from 
one tube to the next. A bulk reaction mix was used in order to minimise the number of pipetting 
steps. Reaction components (including primers) were aliquoted prior to use and stored at -20°C.
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2.2.5.3 Rtaction conditions
The use of high quality reagents is essential for the success of PCR; to facilitate this a number of 
PCR amplification kits, each containing the necessary reagents, were used following the 
manufacturers’ instmctions. Typically reaction mixes were set up in either 50 pi or 25 pi volumes 
using thin walled ependorf tubes (0.5 ml or 0.2 ml respectively). Variable concentrations of primers 
(pM), dATPs, dCTP, dTTP and dGTP (mM), MgCL (mmoVL), DNA polymerase (Units), Ix PCR 
Buffer containing Tris-HCl (mM). KCl (mM) and gelatin was mixed with an appropriate volume of 
DNA or cDNA template (ng). Thermal cycling was carried out using DNA thermal cyclers (Perkin 
Elmer). Two PCR machines were generally used, a Perkin Elmer (PE) 480 which required 
overlaying the reaction mix with mineral oil in 0.5 ml ependorf tubes, and a Perkin Elmer (PE) 
2400 size for the 0.2 ml ependorf tubes requiring no mineral oil. Cycles varied between reactions 
but generally consisted of an initial denaturation of 94°C for five minutes, followed by 25-45 cycles 
of the following; denaturation at 94°C for one minute; annealing at 55-72°C for one minute; 
extension at 72°C for one minute; with a final extension step at 72°C for 4- 30 minutes. Reaction 
products were visualised by agarose gel electrophoresis, generally using 5-10 pi of reaction product 
per well.
2.2.5.4 Purification and asstssmtnt of PCR products
Single PCR products were purified following the QIAquick®PCR purification kit protocol, 
(QIAGEN). Briefly, the DNA adhered to the filter within the column, separating it from all other 
components of the PCR reaction which were washed away with various buffer solutions. The PCR 
products were finally eluted in 30-50pl of sterile water, 4pl of which were assessed by gel 
electrophoresis on a 1% agarose TAE gel by comparing the bands created to a 100 bp molecular 
weight standard (GIBCO BRL)
2.2.6 DNA sequence analysis
2.2.6.1 Autoo/mset s squaming
Sanger dideoxy DNA sequencing is the most commonly used method for DNA sequencing, 
particularly in large-scale genomic sequencing (Sanger et ah, 1977). A variation of automated 
DNA sequencing using dye-labelled terminators, in which the dyes are attached to the terminating 
dideoxynucleoside triphosphates (Prober et al., 1987) has been used in this project.
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 Table 2-2 Commonly used sequencing primers
Primer name Primer sequence (5Z to 3Z) Tm (°C) & GC
(%) content
M13 Reverse (M13F) CAGGAAACAGC TATGAC 68.0 OC : 55.6 %
M13Forward (-20) (M13R) GTAAAACGACGGCCAG 70.9 OC : 58.6 %
GL2 ctttatgtttttggcgtcttcca 57.1 "C :39.1 %
RV3 CTAGCAAAATAGGCTGTCCC 57.3 "C : 50.0 %
RV4 GACGATAGTCATGCCCCGCGCCCACCGGAA 87.0 °C : 66.7 %
2.2.6.1.1 Sample prepanition
During sample preparation, DNA fragments in a sample are chemically labelled with fluorescent 
dyes. The dyes facilitate the detection and identification of the DNA. Typically each DNA 
molecule is labelled with one dye molecule, but up to five dyes can be used to label the DNA 
sample. More specifically, PCR reactions were performed using plasmid DNA samples (200­
500ng) in a total volume of 20pl containing 0.5pM of primers, 40mM Tris-HCl, 1mmol/L MgCL 
and 4pi of Big Dye™ Terminator Cycle Sequencing Ready Reaction (ABI Prism). Samples were 
prepared in the PE 2400 thermal cycler incorporating 25 cycles of amplification, each cycle 
consisting of a denaturation step 96°C for 10 seconds followed by an annealing temperature of 
50“C for 5 seconds, and an elongation step of 60°C for four minutes. DNA was then purified by 
precipitation methods using 3M sodium acetate (Sigma) and ethanol (95%), room temperature for 
15 minutes. Pelleted DNA (14,000 rpm for 20 minutes) was washed in ethanol (70%) and re­
pelleted (14,000 rpm for 5 minutes) before all ethanol was removed and dried at 90"C for 1 minute. 
Template Suppression Reagent (25pi) was then added and the mixture heated to 95°C for 5 minutes 
and chilled before transfer to genetic analyser sample tubes.
2.2.6.1.2 Sample sequencing
Samples were finally loaded and run on the ABI PRISM® 3100 Genetic Analyzer (PE Applied 
Biosystems, UK) under standard sequencing conditions for generation of automated sequence data. 
The ABI PRISM® 3100 Genetic Analyzer is a multi-colour fluorescence-based DNA analysis 
system using the proven technology of capillary electrophoresis with 16 capillaries operating in 
parallel. The 3100 Genetic Analyzer is fully automated from sample loading to data analysis.
2.2.6.1.3 Sequence evaluation
The length of read is 750 bases at the 98.5% base calling accuracy with less than 2% ambiguity. 
The output is in the form of a chromas file. A series of different computational software were 
utilised for sequence analysis including ‘Blast’ search engine within the NBCI database, Genetics 
Computer Group (GCG) and ClustalW (http://www.ch.embnet.org/software/ClustalW.html). 
Transfac and Motif Search.
68
2.2.7 Transient transfection of mammalian cells
Cationic liposome mediated transfection involves the incubation of cationic lipid-containing 
liposomes and DNA to associate and compact the nucleic acid (Kabanov and Kabanov, 1995; 
Labat-Moleur et al., 1996), presumably from electrostatic interactions between the negatively 
charged nucleic acid and the positively charged head group of the synthetic lipid. The 
liposome/nucleic acid complex is dispersed over the culture, entering cells by the processes of 
endocytosis, or fusion with the plasma membrane via the lipid moieties of the liposome (Gao and 
Huang, 1995). The Trans™Fast Transfection Reagent (Promega) is comprised of the synthetic 
cationic lipid, (+)-N,N [bis (2-hydroxyethyl)-N-methyl-N-[2,3-di(tetradecanoyloxy)propyl] 
ammonium iodide and the neutral lipid, DOPE, designed for high efficiency transfer of DNA into 
mammalian cells and was used in all cell types for this project.
Cells were seeded onto plates at various concentrations one day before the transfection 
experiment and incubated overnight at 37‘C, 5% COi. For optimal assay conditions the cells should 
be approximately 80% confluent on the day of transfection. The TransFast™ Reagent was thawed, 
warmed to room temperature and mixed thoroughly by vortexing while the serum-free media was 
pre-warmed to 37°C. DNA to be transfected was re-suspended in TE buffer to a final concentration 
of 0.1-0.5 [Lg/pil and the DNA purity checked by determining the ratio of absorbency at 260nm 
(A26o) and 280nm (A28o) using a spectrophotometer. Transient transfections were carried out using 
a 1:1 ratio of TransMMFast reagent with DNA according to the manufacturer’s instructions. More 
specifically, total DNA (50-100ng) was added to pre-warmed serum free media (40p.l) and 
thoroughly mixed before addition of TransFast™ Reagent (0.3p!) calculated per well using a 96- 
well plate. The DNA/transfection reagent samples were incubated for 10-15 minutes at room 
temperature to allow complex formation before the growth medium on the 96-well plates was 
aspirated and replaced with the transfection samples. The cells were incubated with the complexes 
for 1 hour at 37"C, 5% CO2 before pre-warmed complete medium was added for cell recovery 
overnight at 37°C. Initially an optimisation procedure was performed, testing various amounts of 
DNA (0.25, 0.5, 0.75, 1.0 fig per well) at charge ratios (TransFast™ Reagent to DNA) of 1:1 and 
2:1. For this initial optimisation, serum-free conditions with adherent cells in 24 well plates, using 
an exposure time of one hour was performed.
2.2.8 Genetic reporter systems
Genetic reporter systems are widely used to study eukaryotic gene expression and cellular 
physiology. Applications include the study of receptor activity, transcription factors and 
intracellular signalling in this study.
A dual reporter Assay system has been used in this project to improve experimental accuracy, by 
correcting for transfection efficiency. The term ‘dual reporter’ refers to the simultaneous 
expression and measurement of two individual reporter enzymes within a single system. In the 
Dual-Luciferase® Reporter (DLR™) Assay System, the experimental firefly {Photinst pyralit)
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 luciferase reporter (de Wet et al., 1985) is correlated with the effect of specific experimental 
conditions, while activity of the co-transfected control Rtnilla {Rtnilla. rtniftnnis) luciferase 
reporter (Lorenz et al., 1991) provides an internal control, which serves as a baseline response. 
Normalising the activity of the experimental reporter to the activity of the internal control 
minimises experimental variability caused by differences in cell viability or transfection efficiency. 
Other sources of variability, such as differences in pipetting volumes, cell lysis efficiency and assay 
efficiency can be effectively eliminated. Thus dual reporter assays often allow more reliable 
interpretation of the experimental data by reducing extraneous influences.
Both firefly and Rtnilla luciferase are immediately active upon mRNA translation, and as 
neither is naturally present in mammalian cells, their assays are not interfered with by endogenous 
enzymatic activities. As a dual-reporter system these enzymes also offer the advantage of having 
completely separate evolutionary histories and thus independent biochemistries, allowing their 
luminescent reactions to be distinguished.
DLR™ assays were performed 72 hours post transfection according to the manufacturer’s 
protocol. More specifically, media was removed from the adherent cell mono-layer, washed once 
with PBS and lysed with Passive Lysis Buffer (PLB) (lx) for 15 minutes at room temperature. 
Using a Dynex, MLX luminometer, the activities of firefly and Rtnilla luciferase activities were 
measured sequentially from single samples (per well). The firefly luciferase reporter was measured 
first by adding Luciferase Assay Reagent II (LAR II) (50p.l) to generate a ‘glow-type’ luminescent 
signal. After quantifying the firefly luminescence over 12 seconds, the Stop & Glo® Reagent (50pl) 
was then added to the same well to quench the first reaction (3 seconds) and then quantify the 
second ‘glow-type’ signal of Rtnilla luciferase activity which decayed slowly over the course of 
the 12 seconds measurement. Firefly and Rtnills luciferases, because of their distinct evolutionary 
origins, have dissimilar enzyme structures and substrate requirements, enabling the discrimination 
between their respective bio-luminescent reactions. Firefly and Rtnilla luciferase values were 
obtained for each well and analysed using an Excel Spread- Sheet.
2.2.9 .Analysis of recombinant proteins
The separation and analysis of proteins was facilitated by one-dimensional denaturing 
discontinuous gel electrophoresis (Laemmli, 1970). Proteins are denatured by boiling in the 
presence of SDS and 2-mercaptoethanol. The sample is then loaded onto a discontinuous gel 
consisting of a stacking buffer which concentrates the loaded protein sample into a narrow band 
and a separating gel which separates proteins on the basis of a molecular size, with smaller proteins 
migrating faster towards the anode. Ready Gel Precast Gels (Biorad, Herts) (8.6 cm x 6.8 cm x 1.0 
mm) of specific resolving percentage gels (and 4 % stacking gel) were selected based on protein 
size and used with the Mini-Protean 3 Electrophoresis cell (Biorad, Herts) as recommended by the 
manufacturer. Both the wells and bottom of the gel were rinsed with Ix running buffer to remove 
all traces of the preservative solution and then placed on one side of the electrode core. The buffer 
dam was slotted into the other side and the complete assembly placed into the clamp unit before
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being transferred to the electrophoresis tank. The top chamber and bottom of the tank were then 
filled with Ix running buffer. Protein samples (typically 5-30 pg of protein in 5-25 pi) were 
prepared by the addition of appropriate volume of protein sample loading buffer, followed by 
incubation at 100°C for 2-8 minutes. The samples were briefly centrifuged before being carefully 
loaded into the wells using pipette tips. A Wide Range (6.5 to 205 kDa) Color Markers molecular 
weight standard (10 pi) (Sigma) was loaded into both outer wells to allow the estimation of the size 
of sample proteins. Gels were electrophoresed at variable voltages until the bromophenol blue dye 
reached the lower part of the gel, the gel was removed from the cast and analysed further as 
determined by appropriate protein detection methods.
71
Chapter III
Cloning and expression of canine interleukin-1 receptor 
antagonist (IL-lRa) cDNA
3.1 ABSTRACT
To modify disease progression at the molecular level ‘stmcture-modifying’ therapeutic genes can 
be introduced into arthritic joints to regulate those enzymes responsible for extra-cellular matrix 
(ECM) turnover. Since the matrix metalloproteinases (MMPs) play a central role in the 
development of osteoarthritis (OA), gene-based therapeutics should include mediators for 
controlling the synthesis and activity of these enzymes at the transcriptional and/or post­
translational levels. Candidate proteins that may be of therapeutic benefit in treating OA include 
interleukin-1 receptor antagonist (IL-lRa), soluble tumour necrosis factor receptors (sTNFR) and 
various tissue inhibitors of MMPs (TIMPs). All of these genes have been cloned and sequenced in 
a number of different species and considerable sequence homology has been demonstrated at both 
the nucleotide and amino acid levels. The canine homologues of these therapeutic genes were 
cloned for future use in a homologous gene transfer study for canine disease. This chapter describes 
the cloning and sequence analysis of the cDNA encoding the canine homologue of IL-lRa using 
reverse transcription polymerase chain reaction (RT-PCR) and RNA harvested from canine 
peripheral blood mononuclear cells (PBMCs) as a template. Sequence analysis of the canine IL- 
lRa gene demonstrated an open reading frame of 531 base pairs (bp) encoding a protein of 177 
amino acids showing considerable sequence similarity with the homologous sequences published 
for other species. This chapter also describes the in vitro transcription and translation of candidate 
canine-specific therapeutic proteins including IL-lRa, TIMP~l and TIMP-2 of approximate 
molecular weights 19.5, 22.8 and 24.3 kilo Dalton (kDa) respectively; sTNFRI (23.2 kDa) was 
unable to be expressed using this system.
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3.2 INTRODUCTION
The pathogenesis of osteoarthritis (OA) involves two major components, inflammation of the 
synovial tissues and degeneration of the articular cartilage. Most standard therapies only address 
the inflammatory component since few drugs demonstrate real chondroprotective effects. However, 
the development of gene-based therapeutics promises to control both of these processes with the 
selection of appropriate therapeutic genes.
3.2.1 Candidate tHempeextic proteins
Cytokines are multifunctional glycoproteins that participate in both immune and inflammatory 
responses (Kelso, 1998) and have been implicated in specific disease processes including cardiac 
failure (Sharma et al., 2000), cancer (Burke, 1999), diabetes mellitus (Falcone and Sarvetnick, 
1999) and arthritis (Martel Pelletier et al., 1999b). In OA the regulation of matrix metalloproteinase 
(MMP) activity by cytokines and other cellular signalling molecules is an essential component of 
the pathogenesis, particularly associated with the processes of synovial inflammation and cartilage 
degeneration (Ruggeri et al., 1996). Within this cell-signalling network many potentially 
therapeutic compounds have already been identified to target disease progression at the 
transcriptional level including interleukin-1 receptor antagonist (IL-1Ra) (Caron et al., 1996) and 
soluble tumour necrosis factor receptor (sTNFR) (Mageed et al., 1998). However, gene-based 
therapeutics for OA should not only include mediators for controlling the MMPs at the 
transcriptional level but also at the post-translational level with the direct inhibition of active 
enzyme through the endogenous tissue inhibitors of MMPs (TIMPs) (Carmichael et al., 1989; 
Renggli-Zulliger et al., 1999) (Figure 3-1).
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Figure 3-1 Candidate therapeutic proteins
Therapeutic proteins may be used to control the synthesis and activation of matrix 
metalloproteinases (MMPs) at the transcriptional level using interleukin-1 receptor antagonist (IL- 
1ra) which competitively inhibits the binding of IL-1 to its receptor and the soluble tumour necrosis 
factor type I receptor (sTNFRI) which binds and inhibits TNF. thus preventing receptor activation 
and MMP transcription. Therapeutic proteins can also be used to prevent the activation of pro­
enzyme with the use of the tissue inhibitor of metalloproteinase (TIMPs) which function to prevent 
the removal of the regulatory domain of the MMP. thus inhibiting full activation of the MMPs.
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 3.2.1.1 Intcrtciikin-l annl ret^e^tG^t anttnopist
Interleukin-1 (IL-1) is a potent mediator of inflammation involved in regulating a wide variety of 
physiological and pathological events. This pro-inflammatory cytokine plays a crucial role in the 
pathogenesis of OA where it suppresses the synthesis of important structural components of the 
extracellular matrix (ECM) such the type II collagen and proteoglycans while promoting the 
synthesis of abnormal type I collagen. Furthermore, IL-1 enhances the levels of MMP gene 
transcription resulting in the degeneration of articular cartilage (Martel-Pelletier et al., 1999a: 
1991).
To date the IL-1 family consists of a number of known genes encoding ligands including two 
agonists (IL-1 a and IL-lp), an antagonist (IL-lRa) and a rarely expressed transcript (ILlHYl) with 
52% homology to IL-lRa (Mulero et al., 1999). IL-1 a, IL-1 (3 and IL-lRa share similar structural 
domains, with all three binding to the lL-1 receptor which exists in two forms, Type I (80 kDa) and 
Type II (68 kDa). Soluble forms of these receptors are produced by the cleavage of their extra­
cellular domain and it is now known that the binding of the soluble portion of the receptor to the IL- 
1 ligands may function as inhibitors of this IL-1 family (Symons et al., 1991, 1995). Another 
mechanism for IL-1 inactivation is through the antagonistic behaviour of IL-lRa which contains a 
signal peptide for extra-cellular secretion. Here, IL-IRa functions as a competitive inhibitor by 
binding to the IL-IRI cell associated receptor without inducing the signalling cascade and 
biological response observed with IL-1 (Arend, 1991; Dinarello and Thompson, 1991).
Many substances including adherent IgG, cytokines, bacterial and viral components stimulate 
the production of IL-lRa from cells which enabled the first purification of human IL-lRa protein 
(I8kDa) of 177 amino acids (22 kDa when glycosylated) (Hannum et al., 1990). Human IL-lRa 
cDNA was cloned from a human monocyte library and the 18 kDa molecule, expressed in 
Escherichia coli {E.ctli), demonstrated that the expected IL-1 induced PGE? production by 
fibroblasts was inhibited (Eisenberg et al., 1990). Further studies revealed that the recombinant IL- 
lRa protein was capable of inhibiting IL-1 bioactivity on both T cells and endothelial cells in vitrt
and was also a potent inhibitor of IL-1 induced corticosterone production in vivt (Carter et al., 
1990). Two structural variants of IL-lRa have since been described and include secreted (sIL-lRa) 
and intracellular (cIL-lRa) forms. The sIL-lRa (17 kDa) form is found in most cells capable of 
synthesising IL-1, except possibly endothelial cells and hepatocytes. The cIL-lRa (18 kDa) form is 
generally found in skin where it remains in the cytoplasm of keratinocytes and other epithelial cells, 
monocytes and fibroblasts (Arend et al., 1998). These two isoforms of IL-lRa are transcribed from 
the same gene through the use of alternative first exons to produce unique proteins (Butcher et al., 
1994). The sIL-lRa form (177 amino acids) contains a 25 amino acid leader sequence which is 
cleaved before being secreted as a variably glycosylated (152 amino acids) protein (Eisenberg, 
1990). The cIL-lRa form (159 amino acid) exists in two further forms Type 1 (Haskill et al., 1991) 
and Type 2 (Muzio et al., 1995) created by alternative splicing of clL-lRa. Yet another isoform of 
IL-lRa (16 kDa) has also been described, binding to IL-1 receptors with less avidity than the other 
isoforms (Malyak et al., 1998). The biological significance of these isoforms remains unclear but
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suggests a complex redundancy of protein function. In OA, the imbalance in the ratio of IL-1 and 
IL-lRa suggested that the decreased production of IL-lRa contributed to the destructive process 
rather than the up-regulation of IL-1 alone (Firestein et al., 1994). The suggestion of IL-lRa as a 
therapeutic agent in OA has been reinforced by the use of intra-articular injections of IL-lRa alone 
to reduce the pathological changes associated with osteoarthritis in the dog (Pelletier et al., 1997) 
and in the rabbit (Fernandes et al., 1999).
3.2.1.2 Tumour necrosis factor and receptors
TNF has also been implicated in the pathogenesis of OA (Martel-Pelletier, 1999a) as an important 
mediator of inflammation, tissue destruction and the immune response by inducing cell growth, 
proliferation and apoptosis (Edwards et al., 1994). TNFa is synthesised as an inactive precursor 
(proTNFa) requiring cleavage at the Ala76-Val77 bond for activation via TNFa converting enzyme 
(TACE), an adamalysin enzyme containing an MMP domain (Black et al., 1997) with a suggestion 
that TACE is up-regulated in OA-affected cartilage (Amin, 1999). Many cell types produce TNF 
and its biological effect is mediated by the binding to one of two structurally distinct receptors: type 
I (TNF-RI; p60 or p55) and type II (TNF-RII; p80 or p75). The extra-cellular domains of both 
receptors are shed from the cell surface by proteolytic cleavage by the MMPs and have the ability to 
bind TNFta and act as natural inhibitors. However since dissociation of TNFa from TNF-RI appears 
to be almost irreversible in comparison to the transient binding to TNF-RII it would appear that the 
former would act as a useful therapeutic target (Dinarello and Moldawer, 2000).
The control mechanism inhibiting the biological effects of TNF was first evaluated in the late 
eighties when two distinct TNF receptors were identified containing similar extra-cellular domains 
that bound with equal high affinity to TNF (Hohmann et al., 1989). It was then hypothesised that 
the soluble proteins, isolated from human urine and capable of specifically binding TNF, 
represented shed forms of cell surface cytokine receptor (Englemann et al., 1990). The cloning and 
structural analysis of the TNFR revealed a signal peptide followed by an extra-cellular domain, a 
trans-membrane region and an intra-cellular region (Schall et al., 1990). The prediction that the 
shedding of the extracellular domain of the TNFR might be used as a protective mechanism by cells 
was confirmed with the cloning of a 55 kDa TNF receptor. It was found that this domain bound 
stoichiometrically to TNF neutralising TNF bio-activity in different assay systems (Loetscher et al., 
1991). In OA, imbalance in the ratio of TNF and its receptors, in particular the decreased 
production of sTNFR, may contribute to the destructive process rather than the up-regulation of 
TNF alone (Kammerman et al., 1996). The suggestion of sTNFR as a therapeutic agent in OA has 
been re-inforced by the delivery of sTNFR to SCID mice with B and T lymphocytes to prevent the 
development of arthritis (Mageed et al., 1998).
For the development of a homologous gene transfer study for canine OA the canine homologue 
for sTNFRI was selected. Canine sTNFRI has been cloned and sequenced to reveal an open reading 
frame of 633 bp encoding a predicted protein of 211 amino acid, corresponding to the soluble extra­
cellular domain of the protein (Campbell et al,, 2001b); submitted to Genbank Accession number:
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AFO13955. When compared with the sTNFRl sequences published for other species, the canine 
sequence showed considerable homology at the nucleotide level exhibiting 90, 84, 85. 80 and 80% 
similarity to feline (Accession number: U72344), human (Himmler et al., 1990). bovine (Lee et al., 
1998), murine (Goodwin et al., 1991) and rat (Himmler et al., 1990) sequences respectively. The 
canine sTNFRI protein also demonstrated 89. 79, 71, 69 and 67% sequence similarity with the 
feline, human, bovine murine and rat sequences respectively at the amino acid level. The canine 
sTNFRI amino acid sequence alignment with other species (Campbell et al., 2001b) demonstrated 
24 conserved cysteine residues thought to be important for ligand binding and two potential N- 
linked glycosylation sites. A signal peptide sequence of 21 amino acids starting at the first ATG 
codon for methionine is thought to exist with its cleavage necessary for maturation of the protein 
(Goodwin et al., 1991).
3.2.1.3 Ticsue inhibitors ofmetalloprotetnase
Control of MMP activity is not governed by cytokines alone but involves a system of complex 
protein interactions. One group of proteins particularly implicated in the regulation of the MMPs 
are the TIMPs (Brew et al., 2000), which are present in all connective tissues (Cawston, 1996). The 
TIMPs constitute a family of four polypeptide inhibitors that inhibit the action of MMPs at two 
levels, through the tight binding to the active forms of the MMPs (Murphy and Willenbrock, 1995) 
and through prevention or delay of MMP activation from the quiescent form (DeClerk et al., 1991). 
Human TIMP-l was cloned (Docherty et al., 1985) and shown to be a 20 kDa variably glycosylated 
protein of 208 amino acids (Carmichael et al., 1986) and human TIMP-2 was later described as a 21 
kDa non-glycosylated protein in its secreted form (Stetler-Stevenson et al., 1989). Mammalian 
TIMPs have two domains, at the N-terminal and C-terminals, each stabilised by three disulfide 
bonds (Williamson et al., 1990). The N-terminal domain is capable of forming a stable native 
molecule that has inhibitory activity against the different MMPs (Murphy et al., 1991). For example 
TIMP-l was found to interact reversibly with MMP-1 and MMP-3 (Woessner, 1991) and MMP-9 
(Goldberg et al., 1992), binding with high affinity as a major inhibitor of these enzymes. The C- 
terminal domain enables non-inhibitory complex formation with MMPs demonstrated by the 
binding of TIMP-2 to the pro-form of MMP-2 at a stabilisation site distinct from the active site 
(Kolkenbrock et al., 1991). Both TIMP-l and -2 have been isolated from rheumatoid synovial fluids 
(Osthues et al., 1992) and disruption of the balance between the MMP and the TIMPs in favour of 
the MMP production has been implicated in the destruction of cartilage in OA (Dean et al., 1989). 
Furthermore, a decreased incidence of joint erosion in arthritic mice was demonstrated following 
systemic administration of TIMP-l (Carmichael et al., 1989). Since then it has been found that both 
TIMP-l and TIMP-2 block collagen degradation in IL-1 stimulated cartilage model systems (Ellis 
et al., 1994).
For the development of a homologous gene transfer study for canine OA the canine homologues 
for TIMP-l and TIMP-2 were selected. The canine homologue for TIMP-l was cloned and 
sequenced to reveal an open reading frame of 624 bp encoding a predicted protein of 207 amino
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acids (23 kDa) (Zeiss et al., 1998); submitted to Genbank Accession number: AF077817. When 
compared with the TIMP-2 sequences published for other species the canine sequence was shown to 
share 80-85% nucleotide sequence identity and 66-83% identity in the deduced amino acid 
sequence with homologous mammalian human, bovine, sheep, pig, rabbit, mouse and rat sequences. 
The canine TIMP-1 amino acid sequence alignment with other species (Zeiss et al., 1998) 
demonstrated conserved regions including two potential glycosylation sites and 12 cysteine 
residues, forming six disulphide bonds, that divide the protein into two distinct domains. One 
domain binds the active metalloproteinase, and the other binds the latent, inactive form of the 
enzyme (Matrisian, 1990). A consensus sequence, VIRAK, found in all four TIMPs (Greene et al., 
1996) is present at amino acid positions 41-46 in the canine promoter.
The canine homologue for TIMP-2 was also cloned and sequenced to reveal an open reading 
frame of 663 bp encoding a predicted protein of 220 amino acids (Campbell et al., 2001b); 
submitted to Genbank (Accession number: AF112115). When compared with the TIMP-2 
sequences published for other species the canine sequence showed considerable homology at the 
nucleotide level exhibiting 92, 89, 89 91% similarity to human (Stetler-Stevenson et al.. 1989), rat 
(Cook et al., 1994), mouse (Shimzu et al., 1992), bovine (Boone et al., 1990) sequences 
respectively. Furthermore, canine TIMP-2 protein demonstrated 96, 97, 96 and 93% sequence 
similarity with the human, rat, murine and bovine sequences respectively at the amino acid level. 
The canine TIMP-2 amino acid sequence alignment with other species (Campbell et al.. 2001b) 
demonstrated conserved domains with 12 cysteine residues, forming six disulphide bonds (DeClerk 
et al., 1991). The N-terminal domain necessary for the MMP inhibitory activity is also conserved 
(DeClerk et al., 1993) with the VIRAK sequence present in this domain, thought to be of particular 
importance. A signal peptide of 26 amino acids is present starting at the ATG codon for methionine 
to the first conserved cysteine residue (Shimizu et al., 1992) and as with other published TIMP-2 
sequences there are no predicted N-glycosylation sites within the canine coding sequence.
3.2.2 Consti^ctio]tn of7 therapeutic vectors
Candidate therapeutic genes can be evaluated using appropriate vector systems containing the 
necessary regulatory sequences for efficient gene expression. The therapeutic gene is cloned as a 
transcriptional unit containing the coding region of the gene as complementary DNA (cDNA) or 
genomic DNA (gDNA), and all necessary regulatory sequences in the immediate 5' and 3' 
untranslated regions (UTR) for efficient transcription and translation. However, the effect of the 
therapeutic protein is not only determined by the efficiency of transcription and translation but also 
on the steady state level of proteins.
3.22.1 The coding region of the gene
In eukaryotes most protein-eoding regions of the DNA sequence do not read out co-linearly into 
messenger RNA (mRNA) but are composed of an alternating array of coding sequence, called 
exons separated by intervening pieces of non-protein coding DNA referred to as introns. The
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removal of these intronic sequences from the initial RNA transcript and the joining of all exons in a 
head to tail arrangement occurs through a precise mechanism mediated by the splicing machinery in 
the nucleus to form mRNA (Weiner. 1993). Intronic sequences, present in gDNA, often contain 
functional enhancer elements necessary for efficient translation. It may therefore be desirable to use 
gDNA to express the gene of interest, however these intervening sequences can span up to hundreds 
of kilobases (kb) and present problems associated with the cloning and delivery systems using 
currently available mammalian expression vectors. As an alternative cDNA, which is a direct copy 
of the mRNA transcript, can be made in vitro, and used to directly transcribe and translate genes to 
a functional protein. The cDNAs encoding the therapeutic canine genes IL-lRa, sTNFRI, TIMP-1 
and TIMP-2 are discussed in this chapter.
J.2.2.2 The immediate 5' untranslatedregion (UTR)
The 5' UTR of the gene is important for the initiation of gene transcription since it is responsible 
for the binding of RNA polymerase to the initiation site enabling the addition of nucleotides in a 5' 
to y' fashion to form the primary RNA transcript. The nucleotide at the 5Z end of the transcript is 
usually modified post-transcriptionally by the addition of a methylated guanine (G) residue linked 
by a 5' to 5' triphosphate-bridge. This feature, referred to as a ‘Cap’ structure, is essential for the 
efficient initiation of protein synthesis. The 5' UTR is also important in translation initiation 
enabling the binding of the 40S ribosomal sub-unit to the region immediately up-stream to the 
translation start codon (AUG). This ribosomal component moves to the first AUG where the 60S 
ribosomal subunit joins to produce the first peptide bond. Translation initiation from the mRNA 
template is the rate limiting step in protein synthesis and is controlled by the context and position 
of the AUG with its surrounding secondary structure and length of 5' UTR. The optimal context for 
initiation is 5' GCC(A/G)CCAUGG T where the A of the AUG codon is referred to as the +1 
nucleotide. The most critical residues controlling the efficiency of initiation are purines at positions 
-3 and +4, usually an ‘A’ and ‘G’ respectively. The presence of multiple upstream initiation sites 
serves to suppress the initiation efficiency from the correct site. Position of the AUG codon is also 
extremely important since approximately 90% of vertebrate mRNAs are initiated from the first 
AUG codon without giving preference to an optimal context. Secondary structure of the RNA is 
also of great importance since the hairpin loop, 12-15 nucleotides downstream of the AUG, causes 
the 40S ribosomal subunit to temporarily stall and facilitate initiation. Secondary structure located 
in this position also serves to minimise ‘leaky’ initiation and permit translation from weak AUG 
codons. However, high degrees of secondary structure (hairpins) upstream of the AUG may have 
the opposite effect by preventing the translocation of the 40S ribosomal subunit to the AUG 
required for initiation; this serves as a useful control mechanism for translation. The length of the 5' 
UTR is also a crucial factor in the efficiency of the translation process with a minimum of 
approximately 20 nucleotides required for initiation from an optimal AUG (Kozak, 1991). An 
optimal Kozak sequence (AXXATGG) was incorporated into the 5' end of the cloned therapeutic 
cDNAs described in this chapter.
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3.2.2.3 The immediate 3' untranslated region
The 3' UTR, defined as the mRNA sequence following the termination codon (TAA. TAG) is 
thought to play a role in mRNA transcript stability, providing a determinant of mRNA levels and 
also playing a role in protein synthesis through the control of translation (Jackson and Standart, 
1990). The half-life of mRNA molecules determines the length of time that the template is 
available for protein synthesis and this can vary from several minutes for some cytokines to 100 
hours for stable mRNAs (Peltz et ah, 1991). However, the half-life may not always be constant and 
will change with the conditions of the cell. The rapid turnover of mRNA has been linked to cis­
acting instability elements present within the RNA sequence. One of these instability elements is in 
the class of AU-rich elements (ARE) containing the pentameric motif AUUUA in a U-rich context 
sufficient for rapid mRNA degradation (Vakalopoulou et al., 1991). This rapid degradation process 
is important for transient- induction of molecules and rapid cellular changes that occur in response 
to the environment providing the fine-tuning of protein levels within the cell.
The minimal, mammalian poly(A) signal, also located in the 3' UTR, is composed of an 
AAU AAA motif 20-30 nucleotides in length and serves to control the termination and processing 
of the primary RNA transcript with the formation of the poly(A) tail on the mRNA transcript 
(Proudfoot, 2000). This homopolymeric stretch of adenine (A) residues is added to the primary 
transcript by a post-transcriptional nuclear processing mechanism, termed polyadenylation. The 
importance of the polyadenylation signal is in the formation of the poly(A) tract of the mRNA is to 
provide stability and translatability (Peltz et al., 1991). Lengthening of this poly(A) tract tends to 
control mRNA translation and increase its stability while shortening leads to degradation. An 
optimal mammalian poly(A) signal for the 3' ends of the therapeutic mRNAs was provided by 
mammalian expression vector pTarget (Promega) as described in this chapter.
3.2.2.4 Therapeutic protein stability
The effects of the therapeutic protein are not only determined by the efficiency of transcription and 
translation but also on the steady state level of proteins. The level of protein depends not only upon 
the rate at which mRNA is synthesised, processed, transported, translated and degraded but also the 
rate of protein turn-over. The half-life of a protein determines its steady state level with in the cell 
(Hargrove and Schmidt, 1989). Most proteins are stable, but those proteins that vary with time or in 
response to the physiological status of the cell are regulated by proteolysis (Varshavsky, 1992). 
Proteolysis occurs through cytosolic, ATP-dependent pathways that do or do not require 
ubiquitination, or by lysosomal pathways (Dice, 1990). Protein stability is more difficult to control 
and has not been considered in this chapter since the expression system used, in vitro transcription 
and translation, was independent of cellular function.
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 3.3 MATERIALS AND METHODS
Candidate canine-specific therapeutic genes, IL-lRa, sTNFRl and TIMP-2 were cloned within our 
research group and a full description of cloning procedures can be found in appendix 1 (Campbell 
et ah, 2001). The canine TIMP-1 construct was a generous gift from Dr. Noritake (Japan) (Nontake 
et ah, 1999). Since the cloning procedures were similar for each gene this chapter only describes 
the cloning of canine IL-lRa which was performed entirely by the author. Overviews of the 
experimental procedures employed in this chapter are illustrated in figure 3-2. Briefly, canine 
peripheral blood mononuclear cells (PBMC) were stimulated with lipopolysaccharide (LPS) and 
RNA isolated using RNAzol™B techniques. The canine IL-lRa cDNA was isolated using reverse 
transcription polymerase chain reaction (RT-PCR) and primers based on sequence homology 
between the sequences published for different species. PCR products were cloned into 
pCR21®TOPO vector and sequenced. The canine IL-lRa, sTNFRI, TfMP-l and TIMP-2 cDNAs 
were sub-cloned into pTarget mammalian expression vector (Promega) and expressed using in vitrt
transcription translation protocols (Promega).
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Figure 3-2 Overview of experimental procedures used to clone and express canine
specific therapeutic cDNAs
The canine IL-lRa cDNA was cloned using RT-PCR and the sequence analysed. The canine 
homologues of IL-lRa. sTNFRl. TIMP-1 and TlMP-2 were sub-cloned into pTarget mammalian 
expression vector and expressed using in vitro transcription and translation techniques.
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 3.3.1 Preparation of RNA from canine peripheral blood mononuclear cells
3.3.1.1 Isolation of lipopolysaccharide stimulated canine peripheral blood mononuclear
cells
Canine PBMCs, stimulated with LPS, were used as a substrate for the isolation of canine IL-lRa by 
RT-PCR, based on the knowledge that LPS-activated mononuclear cells are a potential source of 
this antagonist (West et al., 1996). Canine whole blood (30ml) preparations were diluted with an 
equal volume of isotonic Alsevers solution (Scottish Antibody Production Unit) and 5pl aliquots 
were overlaid on Ficoll-Hypaque, Lymphoprep (gradient solution, Nycomed) before being 
centrifuged for 20 minutes at 2000 rpm, room temperature. The cells in the interface between the 
plasma and lymphoprep were removed, divided in two with additional Alsevers to create a final 
volume of 14 ml in each sample and then centrifuged (brake setting low) for 10 minutes at 1000 
rpm, room temperature. The supernatants were discarded and the cells within the pellet slowly re­
suspended in RPM I 1640 medium supplemented with L-glutamine, 10% foetal calf semm (FCS), 
Penstrep, 2-mercaptoethanol (2ME) and LPS (5pg ml') at 37”C under 5% CO2 in air for 24 hours. 
The total number of cells were then calculated with a ten fold dilution of the cell suspension in 
counting stain, viewed under the light microscope and the number of mononuclear cells counted.
3.3.1.2 Isolation of total RNA
Purified RNA was essential as the starting material for the cloning of the IL-lRa gene, and thus 
when isolating the RNA it was necessary to ensure that all the preparation material was free of 
ribonuclease (RNAse) activity. RNAzol™ B solution (AMS Biotechnology) (25ml) was added 
directly to the flasks containing the adherent PBMCs for lysis. Aliquots (1.2ml) of the lysed cell 
solution were shaken for 15 seconds with chloroform (120pl) and RNA isolated as described in 
section 2.2.3. The RNA samples were re-suspended in DEPC water (40jll) and the quality and 
quantity assessed using spectrophotometry and agarose gel electrophoresis.
3.3.2 Reverse Transcription Polymerase Chain Reaction (RT-PCR)
The technique of RT-PCR was chosen to clone canine IL-lRa since there was considerable 
sequence homology between the IL-lRa sequence published for the different species, enabling the 
design of PCR primers based on conserved regions flanking the protein coding sequence. RT-PCR 
also offers a simpler and potentially faster approach than techniques involving the generation and 
screening of cDNA libraries. The ultimate aim of this project was to express the canine cytokine as 
protein using a mammalian expression vector system therefore it was only necessary to obtain the 
protein coding cDNA sequence.
3.3.2.1 Fiat stand cDNA syyithhssi
The synthesis of first strand cDNA followed the basic principles as set out in section 2.2.4. More
specifically, total RNA samples (2|ug) in 9_l of DEPC water were heated for 5 minutes at 65°C and 
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then quenched on ice. Reactions were performed using the heat treated RNA in a 25|h1 reaction mix 
containing 5|il of reverse transcription buffer (5x), 200 units of Molony Murine Leukemia Virus 
reverse transcriptase (MMLV-RT) (GIBCO BRL), lOmM dTT, 250|uM dNTPs, 25 units RNase 
inhibitor and 25|uM random primers. The reaction was incubated at 37°C for 30 minutes followed 
by 42°C for 60 minutes and completed with 95°C for 5 minutes. A Perkin-Elmer (PE) thermal 
cycler 480 was used for the reaction.
3.3.2.2PCR amplification
3.3.2.2,1 Primer design
Primers for PCR were designed as described in section 2.2.5.1, according to regions of sequence 
homology between different species and were synthesised, and supplied by MWG-Biotech (Table 
3-1). The melting temperature (Tm) and guanine/cytosine (GC) content of each primer have been 
noted. These primers were expected to amplify a cDNA of approximately 550 nucleotides in size, 
containing the complete coding sequence of the canine IL-lRa gene.
Table 3-1 Primer sequences for the PCR amplification of canine IL-lRa cDNA
Primer name Primer sequence (S' to 3') Tm (°C) & GC (%)
content
IL-lRaf GCCTTGAATTCGAATTCATGGAAACCTGCAGGT 68.2OC : 45.5%
IE-1Rar GGCCTCTAGATCTAGATTATTCCTTCTGGAAG 66.9°T : 43.8%
3.3.2.2.2 PCR conditions
PCR was performed as described in section 2.2.5. More specifically, canine cDNA samples (100 
ng) were used as a template in a total volume of 50pl containing 0.4pM of both sense primer (IL- 
IRaf) and anti-sense primer (IL-lRar), 0.2mM of dATPs, dCTP, dTTP and dOTP, 1.5 mmol/L 
MgCL and 2 units of Taq DNA polymerase (QIAGEN, UK). Mineral oil was added to the surface 
of the mixture to prevent evaporation, before being placed in the PE 480 thermal cycler. Samples 
were subjected to an initial denaturation at 95°C for 5 minutes followed by 35 cycles of 
amplification, each cycle consisting of a denaturation step of 95OC for one minute and annealing 
temperature of 60°C for 1 minute, followed by an elongation step of 72°C for one minute. A final 
elongation step at 72°C for 30 minutes completed the reaction. Taq polymerase added a single 
deoxy-adenosine (A) to the 3' ends of duplex molecules to enable PCR products to be ligated 
efficiently with the linearised vector containing complementary single 3’deoxythymidine (T) 
residues. PCR products (8pl) were visualised by gel electrophoresis on a TAE agarose gel (1%) and 
compared with a 100 bp molecular weight standard. A negative control containing all PCR 
components (primers, dNTPs, PCR buffer and Taq polymerase) except template was included to
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ensure that there was no contamination of the PCR reactions with extraneous DNA that might serve 
as a template for PCR amplification.
3.3.3. Cloning into pCR®2.1-TOPO
PCR products were cloned using methods described in section 2.2.2. Briefly, PCR products were 
purified following QIAquick®PCR purification kit protocol, and eluted in 50pl of sterile water, 4pl 
of which were assessed by gel electrophoresis on a TAE agarose gel (1%) by comparing the bands 
created to a low DNA Mass™ Ladder. Purified PCR products were directly ligated into the 
pCR®2.1-TOPO plasmid vector following the TOPO TA® cloning protocol. The ligation reactions 
(2|h1) were then transformed into One Shot™ TOP 10 competent cells and spread onto agar plates 
containing ampicillin and X-gal for incubation overnight at 37°C. White, ampicillin resistant, 
colonies were selected from the plates and cultured overnight in LB/ampicillin broth at 37°C and 
glycerol stocks of each culture were prepared for long term storage.
The DNA constructs were isolated from overnight cultures by the alkaline lysis method of 
plasmid DNA isolation following the QIAprep®PCR Spin Miniprep Kit (QIAGEN, UK) and eluted 
in 50pl of sterile water. DNA samples were then assessed by spectrophotometry for quantification. 
Samples were screened for those containing the insert by restriction enzyme digestion. pCR2.1/cIL- 
IRa constiucts (500ng) were digested with £coRl restriction enzyme (7.5 units) and Buffer 6 in a 
total volume of 20pl at 37°C for 4 hours. Samples were analysed by agarose gel electrophoresis to 
identify the presence of inserts.
3.3.4 Sequence evaluation of constructs
Recombinant plasmids were sequenced and analysed as described in section 2.2.6. Briefly, 
recombinant plasmid samples (400 ng) were amplified using the Big Dye™ Terminator Cycle 
Sequencing Ready Reaction (ABI Prism) with 0.5pM of both sense (M13R) and anti-sense (M13F) 
vector-based primers. The DNA was purified using ethanol precipitation methods before samples 
were loaded into the ABI 310 genetic analyser for generation of automated sequence data.
Sequences were stored and managed on a UNIX computer system using Genetics Computer 
Group (GCG) software (University of Wisconsin). ‘Raw’ sequence data was extracted from the 
Chromas files and edited using the ‘SeqEd’ program. The sequence was placed into the Blast search 
engine (NCBI database) to verify that the sequence was the canine homologue of IL-lRa. Three 
independent sequences were then aligned using the ‘pile-up’ command to produce a consensus 
sequence for the canine IL-lRa gene of 531 bp and the amino acid sequence was then predicted 
using the ‘Translate’ software on GCG. The sequence was finally submitted to the Genbank 
database.
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3.3.5 Sub-cloning of therapeutic cDNAs into pTarget™ mammalian 
expression vectors
3.3.5.1 lPhnee design
Sense and anti-sense oligonucleotide primer pairs were designed according to the 5' and 3' ends of 
the canine IL-lRa (cIL-lRaf and cIL-lRar), sTNFRI (csTNFRIf and csTNFRIr), TIMP-1 (cTIMP- 
If and cTIMP-lr) and TIMP-2 (cTIMP-2f and cCIMP-2r) gene sequences respectively (Table 3-2). 
A conserved kozak sequence (A**ACGG) was applied to all forward primers, flanking the start 
site, to provide optimal translation of the gene product. All primers were designed ‘in frame’ with a 
stop site (TAA) present in all reverse primers. Primers were synthesised and supplied by Sigma- 
Genosys.
Table 3-2 Primer sequences for the PCR amplification of canine IL-lRa, sTNFRI,
TIMP-1 and TIMP-2
Primer name Oligonucleotide primer sequence 5' to 3' Tm (°C) & GC
(%) content
cIL-lRaf CCGGATATCATGGAAACCTGCAGGTGTCCT 78.0 OC -53.3 %
cIL-lRar ggcttattccttctggaagtagaa 62.5 tC :41.7 %
csTNFRIf CCGGATATCATGGGCCTCCCCACCGTGCCT 85.5 I : 66.7 %
csTNFRIr GGC TTAGGTGGAGCCTGGGTCCTG 75.0 0C :66.7 %
cTIMP-lf CGGGTCGACTATGGCACCCTTTGCGCCCCTGGC 89.0 °C : 69.7 %
cTIMP-Ir CGGTTAGGCCATCCGGGGCCGCAGGGACTGCCA 91.4 °C: 72.7 %
cCIMP-2f CGGGGTACCATGGGCGCCGCGGCCCGCAGCTT 94.8 °C :78.1 %
cTIMP-2r GGCTTATGGGTCCTCGATGTCGAGAAACTCCTG 79.1°C:54.5%
3.3.5.2 PCR ccondtionn
PCR reactions were performed using lOOng of canine pCR2.1/cIL-lRa, (csTNFRI), (CIMP-1), 
(TIMP-2) samples as template in a total volume of 50pl containing 0.4|iM of both sense primer and 
anti-sense primer pairs (Table 3-2), 0.3mM of dATPs, dCTP, dTTP and dGTP, ImM MgSC>4 and 2 
units of Platinum Pfic DNA Polymerase (GIBCOBRL UK). This high fidelity enzyme provided 
strict proof reading of the sequence to reduce the chance of introducing mutations. Using a PE 
2400 thermal cycler, samples were subjected to an initial denaturation at 95°C for 5 minutes 
followed by 25 cycles of amplification, each cycle consisting of a denaturation step of 95°C for 30 
seconds and annealing temperature of 60°C for 30 seconds, followed by an elongation step of 68°C 
for one minute.
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 3.3.5.3 PurrfCcction oP PCR productt ann anditicti op dATPs
PCR products were analysed using TAE agarose gel (1.5%) electrophoresis and purified using the 
QIAquick®Gel Extraction kit (QIAGEN). Since Platinum Pfx DNA Polymerase can not add dATPs 
to the 3' ends of DNA, required for ligation to the complementary single dTTP residues found on 
the pTarget™ Mammalian Expression vector, an additional elongation step was then performed 
using Taq polymerase. As described earlier, Taq has a non template-dependent activity allowing 
the addition of a single deoxy-adenosine (dATP) to the 3' ends of duplex molecules. The purified 
DNA (35p.l), in a total volume of 50|il containing 0.3mM of dATP, 1.5mM MgCE and 1 unit Taq
polymerase, was incubated at 72°C for 30 minutes. PCR products were purified following 
QIAquick®PCR purification kit protocol (QIAGEN) and eluted in 30pl of sterile water, 4|al of 
which were assessed by agarose gel electrophoresis.
3.3.5.4Ligattnn anA transformation canint thtraptctic cDNAs
Freshly purified PCR products were directly ligated into the pTarget™ Mammalian Expression 
vector following the manufacturer’s guidelines (Promega). The quantity of DNA for each ligation 
reaction was determined using the equation shown in section 2.2.2.8.1: where X is 60ng, Y is 0.6, Z 
is 5.67 and the molar ratio was 3. The ligation reactions were set up in a total volume of lOpl 
containing DNA as calculated above and 3 units of T4 DNA ligase and incubated at 16°C overnight. 
Subsequently, ligation reactions (Ipl) were transformed into JM109 High efficiency Competent 
Cells (50|il). Transformed cells were spread onto agar plates containing ampicillin and incubated 
overnight at 3TC. Ampicillin resistant colonies containing the construct were selected from each of 
the plates and cultured overnight in LB/ampicillin broth at 3TC and glycerol stocks of each culture 
were prepared for long term storage.
3.3.5.5 Isolation anA scrttning odrtcombinantplasmids
The DNA constmcts were isolated from overnight cultures by the alkaline lysis method of plasmid 
DNA isolation following the QIAprep®PCR Spin Miniprep Kit (QIAGEN, UK) and eluted in 50 ftl 
of sterile water. The DNA samples were then assessed by spectrophotometry for quantification. 
PCR product/pTarget vector constructs (500ng) were screened using EctRl restriction enzyme 
digestion as described in section 3.3.3.
3.3.5.6Stqctnct tvalcatinn ndconstructs
Recombinant plasmid samples (400 ng) were sequenced with 0.5 pM of both sense (T7F) and anti­
sense (pTargetR) vector-based primers (Table 3-3) using the ABI 310 genetic analyser as described 
earlier. Chromas files generated from the ABI 310 genetic analyser for each of the cDNAs were 
analysed using ClustalW software to align the correct predicted sequences with the sample 
sequences to check for the absence of mutations.
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Table 3-3 Primers for sequencing pTarget/cDNAs
Primer name Primer sequence (5' to 3') Tm (»C) & GC (%)
content
T7F: TAATACGACTCACTATAGG 50.2 "C : 36.8 %
pTargetR: AGATATGACCATGATTACGCCAAG 68.0 "C :41,7 %
3.3.5.7 Plaamid veedo maps
Using computer software, plasmid vector maps were drawn from the sequence data information 
incorporating all the important components of each vector including the cDNA sequence. CMV 
promoter, T7 promoter, polyadenylation signal and ampicillin resistance gene.
3.3.6 Expression of cDNAs
3.3.6.1 In vitn tirnncciption/tlrnnsSation ctfcDNAs
The in vitro transcription/translation technique for expressing the canine cDNAs was chosen since 
it was a convenient, single tube reaction to verify that the cloned genes could be efficiently 
expressed from the mammalian expression vectors before employment in a tissue culture 
expression system. Using this technique the canine homologues of IL-lRa, sTNFRl, TIMP-2 
(Campbell et al., 2001b) and TIMP-1 (Zeiss et al., 1998) were expressed in vitro from the 
pTarget™ Mammalian Expression vectors using the TNT® T7 Quick Coupled 
Transcription/Translation System (Promega).
The TNT® Quick Coupled Transcription/Translation System enabled the in vitro eukaryotic 
transcription and translation of genes within circular plasmids, cloned down stream of a T7 RNA 
polymerase promoter. Using the radioisotope ['MSSmethionine, the synthesised radioactively labelled 
proteins were then analysed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
autoradiography. To reduce the chance of RNase contamination, precautions were taken as outlined 
in section 2.2.3. More specifically, plasmid samples (500 ng) were mixed with TNT® Quick Master 
Mix (20 jxl), [MS]meehionine (0.38MBq) to a final volume of 25 fil with nuclease free water and 
then incubated at 30°C for 90 minutes and stored at -20°C. The positive control plasmid used in this 
experiment was the Luciferase T7 Control DNA (4331 bp) for the expression of the firefly 
luciferase protein (61 kDa). A negative control was also employed containing no DNA to allow for 
the measurement of any background incorporation of labelled amino acids.
3J.6.2 SDS-PAGE
Recombinant proteins were expressed and analysed using SDS-PAGE as described in section 2.2.9. 
A ready precast gel (8.6 cm x 6.8 cm x 1.0 mm) containing a 10 % resolving gel and a 4 % stacking 
gel with 10 wells was assembled in the Mini-Protean 3 Electrophoresis cell (Biorad, Herts). Protein 
samples (5 pi) were prepared by the addition of 20 pi of protein loading buffer, followed by
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incubation at lOO°C for 2 minutes and loaded onto the gel with a Wide Range (6.5 to 205 kDa) 
Color Markers molecular weight standard (10 pi) (Sigma). The gel was electrophoresed at 200 
volts until the bromophenol blue dye reached the lower part of the gel and was then removed from 
the gel cast.
3.3.6.3 Protcen VV-iuuhss^^aoi
The gel was fixed with ‘fixing solution’ for 30 minutes with slow agitation on an orbital shaker. The 
gel was then placed on a sheet of Whatman® 3MM filter paper, covered with plastic wrap and dried 
at 80°C for 3 hours under a vacuum using a gel drier. Once completely dry the gel was exposed to 
film for 20 hours at -80‘C. Che film was developed and then realigned with the gel to identify the 
positions of the molecular weight markers.
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 3.4 RESULTS
3.4.1 RNA quantity and quality
Full-length, total RNA was isolated from LPS stimulated canine PBMCs using RNAzol™B 
solution. Good quality RNA samples were obtained as determined by ultraviolet spectrophotometry 
(A260/A280 value of >1.6) and agarose gel electrophoresis assessment (Figure 3-3); the RNA 
migrated through an agarose gel (1%) revealing intact 18s and 28s ribosomal RNA components.
3.4.2 PCR amplification and cloning of the canine IL-lRa cDNA
RNA samples (2pg) were subjected to first strand synthesis using MMLV-RT and random primers 
to produce canine cDNA. The cDNA samples were used as the template for the amplification of IL- 
IRa gene using sense (IL-lRaf) and antisense (IL-lRar) oligonucleotide primers and Taq DNA 
polymerase. The PCR products obtained migrated on a agarose gel (1%) to show a DNA fragment 
of approximately 550 bp (Figure 3-4). There were no bands present in the negative control reaction.
Subsequently the PCR products were cloned into pCR21®TOPO plasmid vectors and constructs 
were screened with EcoRl restriction enzyme digestion for those containing the insert. EctRl
restriction sites, present within the vector sequence, were positioned immediately upstream and 
downstream of the insert and released a 550 bp product on digestion. Plasmid clone numbers 2-4 
were positive for a 550 bp product on restriction digestion and clone 1 contained an insert of a 
slightly larger size (Figure 3-5).
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 Figure 3-3 Assessment of RNA quahtY using TAE agarose gel electrophoresis.
The two distinct bands represent the undegraded sub-components (28s and 18s) of ribosomal RNA
Figure 3-4 PCR amplification of IL-lRa from canine cDNA.
A single PCR product was obtained which migrated on a agarose gel (1%) to show a DNA 
fragment of approximately 550 bp. No products were present in the negative control.
Figure 3-5 Restriction enzyme analysis of pCR2.1/cIL-lra for positive clones
Plasmids 2, 3, 4 contain an insert of the correct size, approximately 550 bp, on EcoR I digestion
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 3.4.3 DNA sequence analysis of the canine IL-IRa gene
Three independent PCR products independently cloned into pCR2.1®TOPO plasmid vectors and 
were selected and sequenced on an automated ABI310 genetic analyser using both forward (M13R) 
and reverse (M13F) vector-based primers. The three sequences were subjected to computational 
analysis.
3.4.3.1 Searching database with sequence
The nucleotide sequences determined from the genetic analyzer were assessed using the ‘Blast’ 
search engine within the NBCl database. The nucleotide sequence was compared to every gene 
sequence within the data bank to identify those genes with which this new sequence shared the 
greatest homology. Che results revealed that the nucleotide sequences were comparable to the IL- 
IRa sequence already cloned in other species, confirming that a unique canine IL-lRa gene had 
been cloned.
3.4.3.2 Nucleotide and deduced amino acid sequence of canine IL-lRa cDNA..
The sequence data obtained from the cloned individual PCR products were analysed using the GCG 
DNA sequence analysis software. The nucleotide sequences were aligned and examined for 
identical base pairs between sequences. Any anomalies were corrected by referring back to the 
appropriate chromas files until a consensus nucleotide sequence had been created. Che canine IL- 
IRa nucleotide sequence demonstrated a single open reading frame of 531 base pairs (Figure 3-6) 
encoding a protein of 177 amino acids (Figure 3-7) as determined by the GCG translation software.
3.4.3.3 Comparison of canine IL-lRa nucleotide and protein sequences to other
species.
Canine IL-lRa was analysed in an alignment with the IL-lRa nucleotide (Figure 3-8) and protein 
(Figure 3-9) sequences for the different species to identify regions of conserved sequence. The 
results showed that the canine sequence exhibited 85%, 84%, 85%, 88%, 83%, 88% similarity to 
human (Carter et al., 1990), murine (Zahedi et al., 1991), rabbit (Goto et al., 1992), equine (Kato et 
al., 1997), rat (Eisenberg et al., 1991) and porcine (Genbank L38849) sequences respectively (Table 
3-4), A high level of sequence similarity was also evident at the protein level with canine IL-lRa 
sequence demonstrating 79%, 77%, 76%, 79%, 75% and 83% amino acid sequence similarity with 
human, murine, rabbit, equine, rat and porcine sequences respectively (Table 3-4). The canine IL- 
IRa amino acid sequence alignment demonstrated a conserved N-linked glycosylation site present 
at the amino acid position 109-111 and five cysteine residues at amino acid positions 25, 91, 94, 
141 and 147.
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Figure 3-6 The cDNA sequence of canine IL-lra
The sequence has been deposited in Genbank DNA sequence database (Accession number: 
AF216526)
1 ATGGAAACCT GCAGGTGTCC TCTCAGCTAC CTAATCTCTT TCCTCCTTTT
51 CCTGTCCCAT TCAGAGACAG CCTGCCGTCC CTTGGGGAAG AGACCTTGCA
101 GGATGCAAGC CTTCAGAATC TGGGATGTTA ACCAGAAGAC CTTCTACCTG
151 AGGAATAACC AACTAGTCGC TGGATACTTG CAAGGATCAA ATACTAAATT
201 AGAAGAGAAG TTAGATGTGG TGCCCGTCGA GCCTCATGCC GTGTTCTTGG
251 GGATCCATGG GGGGAAGCTG TGCCTGGCCT GTGTCAAGTC TGGAGATGAG
301 ACCAGGCTCC AGCTGGAGGC CGTTAACATC ACTGACCTGA GTAAGAACAA
351 GGATCAAGAC AAGCGCTTTA CCTTCATCCT CTCAGACAGT GGCCCTACCA
401 CCAGCTTTGA GTCTGCTGCC TGCCCTGGCT GGTTCCTCTG CACAGCACTG
451 GAGGCCGACC GGCTTGTCAG CCTCACCAAC AGACCAGAAG AGGCCATGAT
501 GGTCACTAAG TTCTACTTCC AGAAGGAATA A
Figure 3-7 The deduced amino acid sequence of canine IL-lRa
1 METCRGPLSY LISFLLFLSH SETACRPLGK RPCRMQAFRI WDVNQKTFYL
51 RNNQLVAGYL QGSNTKLEEK LDWPVEPHA VFLGIHGGKL CLACVKSGDE
101 TRLQLEAVNI TDLSKNKDQD KRFTFILSDS GPTTSFESAA CPGWFLCTAL
151 EADRLVSLTN RPEEAMMVTK FYFQKE*
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Figure 3-8 Alignment of the IL -lra nucleotide sequences of different species
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Figure 3-9: Alignment of the IL-lra amino acid sequences of different species
Alignment of different species: canine, murine, rat, porcine, human, rabbit and equine. Conserved 
cysteine residues are identified by an asterix (*) and the conserved N-linked glycosylation site is 
identified by an inverted arrow (A). The cleavage site, indicated by an arrow ( allows formation 
of the mature protein.
1 ▼ 50
canine
murine
rat
METCRCPLSY 
..I.WG.Y.H
LISFLL--FLS
...L..IL.F
...L..IL.F
HSETACRPLG
...A....S.
KRPCRMQAFR IWDVNQKTFY
.... K............
....K............
. . . T...............
. . .T................ . I. .G.Y.H R. .S.GH.A.
porcine . .VS .YLC.. ........................ F . ...H. . .
human . . I . .GLR.H . .TL............ F . . I . . . S . RKSSK............
rabbit .RPS .STRRH . . . L............ F ...............s.
equine . . IR .RSVRH . . . L............ F Y, . .. .H. . . .K............
51 100
canine LRNNQLVAGY LQGSNTKLEE KLDWPVEPH AVFLGIHGGK LCLACVKSGD
murine . . I. . . . . .P.I.... . I .M..IDL. S . , S.A....
rat . . I. . . . . . P............... . T • M..IDFR N. . S...............
porcine ... P............... . T F . . S...............
human ...P.VN... . T . ...1. . . .T. M. S...............
rabbit ...P.A.... RI . . ..L..Q LL. . . .QR. . S...............
equine M. . . . -E............ Q. . T . . . .1. -D .Li. ..L..R.
101 150
canine ETRLQLEAVN ITDLSKNKDQ DKRFTFILSD SGPTTSFESA ACPGWFLCTA
m^irine DIK. ...E.. ..................... EE ............ R.E K. . .................. T
rat D.K. ...E.. ....N..-EE ............ R.E T. . ............... L ............... T
porcine .MK. ..D... ....R..SE. ............ R. .
human .............E .RK. ..A..R..
rabbit KMK. H............ ....G...E. ............ R.N ..T.... S.
equine .I.F ......................EE M . ............ R.N
* ★
151 179
canine LEADRLVSLT NRPEEAMMVT KFYFQKE
murine . P . . . . .T...PLI.. ...EDQ
rat HEP ... .T.K.PCT.. ...EDQ
porcine QP.G.. .T.KA.VK.. ■..QDQ
human M. . . QP-- -. .M.D.GV... ...EDE
rabbit QP-- -. .T.DDSIV.. -..EDQ
equine Q. - . .P.... .K.K.SF... .L.EDQ
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Table 3-4: The percentage of sequence homology between the canine IL-lra nucleotide and
amino acid sequences and other species
Species Percentage of nucleotide homology Percentage of amino acid homology
to canine IL-lra to canine IL-lra
Equine 88 79
Pig 88 83
Human 85 79
Rabbit 85 76
Mouse 84 77
Rat 83 75
3.4.4 Sub-cloning of cDNAs into pTaiigei expression vector
PCR reactions were performed using canine pCR2.1/cIL4Ra, (csTNFRI), (cTIMP-1), (cTIMP-2) 
samples as template and sequence-specific primer pairs with high fidelity Platinum Pp: DNA 
Polymerase. The PCR products obtained migrated on a TAE agarose gel (1.5%) to show DNA 
fragments of 550 bp, 600 bp, 620bp and 650 bp representing IL-lRa, sTNFRI, TIMP-1, TIMP-2 
respectively (Figure 3-10). Subsequently the PCR products were cloned into pTarget™ Mammalian 
Expression vector and screened with restriction enzymes for those containing the insert. One clone 
was selected from each and sequenced on an automated ABI310 genetic analyser using both 
forward (T7F) and reverse (pTarget) vector-based primers to confirm the sequence and ensure that 
no mutational errors had occurred during the cloning procedure. Vector maps for the canine 
cDNAs in pTarget mammalian expression vector (Promega) were drawn for pTarget/cIL-lRa 
(Figure 3-11), pTarget/csTNFRI (Figure 3-12), pTarget/cTIMP-1 (Figure 3-13) and 
pTarget/cTIMP-2 (Figure 3-14).
3.4.5 Expression of cDNAs
The in vitro transcription/translation technique was used to express the cloned canine specific 
cDNAs from the pTarget mammalian expression vector. The radioactive isotope }35S |methionine 
was used to visualise the proteins using autoradiography (Figure 3-15). The positive control showed 
a strong band at 61 kDa and there were no bands evident in the negative control. Bands of 
approximately 19.5 kDa, 22.8 kDa and 24.3 kDa were clearly visible for IL-lra, TIMP-1 and TIMP- 
2 respectively providing evidence for their expression from the vector. No band was seen in the lane 
corresponding to the sTNFRI.
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 Figure 3-10 PCR amplification of the canine homologues of IL-lra, sTNFRI, TIMP-1
and TIMP-2 for subcloning into the pTarget Mammalian expression vector.
The PCR products obtained migrated on a 1,5% TAE agarose gel to show a DNA fragments of 550 
bp. 600 bp. 620bp. 650 bp representing IL- lRa. sTNFRI. TIMP-1. TiPM-2 respectively
TIMP-l TIMP-2
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Figure 3-11 Vector map for pTARGET/cIL-lRa
Figure 3-12 Vector map for pTARGE'T/csTNFRI
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Figure 3-13 Vector maps for pTARGET/cTIMP-1
Figure 3-14 Vector maps for pTARGET/cTIMP-2
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 Figure 3-15 Expression of canine IL-lRa, sTNFRI, TIMP-1 and TIMP-2 from pTarget
mammalian expression vector.
The positive control showed a strong band at 61 kDa and there were no bands evident in the 
negative control showing low background levels. Bands of approximately 19.5 kDa. 22.8 kDa and 
24.3 kDa were deedy visible for CL-1do. TIMP-J and TIMP-2 respeetivvly provvdhng evidence of 
their expression from the vector. No band was svvc in the lane corresponding to the sTNFRl.
Color marker
IL-lRa sTNFR TIMP-1 TlMP-2 Positive Negative (kDa)
45.000
29.000
20.000
66.000
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3.5 DISCUSSION
For the development of a homologous gene based therapy for canine OA, the canine homologue of 
IL-lra was isolated, cloned and sequence analysed. Candidate canine specific proteins IL-lra, 
sTNFRI, TIMP-I and TIMP-2 were also analysed using in vitro transcription and translation 
techniques.
3.5.1 Prediction of canine IL-lRa biological function based on sequence
homology
The assumption that the cloned gene is the canine IL-IRa equivalent is based on the high degree of 
sequence homology at both the nucleotide (Figure 3-8) and protein levels (Figure 3-9) with other 
species of IL-lRa. The high level of nucleotide sequence conservation between the different species 
is not discussed in detail since it directly reflects the deduced amino acid sequence which is closely 
related to biological function.
The sequence alignments show many areas of homology including an N-linked glycosylation 
site present at amino acid positions 109-111 and five cysteine residues at positions 25, 91, 94, 141 
and 147. The first cysteine residue at position 25 is thought to act as the cleavage site for the 
removal of the N-terminal 25 amino acid leader sequence via a leader peptidase to produce a single 
mature non-glycosylated protein of 152 amino acids (17kDa) (Eisenberg et al., 1990).
Extensive site-directed mutagenesis studies have been used to identify residues in IL-1Ra and 
IL-I involved in the binding to IL-IRI. These studies revealed that the two IL-la/3 agonists 
contained two sites for IL-IRI binding whereas the IL-lRa molecule only contained one. It was 
subsequently hypothesised that the presence of these two receptor binding sites was necessary for 
agonist activity (Evans et al., 1995a). Specific amino acids necessary for receptor activation once 
binding has occurred were subsequently identified by a series of amino acid substitution 
experiments where it was revealed that replacing the aspartate (D) residue at position 145 with 
lysine (K) conferred agonist activity to IL-lRa. Furthermore, it was shown that the substitution of 
the (-pleated sheet structure (QGEESN) found within IL-1 at residues 48-53 into IL-lRa sequence 
after position 51 or 53 resulted in a 3 to 4 fold increase in bioactivity (Greenfeder et al., 1995). The 
structural similarities of canine IL-lRa with other species predict that the canine IL-lRa will share 
the same basic biological functions. The high degree of homology within the sequences indicates 
the importance of this inhibitor among several mammalian species.
3.5.2 In vitro transcription/translation of the canine IL-lRa, sTNFRI, 
TIMP-1 and TIMP-2
The in vitro transcription and translation of candidate therapeutic proteins was used to assess the 
expression levels from the pTarget mammalian expression vector system. Proteins of the predicted 
sizes for the non-glycosylated canine homologues of IL-lra, TIMP-1, and TIMP-2 were evident on 
SDS PAGE analysis, although sTNFRI was not (Figure 3-15).
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The predicted size for the erninr nvn-glyeosylrtre soluble IL-lra protein was approximately 
19.5kDa based on the eee-drtrrmicee amino acid sequence. In efmerrisfc the human soluble IL- 
IRa is translated with a lrrerr sequence and promptly processed to a 17 kDa eretiee, glycosylated, 
and prerrtrd by cells as a 22 to 25 kDa species (Eisenberg et al., 1990). This protein is distinct from 
the intracellular form of IL-lRa which is an 18 kDa eeetier that lacks the lrrere sequence, is not 
glycosylated and remains within the icter-eellulae seaes (Haskill et al., 1991). The predicted size for 
the cndide nod-glyeosylnted TIMP-1 is 22.8 kDa protein (Zeiss et al., 1998) which is larger than the 
human TIMP-1 described as a 20 kDa variably glycosylated protein of 184 amino acids 
(Carmichael et al., 1986). The predicted size for the canine cvc-glyevsylntre TIMP-2 was 24.3 kDa 
which again is larger than the human TIMP-2 protein which has been erseribse as a 21 kDa non- 
glycosylated protein of 194 amino acids in its sreertee form (Strtlrr-Strvsnsvn et al., 1989).
The predicted size for the nvn-glycvsylntre sTNFRI molecule was 23.2 kDa; however expression 
of sTNFRI protein from the eTarget/sTNFR construct was not possible. This could be due to the 
eeesrner of a strong hairpin secondary structure in the 5' UTR of the plasmid sequence which can 
impair translation efficiency (Frrdees et ah, 1992). There may also be an neditivdal start codon 
(ATG), introduced into the 5' end of the cloned region, that was not identified on sequence analysis. 
If the ribosome scans from the 5'' end of the RNA and begins translation at the first start site 
encountered, the gedvrntiod of false sites may initiate translation prior to the desired start codon 
resulting in a frame shift of the open reading frame and the formation of a ti^cated protein. The 
sequence of the sTNFRI drrds to be reanalysed before rreertidg the in vitro transcription 
translation procedure.
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3,6 SUMMARY
This chapter describes the isolation and expression of the canine specific therapeutic gene IL-lRa. 
Three additional candidate proteins were also analysed including sTNFR, TIMP-1 and TIMP-2. 
These therapeutic proteins were selected for incorporation into the gene-based therapy for canine 
OA based on the current understanding that they are intimately involved in the regulation of MMP 
activity in the joint where they play a critical role in tissue homeostasis.
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Chapter IV
Cloning of canine matrix metalloproteinase -9 and -13 
gene promoters
4.1 ABSTRACT
Levels of therapeutic gene expression are strictly controlled at the transcriptional level by 
regulatory regions of DNA termed promoters. Candidate promoters that have potential for use in 
driving disease-specific expression in arthritic joints include those that are up-regulated by pro­
inflammatory cytokines and growth factors associated with the pathogenesis of osteoarthritis (OA). 
Since it is well documented that elevated levels of matrix metalloproteinases (MMPs) in the joint 
are primarily implicated in the degeneration of articular cartilage it was thought that MMP 
promoters would be useful in this targeting strategy. Many MMP genes and their promoters have 
been cloned and sequenced in a number of different species and considerable sequence homology 
has been demonstrated at both the nucleotide and amino acid levels. The canine homologues of 
MMP promoters were cloned for use in a homologous species-specific targeted gene transfer study 
for canine disease. This chapter describes the cloning and sequence analysis of the canine MMP-9 
and MMP-13 gene promoters. The 5' untranslated regions (UTRs) were obtained by genome 
walking upstream of the canine MMP-9 and -13 translation start sites using genomic DNA (gDNA) 
as template. DNA fragments of 1894 and 1494 bp were isolated and on analysis demonstrated 
regions of sequence homology with the equivalent promoter sequences already determined for 
other species. In general, conserved regions correlated with numerous putative DNA binding motifs 
including Activator Protein-1 (AP-1) sites and a Nuclear Factor (NF)-kB binding domain. A 
consensus TATA-(like) box was identified in each case and shown to direct transcription initiation 
from specific positions upstream of the translation start site.
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4.2 INTRODUCTION
4.2.1 Targeting gene therapy
Successful gene therapy not only requires the identification of appropriate therapeutic genes but 
also on an accurate targeting system to limit therapeutic gene expression to specific cell types. 
Numerous gene delivery systems, both plasmid and viral, have been manipulated to improve 
targeting specificity at the cell s unface and transcriptional levels. Targeting at the cell surface level 
can be achieved by manipulating the surface recognition components of vimses and liposomes and 
at the transcriptional level by incorporating transcriptional elements into plasmid or viral genomes 
such that the therapeutic gene is expressed only in certain cell types.
To target therapeutic gene expression at the level of the cell surface, retroviral vectors have been 
manipulated by replacing or altering the glycoprotein (Env) on the lipid envelope to recognise 
specific receptors on the host cell surface (Miller and Vile, 1995). Ligands, such as lactose, have 
also been coupled to the outside of retroviral particles allowing them to be recognised by 
asialoglycoproteins and internalised by hepatocytes (Neda et a., 1991). Adenoviral vectors have 
been targeted in a similar manner by covalently linking the fibre carbohydrate, responsible for viral 
binding and internalisation, to an asialoglycoprotein polylysine conjugate (Wu et al., 1994). 
Liposomes can also be targeted for in vivo use by displaying appropriate tropic and fusogenic such 
as transferrin used to increase specificity to bone marrow erythroblasts (Stavridis et al., 1987) and 
surfactant protein A for tropism to alveolar cells (Walther et ai., 1993). Targeting of plasmid DNA 
can be achieved by coupling DNA to ligands with demonstrated cell or tissue affinity. For example, 
a polycation (e.g. polylysine) can be covalently linked to a ligand, to condense the plasmid DNA 
and expose the ligand on the cell surface (Michael and Curry, 1994) such as insulin (Rosenkranz et 
al., 1992), epidermal growth factor (EGF) (Chen et al., 1994) and lectins (Batra et al., 1994).
Gene therapy vectors can also be targeted at the genetic level by placing therapeutic gene 
expression under the control of regulatory promoter elements that possess binding sites specific for 
transcription factors required for controlling levels of gene expression. The transcriptional targeting 
approach for regulating therapeutic gene expression in response to the disease progression is 
discussed in this chapter.
4.2.2 Candidate disease-specific promoters
Mammalian matrix metalloproteinase (MMPs) constitute a family of proteolytic enzymes acting 
together to degrade the components of extra-cellular matrices thereby regulating connective tissue 
turnover and they have been implicated in many physiological processes including embryonic 
development and tissue remodelling (Matrisian, 1992). Furthermore, unregulated activity of MMPs 
have been associated with pathological processes such as tumour invasion (Nelson et al., 2000), 
heart failure (Spinale et al., 2000) and inflammatory processes such as arthritis (Martel Pelletier, 
1999b). Of the MMPs, the gelatinase and collagenase groups have been intensively studied and 
associated with the development of arthritis. The gelatinase, MMP-9 and the collagenase, MMP-13
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were therefore selected and the canine homologues of their promoters cloned and sequenced for 
driving disease specific expression of therapeutic genes.
4.2.2.1 Matrix metalloproteinase-9
The gelatinases are known to comprise two collagenases. MMP-2 (Gelatinase A) and MMP-9 
(Gelatinase B) with substrate specificity for native type IV collagen, denatured collagen (gelatin), 
type V, VII, X, and XII collagens, elastin and vitronectin, but not type I collagen, proteoglycan or 
laminin (Huhtala et al., 1991). The MMP-2 gene is constitutively expressed from a wide range of 
cell types, in comparison the inducible MMP-9 gene is selectively expressed in neutrophils, 
monocytes and macrophages. Originally MMP-9 was identified as a product of polymorphonuclear 
leukocytes (Murphy et al, 1982) and pulmonary alveolar macrophages (Hibbs et al., 1987); yet it 
was not until the early 1990’s that the sequence of the MMP-9 gene was determined (Huhtala et al., 
in 1990, 1991). The role of gelatinases in joint disease has been studied in man with elevated levels 
of MMP-9 demonstrated in human rheumatoid arthritis (RA) synovial fluid (Koolwikj et al., 1995). 
High levels of MM-9 have also been demonstrated in canine disease from both osteoarthritic 
(Coughian et al., 1995) and rheumatoid synovial fluid samples (Goughian et al., 1998) in addition to 
equine articular tissues (degg et al., 1997). More specifically, gelatinase B is intimately associated 
with the development of chronic synovitis (Grillet et al, 1997) and bone remodelling associated 
with the arthritic processes (Okada et al., 1995). The desire to determine the role of MMP-9, in both 
physiological and pathological states, has prompted the cloning and sequences analysis of the gene 
encoding this enzyme. As such the gene, along with the promoter in some cases, has been analysed 
in a number of different species including the human (Huhtala et al., 1991), rabbit (Fini et al.,
1994) , mouse (Masure et al., 1993) and rat (Eberhardt et al., 2000).
4.2.2.2 Matrix metaUoprotennase-13
The collagenase group has been shown to comprise four different enzymes, MMP-1 (interstitial 
collagenase), MMP-8 (neutrophil collagenase), MMP-13 (collagenase-3) (Gawston, 1996) and 
MMP-18 (Stowlow et al., 1996). The collagenases degrade fibrillar collagens cleaving all three a 
chains of Type I, II and III collagens at a single site, producing fragments approximately % and 1 
the size of the original molecule, and in addition degrade type X collagen and serum amyloid A 
(Gawston, 1996). Human MMP-13 was first discovered in tissue samples taken from a breast 
carcinoma and found to be homologous to rat interstitial collagenase (MMP-1) (Frieje et al., 1994). 
However, there is only one rodent interstitial collagenase that has been described and this shares 
86% homology with human MMP-13, but not with the human or rabbit MMP-1 (Schorpp et al.,
1995) . Elevated levels of MMP-13 have been found in a variety of connective tissues including 
osteoarthritic synovial tissue (Wernicke et al., 1996) and articular chondrocytes (Mitchell et al. 
1996; Shlopov et al., 1997). Further evidence to support the role of MMP-13 in OA arose from 
studies showing that MMP-13 expression co-localised with type II collagen degradation in active 
OA lesions where it degraded type II collagen more rapidly than MMP-1 (Mitchell et al., 1996).
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Additionally, inhibition of MMP-13 in errtilrgr explaint models greatly reduced type II collagen 
destruction while its ovsr-exeeession in transgenic mice erusee cartilage destruction strongly 
resembling OA (Neuhold et al., 2001). The desire to determine the role of MMP-13 in both 
physiological and pathological states has prompted the cloning and sequence analysis of the gene 
encoding this enzyme. As such the genes, along with the promoter in some eases. has been 
analysed in a number of different seseivs including human (Tardif, Pelletier et al.. 1997) and rabbit 
(Vincenti, Coon et al., 1998). These gene sequences also show considerable sequence similarity to 
the eollngecnse-1 (interstitial efllngedass) promoter region identified in the mouse (Sehorep, 
Mattei et al., 1995) and rat (Rajah-imar and Quinn, 1996).
4.2.3 Construction of anti-arthritic therapeutic vectors
Disease-inducible promoters are evaluated using appropriate vector systems containing all the 
necessary regulatory sequences for efficient gene expression. The promoter region of a gene refers 
to the DNA sequence immediately 5' to the translation start site containing those elements required 
for controlling the rate of gene tradseriptiod initiation. The DNA sequence of the promoter has no 
coding function, but contains a series of sequence motifs, ranging from a few to up to tens of 
nucleotides in length, that serve as sites for the interaction with fra/ty-acting protein components of 
the transcriptional machinery. The locus control region (LCR) also serves to regulate genes 
positioned in the down-stream location. (Figure 4-1).
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Figure 4-1 Transcription
The transcriptional unit in genomic DNA consists of the structural gene and the Hanking extra­
genic DNA containing the promoter. The position marked ( l^% corresponds to the nucleotide 
position at which initiation of RNA transcription of the gene begins, this defines the start of the 
structural gene. The promoter is further dissected into component parts, the core promoter, 
upstream activator sequences (UAS). enhancers and locus control region (LCR). The binding of 
TBP and TAFs to the TATA box and formation of the TFllD complex results in the recruitment of 
RNA polymerase to the transcription initiation site. The folding of the DNA in this region allows 
transcription factors bound to up-stream DNA motifs to participate in promoter activation and gene 
transcription. In most cases the primary RNA transcript begins at a sequence which serves a non­
coding function in the final mRNA product. The translation start codon (ATG: methionine) is 
found down stream of the transcription initiation site, in the first exon. The protein coding sequence 
of the RNA transcript terminates at the stop codon (TAA. TAG or TGA) and then continues into 
the 3' region incorporating the polyadenylation signal (AATAAA) which signals the termination of 
the transcript and the addition of polyA residues. Splicing of the primary RNA transcript joins the 
different exons in a precise head to tail fashion followed by capping of the 5' end giving rise to the 
final mRNA transcript.
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4.2.3.1 S' Untranslated region
The promvtvr/eegulntory region of the gene comprises four important components fucctifding 
together to recruit RNA polymerase to the transcription site. These include the core
promoter, adjacent up-stream activator sequences (UAS), enhancers and a locus control region 
(LCR) (Whalen, 1994). The coos promoter can be defined as the 30 or 40 duelvotiees immediately 
5' to the transerietifd initiation site. Within this short region most promoters usually contain a 
TATA box sequence motif TAT(a/t)(ViO(a/t)(a/t), one of the minimal elements necessary for 
transeriptiodal initiation providing low levels of transcription. Upstream activator sequences 
comprise a collection of regulatory elements found within several hundred nucleotides upstream of 
the core promoter. These motifs appear to play a major role in stimulating transcription by 
interaction with the core promoter elements. The enhancer region forms part of the complex areay 
of regulatory elements, usually spndcidg several kb and functioning bi-directionally. They are also 
located throughout the coding region, within inti'mic sequence, and can also be ffude in the 3' 
UTR.
The LCR is composed of several types of activator elements. Although the precise eole of this 
region still needs to be defined, it has a major effect on gene expression. A series of in vitro and 
transgenic mouse studies of the human P-globin gene have shown that the LCR appears to confer 
position and copy number independent expression of thv genes plnese under its control suggesting 
that the LCR-peomoter-gene complex functions as an independent regulatory unit. The LCR is 
eodsievred an area of chromatin containing DNA sequence motifs accessible to numerous GATA- 
1, NF-E2 (Andrews et ah, 1993) and SPl proteins alrerey known for their importance in promoter 
regions. However, these sequence motifs may not deeessrrily be involved in the binding of these 
proteins but instead have roles unique to the LCR. It has also bvvn demonstrated that if a foreign 
promoter is experimentally introduced closer to thv LCR than the endogenous gene that it eegulates 
then the introduced transgede is activated at the expense of the endogenous one (Kim et ah, 1992), 
The mechanism of this action is still not elucidated and requires further research; two ^00^1 
theories of action are shown in Figure 4-2.
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Figure 4-2 Mechanism of action of the LCR
Two theories have been offered for the mechanism of action of the LCR using the human [3-globin 
gene as an example. The first is the polar effect on expression on the different genes during 
development. It is thought that in this model the activation effect of the LCR is proportional to the 
distance from the individual promoters. The second model is that the differential expression of 
genes is due to competition between the different genes based on the promoter components. A final 
explanation may be a combination of both theories.
Proximal Trans-acting Transcription Factors
no
4.2.3.2 Transcription factors
The final component of a functional promoter is the eresenee of transacting factors (protein 
transcription factors); representing the trrnserietional machinery that binds to specific DNA 
sequences within the 5' regulatory region (Whalen, 1994). Several classes of these proteins exist 
which can be differentiated based on their protein structure which enables specific interaction with 
DNA or other proteins to form multimers (Harrison, 1991). Examples of protein domains that 
participate directly in the binding to DNA include the homevdomnin proteins containing helix-turn- 
helix motifs and the Zinc finger containing proteins. Examples of protein domains that participate 
directly in the binding to other proteins and form multimers through a eimerisrtion motif are 
known as leucine zippers and include tracseriptivn factors c-Fos and c-Jun (Albee, 1992); the 
adjacent basic region allows the dimer to bind DNA. Dimeeisation is an important feature of 
transcription factor formation especially where heterodimers can be formed since there is the 
potential for a combinatorial increase in the possible regulatory elements formed. Ac example of 
this is the AP-1 teacscriptioc factor complex efntaicicg both c-Jun and c-Fos proteins. The 
dimension process also applies to all proteins containing the helix-loop-helix (HLH) motif 
responsible for prfteic-protvic ictveaetiocs and includes c-myc and MyoD.
4.2.3.3 Gene transcription
The binding of transcription factors to the promoter regions of DNA is necessary for the process of 
transcription with the recruitment of RNA polymerase to the tracserietioc initiation sites. Basal 
levels of tencseeiptioc icitirtioc involve the binding of specific proteins to the efre promoter. A 
protein cnllee TBP (TATA-binding protein) binds to the TATA box sequence within this region 
(Nikolov et al., 1992), in addition to other proteins erllee TAFs ^BP-Associated Factors) 
(Greecblatt, 1992), A protein complex is then built up around the TBP (referred to as TFIID) 
providing multiple points of interaction with factors binding to other regulatory elements capable 
of interacting with the TAFs of the core promoter protein-DNA complex (Gill and Tym, 1992). 
The arrangement of these transcription factors at this site helps to position the RNA polymerase 
molecule in the vicinity of the start site so that accurate initiation can take place (Rosdvr, 1991). 
The basal level of gene transcription varies between promoters due to specific combinations of 
transcription factors TFIIB, TFIIE, TFIIF and TFIIE involved in the transcription initiation 
complex (Parvm et al., 1992). However, these levels can be increased with the involvement of the 
upstream activation sequences (UAS). Although the multiple UAS for the binding of transcription 
factors appear to lie within a linear sequence, the precise 3-dimecsifcal rrracgvmect is somewhat 
different and provides an important contribution to the level and specificity of tracserietiocal 
activity driven from the core promoter. It is now widely known that the interaction of the 
transcription factors with TBP and TAF complex invokes specific bending of the DNA to bring all 
necessary factors into contact; the actual linear sequence of the UAS may not be a crucial 
detelTninnct of promoter function.
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4.3 MATERIALS AND METHODS
Overviews of the experimental procedures employed in this chapter are illustrated in figure 4-3. 
Briefly, the canine MMP-9 and MMP-13 promoters were cloned from genomic DNA isolated from 
peripheral mononuclear cells (PBMCs) using GenomeWalking™ techniques (Clontech) (Figure 4­
4) and primers designed on the 5" end of the cDNA sequences encoding the canine MMP-9 and 
MMP-13 genes. Two walks were performed for each promoter and all PGR products generated 
were cloned into pCR2.1®TOPO and sequenced. A consensus sequence was generated for each 
promoter from three independent PCRs and the sequences were finally submitted to the Genbank 
database. Transcription initiation sites were determined using GeneRacer™ techniques (Invitrogen) 
(Figure 4-5) within both the endogenous MMP-9 and MMP-13 gene sequences and the cloned 
promoter sequence within pGL3/cMMP-9(1894), pGL3/cMMP-13(1494) constructs.
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Figure 4-3 Overview of the experimental procedure used to clone canine MMP-9 & -13
promoters
The canine MMP-9 and MMP-13 promoters were cloned from gDNA using GenomeWalking™ 
techniques (Clontech) and the subsequent sequences analysed. The transcription initiation sites 
were determined using GeneRacer’M techniques (Invitrogen) for both the endogenous MMP-9 and 
MMP-13 genes and the cloned promoters in pGL3/cMMP-9( 1894). pGL3/cMMP-l 3( 1494).
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Figure 4-4: Summary of Genome Walking
Canine genomic DNA (gDNA) was first digested with four different restriction enzymes. Genome 
Walker adaptors were then ligated to 5' ends of the cut fragments to form four libraries. These 
libraries were then used as template for each Genome™Walk consisting of two PCR amplifications 
using sense adaptor primers and anti-sense gene specific primers (GSP).
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Figure 4-5: of GeneRacer™ protocol
The isolated RNA was evehvpehveylatve and evcaeeve before ligating to the GvceReve6T6 RNA 
Oligo. Rvvvrpv tracpeeietivc was then evefvemve using random erimvrp fvllvwve by PCR using 
rvvvrpv primers based on the 5' ends of the MMP-9. MMP-1 3 or lueifvrapv cDNA pvquecevp.
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 4.3.1 Amplification of canine MMP-9 & -13 gene promoters, 5' UTRs
using GenomeWalker™ techniques
The GenomeWalkeM™ technique (Clontech) provides access to a novel method for walking up­
stream. towards promoters, in gDNA from known cDNA sequences (Siebert et al., 1995) and is a 
simpler and potentially faster approach than those protocols involving the generation and screening 
of gDNA libraries. In summary, canine gDNA was digested with four different restriction enzymes 
and GenomeWalker Adaptors were then ligated to 5' ends of the cut fragments to form four 
libraries. These libraries were then used as templates for each genome walk consisting of two PCR 
amplifications using sense adaptor primers and anti-sense gene specific primers (Figure 4-4). The 
gene specific primer (GSP) sequences were based on the 5' end of the canine MMP-9 and MMP-13 
cDNAs available in the Genbank database. PCR products were cloned and sequenced allowing the 
design of new gene specific primers for the second genome walk.
4.3.1.1 Primer design
Two primers per cDNA sequence were designed for each nested PCR as described in section 2.2.5.1 
and were synthesised and supplied by MWG-Biotech (Table 4-1). Each primer of 25-28 nucleotides 
in length required 40-60% GC content to ensure that primers would effectively anneal to the 
template at the recommended annealing and extension temperature of 67°C. Primer sequences were 
designed to prevent the folding and formation of intra-molecular hydrogen bonds and particular 
attention was paid to reducing the GC content at the 3' end of the gene specific primers to prevent 
their binding to the 3' end of the adaptor primers.
4.3.1.1.1 MMP-9 ^promoter specific primers
Using these criteria, two anti-sense oligonucleotide primers (MMP-9GSP1R and MMP-9GSP2R) 
were designed according to the 5' region the MMP-9 cDNA sequence. On completion of the first 
genome walk it was possible to design two more anti-sense oligonucleotide primers (MMP- 
9GSP3R and MMP-9GSP4R) for the second genome walk along the MMP-9 promoter sequence 
(Figure 4-12).
4.3.1.1.2 MMP-13 pro rn o tc r . spec ifi c p rimers
Two anti-sense oligonucleotide primers (MMP-13GSP1R and MMP-13GSP2R) were also designed 
according to the 5' region the MMP-13 cDNA sequence. On completion of the first genome walk it 
was possible once again to design two more anti-sense oligonucleotide primers (MMP-13GSP3R 
and MMP-13GSP4R) for the second genome walk along the MMP-13 promoter sequence (Figure 
4-14).
116
4.3.1.1.3 GcnomeVS alkcr \duptor primer-
Forward primers, specific to the Adaptor sequence attached to the 5' end of the gDNA fragments, 
were supplied with the kit and are referred to as Adaptor primer-1 (API) and nested Adaptor 
Primer-2 (AP2) (see 4.3,1,4)
Table 4-1 Primer sequences for genome walking
Primer name Oligonucleotide primer sequence 5zto 3' Tm ("C) & GC (%)
content
MMP-9GSP1R TGGAAAGACCACAACGGTGGGCTTGTG 68.0 "C : 55.6 %
MMP-9GSP2R ATA^GAGCAGCAGCCCAGCACCA^GGAACAC 70.9 °C : 58.6 %
MMP-9GSP3R AGGGAGAGAGTTAAGGCTACAGGACTC 66.5°C :51.9%
MMP-9GSP4R TAAGTGGTCAGCCTAAGGGCAAGGGAT 66.5 °C: 51,9%
MMP-13GSP1R CTGCAAGCTGGAAGTCTTCCTCAGACA 66.5 °C:51.9%
MMP-13GSP2R AGCACTGAGTCCAGCTCAAGAAGAGGA 66.5°C : 51.9 %
MMP-13GSP3R CCCTCTGTAGAAAAGCAGCTACTTTTACTC 65.4°C : 43.3%
MMP-13GSP4R CAAGAGTATCAAGATGATGCTCTCACTTCC 65.4OC:43.3%
API GTAATACGACTCACTATAGGGC 58,4°C : 45.4%
AP2 ACTATAGGGCACGCGTGGT 58.8OC:57.9%
4.3.1.2 Preparation of canine genomic D24A from peripheral blood mononuclear cells 
Any canine cell line could be used for isolating canine gDNA for use as a template in the isolation 
of the promoter sequences, since gDNA is identical in every cell, so PBMCs were selected. Canine 
whole blood samples (5 ml) were mixed with lysis mix (45 ml) and incubated on ice for 10 mins. 
The mixture was then centrifuged at 2800g for 10 mins and 4°C and the pellet re-suspended in 
nuclei lysis mix (3 ml). After addition of 10% SDS (200pl) and 75pl of proteinase K (lOmg/ml) the 
mixture was incubated at 55°C for 2 hours. Two extractions with 3ml phenol/chloroform (50:50) 
were performed, each centrifuged for 10 mins at 2800g and room temperature. The upper aqueous 
phase was then transferred to a fresh tube and the DNA precipitated by adding 3 volumes of 100% 
ethanol. The DNA was then re-suspended in 250pl of TE Buffer and the quantity and quality of 
gDNA was assessed using UV spectrophotometry and agarose gel electrophoresis.
4.3.1.3 Digestion and purification of canine genomic DNA
Four blunt ended digestions of canine gDNA (2.5pg) were performed, each in a total volume of 
lOOjpl with the appropriate restriction enzyme Stu I, Dm I, Pvu II or EcoK V (80 units) and 
restriction enzyme buffer (Ix) combination (Table 2.1). Reactions were incubated at 37°C overnight 
before samples (5pi) were analysed for complete digestion by TAE agarose gel (1%) 
electrophoresis. For the purification of DNA, phenol (95pl) was added to each reaction, vortexed 
and flash spun to separate the aqueous and organic phases. The upper aqueous layer from each tube
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was mixed with an equal volume of chlorofomi added, vortexed and briefly spun to separate the 
aqueous and organic phases. This time the DNA in the upper layer was precipitated with 2 volumes 
of ethanol (95%). 1/10 volume 3M NaOAc (pH 4.5) and 20pg of glycogen. After vortexing and 
centrifugation at 15.00()rpm for 10 minutes, supernatants were decanted and the pellet washed in 
lOOpl ethanol (80%). After a final centrifuge at 15.000 rpm for 5 minutes and supernatant discarded 
the pellet was air-dried and dissolved in 20pl of Tris-EDTA (10/0.1. pH 7.5). The quality of gDNA 
was again assessed using TAE agarose gel analysis.
4.3.1.4 Ligation of digested cancncgDNA to GcdcmcWalkcsAdintoni
The digested, purified DNA (4pl) was ligated to the GenomeWalker Adaptors (25pM) in a total 
volume of 8 pi with T4 DNA ligase (4 units) and ligation Buffer ( 1x) at 16llC overnight. The 
reactions were incubated at 70’C for 5 minutes before dilution to a total volume of 80 pi with Tris- 
EDTA (10/1 pH 7.4).
Gcnonic\e alkor Adaptor sequence
API(_______________________________ ,
5' GTAATACGACTCACTATAGGGCACGCGTGGTCGACGGCCCGGGCTGGT3'
S-------------------- _______________ <
AP2
4.3.1.5 PCR-baned DNA Walking in GedcmicWanics Libranios
The four different libraries were subjected to two rounds of PCR (primary and secondary) using a 
PE 2400 thermal cycler. For the first genome walk, the primary round of amplification used the 
adaptor-ligated gDNA as template with 0.2pM of sense primer ‘Adaptor Primer 1’ (API) and anti­
sense ‘Gene Specific Primers’ (MMP-9GSP1R or MMP-13GSP1R) (Table 4-1). Tth PCR Reaction 
Buffer (40 mM Tris-HCl. 15 mM KO Ac. 0.02% Triton X-1OO). dNTPs (0.2mM). Mg(OAc)2
(l.lmM) and Advantage Genomic Polymerase Mix (Ix) (5 units of Tth DNA polymerase. 0.5pg of 
TthStart Antibody. 1% glycerol. 0.2 mM Tris-HCl pH 7.5 and 4.6 mM KCl) (see 2.1.7.5) in a total 
volume of 50pl. Primary PCR conditions were 94"C for 2s. 70"C for 3 mins for 7 cycles, and 94"C 
for 2s. 65’C for 3 mins for 32 cycles, then 65°C for 4 mins. Primary PCR products were diluted 50 
fold and Ipl was used as a template for secondary, nested PCR with 0.2pM of sense primer 
‘Adaptor Primer 2’ (AP2) and anti-sense ‘Gene Specific Primers’ (MMP-9GSP2R or MMP- 
13GSP2R) (Table 4-1) in a reaction mix as described for primary PCR. Secondary PCR conditions 
were 94"C for 2s. 70°C for 3 mins for 5 cycles, and 94“C for 2s. 65 ’C for 3 mins for 20 cycles, then 
65‘C for 10 mins.
The second genome walk used anti-sense ‘Gene Specific Primers’ (MMP-9GSP3R and MMP- 
13GSP3R) in the primary round of PCR and nested primers (MMP-9GSP4R and MMP-13GSP4R) 
in the secondary round of PCR. PCR conditions were altered slightly with the annealing 
temperature reduced from 70 to 69°C and 65 to 64’C in secondary PCR. A negative control 
containing all PCR components (primers. dNTPs. PCR buffer and Advantage Genomic Polymerase
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Mix) except template was performed to ensure no contamination of the PCR reactions with 
extraneous DNA that might serve as a template foe PCR amplification
4.3.2 Cloning of canine MMP-9 and MMP-13 promoter fragments
PCR products were cloned using methods described in section 2.2.2.
4.3.2.1. Purification, ligation and transformation
PCR products were purified following QIAquick^Gel Extraction Kit (QIAGEN, UK) and eluted in 
50|il of sterile water, 4pl of which were assessed by gel elsetroehoresis on a TAE agarose gel (1%) 
by comparing the bands created to a 1 kb molecular weight standard. Purified PCR products were 
directly ligated into the pCR®2.1-TOPO plasmid vector following the TOPO TA® cloning protocol. 
The ligation eeactifds (2jil) were then transformed into One Shot™ TOP 10 competent cells and 
spread onto agar plates containing ampieillid and X-gal foe incubation overnight at 37”C. White, 
ampieillic resistant, colonies were selected from the plates and cultured overnight in LB/ampicillin 
broth at 37°C and glycerol stocks of each culture were prepared for long-term storage.
4.3.2.2 Isolation and screening of recombinant plasmids
The DNA constructs were isolated from overnight cultures by the alkaline lysis method of plasmid 
DNA isolation following the QIAprep® PCR Spin Miniprvp Kit (QIAGEN, UK) and eluted in 50^ 
of sterile water. The DNA samples were then assessed by spectrophotometry for quantification. 
Constructs were screedee for inserts using PCR techniques in a total volume of 50|il eoctaididg 
0.4|tM of both sense primer (AP2) and appropriate rnti-sedse primer (MMP-9GSP2R, MMP- 
9GSP4R, MMP-13GSP2R and MMP-13GSP4R), 0.2mM of dATPs, dCTP, dTTP and dGTP, 1.5 
mmol/L MgCE and 2 units of Taq DNA polymerase (QIAGEN, UK). Using a PE 480 thermal 
cycler, samples were subjected to an initial eedaturrtion at 95°C foe 5 minutes, followed by 35 
cycles of nmplrfiertifc with each cycle consisting of a decrtuertion step of 95”C for one minute 
and annealing temperature of 58‘C for 1 minute, followed by an elongation step of 12°C for one 
minute. A final elongation step at 72°C for 30 minutes completed the eeretioc. PCR products (8p.l) 
were visualised by gel electrophoresis on a TAE agarose gel (1%) to visualise those constructs 
containing the insert.
4.3.3 Sequence evaluation of constructs
Recombinant plasmids were sequenced and analysed as described in section 2.2.6. Briefly, plasmid 
samples were prepared for sequencing with PCR eeaetrfcs using plasmid DNA samples (400 ng) 
and 0.5|lM of both sense (M13F) and anti-sense (M13R) vector-based primers and the Big Dye°° 
Terminator Cycle Sequencing Ready Reaction (ABI Prism). Samples were amplified, and the DNA 
purified by precipitation methods before samples were loaded into the ABI 310 genetic analyser for 
generation of automated sequence data.
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Sequence data was stored and managed on a UNIX computer system using Genetics Computer 
Group (GCG) software (University of Wisconsin). ‘Raw' sequence data was extracted from the 
Chromas files generated from the ABI 310 genetic analyser and edited using the ‘SeqEd' program. 
The Blast search engine (NCBl database) was used to verify that the sequences were the canine 
homologues MMP-9 and MMP-13 promoter sequences.
4.3.4 Isolation and sequence analysis of tRe canine MMP-9 (1894 bp) and 
MMP-13 (1494 bp) promoter fragments
4.3.4.1 Primer design
Primers pairs were designed for the amplification of the canine MMP-9 and MMP-13 promoter 
fragments as described in section 2.2.5.1 and were synthesised and supplied by MWG-Biotech 
(Table 4-2). Each primer was 30 nucleotides in length but the GC content and therefore Tm varied 
between the primers, as the 3' region of DNA over which the reverse primers could be designed was 
limited. However, the design of forward primers at the 3' region was more flexible and attempts 
were made to match Tm of primer pairs as close as possible.
4.3.41.1 MMP-9 promoter specific pr imcrs
Using these criteria, two oligonucleotide primers. cMMP-9F and cMMP-9R. were designed 
according to the 5' and 3' regions of the MMP-9 promoter sequence respectively to amplify the 
1894 bp promoter fragment (Figure 4-12).
4.3.4.1.2 MMP-13 promoter specific primers
Two oligonucleotide primers. cMMP-13F and cMMP-13R. were also designed according to the 5' 
and 3" regions the MMP-13 promoter sequence respectively to amplify the 1494 bp promoter 
fragment (Figure 4-14).
Table 4-2 Primers to amplify the canine MMP-9 and -13 promoter sequences
Primer
name
Primer sequence (5' to 3') Tm ("C) & GC (%) content
cMMP-9F GGTCTGGGTGACTCCAAAGCCAATGCTCAT 69.5 °C : 53.3 %
cMMP-9R GGTGAGGGTAGTGGTGTGTCTAGCTACTAG 69.5 ”C : 53.3 %
CMMP-13F GCGTTGCTGGTTGAGCCCAATTCTAATCTC 68.1 "C : 50.0 %
CMMP-I3R CTTGGTGGTTGTGCCTGGAGCCTGCTGTCT 72.2 "C : 60.0 %
4.3.4.2 Amplification ani cloning of caning MMP-9 a ni M'MP-13 pronmfee frrgments 
PCR was performed as described in section 2.2.5 to amplify the canine MMP-9 and -13 promoter 
sequences from gDNA. More specifically, canine gDNA (150ng) samples were amplified in a total
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volume of 50|ll containing 0.4jiM of both sense primers (cMMP-9F and cMMP-13F) and rcti-secse 
primers (cMM-9R and cMMP-13R), 0.2mM of dNTPs, 1.5mmol/L MgCF and 2 units of Taq
polymerase (QIAGEN, UK) (see 2.1,7.3). Using a PE 2400, thermal cycler samples were subjected 
to an initial eenaturatioc at 95"C for 5 minutes followed by 35 cycles of nmplifiertion, each cycle 
consisting of a decaturatifc step of 95°C for one minute and rdderling temperature of 60“C for 1 
minute, followed by an elongation step of 72‘C for two minutes. A final elongation step at 12°C for 
30 minutes completed the renetioc. PCR products were analysed by electrophoresis on a agarose gel 
(1.5%) and cloned into pCR®2.1-TOPO vector (Invitrogen) as eeseribee for the genome walking 
promoter fragments. Clones were screecee foe insert using PCR reagents and coceitifcs as 
dsscribse for their original amplification.
4.3.4.3 Scqu^mc evaluation of cc^o^strr^cts containing wholi MMP-9 and MMP-13 
promo ter fragm en ts
4.3.4.3,1 Primer design _for sequencing
Primers were designed for sequencing the internal region of the ercice MMP-9 and MMP-13 
promoter fragments. Each primer was varied in length and GC content. All primers were 
synthesised and supplied by MWG-Bioteeh (Table 4-3). Two oligonucleotide primers (MMP- 
9SEQF and MMP-9SEQ2F) were designed according to the internal sequence of the eanide MMP-9 
promoter sequence (Figure 4-12). One oligonucleotide primer (MMP-13SEQF) was designed 
according to the internal region the cacicv MMP-13 promoter sequence (Figure 4-14).
Table 4-3 Primers for the internal sequencing of the canine MMP-9 and -13 promoter
sequences
Primer name Primer sequence (5' to 3') Tm ("C) & GC (%) content
MMP-9SEQF CCAATAATGGCCATGGTCGTT 57.9 "C : 47.6 %
MMP-9SEQ2F TATTATTCATTCATGAGAATC 48.1 °C: 23.8%
MMP-13SEQF GTCCTTGTCTTCTTGTGTTCCGGACCT 66.5 °C:51.9%
4.3.4.3.2 Sample preparation and _ data analysis
Recombinant plasmid samples were prepared for sequencing as evscribee previously with PCR 
reactions using plasmid DNA samples (400 ng) and the Big Dye™ Terminator Cycle Sequencing 
Ready Reaction (ABI Prism). A series of different primers (0.5pM) were used to cover the entire 
length of each promoter fragment. These included both vsctfr-bnsee primers M13F and M13R (see 
Table 2-2) and sequence based primers cMMP-9F, cMMP-9R, cMMP-9GSP3R, cMMP-9GSP4R, 
MMP-9SEQF, and MMP-9SEQ2F foe canide MMP-9 promoter sequence and MMP-13F, MMP- 
13R, MMP-13GSP3R, MMP-13GSP4R and MMP-13SEQF for camne MMP-13 promoter 
sequence (Tables 4-1,4-2 and 4-3). Samples were amplified, and the DNA purifive by preeieitatrvd
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 methods before samples were lfreee into the ABI 310 genetic analyser for gvceratroc of automated 
sequence data.
Sequence data was stored and managed on a UNIX computer system using Genetics Computer 
Group (GCG) software. ‘Raw’ sequence data was extracted from the Chromas files and edited 
using the ‘SeqEd’ program. Three rcdepecdedt sequence derived from three different PCR products 
were aligned using the ‘pile-up’ command to produce a eocsscsus sequence foe the cncice MMP-9 
and MMP-13 promoter sequences. The promoter sequences were then further analysed for DNA 
binding motifs using the web-based ‘Sequence Motif Search’ (htte://motif.gecome.re.jp/) for 
searching nucleic acid sequence motifs. The sequences were finally submitted to the Gecback 
sequence database.
4.3.4.3.3 AHgnment of tine ecmine sequence witii homologous sequences published for 
other peve'ics
The camne sequence was compared to those sequences already published foe others species using 
ClustalW (http://www.eh.embcet.org/software/ClustalW.html). This software enables the easy 
manipulation and alignment of regions of homologous (DNA binding motifs) between sequences 
rather than finding the best-fit over the whole promoter sequence. Foe this rppliertioc the chromas 
files were efdvertee to ‘FASTA’ format and saved as ‘Word’ documents where they were 
manipulated into the eorrset format. All conserved regions were ^dectifiee.
4.3.5 Determination of transcription initiation sites using GeneRacer™ 
techniques
The Rapid Amplification of cDNA ends (RACE) technique is a simple PCR-based approach for the 
identification of transcription initiation sites. The Gene°°1Racer Kit (Invitrogen) is based on RNA 
ligase-mediated (RLM-RACE) and fligo-cappidg RACE methods. This results in the selective 
ligation of the RNA oligonucleotide (GeneRacer™ RNA Oligo) to the 5' ends of the eeeaepee 
mRNA using T4 RNA ligase (Maruyama and Sugacf, 1994; Volloch et ah, 1994; Schaefer, 1995). 
In summary, RNA samples were first evphosphoeylatee and decappee before GecvRacee™ RNA 
Oligo adaptors were ligated to the 5" ends mRNA molecules. Reverse transcription was then 
peeformee using random primers and the cDNA generated used as template for each PCR reaction 
consisting of two PCR amplifications using sense Gece™Rncer primers and rcti-secse gene 
specific primers (see Figure 4-4). All PCR products isolated were then cloned and sequenced to 
identify the position of tracseeietion initiation.
This protocol is based on RT-PCR to amplify the 5' end of cDNA generated from the endogenous 
expeession of the eanidv MMP-9 and MMP-13 genes in the eadrne MDCK cell lme. However, to 
identify the transcription initiation sites within the cloned MMP-9 and MMP-13 promoter 
sequences the pGL3/cMMP-9(1894) and pGL3/cMMP-13(1894) luciferase reporter constructs (as 
described in chapter V) were utilised. The constructs were transfected into the MDCK cells
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(although any cell line could be used) with the PCR reverse primers based on the luciferase reporter 
gene.
4.3.5.1 Primer design
Two primers per gene sequence were designed for nested PCR as described in section 2.2.5.1 and 
were synthesised and supplied by SigmaGenosys (Table 4-4). Each primer of 23-28 nucleotides in 
length required 50-70% GC content to obtain a high annealing temperature (70"C) for improving 
the binding specificity within the PCR . Low GC contents at the 3' end of primer sequence's 
minimised extension by DNA polymerase at non-target sites. Additionally, no self-complementary 
sequences within the primer itself or to the kit-based primers prevented primer dimer formation. All 
gene specific primers were located approximately 400 bp downstream of the translation start site to 
optimise the PCR.
4.3.3. Li MMP-9 <enc specific primers
Using these criteria, two anti-sense oligonucleotide primers (MMP-9TISR and MMP-9TISnestedR) 
were designed according to regions within the canine MMP-9 cDNA sequence to identify the 
transcription initiation site within the endogenous promoter (Figure 4-13).
4.3.5.1.2 MMP-13 gene specific primers
Two anti-sense oligonucleotide primers (MMP-13T1SR and MMP-13TLSnestedR) were also 
designed according to regions within the MMP-13 cDNA sequence to identify the transcription 
initiation site within the endogenous promoter (Figure 4-15).
4.3.5.1.3 Firclly luciferase gcnc specific primers
Two anti-sense oligonucleotide primers (FFLR and FFLnestedR) were designed according to 
regions within the firefly luciferase cDNA sequence present in the pGL3-Basic reporter vector to 
identify the transcription initiation site within the luciferase plasmid vectors. pGL3/cMMP-9( 1984) 
and pGL3/cMMP-13( 1494).
___________________________________________________________________________________________
Luciferase reporter gene
4.3.5.1.4 Genel Racer M primers
Forward primers specific to the GeneRceef™ RNA Oligo sequence ligated to the 5' end of the 
cDNA fragments were supplied with the kit and are referred to as GeneRac^™ 5' Primer and 
GknkRaeerCc 5' Nested Primer (see 4.3.5.8).
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Table-4-4 Primer sequences for RACE techniques
Primer name Primer sequence (5' to 3') TM («C) & GC
(%) content
MMP-9TISR GTCGTCGAAGTGGGCGTCTCCCTGAAT 78.1 "C : 59.3 %
MMP-9TlSnestedR TTCTTCCCATCGAAGGGATACCCATCT 65.0°C:48.1 %
MMP-13TISR C C CAGGAGGAAAAGCATGAGC CAGAAGA 76.8 "C : 53.6 %
MMP-13TISnestedR GGACCACTTGAGAGTTCGGGGGAAAAC 74.8 "C : 55.6 %
FFLR CGCGGGCGCTAACTGCAACTCCGATAAA 69.5 "C : 59.3 %
FFLnestedR TTCATAGCTTCTGCCAACCGAACGGA 64.8 T : 50.0 %
GeneRacei*™ 54 Primer CGACTGGAGCACGAGGACACTGA 74.0"C:60.9%
GeneRaceM™ 5' Nested Primer GGACACTGACATGGACTGAAGGAGTA 79.1 °C 5 50.0%
4.3.5.2 Cell line and transfections
Madin Darby Canine Kidney (MDCK) cells, maintained in DMEM with gluatamax-1 medium 
described in section 2.2.1.2.1, were seeded onto 6 well plates at a concentration of 6xl04 cells/ml. 
The pGL3/cMMP-9(l 894) and pGL3/cMMP-13(1494) luciferase reporter vectors (construction 
described chapter V) were transiently transfected into cells using the cationic liposome mediated 
transfection system, TransFatt™ Transfection Reagent (see 2.2.7). Briefly, transient transfections 
were carried out using DNA (2 [tg per well) in a 1:1 ratio with the TransFast™ Reagent, in a total 
volume of 1 ml of serum free media per well. After one hour of incubation at 3TC, cells were left 
to recover overnight in supplemented media and 48 hours later all cells were harvested.
4.3.5.3 Isolation of total RNA
To enable the amplification of the 5f UTR of the MMP-9 and MMP-13 promoters, purified full- 
length RNA was essential as the template and therefore all preparation material was free from 
ribonuclease activity. The media was removed from the 6 well plates and RNAzofM B solution 
(500|xl/well) was added directly to the wells containing the adherent MDCK cells for lysis. Aliquots 
(1ml) of the lysed cell solution were shaken for 15 seconds with chloroform (lOOpl) and then the 
RNA isolated as described in section 2.2.3. The RNA samples were stored in 70% ethanol at -20°C 
until required.
4.3.5.4 DNase Treatment and removal of reagents
The RNA was resuspended in 40pi of DEPC treated water and quality analysed by 
spectrophotometry and agarose gel electrophoresis. Contaminating DNA was removed using DNA- 
free™ (Ambion) methods (2.2.3.4). Briefly, 0.1 volume of lOx DNase I and 2 units of DNase I were 
added directly to the RNA (35pl) samples, mixed and incubated at 37°C for two hours. The enzyme 
was inactivated by the addition of DNase Inactivation Reagent, which was later removed, and the 
supernatant containing the pure RNA was stored at -20°C.
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4.3.5.5 Dephosphorylation of RJNA
Phosphatase treatment of total RNA removed thv 5' phosphates to eliminate teuneatve mRNA and 
nvn-mRNA from pubpvquvct ligation with the GeneRaci^™ RNA Oligo. Brivfly. in a total volume 
of lOpl. total RNA (Ipg) was incubated with 10 units of Calf Intestinal Phosphatase (CIP). CIP 
buffer ( I x) and RNASEOUT™ (40 units) for I hour at 50"C.
4.3.5.6 Purification ofRNA
RNA was then eueifive using the following eeveieitativc protocol. DEPC water (90pl) was added to 
the reaction with ehvnvl:ehlvrvfvem (lOOpI). vvetvxve for 30 pvevnep before evnteifugativn foe 5 
minutes at 14.000 epm. The aqueous (top) phase was tranpfvrree to a new tube* and thv RNA 
ereeieitatve with 2pl mussel glycogen (lOmg/ml). lOpl 3M sodium acetate (pH 5.2) and 220pl 
ethanol (95%). After briefly vortexing. the RNA was rapidly frozen on dry icv foe 10 minutes. The 
RNA was then evllvtve al 14.000 epm foe 20 minutes at 4°C and the puee*enatact carefully removed. 
500pl of ethanol (75%) was then aeeve. mixed and evcteifugve at 14.000 epm foe 2 minutes at 4"C. 
the puevedatant was vnev again removed and the pvllvt air dried for 2 minutes before ev-pupevnpivc 
in 7pl of DEPC water.
4.3.5.7 Removal of the mRNA cap structure
Pyrophosphatase treatment of evehvpehvrylatve RNA removed the 5' cap structure from intnet. full- 
length mRNA. This treatment left a 5' phosphate required for ligation to thv GvnvRace°™ RNA 
Oligo. Briefly. in a total volume of lOpl. evehvpehvrylatve RNA (Ipg) was incubated with 0.5 
units of tobacco acid eyrvehvpehatnpv (TAP). TAP buffer (Ix) and RNASEOUT™ (40 units) for 1 
hour at 37''C. RNA was eeveieitatve as evpeeibve ic 4.3.5.6 and rv-pupevneve in 7|il of DEPC water.
4.3.5.8 Ligation of the GeneRacer™ RNA Oligonucleotide to the decapped mRNA 
Ligation of the GvcvR^v^i^^™ RNA O^os’ to thv 5' vdep of the evehvpehorylatvd. eveaeeve mRNA 
was evefvemve using T4 ligase. Thv GvdvRaevr™ RNA eevvieve a known priming site foe the 
GvcvRacer™ PCR primers after teanpeeietivd of the mRNA to cDNA.
(leneRacer™ RNA Oligo sequence:
GvcvRacer™ 5' Primer
5'CGACUGGAGCACGAGGACACUGACAUGGACUGAAGGAGUAGAAA 3'
'-------------------------------------- - >
GvcvRacer™ 5" Nested Primer
Briefly, evehvpehveylatve, eveaeeve mRNA (7|il) was added to the erv-aliquvtve. lyophilized 
GvcvR^s^i^™ RNA Oligo (O^iig), mixed acd heated to 65"C for 5 minutes to relax the RNA 
pvevnenry structure. Thv RNA/vligv mixture was then chilled on icv before ligation in a total
125
volume of lOjil incubated with 5 units of T4 RNA ligase, Ligase Buffer (Ix). ImM ATP and 
RNASEOUT™ (40 units) for 1 hour at 37"C. RNA was precipitated as described in 4.3.5.6 and re­
suspended in IOlI of DEPC water,
4.3.5.9First strand cDNA synthesis
The synthesis of cDNA followed the basic principles as set out in section 2.2.4. Reverse 
transcription of the ligated mRNA used reverse transcriptase and random primers to create RACE- 
ready cDNA with known priming sites at the 5' ends. Briefly, random primers (Ipl) were added to 
RNA samples (lOpl), heated for 5 minutes at 65^ to remove any RNA secondary structure and 
then quenched on ice for two minutes. First strand synthesis reactions were performed using the 
heat treated RNA in a 20pl reaction mix containing 5 units of Avian Myeloblastosis Virus Reverse 
Transcriptase (AMV-RT), Reverse Transcription (RT) Buffer (Ix), 5mm dNTPs and 
RNASEOUT™ (40 units). The reaction was incubated at 42°C for 1 hour followed by 85°C for 15 
minutes to inactivate AMV-RT. A PE 480 thermal cycler was used for the reaction.
4,3,5.10 PCR amplificction
Amplification of the 5' ends used a reverse gene-specific primer and forward GeneRacer™ 5' 
Primer homologous to the GeneRacer™ RNA Oligo. Only mRNA with the GeneRaerr™ RNA 
Oligo ligated to the 5' end completely reverse-transcribed would be amplified during PCR. Primary 
rounds of PCR were performed using Ready - To -Go™ PCR Beads (Amersham) and a PE 2400 
thermal cycler. Canine cDNA samples (2pl) were mixed in a total volume of 25pl with 0.4pM of 
both sense primer (GeneRacer™ 5' Primer) and gene specific anti-sense primers (MP9TTSR. 
MP13TISR) (Table 4-4), 0.2mM of dNTPs, 50mM KCl, 1.5 mM MgCL and 1.5 units of Taq DNA 
polymerase. Reaction conditions as shown in table 4-5 employs touch down PCR (Don et al., 1991: 
Roux, 1995) that exploits the high annealing temperatures of the primers used in this protocol to 
selectively amplify the gene specific cDNAs tagged with the GeneRacer™ RNA Oligonucleotide. 
By starting at a high annealing temperature only gene-specific or GeneRacer™-tagged cDNAs are 
amplified, allowing the desired product to accumulate. Decreasing the annealing temperature 
through the remaining PCR cycles permits efficient, exponential amplification of the tagged, gene 
specific template.
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Table 4-5 PCR conditions for RACE protocols
Temperature Time Cycles
94°C 2 minutes 1
94°C 30 seconds 1
70 °C 3 minutes
94 °C 30 seconds
J
68 °C 30 seconds 5>
72 "C 3 minutes
94 °C 30 seconds •<
68 °C 30 seconds 45
72 "C 3 minutes
72 "C 10 minutes J 1
A second round of nested PCR was then performed, again using Ready- To - Go™ PCR Beads 
(Amersham) and a PE 2400 thermal cycler. Primary PCR samples (0.5 pi) were mixed in a total 
volume of 25pl with 0,4pM of both sense (GeneRacer™ 5f Nested Primer) and nested gene specific 
anti-sense primers (MP9TISnestedR, MP13TISnestedR) (Table 4-4), 0.2mM of dNTPs, 50mM 
KCl, 1.5 mM MgCh and 1.5 units of Taq DNA polymerase. Samples were subjected to an initial 
denaturation at 94”C for 2 minutes followed by 25 cycles of amplification, each cycle consisting of 
a denaturation step of 94”C for 30 seconds and annealing temperature of 68°C for 30 seconds, 
followed by an elongation step of 72°C for 1 minute. A final elongation step at 72°C for 10 minutes 
completed the reaction.
4.3.5.11 Cloning into pCPF2.1-TOPO vector
PCR products were cloned using methods described in section 2.2.2. Briefly, PCR products were 
purified using the QIAquick®Gel Extraction kit (QIAGEN) and purified products were directly 
cloned into the pCR®2.1-TOPO plasmid vector (3,9kb) following TOPO TA® cloning protocol. 
DNA constmcts (500ng) were screened using PCR techniques as described in the secondary/nested 
PCR reaction (see 4.3.5.10) for those clones containing an insert.
4.3.5.12 Sequence evaluation of the transcription initiation sites
Recombinant plasmids were sequenced and analysed as described in section 2.2.6. Briefly, plasmid 
DNA samples were prepared for sequencing with PCR reactions using plasmid DNA samples (400 
ng) and vector-based primers M13F (0.5jxM) on the ABI 310 genetic analyser.
Ten positive clones for each initiation site were sequenced and the Chromas files were analysed to 
identify the transcriptional start sites relating to both the endogenous and vector-based promoter 
sequences for each MMP promoter. The transcriptional start sites were then mapped on the 
promoter sequence as shown in Figure 4-16 and 4-17 for MMP-9 and MMP-13 respectively.
127
 4,4 RESULTS
4.4.1 Isolation of the canine MMP-9 and MMP-13 promoter sequences
using GenomeWalking™ techniques .
4.4.1.1 DNA quantity and quality
gDNA was isolated from canine PBMCs and the quality of samples assessed by ultraviolet 
spectrophotometry (A260/A280 value of >1,6) and agarose gel electrophoresis (Figure 4-6). The 
gDNA migrated through the agarose gel (1%) consistent with high molecular weight molecules. 
The gDNA was completely digested with four restriction enzymes and analysed using agarose gel 
(1%) electrophoresis (Figure 4-7). The digested gDNA migrated through the gel over a wide range 
of molecular weights demonstrated by the long smears.
4.4.1.2 PCR Amplification of the promoter fragments.
Digested canine gDNA samples were used as the template for the amplification of the canine MMP 
promoter regions using anti-sense oligonucleotide primers (Table 4-1) and Advantage^Genomic 
Polymerase Mix. In all cases the negative control showed no contamination.
4.4.1.2.1 MMP-9 promoter genome walk
The first genome walk amplified a PCR product that migrated on an agarose gel (1.5%) to show a 
single DNA fragment of approximately 600 bp within the Stu I library (Figure 4-8); no bands were 
observed in the other lanes. The second genome walk amplified two PCR products that migrated on 
an agarose gel (1.5%) to show DNA fragments of approximately 1 kb and 1.5 kb for the Dra I and 
Pvu II libraries respectively (Figure 4-9). Again no bands were visible in any of the other libraries.
4.4.1.2.2 MMP-13 promoter genome walk
The first genome walk amplified a PCR product that migrated on a agarose gel (1.5%) to show a 
single DNA fragment of approximately 550 bp within the Stu I library (Figure 4-10). The second 
genome walk amplified a PCR product that migrated on a agarose gel (1.5%) to show a DNA 
fragment of approximately 1.1 for the Dm I library (Figure 4-11).
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 Figure 4-6 Purified genomic DNA samples
The genomic DNA samples migrated through an agarose gel showing good quality, high molecular 
weight DNA. The absence of DNA smears suggested undegraded DNA
Figure 4-7 Digested genomic DNA samples pre (a) and post (b) purification
Genomic DNA samples were digested with four different restriction enzymes (EcoRV. Pvu II. Dra I
and Stu 1) and analysed for complete digestion, by agarose gel electrophoresis. The DNA migrated 
through the gel with a range of molecular weights shown by the long smears on the agarose gel; all 
samples have been completely digested.
I kb EcoR V Pvu II Dra 1 Stu 1 
a b ah ah ab
w £ / !
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Figure 4-8 First genome walk for the MMP-9 promoter sequence
The first genome walk amplified a PCR product that migrated on an agarose gel to show a single 
DNA fragment of approximately 600 bp within the Stu 1 library, no bands were observed in the 
other lanes.
1 kb Neg Stu 1 Dm 1 Pvu II EtoK V
w
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Figure 4-9 Second genome walk for the MMP-9 promoter sequence
The second genome walk amplified two PCR products that migrated on an agarose gel to show 
DNA fragments of approximately 1 kb and 1.5 kb for the Dra I and Pvu II libraries respectively: no 
bands were visible in the other libraries.
i kh 231 DQJPZulfSiftullkEg
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Figure 4-10 First genome walk for MMP-13 promoter
Thv first genome walk amplified a PCR product that migrated on a 1.5% agaevpv gvl to show a 
single DNA fragment of approximately 550 bp within thv Stu 1 library
EZQyQQQ p»hC /99QRQ QCu
a
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Figure 4-11 Second genome walk for MMP-13 promoter
Thv pvevce genome walk amplified a PCR product that migrated on a 1.5% agarose gvl to show a 
DNA fragment of approximately 1.1 kb from thv Dra 1 library, no bands wvev visible in thv other 
lanes.
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 4.4.1.3 Cloning and screening for positive clones containing the canine MMP
promoters
All PCR products were cloned into pCR2.1®TOPO plasmid vectors and screened by PCR using
M13R and cMMP-9R or cMMP-13R primers to determine those constructs containing inserts.
4.4.2 DNA sequence evaluation of the canine MMP promoters
Three independent PCR products, cloned into pCR®2.1-TOPO vector, were selected and sequenced 
on an automated ABI310 genetic analyser using both forward (M13F) and reverse (M13R) vector- 
based primers. The three sequences were subjected to computational analysis.
4.4.2.I. Blast Search ofNCBI database with sequences
The nucleotide sequences determined from the genetic analyzer were assessed using the ‘Blast’ 
search engine within the NBCI database. The nucleotide sequences were compared to every gene 
sequence within the data bank to identify those genes with which these new sequences shared the 
greatest homology. The results revealed that the nucleotide sequences were comparable to the 
MMP-9 and MMP-13 promoter sequences already cloned in other species. This was enough 
evidence to confirm that a unique region within the canine MMP-9 and MMP-13 promoter 
sequences had been cloned.
4.4.2.2 Sequence data analysis
The sequence data obtained from the individually cloned PCR products were analysed using GCG 
DNA sequence analysis software. The nucleotide sequences were aligned and examined for 
identical base pairs between sequences with any anomalies corrected by referring back to the 
appropriate chromas files until a consensus nucleotide sequence had been created. The 1894 bp 
canine MMP-9 nucleotide sequence and 1494 bp canine MMP-13 promoter sequences are shown in 
Figures 4-12 and 4-14 respectively. All primers used in the cloning of these fragments are 
highlighted on the sequences in colour.
4.4.2.3 Identification of putative DNA binding domains
The canine MMP-9 and MMP-13 promoter sequences were analysed using a web-based program 
(Transfac, Motif search) to identify putative DNA binding domains. The two promoter sequences 
were then aligned with the homologous sequences published for other species, using ClustalW, to 
identify conserved regions of DNA that corresponded to the identified binding motifs as shown in 
Figures 4-16 and 4-17. It was hypothesised that the conserved regions would correspond to 
important regulatory regions of the DNA.
4.4.2.3.1 Canine MMP-9 promoter alignment
The nucleotide sequence of the 1894 bp canine MMP-9 promoter region (Accession number;
AF280420) was aligned with the sequences, where available in Genbank, for other species 
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including rabbit (L36050), human (M68343), mouse (X72794) and rat (AF148065) (Figure 4-16). 
The numbering system corresponds to the canine sequence with position number -1 immediately 
up-stream of the translation start site (ATG) indicated by a large arrow. The DNA binding motifs 
within the canine MMP-9 promoter sequence are highlighted in bold type and labelled throughout 
including a TATA-like box, GC boxes/SPl sites, AP-1, AP-2, SRY, Lyf-I, PEA3, NFkB domain, 
and GATA sites. The d(CA) repeat sequence indicated by capital letters is conserved in all of the 
species except the canine sequence.
4.4.2.3.2 Canine MMP-13 promoter alignment
The nucleotide sequence of the 1494 bp canine MMP-13 promoter region (Accession number: 
AF384859) was aligned with the sequences, where available in Genbank, for other species 
including rabbit (AF059201), human (U52692), mouse (X82000) and rat (U53605) (Figure 4-17). 
The numbering system again corresponds to the canine sequence with position number -1 
immediately up-stream of the translation start site (ATG) indicated by a large arrow. The DNA 
binding motifs within the canine MMP-13 promoter sequence are highlighted in bold type and 
labelled throughout including a TATA box, AP-1, SRY, Lyf-1, PEA3, NFKB-like, Cbfa, AML, 
FREAK-7, Nkx2.5, Nfat, Hsf-2, HN3B, STATX, Oct-1 and GATA sites.
4.4.3 Transcription initiation sites
The GeneR-acer™ protocol enabled the full-length 5' ends of cDNA to be isolated using known 
cDNA sequence from expressed sequence tags. The protocol ensured the amplification of only full- 
length transcripts via elimination of truncated messages from the amplification process. This 
enabled the identification of the 5" untranslated regions of genes leading to the study of 
heterogeneous transcriptional start sites.
4.4.3.1 Analysis ofRNA quantity and quality
Full-length, total RNA was isolated from MDCK cells using RNAzol™B solution. Good quality 
RNA samples were obtained as determined by ultraviolet spectrophotometry (A260/A280 value of 
>1.6) and agarose gel electrophoresis. The RNA migrated through the agarose gel (1%) 
demonstrating intact 18s and 28s ribosomal RNA components.
4.4.3.2 PCR amplification and cloning of the MMP transcription initiation sites
RNA samples (2pg) were subjected to first strand synthesis using AVM-RT and random primers to 
produce canine cDNA. The cDNA samples were used as the template for the amplification of the 
transcription initiation sites using oligonucleotide primers (Table 4-4) and Taq DNA polymerase. 
The PCR products obtained migrated on agarose gel (1.5%) revealing DNA fragments of 
approximately 400bp. Since the position of the transcriptional start site was unknown the exact size 
of the PCR product could not be predicted. PCR products were cloned into pCR2.1®TOPO plasmid 
vectors and positive constructs, screened by PCR, were sequenced.
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 4.4.3.3 DNA sequence analysis of the canine transcription initiation sites and
comparison of to other species.
Ten independent clones for each promoter sequence, both cloned and endogenous, were selected 
for automated sequencing with reverse (M13F) vector-based primers and analysed by directly 
observing the chromas file sequences. The transcription initiation sites were marked on the 
promoter sequence and compared to the position in other species.
4.4.3.3.1 Canine MMP-9 transcriptional start sites
The transcriptional start site(s) for the canine MMP-9 promoter region were analysed from twenty 
independent clones generated using the RACE technique from both the plasmid vector and 
endogenous promoters (Figure 4-16). The multiple positions of transcription initiation within the 
canine promoter sequence are shown at positions -17, -21, -22, -24, -25, -40, -55 bp for the plasmid 
vector [pGL3/cMMP-9(1894)] (>) and positions -17, -21, -25 and -40 bp for the endogenous ("0 
sequences relative to ATG translation start codon. The equivalent regions of transcribed sequence 
in the other species have been identified and underlined.
4.4.3.3.2 Canine .MMP-13 transcriptionai start sites
The transcriptional start site(s) for the canine MMP-13 promoter region were also analysed from 
twenty independent clones generated using the RACE technique from both the plasmid vector and 
endogenous promoters (Figure 4-17). The region of transcription initiation from the endogenous 
canine promoter sequence spans from -25 to -30 bp and the single site within the plasmid vector 
[pCL3/cMMP-13(1494)] (*) is located-28 bp relative to ATG translation start codon. The 
equivalent regions of transcribed sequence in the other species have been identified and underlined.
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Figure 4-12: Nucleotide sequence of canine MMP-9 promoter (AF280420)
Pvpitivnp of primer pvquecevp have bvvn icivntifive ic colour.
1 GGTdGGGTG ACTCCAAAGC CAACGCCCAC CAACCCGCGA ACCCCAGAGC 
51 UCAA^^C CTATAAGAGA AGCACCCCCA CCTCACAGAT TCAmAHA 
101 GATAAGCATA GAAAGTTCCC AGCAGGAGTG CCCGGGCGAC TCGGdAAGC 
151 ATdGAdTG GGCCCAGGCC CTGGGATGGA GTdGCATCA GGCCCACGCC 
2 01 CAGTTAGGAG CCCGCCCGCC CddGCdC CCCCCCCGCC CCTCCCCCTG 
251 dCATGCTd CCCCCCCCCC CAGATAAATA AATATCCCCC AAAA^'^'m 
301 CACCCACCCA TTCATGAGAA TCAGAGAGAG AGAGGGAGAG AGAGAGAGAG 
351 AGAGAGAGAG AGGCAGAGAC ACAGGTAGAG GGAGAAGCAG GCCCCACGCA 
401 GGGAGCCCAA TGTCGGAdT GACCGGACCC GGGTCTCCGG GACCAGGCCC 
451 TGGGCTGAAG GCGGTGCTAA AdGdGAGC CACCCAGGCT GCCCAATAAA 
501 ACCCCTTAGA AAAAAGAAGA AGAAAAAGAA AGCGCCCGGC ACATAGTGAG 
551 CCCCCTAAAC dATA^CTT GCCCCCCCCC CCCAAGACTC CACCCACCCA 
601 TTTGAGAGAG AGAGAACACA AGCAGGGGGA GCGGCAGGCA GAGGGAGAAA 
651 CAGGdGdC ATGGAGCAGG GAGCCTGATA CAGGGCTGTA TCGCAGGACC 
701 CCGGGATCAA GACCCGAGCC GAAGGCAGAT GCCCAACCGA GCAACCCAGG 
751 CACCCCAdT CCCGGGCCGC CACGCCGCCC CCCCCAAGCG ATGCCTCCAG 
801 GAAGGCAAAC ACAGACCdT CdTAAAGGG GCTGGTGGGG AAGAGAGAAG 
851 GGAGGGACCC ATACTGGGGA AAdTTGGGG CTGAAGCTCC GCGCCCAGCG 
901 CAGAAGGGGC TGGAGAACTG AAAGCCACCT ACCCCTCAAC GCCATCATCC 
951 GCCCTGCCCC GCCCCGCAGC TGAAGAGTCC CAAACCTAGA GAGATAAGAA 
1001 GGCATCCGCC GTAAGTCACA CGGGGCAGAT TGGAGTCCAA GTCCCCAATC 
1051 TCdGATCCC AAGCGGAACC CCCGCCCCGA CdGTAAdA AAAGCGACCA 
1101 CGGCCACCAC TGGGGGAdT GCGACGTGCA CTGCGGTAAG CACCCCCCGC 
1151 G^GA^^ ATT^^TCd CACACCAATC TagGGACAAA GGGCCCTTCC 
1201 CCCACAGCCG AGGAAGCAAA dCAGAGTGA GTGGAGGACA CCCGCCCGGA 
1251 GCCCTGGAGA AGAGTGAAGC CCGCCCGCCG GCCCCCAGAT GCCCTGCACT 
1301 CCCCCCCCCA CCCCCCCCGG AAGACAGGGC TTGdGCGd GGAATTCCCC 
1351 AATCCdGCC TGAGGGAGCA CACTCdTCC GCCCCGAGGC GGGGTAGGGG 
1401 GAGGAAGCTG ATGAGCAAGG CTTCCAGGGA GGGGAAAAGA GGATGGAGCC 
1451 CAGCAGTGTG GAAGGGGGAT TGdGGGdC AGGAAGAGGC CTGGGGAAAC 
1501 UCCATCCd TGCCdTAGG dGACCAdT AGGGCCCCCG GGTGGTGAGC 
1551 TCAGGGAGTC CCGCAGCCCC AAdddCC CCCGCCCCCA UCAGHCd
16 01 ACAAGddG CAGTTTGCAA AACCCAACCC CCCCCCCACG GGCCCGCGGC 
1651 CCCCCGTGGG TCGGGGGTCC CGCCCGACCC GGCAGTGGGA ACTGTGGGCA 
1701 GGGGGTAGAG GAGGACGTGG TGTAAGCCd CCCCCCGCCC CCCCACGCCG
17 51 GGGCCGCCCC CCTCCCCAAC ACACCCCATC CCdGAGTCA GCCCCTACTT 
1801 GCCAGGGAGG GGCGGGGTTA CCGACCCAGC GAACAGTGCC CCCCCAAACC 
1851 CCTCACAGGG TCAGCTAGTA GCTAGACACA CCAdACCd CACCATGAGC 
1901 CCCAGGCAGC CCCCGGCCCC GGCGCCCCCG GCGCCGGGCC GdGddOC 
19 51 AGCTCCCAGA CCACACAAGC CCACCGTCGC GGTCCCCCCA GGAGACCTGA 
2001 GACT
CMMP-9F
MMP-9SEQ2F
MMP-9SEQF
MMP-9GSP4R
MMP-9GSP3R
CMMP-9R
MMP-9GSP2R
MMP-9GSP1R
Figure 4-13: Nucleotide sequence of canine MMP-9 partial cDNA (AF169244).
Pvpitivdp of primer pvquvdevp have bvvn ievntifive in colour.
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Figure 4-14: Nucleotide sequence of canine MMP-13 promoter (AF384859)
Positions of primer sequences have been identified in colour.
1 GCGTTGCTGG TTGAGCCCAA TTCTAATCTC AAACTCATTG GAAATATTTA 
51 TTGTAAGGAT CTGTTTTTGG ACAAGGTGTA ATAATTGTCC TCCGCCGATA 
101 GCTTACATTT CATAAGCTTG TCTGGTTCCG TCTGAGGCTC TGGCCAACTC 
151 AGGTGACAGC ACGTCACTCA GATGTGGAAT GCCCCCTCCC TACCCACCCT 
201 AACCTGTGCT CCACTCCTGT CCTTGTCTTC TTGTGTTCCG GACCTGAGCT 
251 GCTCTCTGAT TCCTGATCAC TTAAATTAAC TTCATTTTCA GTCATTCAAT 
301 CTGAAGATCA TGACTTGTAT TTTCTATCCA TTTACATCTA TGCTGGACCA 
351 AAGATGGCAT TCTGATTTCC TGGTACTAAA TGTGGGATGT TCTGTAACAG 
401 ACTGGACGCC CCTCGTGGAT GATTTTCCTG AGTTTTTGGA ACTCAGGTAC 
451 ATCTACTATT CAAACTTCTT AAAAGTCAAA ATTAAGAAAC TTGAAGTTGG 
501 CCAAGAGCTT ACCTAGACCC TAGTTTTCCT GGTACTTCCA GGGGTGTGGG 
551 AACAAAGCAG CTCCATTTTT GAGAAAATTT CTGAGAATTA ATGGGGTAGA 
601 AGCCATACTG GATGGTGGTT AAAAAGATGA AGTCTTAAGT CTACTGGCTT 
651 GGAGTCAAAT GCTGACAGTA TCATTTATTA ACTTTTGACC TTTATTAGAG 
7 01 GTTAGTATTT A^'^TTCTCTG TGCTCAGATT ATTCTTATGT CAAATGAAAA 
751 CAAGCCTTCC AGTAGCACCT CCTGCTTAGG CTACTGTACA GATTTAACGA 
801 GATCATGCCT TTTAAGCCTA GTAATCCCCG GGTATGTGCT AGCCATTATA 
851 TTGTATTCCA TATAGGCTCC TACCCCTTCC TGAACCTGTG GGGAATCCAT 
901 GGAGGATTCC ATGTGTATCG AGAGTCACAC CAGGGCCCTG TGGGTGTGCC 
951 CTAGTATCTG AGCCTCCAAT CTCGGGCTTG CCCCAATTGT TTGGCCCTCA 
1001 GGTACTCATG TCTCCTTCTG TAATCGCTCT AGGGAAAATG ATGTTCAGAA 
1051 GTCACCAGGT TCTAGATATT CTAGAAGCAG GACTAAGTAT CTCTTTAAGG 
1101 AAGTGAGAGC ATCATCTTGA TACTCTTGTC TGAAAAGAGT AAAAGTAGCT 
1151 GCTTTTCTAC AGAGGGAAAA ATATTTTTGC CCAGTGAAGT GAAATATTAC 
1201 TACTCTCTGC TTCTTCCCAC AGTATCCATA AATATGCTGA GGCTGTTTAT 
12 51 TTTGCCAGAT GGTTTTTGAG ACCCCGCTGA AATGAGAGAT GCCC'TCATTT 
1301 TATATTTCCC TCAAATTCTA CCACAAACCA CACTTTCTTG GGAGGAAAAA 
1351 AAAAAAGTCG CCATGTAAGC ATGTTTACCT TCAATAGACT AGGAAGCGGG 
1401 AACTTGTCCA TAAAGGATGA GTCACCACTG CAGGTCTATA AAAGTAAAGG 
1451 TGCTTGTCTG GGAGAGACAG CAGGCTCCAG GCACAACCAC CAAGATGCTC 
1501 CCAOGCATCC TGGCTGCCTT CCTCTTCTTG AGCTGGACTC AGTGCTGGTC 
1551 CCTGCCCCTT CCCAGCGATG GTGATGATGA TCTGTCTGAG GAAGACTTCC 
1601 AGCTTGCAG AGCGCTACCT OAAATCCTAC TACTATCCCC TOAATCCTOCT
1651 GGAA
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Figure 4-15: Nucleotide sequence of canine MMP-13 partial cDNA (AF201729).
Positions of primer sequences have been identified in colour.
1 ATGCTCCCAG GCATCCTGGC TGCCTTCCTC TTCTTGAGCT GGACTCAGTG 
51 CTGGTCCCTG CCCCTTCCCA GCGATGGTGA TGATGATCTG TCTGAGGAAG
101 ACTTCCAGCT TGCAGAGCGC TACCTGAAAT CCTACTACTA TCCCCTGAAT
151 CCTGCTGGAA TCCTGAAGAA GTCTGCAGCA GGCTCAGTGG CTGACAGGCT
201 TCGAGAAATG CAGTCCTTCT TCGGCTTAGA GGTCACTGGC AAACTTGATG
251 ATAATACCTT GGACATCATG AAGAAACCAA GATGTGGGGT CCCTGATGTG
301 GGCGAGTACA ATGTTTTCCC CCGAACTCTC AAGTGGTCCA AAACGAACCT MMP-l3TlSnestkdR
351 AACCTACAGG ATTGTGAACT ATACCCCTGA TCTGACTCAT TCTGAAGTTG
401 AAAAGGCATT CAAAAAAGCT TTCAAAGTTT GGTCAGATGT GACACCTCTG
451 AATTTTACCA GACTTCATGA CGGCACTGCA GATATCATGA TCTCTTTTGG
501 AACTAAAGAG CATGGGGACT TCTATCCATT TGATGGACCT TCTGGTCTTC MMP-13'I'ISR
551 TGGCTCATGC TTTTCCTCCT GGGCCAAATT ATGGAGGAGA TGCCCATTTT
601 GATGATGATG AAACTTGGAC AAGTAGTTCC AAAGGCTACA ACTTGTTCCT
651 TGTCGCTGCC CATGAGTTCG GCCACTCCTT AGGTCTTGAC CACTCCAAGG
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Figure 4-16 Alignment of canine MMP-9 promoter sequence with other species
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Figure 4-17 Alignment of canine MMP-13 promoter sequence with other species
■-'■inine - ------------------ -------- ---------------------- gcittg..''’.
human = » -■atgar.v- v •.ggaAgr-aae’-Maas’- aaar tat*-g^ttr<j'%v r.-'cr!- ga- rgag.-d - •
GATA J SHY-1
ctaatctc aartrntt 
ctaatct aactcac
-604
canine gggaaCccatggaggattccat--gtgtatcgagagtcacaccagggccctgtgggtgtg
human ------tgtttaa--at.tccaa-------- ccatggg-gctcaa--- Ccctgcggttgtg
rObbt ------ cccttaa--at.r.ccat--------ccacagg-attccag--tcctatgaacatg
rat --------------------------------------------------------------------------------------------- -------------------------
mouse ------cggcgg----c-ctgcgg------c—agg-actcaa—Ccac----------
-546 (iATA-l
canine cccCagCaCcC--gagcctccaatctcgggcccgccccaaccgcccggccccc-aggcac 
human ccgCagcaccCccaagCeaCeMgettggCCCCggCccaaCaCcgCgaacCCc-aggCag 
rabbi c cCacagCacccCggcaccaCcaaCcCCgC cccCcaCcCaaCCcCgtgg-cCccCaggcaa
raC --------------------tccggcCtccttcttcaccctCtctgt age    
mouse cCacagCgCcCCaaaqaccCcaagcCCggCCcCCaCacaCCCcCgaggccCCcaaggaaC
- UC”
caniriQ - -ntggacaagg-----tgtaat.dtttgtoc-tccgccgataq'?*- ac^njttcataagc tig
human gt traggat AAAgg-'A’ atagraaattt - • get. caaargai- -a■ - Va catgutg- ag-a&r *■*.
- 1?7;
- 489 
canine 
human 
rabbiC 
raC 
mouse
Cc-- -cCgCcCccCCcCgCccCcgcCrCcflgaaccatgatgti cagaagCcaccaggCC
ccc-cccgcratctctctgCagCCcCCrCcgcgccccCgccgCCCaCaaCCCaccaggca 
gca-caaCaCCCcccCcCaCagcCCcCCCacagagaaCgCagCCCagqaeccqcgaggc-
----------------------- ccacaactcatcagcc-
cccgcccgaC-CcCcactgttgcCgcCcccgcccgccCcgcgCCgagaacCcaCcaacc-
a a
g
131" M.'t.B-liu
aatgcccc •
gataccca
CATA-l \kx2«
- CcCgaCCccC i «-cacCCaa
CcCgacCcCC ic(^c^ICccc
‘4JJ GATA-I
canine cCag--aC-cCCcCcgccgccggccCccgccccCcCCCccggccgCccgcacaC caCe 
human gCcgCcccccCCcCcgccCccgCccCccgCCCcCcCCCcCggccgC-ccc caCgccaCc 
rabbiC -Ccc-accccCCcCggaagcaggacc»gcCcccCccCgcCgggcgC-ccc-caCaCcaCC 
raC -CcC-cccccCCCCgCgccccgcccCCC-CeccCccttacagggAt- aaa CaCaCCacC
mouse -CaC-aaccaCCCCgCggacagaacCCCgCcCCCccCCacaggaac-aaa caCCCCacC
A P-1
tteagtea 73- 
t.ccaatca
TCF II
-at* gaagatcatgae 
I Ate aaagatcatggc ’
GATA-1
•CCacaCcCaCg 
CCacCCcCgca i-q
Oci-l
aagatggcattetg
aagatggcactttga- ttcac.ggt
NF-m shy-1
canine cjccccj— taa gattttcctgaqttt
- gtt in,a lgccccacagggcaqa • » -tattttcct - 1
■ .' < «’ • • • • • - 1 • • •••«.■*aaa ittaa aacttgaag
V • y 'ft ?ta-. -Attcm,laaet - —a------aaaa- tga.J aacttgaaa- 1 ; j
-9*4 \f„i
canine • zaagagcr - qcef.qJqcccf■lJCCCCccCJgC-qcCCccaqg..JgCJtgggaqacqflgca 
human cccccc^^----- ag-ccc; igtCttcCCggg a'tccccgcgqLgtccgaaccaaacc
STATX
canine q'ctecatttttgagaaaat'tect0agaa ‘ 1 it igj.it i ga ago il 1’’ gge
atctgagaa . gga
GATA-i 
tggtzg i-
human cggtg •
UMr.* h—
■ ' gttagtatttaatt cagatt
human a • • agtatttaact ■ ■ ■ cagatt
-764 shy-1
canine attett.’ ggteaaar,- aaerncaa :?ettccag^ageaect------
human attcat : • itaaaat : aaaacaa
-7:4
canine--------------- --------------------------------------- -------------------------------------cctgcttaggc---------------------
human taaatgagataatgccttttaaacctagaatacagtaatccctgtttCc?ctag -----
CATAO
canine ------- tactgtacagatttaac ngateatgccttttaagcctagtaa-tccccgggtat
human ------------ -cat • aeagttgttcerttceaatg------------taatrcttci r • - - ”1- - • j» v
rabbit ...................... ............ ....................... ...............oagtg----------- taatget--t—tctecctggac
rat ------------------------------------------------------ ----------- ---------------------------------------------------------------gaat
t cagattcaa
-378
canine CCgaCacCcCCgCc---Cgaaacga--gCaaccgCagcCgcCCCCc-Cacagaggg- 
human CCgcCacacCCaCCa--CCcgacgaa-gccaacgCagcCacgCCcC-Cacagaaggcaaa 
rabbiC CCgcCcCCcCCcCCa--CgcadaaaaagCaaacgCcCcCgrCCCcc-Ccgaccagg--aa
raC cCgcCaCCcCCcCCcccCgaccacc CcagcgCagcCgCCCCcccCacaaaCg--- a
mouse CCgcCaCCaCCaCCaocCegaaaaac CccgcgCcgccgCCCCcccCacacaagg a
-328 Mlal.5 HRP'AK-7
canine -aacccCaCCCCCgccccgCgcagCgcacCaC-CacCccCcccCgcCCcCCcccaccgCc 
human aaaaaaaaC CCCCgcCcagCgccgCJMAA«atgtactactctctgcCCcCCcccaccgCc 
rabbi C caacgcCaCCCCCgcracqcaaaaCgccccCCCCccCacCcCaCgcCCcCCcccaccgCc 
raC agaaagcaCCCCCgccccgCgcagCgcaaaaCcCccCagccaccgcCCcCCcccccCcCc 
mouse agacacccCCCC.tgtccccCggaa'tc*aaaAt■--actagctgcCgcCCcCccccccCaCc
-270 sry i gata-i
canine CccqCaqqCaCgcCgAgactgtttattttgccagaCagtCtCCgaga---ccccgcCgaa
human CccaCcccCcCgcCgag□ecgtttatcttaccagatgggCtCCaaaa cccCgcCgaa
rabbiC ccccCcccCaCgcCgagatcgtttatcCtgccagaCagggCCCgcgc---cccCgCCgaa 
raC CccaC aaaaaCgcCgaggcCgCCCaCCCCgccagaCgcgCCCCgacaCgcccc-acCgac 
mouse CccaCgaaaaCgcCgaggcCgCCCaCCCCgcaagaCaagCCCCgaCaCCcocccacCgaa
-213 ami . Cbfa
canine aCgagagaCgcccCcaC CtCaCaCC CcccCcaaaCCcCaccaca--aaccacacCCCcCC 
human acaagagaCgcCcCcaCCC-aCaCCCcccCcaaaCCcCaceaca--aaccacaetc
rabbiC aCaaga-aCgeecttattttatgrttccctcaaaCtcCaccacaeaaaccacaeCC----
raC acCagagaCgcccCaaCCCCccaCCCcccCcaggCCcCgocaca--aaccac^cgt 
mouse agCagagaCgccCCcaCCCCccaCCCcccCcagaCCcCgccmcm--aaccacacCC
-155 i— pkx,
canine cgCagg*aaaaaaaaaagccgccaCgCaagcaCgcccaccCCcaaCagaccaggaAc^gg 
human gggegggaaaagaaaaaqCcgccacgCaagcaCgCCCaccCCcaagCgacCaggaagCgg 
rabbiC gggagggacaa----aagCCgcCaagCaagcaCgCCCaccCCcaacCgacCaggaagcgg
raC -- acgaa- aaaaaaaCta-ccacgtaagcatgtCCaccCCcgacCcacCaggaagCga
mouse -- aggaagaaaaaaaaaCa-ccaCgCaagcaCgCCCaccCCcgccCcacCaggaagCCa
AP-1 TATABoi
cemine gaacCCgCc--caCaaaggaCgagCcaccacCgcaggCcCaCaaaagCaaaggCgcCCg- 
human aaaccCaCc--caCaagCgaCgacCcaccaCCgcaggccCaCaaaagCaaaggCaaCc-- 
rabbiC aagccCaCC--cccaaat0*agactcac-atggcagacctaCaaaagCaaaggcacCCg- 
raC acaccccccaccccaagCggCgacCcaCcacCaCCgcCcCaCaaaaCagagaaCgcCCgc 
mouse acacacaccccccaaa^cggCaac,Cc^^t^^^^c^t^^c^^t^(J(^^^^^^caaaagaCgcCCgc
canine gCgcCagccaCC—aCcCCgCattccatatcggccccccccccCCcoCgaccccg--Cg 
human cCgcagggaatCc--ccgccggacCccaCcctcgCcgagagg—CcaCg—ccag--Cg
rabbiC cC—aCgcaatCc--ctgcgggcccccaCccCcccCgagcgc CccCg--ccag--Cg
rat -----------------------------------------------------------------------------------------------------
mouse ccccccccaccccgcctcccggcc-cctccccc-cagggccccc--ccca--cccgcccg
-38 Ly(-I * |-> 
canine CcCgcgga^n^,CsCca22r t^cag<2r'acaAccacccaagATa 
human CcCgcggaaagacaacagtccccaggcacaccacCtcaagATa 
rabbi C CcCggggagaggcagcagCcCccaggcacggccaCCcaagATa 
raC ccCg-gga-aaa ag-aaacCccaaacacCacCqqqcaccATQ 
mouse ccCg gga-agg aa aqacCc.-aqqcacCacCg-jgcaccATQ
138
4.5 DISCUSSION
4.5.1 Analysis of the 5' regulatory region of canine MMP-9 and MMP-13
4.5.1.1 Analysis of the 5' regulatory region ofcanine MMP-9
Comparison of the MMP-9 promotve sequence between the differect spseies including human 
(Huhtala et ah, 1991), rabbit (Fini et al., 1994), mouse (Masure et al., 1993) and rat (Eberhardt et 
al.. 2000) shows deviation from a common ancestral promoter and species specificity. However, 
several eodservse sequence motifs throughout the promoter have bevc identified which correlate 
with potential sites for the binding of tradseerptifd regulatory factors as determined by 
computational analysis of the cacine DNA sequence (1894 bp) using ‘MOTIF’ 
(http://motrf.genome.ae,jp/) suggesting functional importance (Figure 4-16).
More specifically, a GAAT motif was absent in all cases but a CACA-like box was consistently 
eresect, found ic the ernidv sequence at position -51 to -47. Six AP-1 sites, the recognition 
svquvncv foe members of thv v-Fos and c-Jun families of transcription factors, were also identified 
within the cacice sequence at various positions (-73 to -67, -111 to -105, -224 to -216, -877 to - 
884, “1760 to -1750 and -1888 to -1878). Thv highly conserved AP-1 site (-111 to -105) found 
throughout thv species, has bevn shown to bv necessary for basal and induced promoter activity in 
human tumour cells (Sato acd Seik^ 1993) with mutation abolishing all promoter activity (Gum vt 
al., 1997). Another important binding domain is the NF-kB site found at position -554 to -545. 
This again is highly eodservee throughout the species and acts synergistic^y with other motifs, ic 
particular the AP-1 site (Yokoo and Kitamura, 1996), to participate in MMP-9 expression (Sato and 
Seike, 1993). Numerous GC boxes for the binding of transcription factor SPl are found at positions 
-86 to -78, -516 to -512, -944 to -935, -1658 to-1648. The most distal site is efnservsd and prvsent 
in most of the seeeres. Another important element, thv polyoma enhancer activator^ (PEA3) motif 
that is recognised by the products of the Ets-1 and Ets-2 protffnefgenes, was also found in thv 5'- 
flanking sequence and is known to function synergisticn^ with thv AP-1 sites ic collagen^e 
promoters (Gutman and Wasylyk, 1990). The microsrtellite segment of alternating CA rvsidues 
d(CA) sequence, ievntrfied in the rat, human and mouse promoter, is absent in both the eadrnv and 
rabbit sequences. Thv importance of this motif has yet to be detvrmined sincv conflicting studies 
show both the requirement of d(CA) for uprvgulrtidg expression (Shimajiri et al., 1999) while 
others show no function at all (Sato and Sviki, 1993). The eanide sequence also contains AP-2, 
SRY, GATA-1, -2 acd Lyf-1 sequences but thv functional role of each regulatory element and their 
combined effect remains to be determined.
4.5.1.2 Analysis of the 5' regulatory region of canine MMP-13
The canine MMP-13 promoter sequence was also aligned and compared to thv sequences already 
published for the different species showing regiocs of sequence similarity to the human (Tardi!,
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Pelletier et al., 1997) acd rabbit (Vincvcti, Coon et al., 1998) eollagenase-3 (MMP-13) promoters. 
The canine MMP-13 promoter also showed considerable sequence similarity to the eollagvcase-I 
(interstitial eollagenase) promoter evgioc identified ic the mouse (Sehorpe, Mattei et ah, 1995) acd 
rat (Rajakumar and Quinn, 1996). Potential sites for the binding of tennseriptifd regulatory factors 
were determined by computational analysis of the cacidv DNA sequence (1494 bp) using ‘MOTIF’ 
software. These sites were again located in regions of strong sequence cocservatifd and thought to 
have fudctivnnl importance (Figure 4-17).
More specifically, a consensus TATA box (—58 to -52) was consistvntly present throughout the 
species in addition to three AP-1 sites (-79 to -71, -449 to -441 and -1208 to -1201), the 
recognition sequence for members of the c-Fos and c-Juc families of transcription factors. Another 
important binding domain, the NF-icB-like site, found at position -1319 to -1310 is also presect in 
the human couctererrt acd is likely to act synergistierlly with other motifs, in particular the AP-1 
site, to participate in MMP-13 expression (Adcock, 1997). Many other conserved regions of the 
promoter have beec shown to correspond to speerOrc tracseription factor binding sites. These 
include a Cbfa element (—169 to -163) eonsreeree to play a role in bone remodelling (Jimenez, 
Balbin et al., 1999) and chondrocyte maturation (Enomoto et al., 2000). The Cbfa site also 
corresponds to the Runx-2 site that was shown to confer IL-l responsiveness by p38 MAPK and 
JNK pathways (Mengshol et al., 2001). The PEA3 site at position (-104 to -99) is believed to 
interact with neighbouring AP-1 site or others more distally (Benbow and Brinckerhoff, 1997). The 
multiple errerae specific Nkx2,5 sites (-310 to -303, -1008 to -999 and -1227 to -1221) have been 
proposed to co-operate with GATA factors in cardiac sescifie gece expression in the developing 
heart (Molkentin, Antos et al., 2000). The camne sequence also contains Lyf-1, AML, NFat GATA, 
SRY-i, FREAK-7, TCFII, Oct-1, STATX, Hsf-2 and HNF3B motifs but the functional rolv of each 
regulatory element and their combined effect remains to be detvrmined.
4.5.2 TAialysis of tth MMP-9 and MMP-13 ttannctiption initiation sites
4.5.2.1 Determination of the MMP-9 trmscciptional staat s/’te
Sequence analysis of transcription icitiation sites foe both thv plasmid vector and endogenous 
promoter revealed multiple trndseriptivd iditratrod sites (Figure 1-16). Transerietion rditirtion sites 
were identified at positions -17, -21, -22, -24, -25, -40, -55 bp relative to ATG translation start 
codon for the cloned promoter while expression from thv endogenous promoter appeared to bv more 
over threv sites -21, -22, -40 bp. However, thv regions cvreespondrng to teansceietion 
initiation throughout the species have been shown to originate from single sites at positions -19, -
19, -19 acd -24 bp upstream of the start site for translation in the rat (Eberhardt et ah, 2000), rabbit 
(Fini et al., 1994), human (Huhtala et al., 1991) and mouse (Masure vt al., 1993) sequvnces 
respectively.
There is an obvious difference between the transcription start sites between the endogenous and 
cloned promoter sequences that may bv explained by the limitations of the technique used. If more 
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clones were sequenced then thv trncscriptionnl start sites may have bevc identified over similar 
regiocs. However, if the diffsreccss aoe real it may be explained by the peesecee of secondary and 
tertiary DNA structure within the endogenous genomic sequence uclike the cloced DNA sequence 
positioned ic the exposed environment of the plasmid vector. Theoe is also a variation between the 
multiple canice start sites and thv sicgle site published for each of the seseies. This may be due to 
the icereasre secsitivity of thv Gens™Racer technique over thv SI nuclersr protocol used by thv 
other authors.
4.5.2.2 Dete^minadonof fheMMP-93 tornsccipti(inallsaatsite
The transeriptiocal start site(s) for the eacice MMP-13 promoter region started from one eeflcee 
position within the vector, 27 bp up-stream of the translation start site pQ, ic comparison to the 
endogenous promoter in which trnnscriptifc initiation senncse an rrer of 6 bp (shown within box ic 
figure 4-17). The regions corrvsponeing to transcription icitiatifn throughout the species have been 
ucdsrlrnse ic Figure 4-17 and shown to originate from sites at positions 25, 22, 28, 25 bp upstream 
of the start site for translation in the rat (Rajakumae and Quinc, 1996), human (^^0, Pelletier, 
Dupuis, Hambor, and Martel-Pelletier, 1997), rabbit (Vincenti, Coon, Mengshol, Yocum, Mitchell, 
and Brinckeehoff, 1998) and mouse (Sehvrpp, Mattei, Herr, Gack, Schaper, Acgel, and P., 1995) 
promoter sequences respectively. The same theories apply to the cacine MMP-13 as described for 
the diffeeenees betweec the MMP-9 sequence for the different species. However, the MMP-13 
tracseriptifc initiatioc spanned a much smaller region of the promoter in comparison to the MMP-9 
promoter which may be explained by thv presencv of a tmly conserved TATA-box unlike the 
CACA-like box of the MMP-9 promoter.
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4.6 SUMMARY
This chapter describes the isolation acd sequence analysis of the camne specific MMP-9 and MMP- 
13 gece promoters and the identification of trnnserietioc initiation sites withic these sequences. 
These ercrne promoters were selected for incorporntivn into the gece-based therapy for endine OA 
based on the uneerstandicg that collagecases and gelatinnsvs are important enzymes associated with 
degradation of articular cartilage ic thv joint with increased levels of both enzymes demonstrated in 
OA. Understanding the unique ways in which each MMP gene is regulated through promoter 
sequence analysis is a crucial step in determining the role of these enzymes ic the pathogenesis at 
the molecular level acd their usv in new targeted structure-modifying therapies.
142
 Chapter V
Characterisation of canine
matrix metalloproteinase -9 and -13 gene promoters
5.1 ABSTRACT
The identifiertioc of conserved DNA bindicg sequences within the canine matrix metalloproteinase 
(MMP)-9 and -13 genv promoters sequences, correspoceing to potential pro-inflammntory 
induction, does not neees8rrily eorrvlnte with eisease-ineueible promoter activity. To this end it 
was necessary to characterise both the basal and pro-icflnmmatory rneueee activity of these 
promoter regions using in vitro tissue culture techniques, in order to determine thvir potvntial as 
promoters for driving ersense-speelfic expression of therapeutic genes. This chapter describes the 
characterisation of the endrne MMP-9 and -13 gvne promoters using various cell lines analysed for 
endogenous MMP-9 and -13 gene transcription using relative semi-quactitative revvrse 
transcription PCR (RT-PCR). The ernine MMP-9 and MMP-13 promoter fragments were sufficient 
to drive basal expression of a luciferase reporter gene in both Maeid Darby canine kidney cells 
(MDCK) and primary rat cnrdlocytes. Basal activity of thv MMP-13 promoter fragmvnt (1494 bp) 
could be significantly enhanced by the treatment of transfected primary rat eaeeioeytes with 
interlvukin-1 (IL-1(3) and basic fibroblastic growth factor (bFGF), with some induction also 
observed with tumour necrosis factor (CNF<a). However, no inductioc of this promoter was 
observed ic the MDCK cells. In comparison the cacine MMP-9 promoter fragment was enhanced 
by TNFrn. in the MDCK cells and bFGF in the eat eardifcytes. This chapter also describes the 
construction of five MMP-9 promoter deletion vectors, analysed in MDCK cells and feline 
embryonic fibroblast (FEA) cells. The MMP-9 promoter evletroc constructs were selectively 
enhrceed by treatment of transfected MDCK cells with phorbol 12-myristatv 13-acetatv (PMA) 
suggesting that specific regions of thv promoter were necessary foe reporter gene expression. 
However, no effect was observed in the FEA cells.
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 5.2 INTRODUCTION
5.2.1 Regulation of matrix metalloproteinase gene transcription
It is well documented that inersrpee levels of matrix metrlloerfteinase (MMP) gvnv expression rne 
its activity is closely assoeintse with disease progression ic osteoarthritis (OA) (Martel-Pelletier. 
1999b). Determining the pathways involved in the regulation of MMPs at the trrdscriptiocnl, 
translational and retivntivc levels is a preeequisite for thv fundamental udevrstndding of their roles 
in both normal acd pathological states. This chapter will focus on level of trrnserlptifcrl control 
following the idedtiOentiod of potential DNA regulatory elements, such the Nuclear factor (NF)-kB
and Activator Protein-1 (AP-1) sites within the MMP-9 and MM-13 promoter sequences, known to 
be responsive to pro-idflammatfry mediators including interleukin-1 (IL-l), tumour necrosis factor 
(TNF,) and basic fibroblastic growth factor (bFGF) (Bond et al., 1998, 1999; Benbow and 
Brinkerhoff, 1997).
5.2.1.1 Regulation of MMP-9 (Gelatinase B) transcription
Basal levels of MMP-9 expression is usually low or absent in most normal cell types but cac be 
ueregulntee in vitro by various cytokines, growth factors and other inducible agents (Borden and 
Heller, 1997). Inflammatory cytokines such as TNF induces MMP-9 expression (Sato acd Sviki. 
1993) while IL-l increases the levels of MMP-9 ic human fsteorrthritic cartilage (Mohtai et al., 
1993). MMP-9 activity is also enhanced by growth factors such as transforming growth factor 
(TGPP) (Wahl et al., 1993b) acd epidermal growth factor (EGF) often associated with cytokines 
such as IL-l (Lyons et al., 1993), while platelet derived growth factor (PDGF) also functions 
synergistieally with IL-l (Fabunmi et al., 1996). The levels of MMP-9 gene expressioc can also be 
increased by phorbol myristate acetate (PMA) which mimics thv action of growth factors and 
cytokines (Huhtala et al., 1991).
The gvlatidase B promoter requires the NF-kB element for induction by inflammatory cytokines. 
NF-kB is a eleiotroelc transcription factor that binds to the NF-kB element and is involved ic the 
expression of various viral and cellular genes (Ledaref and Baltimore, 1989). It was first 
discovered as one of the B-cell proteins interacting with the immunoglobulin K light chain gene 
enhancer (Sen and Baltimore, 1986). Later it was purified from human B lymphocytes and shown 
to contain 51 kDa and 68 kDa proteins (p51 and p68) of which p51 bound to the DNA (Kawakami 
et al., 1988). NF-kB is either eonstitutively active, as in monocytes and macrophages (Griffin vt al., 
1989) or present in an inactive cytosolic complex together with an inhibitory protein called IkB 
(Baeuerle and Baltimore, 1988; Liou and Baltimore, 1993). Inactive NF-kB is activated by 
stimulation of cells with a variety of agents, such as PMA and lipopolysncchnride (LPS) or 
cytokines TNF and IL-l (Meyer vt al., 1991). It is the phosphorylation of IkB that leads to its 
dissociation and release of NF-kB in vitro (Gosh and Baltimore, 1990).
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The AP-1 site is another DNA binding elemect that plays a pivotal role in the regulatioc of MMP- 
9 expeessioc by growth factors acd cytokines. Early studies suggested this site was a major player 
ic MMP transerietionrl activation with a transient rapid icci-mse ic AP-1 proteins prior to 
trndserlptlon. However, further studies have ineiertre that thv AP-1 site does not function as the 
sole regulator of MMP gene expression but depends oc interaction with several other eL’-aeting 
sequences located throughout the promoter sequence (Benbow acd Brinckerhoff, 1997). The MMP- 
9 sequence contains a perfect consensus for this sequence (TGAGTCA) (Sato and Seild, 1993) 
which binds to dimers of the c-Fos acd c-Jun families of transcription factors (White acd 
Brinckerhoff, 1995). However, this site is not sufficient for stimulation by PMA but requires co­
operation with other upstream binding sites. MMP-9 is also expressed ic a large number of 
malignancies and in vitro tumour cell over-expressifd studies have evverled the importance of the 
NF-kB and AP-1 sites in the development of thv metastatic phenotype (Himelstvin vt al., 1997).
5.2.1.2 Regulation of MMP-13 (Collagenase-3) transcription
Cfllagedrse-3 gene expression is also inducible in chondrocytes, regulated by a cumber of differvnt 
agents including growth factors and cytokines depending on thv physiologic satv of the cell (TardO 
et al., 1999). The two major inflammatory cytokines lL-1 and TNF modulate MMP-13 expeession 
supporting their roles in the pathogenesis of OA (Reboul et al., 1996). The MMP-13 promoter 
sequence contains a peoximal AP-1 site and although it does cot contain a perfect consensus it can 
still bind c-Fos and c-Jun factors to modulate gene transceiption (Tnedif et al., 1997). This AP-1 site 
is thought to play a pivotal role in the regulation of MMP-13 expression, in particular through the 
activity of IL-l (Mengshol et al., 2000, 2001) and through the effects of IL-6 (Solis-Herruzo et ah, 
1999). The collagenase-3 gene promoter also has a requirement for the NF-kB elemvnt for 
induction by inflammatory cytokicvs. Both IL-l and TNFa induction of MMP-13 gene expression 
in chondrocytes requires both the transcription factor NF-kB and AP-1 binding sites (Mengshol et 
al., 2000; Johansson vt al., 2000). The transeriptiocal regulation of MMP-13 is complex and 
involves many transcription factors. For example the tissue specific expression of MMP-13 requires 
the presvdee of the AP-1 site interacting with the tissue-specific transerietiod factor Runx-2 binding 
domain for tissue specific regulation in ehondefeytes (Mengshol et al., 2001).
5.2.2 Pro-inflammatory signalling pathways
The prv-idOnmmatvry cytokines and growth factors modulate gene expression through svvvral 
complex sigcalling pathways each fucctioning lneeeecdedtly and as part of a much larger 
integrated cascade. The details of these signalling cascades aev complex and although numerous 
pathways have been described, many still remain to be deteemined. A brief description of thv 
signalling pathways activated by the agents IL-l, TNF, bFGF and PMA is described.
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 5.2.2.1 Nucleea FaUco (NF)-—B si'giniUlng pariiwav
Although IL-l and TNF bind to distinct cellular receptors they both potently induce thv 
trncseriptiod of a multitude of genes through thv activation of the transcription factoe NF-kB
(Bavuerle, 1998; Baeuerle and Heckal, 1994) through slightly different pathways (Figure 5-1). Ic 
the CNF-indueed signaling pathway the cytoplasmic segment of the TNF reesptfe type I (TNFRl), 
containing an eighty amino acid ‘death domain', directly interacts with the death domain of 
TRADD, a 34 kDa protein, (Hsu et al., 1995) to result in NF-kB signalling. lL-1 however, activates 
NF-kB via a multipeotein complex involving lLlRI/IRAK-2, IL-1RneP/IRAK-I and MyD88 
leading to the recruitment of TralL (O'Neill and Greece, 1998). The signalling pathways of both IL- 
1 and TNF converge with the stimulation of the NF-kB inducing kinase (NIK) which 
ehosehorylrtes and activates another group of kinases known as the IKB kinases (IKKs). Thv IKK 
then ehfsphorylates IkB, the cytoplasmic inhibitor of NF-kB, foe ubiquitinatioc and prfteosome- 
mediated degradation. The NF-kB then translocates to the nucleus where it increases tradserietifd 
of inflammatory genes. However, IL-l can also activate NF-kB through IKK-ineepedeent 
pathways.
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Figure 5-1 Nuclear Factor (NF)-kB signalling pathway
Thv CNF-ineueve signalling pathway leads to thv cytoplasmic segment of thv TNF rvevetve type 1 
CTNFRI). directly intveaeting with TRADD to rvsult in NF-kB signalling. Thv IL-l-ineueve 
signalling pathway however, aetivatvp NF-kB via a multierotvin complex involving ILIRI/IRAK- 
2. IL-1RacP/IRAK-1 and MyD88 leading to thv evceuitmvnt of Traf6. Chvpv two signalling 
pathways evnvvrgv with thv stimulation of thv NF-kB inducing kinase (NIK) which phosphoryla^ 
and activates another group of Kinnpvp teemed thv IkB kinases (IKKs). Thv IKK then ehvpehveylntv 
IKB. thv cytoplasmic inhibitor of NF-kB foe ubiquitinntivn and eevtvvpvmv-meeiatve degradation. 
Thv NF kB then tranplveatvp to thv nucleus to ue-rvgulatv tranpeoietivn of inflammatory genes.
Phosphorylation
...DNA
Cracpcriptivcal activation of 
NF-kB regulated promoters
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S.2.2.2 Mitogen-activated protein kinase (MAPK) pathway
Concomitant with the activation of the NF-kB pathway. IL-l and TNF induce a group of serine and 
threonine kinases known as the mitogen-activated protein kinases (MAPK). Once active, the 
MAPK travel to the nucleus where they phosphorylate and activate specific transcription factors 
involved in inflammatory and growth responses. Three main subgroups of MAPK have been 
described (Figure 5-2). The extra-cellular stimulus-regulated kinases (ERK) become active in 
response to cytokines, phorbol esters such as PMA and growth factors such as bFGF and activate 
the AP-1 family member c-Jun (Pulverer et al., 1991; Frost et al., 1994). The stress-activated 
protein kinases/c-Jun N-terminal kinases (SAPK/JNK) are primarily activated in response to 
cytokines (IL-l and TNF) or stresses such as UV radiation, hyperosmolarity and hypoxia (Minden 
and Karin, 1997). The third group of MAPK consists of the p38 or reactive kinases, which are 
similar to the SAPK/JNK with respect to the extracellular stimuli that activate them and the 
transcription factors they target (Raingeaud et ah, 1995). In general all of the MAPKs become 
catalytically active when phosphorylayed by MAPK kinases (MAPKK) which are in turn activated 
through phosphorylation by MAPKK kinases. The SAPK/JNK and ERK kinases can phosphorylate 
and activate c-Jun directly and p38 activates ATF2 which mediates transcription of the c-Jun gene. 
This suggests that all of the MAPK cascades can contribute to AP-1 dependant transcription 
(Barchowsky et ah, 2000).
More specifically, the MAP kinase (p42 and p44) or Erkl and 2 (extra-cellular signal-regulated 
kinase) cellular signalling pathway is activated by a variety of mitogens including phorbol esters 
(PMA) (Rossomando et ah, 1989) and growth factors such as bFGF (Berrou et ah, 1996). This 
pathway consisting of Ras, Raf, Mek, MAP kinase and Rsk spans from the plasma membrane to 
the nucleus and serves to transduce mitotic signals downstream from the membrane receptor 
tyrosine kinases. This pathway requires the transient phosphorylation of Erk (42 kDa protein) on 
tyrosine (Y187) and threonine (T185) residues for full activity (Blumer and Johnson, 1994) which 
is mediated by a MAP kinase kinase (MAPKK or MEK). The functional significance of the MAP 
kinase pathway is through the phosphorylation of intra-cellular protein kinases and activation of 
transcription factors (Marshall, 1995).
The stress-activated MAPKs require phosphorylation on tyros y1 and threonyl residues for 
activation (Blumer and Johnson, 1994). p54 MAPKs (stress-activated kinase; SAPK-1 or c-Jun N- 
terminal kinase: JNK) (Kyriakis et ah, 1994) and p38 MAPK (ASPK-2, reactivating kinase, 
cytokine suppressive binding protein) are only weakly activated by mitogens, but are strongly 
activated by cell stresses, bacterial LPS, IL-l and TNFa (Lee et al., 1994). P54 MAPK/JNK 
strongly phosphorylates the —ans-activation domains of the c-Jun (Pulverer et ah, 1991) playing a 
role in the activation of AP^-dependent genes. IL-l activated MAPK/JNK pathways affect 
numerous regulatory processes, including the synthesis and activity of the AP-1 transcription factor 
composed of c-Fos/c-Jun heterod^^s and c-Jun/Jun homodimers (Karin et ah, 1997).
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Figure 5-2 Mitogen activated protein kinase pathway (MAPK)
IL-l and TNF induce a group of serine and threonine kinases known as the mitogen-activated 
protein kinases (MAPK) through receptor (R) binding. Once active, the MAPK travel to the 
nucleus where they phosphorylate and activate specific transcription factors involved in 
inflammatory and growth responses. Three main subgroups of MAPK have been described. The 
extracellular stimulus-regulated kinases (ERK) become active in response to cytokines, phorbol 
esters such as PMA and growth factors. The stress-activated protein kinases/c-Jun N -terminal 
kinases (SAPK/JNK) are primarily activated in response to cytokines (lL-1 and TNF) or stresses 
such as UV radiation, hyperosmolarity and hypoxia . The third group of MAPK consists of the p38 
or reactive kinases, which are similar to the SAPK/JNK with respect to the extracellular stimuli that 
activate them and the transcription factors they target.
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5.3 MATERIALS AND METHODS
Overviews of the experimental procedures employed in this chapter are illustrated ic figure 5-3 
Brivfly, the crnice MMP-13 acd MMP-19 promoters, plus the MMP-9 deletions, were sub-cloned 
into pGL3-Brsle luciferase reporter vector (Peomega) using evstrietion enzyme digestion {Kpn 1 
and EcoPNISmaX) and ligation techniques. Madic Darby crdine kidney (MDCK) cells and primary 
eat caleiocytes were analysed foe basal and induced (IL-lp, TNFta and bFGF) endogenous levels of 
MMP-9 and MMP-13 gece teadscrlptifc using reverse teanseeiptioc (RT)-PCR to be used for 
analysing the cloned promotve fragments. The cloned canine MMP-9 and MMP-13 promotve 
fragments, eGL3/eMMP-9(1894) acd pGL3/cMMP-13(1894) were teansfsctee into the two cells 
lines, stimulated with IL-1(3, TNF^ and bFGF and activities determined using Dual- 
Luciferase®Repoeter Assays (Peomega). The cloned ernine MMP-9 promoter deletion constructs 
pGL3/cMMP-9( 1894), (984), (628), (534), (176) and (102) were transfected into the MDCK cells 
and felice embryonic fibeoblasts (FEA), stimulated with PMA and activities deteemined using 
similar Dual-Lueiferasv®Reefrter Assays (Promega).
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Figure 5-3 Overview of the experimental procedures used to characterise the canine
MMP-9 and MMP-13 promoter fragments
The canine MMP-13 and MMP-19 promoters (plus MMP-9 deletions) were sub-cloned into pOL3- 
Basic luci-erase reporter vector. Appropriate cell lines were then analysed for endogenous 
transcription of MMP-9 and MMP-13 using RT-PCR. Finally activity of the cloned MMP-9 and 
MMP-13 promoter fragments were analysed using Dual-Luciferase*Reportkr Assays
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5.3.1 Cloning of MMP-9 promoter deletion constructs into pCR®2.1- 
TOPO
5.3.1.1 Primer design
For the PCR-based cloning of the MMP-9 promoter deletions into pCR®2.1-TOPO vector, six 
forward (sense) primers and one reverse anti-sense primer were designed as eeserlbee in ssetioc
2.2.5.1 and sueeliee by M^WG-Biotech (Table 5-1). The forward primers were based on specific 
regions of the ernice MMP-9 promoter sequence, guided by motif location as described in figure 4­
16. Each primer of 25-28 nucleftiers in length required 40-60% GC content and also contained 
Xho\ restriction eczyme sites for the sub-cloning into the luciferase eeporter vector, pGL3-Basie 
(Promega). Using these criteria, sense oligonucleotide primers (cMMP-9(1894)f, cMMP-9(984)f, 
cMMP-9(628)f, cMMP-9(534)0 eMMP-9(176)f, cMMP-9(102)f) and nnti-sense oligonucleotide 
primer (cMP9X/io1R) wvre designed according to the canice MMP-9 promoter sequence (Figure 5­
4).
cMMP-9(1894)f
------ ►
(984)f (628)r (534)f (176)f (102)f cMP9X/iolR
-----► ------ ► ------ ► ------k ------
Crdids MMP-9 promoter
Table 5-1. Primer sequences for the PCR amplification of the canine MMP-9 promoter
deletion constructs
Primer Oligonucleotide primer sequence
Identification (5'-3')
Tm («C) & GC (%)
content
cMMP-9(1894)f
cMMP-9(984)f
cMMP-9(628)f
cMMP-9(534)f
cMMP-9(176)f
cMMP-9(102)f
cMP9XhoiR
GGCTCTCGAGCTCGAGTCTGGGTGACTCCAAA
CGGCTCGAGCTCGAGTGGAGAACTGAAAGCCACCT
CGGCTCGAGCTCGAGAAGCCTGTCTGCTGGTTT
CGGTTCTCGAGCTCGAGTGAGGGAGCACACTCCTT
CGGCTCGAGCTCGAGGGTGTAAGCCCTTTCTTTGC
CGGTTTTCTCGAGCTCGAGCCCTACTTGCCAGGGA
GGCTTTCTCGAGCTCGAGGGTGAGGGTAGTGGTGT
73.3 °C ; 59.4 %
75.0 °T : 60.0 %
74.5 °C : 60.6 %
75.0 °C : 60.0 %
75.0 °C : 60.0 %
75.0 "C : 60.0 %
75.0 “C: 60.0 %
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Figure 5-4 MMP-9 promoter deletion fragments
Illustration of the MMP-9 promoter deletion constructs with sequential portions of the 5' region of 
the promoter removed to eliminate cytokine responsive elements. Constructs have been named 
cMMP-9(1894). cMMP-9(984). cMMP-9(628). cMMP-9(534). cMMP-9(l76). cMMP-9(102) with 
each number corresponding to the size of the promoter deletion construct in base pairs.
SRY.': AP-2. A: LYF-1. O] PEA3.«B: GATA-1 GATA-2. O
cMMP-9(1894)
AP-lAP-lSPl SPl AP-1 NF-Kli SPl AP-I
a k;
AP-I SPl AP-I TALA p I.uciffrase
cMMP-9(984)
SPl API AP-I NI-cB SPl
^□iQ nr m Ati~irr a
AP -I SPl AP-I IAIA
A.
atg
• Luciferase
cMMP-9(628)
. NF-kB SPl AP-I AP-I SPl AP-I
0-0 o
at(;
I'AT 'A Luciffrase
cMMP-9(534)
SPl
atg
AP-I AP-I SPl AP-I I A’I A MI l.uciferasc
cMMP-9(176)
atg
AP-I SPl AP-I IAI - A Luciferase
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SPl AP-I I - AI - A
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153
 5.3.1.2 PCR amplification of the canine MMP-9 promoter deletions
PCR was performed as eeseribee ic ssetiod 2.2.5 using pCR®2.1/cMMP-9 vector samples (100 ng) 
as template in a final volume of 50pl containing 0.4pm of both foeward primer (cMMP-9( 1894)0. 
cMMP-9(984)f. cMMP-9(628)O cMMP-9(534)f, cMMP-9(176)f and cMMP-9(W2)O) and reverse 
primer (MP9X/wlR) pairs, 0.2mM of dNCPs, 1.5Mm MgCli and 2 units of Taq DNA polymerase 
(QIAGEN). Using a PE 480 thermal cycler samples wvre covered ic mineral oil and subjected to an 
initial dednturatiod at 95°C for 5 micutes followed by 35 cycles of amplification, each cycle 
consisting of a eecrturatlon step of 95"C foe 1 min and an ancealing tvmperatuev of 70"C for oce 
minute followed by an elongation step of 12X2 foe one minute. The final elongation step of 72°C for 
10 minutes completed the eeaction. PCR products (8 pi) wvre visualised by agarose gel 
electrophoresis (1.5%) gel by comparing the bands erentee to a 100 bp molecular weight standard.
5.3.1.3 Cloning into pCR2.lFTOPO vector
PCR products were cloned using methods dvseribee ic section 2.2.2. Briefly, PCR products wvre 
purified following QIAqt^^c^l^® Gel Extraction Kit (QIAGEN, UK) acd eluted in 50pl of sterile water 
4pl of which were assessed by gel electrophoresis on a TAB agarose gel (1%) by comparing thv 
bands created to a 1 Kb molecular weight standard. Purified PCR products were directly ligated into 
the pCR®2.1-TOPO plasmid vector following the TOPO TA® cloning protocol. Thv ligatioc 
reaction (2pl) was then transformed into One Shof™ TOP 10 competent cells and spread onto agar 
plates containing ampicillin and X-gal foe incubation overnight at 37°C. White, rmpicillin resistant, 
colonies were selected from the plates and cultured oveenight in LB/ampicillin broth at 37°C acd 
glycerol stocks of each culture were elepared for long-term stoeage.
The DNA constmets were isolated from overnight cultures by the alkaline lysis method of 
plasmid DNA isolation following the QlAprep® PCR Spin Minierep Kit (QIAGEN, UK) and 
eluted in 50pl of sterile water. The DNA samples were then assessed by speetrophotfmetey for 
quantification. Samples wvre screened for those containing the insert by rvstrietivc enzyme 
digestioc. Briefly, each eCR2.I/eMMP construct (500ng) was digested with Xhoi restriction 
enzyme (7.5 units) and Buffer 6 in a total volume of 20pl at 37°C foe 4 hours. Samples werv 
analysed by agarose gvl electrophoresis to identify the presencv of inseets.
5.3.2 Sub-cloning of the entire MMP-9 & MMP-13 promoter fragments 
and MMP-9 promoter deletions into pGL3-Basic luciferase reporter vector
Originally it was intended that thv Xhol restriction sites would be used to sub-clone the promoter 
deletion fragments into the pGL3-Brsie luciO'erase reporter vector. However, after multiple 
unsuccessful attempts, an uni-directional sticky/blunt ended ligatioc reaction was successfully used 
instead. This involved ligating the Kpn I and Sma I restriction enzymes sites located in the multiple 
cloning site (MGS) of the pGL3-Basie reporter vector with the Kpn I and EcoK V restrictivd 
enzymes sites positioned either side of the promoter fragments cloned into the pCR®2.1-TOPO
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vector. To enable this procedure it was necessary to ensure that promoter sequences did not contain 
Kpn I or EcoR V restriction enzyme sites within their sequences.
5.3.2.1 Restriction annym digestion of vvecooe
All pCR®2.1/cMMP vector constructs, including the entire canine MMP-9, its deletions and the 
MMP-13 promoter, were digested with Kpn I and EcoR V restriction enzymes. The luciferase 
reporter vector, pGL3-Basic (Promega) was digested with Kpn I and Sma 1 restriction enzymes. 
More specifically, the pCR®2.1/cMMP vectors (5jig) were digested for four hours with Kpn I (5 
units) and EcoR V (5 units) in MULTI-CORE™ (Ix) buffer at 37°C. The recipient pGL3-Basic 
luciferase reporter vector (5pg) was digested with Kpn I (5 units) and Sma I (5 units) at 37°C and 
30°C for 2 hours with each enzyme respectively.
5.3.22. Purification, ligation and transformation
Digested DNA samples (linearised pGL3-Basic and released cMMP promoter fragments) were 
purified following QIAquiek®Gkl Extraction Kit (QIAGEN, UK) and eluted in 30pl of sterile 
water. The DNA was quantified (4pl) by gel electrophoresis on a TAE agarose gel (1%) by 
comparing the bands created to a Low DNA Mass™ Ladder (4pl).
The quantity of vector (pGL3-Basic) and insert (promoter fragment) for each ligation reaction 
was calculated according to the equation shown in 2.2.2.8.1. For each calculation the vector mass 
(X) was 50 ng, the insert size (Y) were approximately 2, 1, 0.5, 0.6, 0.5, 0.15 and 0.1 kb for the 
MMP-9 promoter and its deletions (in descending size) and 1.5 kb for MMP-13 promoter. The 
molar ratio of insert to vector used was a value of three. The cut ends of the inserts were then 
ligated to complementary ends of the cut pGL3-Basic vector using T4 DNA ligase (Promega) over 
night at 16°C. The ligations (20ng) were transformed into 25ftl of JM109 competent cells, heat 
shocked for 45 seconds at 42°C and then grown overnight at 37 °C on LB/ampicillin agarose plates. 
Six colonies were selected from each plate and transferred to LB broth for overnight culture at 
37°C.
5.3.2.3 Isooation andscceening of feeombinantplaamidd
The DNA constructs were isolated from overnight cultures by the alkaline lysis method of plasmid 
DNA isolation following the QIAprep®PCR Spin Miniprep Kit (QIAGEN, UK) and eluted in 50pl 
of sterile water. The DNA samples were then assessed by spectrophotometry for quantification. 
pGL3/cMMP-9 constructs were screened with Xho 1 restriction enzyme as described in section 
5.3.1.3. The clones containing the pGL3/cMMP-13 constructs did not contain flanking Xho 1 
restriction enzyme sites incorporated into the primer sequences and could not be screened in the 
same manner as the MMP-9 constiucts. In addition, the Kpn I and EcoR V restriction enzyme 
reaction used in the vector construction, could not be used in the screening process either since the 
blunt ended ligation of the EcoR V and Sma I sites abolished the use of either site for this purpose.
Instead a PCR-based screening protocol was applied using reagents and conditions similar to those 
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 described eailive for thv amplification of thv MMP-13 promoter as eeseribse in 4.3.4. Since all thv 
promoter inserts were directionally elocse it was not neeessaey to screen for correct orientation.
5.3.2.4 Sequence evaluation
Recombinant plasmids were sequenced acd analysed as described ic section 2.2.6, Briefly, plasmid 
samples wvev prepared for sequencicg with PCR reactions using plasmid DNA samples (400 ng) 
and the Big Dye™ Terminator Cycle Sequencing Ready Reaction (ABl Prism) with 0.5fM of both 
sense (RV3) and rnti-ssnse (GL2) vector-based primers. Samples were amplified, and the DNA 
purified by preeipltrtifd methods before samples were loaded into the ABI 310 genetic analyser for 
generatioc of automated sequence data. Sequence files were downloaded from the chromas file, 
saved as Word documents using the nperfpeirte format, and then lined up with thv relevant correct 
sequence for the MMP-9 and MMP-13 sequences using ClustalW to check for the absence of 
mutational ereoes.
5.3.2.5 Plasmid vector maps
Using computer software, plasmid vector maps werv drawn from the sequecce data infvrmativd 
incorporating all important components of each vector including the lueifelase cDNA sequvnce, 
relevant endine MMP promoter sequence, pflyadenylntioc signal and ampieillid resistance gvne.
5.3.3 Analysis of endogenous MMP-9 and MMP-13 gene
using relative semi-quantitative RT-PCR
Semi-quantitative eevvrsv trrnserietifd (RT)-PCR has previously been used to detect and analyse 
cytokine mRNA levels in various cell lines and tissues (Walker, 1998). This system was therefoee 
adapted to measure the relative levels of endogenous MMP-9 and MMP-13 transcription from 
different cell lines to assvss their suitability in the characterisation of thv MMP-9 acd MMP-13 
promoter fragments. RT-PCR is a sensitive technique that cac detect minimal levels of gene 
transceiption, due to the amplification step, unlike standard Northern blot protocols. Additionally, 
the results generated from the RT-PCR directly reflected levels of gene transcription rather than the 
absolute levels of protein expression as determined by Western blot analysis. Thv lattee technique 
could not be used since camce specific antibodies to both MMP-9 and MMP-13 were unavailable.
Both basal and induced levels of endogenous MMP-9 and MMP-13 genv transcription were 
analysed in the MDCK cells and primary rat eardiocytes using RT-PCR. However, it was not 
possible to assess the FEA cells since the feline sequence for MMP-9 cDNA was not available in 
the database, for primvr design.
5.3.3.1 CcH llnce and reagents
MDCK cells wvrv maintained in Dulbecco’s MEM with gluatamax-1 medium supplemented with 
10% foetal calf serum (ECS) as described in section 2.2.1.2.1. Primary rat eardioeytes, a gift from
Dr. Arvind Sood, wvev cultured in a mix of Dulbeeco’s modified Eagle’s medium and medium 199 
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(at a ratio of 4:1) supplemented with 4% horse serum and 5% FCS as described in section 2.2.1.2.3. 
MDCK cells and rat primary cardiocytes were seeded onto 6 well plates at a concentration of 6x 
lO* and 5x 10' cells/ml respectively and allowed to grow to confluence over 24 hours at 37°C and 
5% CO2.
5.3.3.2 Stimulation of cells
MDCK cells and primary rat cardiocytes used in the comparison of fuit-length MMP-9 and MMP- 
13 transcripts were serum-starved for 24 hours prior to stimulation with IL-lp (10 ng/mt), TNFa 
(10 ng/mi) and bFGF (20 ng/mt) for a further 24 hours. MDCK cells used in the characterisation of 
the MMP-9 promoter deletion constructs were not semm starved but were immediately exposed to 
Phorbol Myristate Acetate (PMA) (S^M) for the 24 hours prior to harvesting cells.
5.3.3.3 Isolation of total RNA
Total RNA was harvested from both untreated (basal) and treated (PMA, IL-1 (3, TNFa and bFGF) 
cells using RNAzol'' B solution (AMS Biotechnology) (500pt/well) added directly to the wells 
containing the adherent MDCK cells and rat cardiocytes for lysis. Aliquots (1 ml) of the lysed cell 
solution were shaken for 15 seconds with chloroform (lOOpt) and RNA extracted as described in 
section 2.2.3. The RNA samples were re-suspended in 40pl DEPC water and the quality and 
quantity assessed using spectrophotometry and agarose gel electrophoresis. Care was taken when 
estimating the RNA concentrations to enable equal amounts of RNA (2pg) to be used for each 
reaction in semi-quantitative RT-PCR. Steps were also taken to ensure no contamination of 
genomic DNA by treating all RNA preparations with DNase 1 (DNA-freee™. Ambion) as described 
in section 2.2.3.4.
5.3.3.4 First strand cDNA synthesis
The synthesis of first strand cDNA followed the basic principles as set out in section 2.2.4. More 
specificatty, total RNA samples (2p,g) in 9|4l of DEPC water were heated for 5 minutes at 65'C and 
then quenched on ice. Reactions were performed using the heat treated RNA in a 250-1 reaction mix 
containing 51x1 of reverse transcription buffer (5x), 200 units of Molony Murine Leukemia Virus 
reverse transcriptase (MMLV RT) (GIBCO BRL), tOmM dTT, 250joM dNTPs, 25 units RNAse 
inhibitor and 25|oM random primers. The reaction was incubated at 37°C for 30 minutes followed 
by 42°C for 60 minutes and completed with 95°C for 5 minutes. A PE 480 thermal cycler was used 
for the reaction. The cDNA concentration of each sample was determined using UV 
spectrophotometry.
5.3.3.5 Primer design
PCR primers were designed as described in section 2.2.5.1 and were synthesised and supplied by
Sigma-Genosys (Table 5-2). In order to amplify portions of the canine MMP-9 & MMP-13 cDNA
sequences for both canine and rat species it was necessary to design oligonucleotide primer pairs 
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 spanning a 350 bp region of each sequence. Both sense and anti-sense species-specific primers 
pairs were designed within the MMP-9 cDNA sequence for canine (cMMP9f and cMMP9r) and rat 
(ratMMP-9f and ratMMP-9r). Similarly. Primers were designed within the MMP-13 cDNA 
sequence for canine (cMMPl3f and cMMPl 3r) and rat (ratMMP-13f and ratMMP-l 3r).
The constitulively expressed cyclop^lm gene, encoding a periplasmic protein involved in 
protein folding (Andreeva et al.. 1999) was used as an internal control for the canine (AF243140) 
and rat (NM_01710I) species. Species specific primers were subsequently designed within the 
cyclopl^lm cDNA sequence* for the canine (eCyelophilinf and eCyelophilinf) and rat 
(ratCyclophilinf and ratCyclophilinr) to amplify a region of 265 bp from the cDNA templates. The 
position of the control primers, based on the cDNA sequence to span an intron, enabled the 
identification of contaminating gDNA as a 450 bp fragment. Primer pairs (27 bp) were matched as 
closely as possible for Tm (7()°C) and GC (40-60%) content.
Table 5-2 Primer sequences for RT-PCR 9(MMP-9, MMP-13, cyclophilin)
Primer
Identification
cOycR^^l^-'
eCyelophilinf
cMMP9f
cMMP9r
cMMP13f
cMMPl 3r
ratCyclophilinf
^Cyclop^l^r
ratMMP-9f
ratMMP-9r
ratMMP-13f
ratMMP-13r
Oligonucleotide primer sequence
(5'-3>
CGTGCTCTGAGTACTGGAGAGAAGGGA
CCACTCAGTCTTGGCGGTGCAGATGAA
GC TGGACAAAAC CAC CC TGGAGGC CAT
GTCGTCGAAGTGGGCGTCTCCCTGAAT
CTCTTCTTGAGCTGGACTCAGTGCTGG
GGACCACTTGAGAGTTCGGGGGAAAAC
GTGCTCTGAGCACTGGGGAGAAAGGAT
CCACTCAGTCTTGGCAGTGCAGATAAA
AACCTTCGAAGGCGACCTCAAGTGGCA
CGTCCCTCGAAGGTGAAGGGAAAGTGA
CCCTCGAACACTCAAATGGTCCCAAAC
AGTGGCCAAGCTCATGGGCAGCAACAA
Tm (”C) & GC (%)
content
72.1 °C : 55.6 %
77.7 °C : 55.6 %
79.1 °C : 59.3 %
78.1 °C : 59.3 %
72.8 °C : 55.6 %
74.8 0C ; 55.6 %
74.-4 °C : 55.6 %
71.6 °C :48.1 %
78.2 °C : 55.6 %
76.3 °C : 55.6 %
74.7 °C : 51.9 %
79.9 ”C : 55.6 %
5.3.3.6 PCR amplifioation of MMP regions using PCR
PCR was performed as described in section 2.2.5 using Ready-To-Go™ PCR beads (25 pi) 
(Amersham. Pharmacia) with cDNA samples (Ipg) as template and 0.4pM of species specific 
primer pairs for MMP-9 or MMP-13 each with 0.1 pM of species specific cyclop^lm primers as an 
internal control (Table 5-2). Samples were subjected to an initial denaturation at 95°C for 5 min
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 followed by a variable number of cycles for amplification, each cycle consisting of a denaturation 
step of 95 °C for 1 min, an annealing temperature of 67*10 followed by an elongation step of 72 °C 
for 1 min. A final elongation step of iTC for 10 min completed the reaction.
Only PCR samples taken from the exponential phase of the reactions (basal and treated) could be 
directly compared to semi-quantify the levels of transcription. This was determined by removing 
samples at multiple (3 to 5) intervals 5 cycles apart and comparing the density of the PCR products. 
Alt PCR products were analysed using agarose gel (1.5 %) electrophoresis. PCR products (8pt) 
were analysed by TAE agarose gel (1%) electrophoresis by comparing the bands created to a 100 
bp molecular weight standard. Care was taken to toad equal volumes of each PCR sample into 
wells on the agarose to enable accurate comparison between samples. A negative control 
containing the PCR bead with all components (dNTPs, PCR buffer and Taq polymerase) and 
primer pairs without template was included to check that there was no contamination of the PCR 
reactions with extraneous DNA that might serve as a template for PCR amplification.
5.3.4 Luciferase reporter assayy to analyye the aattvity of the cloned canine 
MMP-9 and MMP-13 promoter fragments
The pGL3-Basic luciferase reporter vector was chosen to analyse the canine MMP-9 and MMP-13 
promoters since luciferase reporters offer an extremely sensitive system for measuring the activity 
of regulatory regions of DNA such as promoters. A variety of tuciferase-based vectors are available 
enabling strictly controlled experiments including a negative control (promoter-less vector, pGL3- 
Basic), positive control (SV40 luciferase, pGL3-Control) and a Renilla luciferase vector (pRL- 
CMV) as an internal standardised control. This Dual-Lucifeease®Reportee assay system has the 
unique ability to assay both the fire-fly and Renilla luciferase activities sequentially in the same 
wett to control for both cett number and transfection efficiency. A modern luminometer housing a 
96-well plate format and dual injector system was available for use enabling multiple, fast and 
accurate assays to be performed.
5.3.4.1 TTrarnfcetion of ccUl iwth luccfeerae lepo^er constructs
Maintenance of MDCK cells and primary rat cardiocytes is described in section 5,3.3.1. FEA celts
were maintained in Dutbecco’s MEM supplemented with 10% FCS as described in section
2.2.1.2.2. Whiie, tissue culture -reated ViewPlate™-96 (PPakaad) were sseded wiih MDCK, FEA3
and primary rat cardiocytes at concentrations of 6x10' cetls/ml, 5x104 celts/ml and 5xt05cetls/ml
respectively and incubated overnight at 37°C, 5% CO2. Ceils should be approximately 70-80%
confluent on the day of transfection for optimal assay conditions. Transient transfections were
carried out using the cationic liposome mediated methods as described in section 2.2.7 with
TransFaat™ Reagent (Promega) used at a 1:1 ratio with DNA according to the manufacturer’s
instructions. More specificatty, total DNA (50-100ng) was added to pre-warmed serum free media
(40|il) and thoroughly mixed before addition of TransFast^™ Reagent (0.3pl). The
DNA/transfection reagent samples were incubated for 10-15 minutes at room temperature to allow 
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complex formation before the growth medium on the 96-wvll plates was aspirated and leplneee 
with the teansfectlvc samples. The cells were incubated with thv complexes for 1 hour at 3TC. 5%
CO] bvforv pre-warmed complete medium was added foe cell recovery oveenight at 3TC
5.3.4.2 Stimulation of cells
To induce transcription from the MMP promoter constructs, transfected cells were treated with 
different stimulants foe the 24 hours prior to lueiferase assays. MDCK cells acd primary eat 
cneeioeytes used in the comparison of full-lvcgth MMP-9 and MMP-13 transcripts were serum- 
starved foe 24 hours prior to stimulation with IL-1 (3 (10 ng/ml), TNFa (10 ng/ml) and bFGF (20 
ng/ml) (R&D Systems) for a further 24 hours. MDCK cells used in the characterisation of the 
MMP-9 promoter deletion constructs were cot serum starved but were immediately exposed to 
PMA (5‘9M) (Sigma) for the 24 hours prior to harvesting cells.
5.3.4.33.Luciferase assays
Dunl-Luciferase®Reefrter assays were performed as described in section 2.2.8. Briefly. 72 hours 
post teansfeetiod the media was removed from the adherent cvlls, washed once with Phoshate 
Buffered Saline (PBS) and lysed with Passive Lysis Buffer (PLB) (Ix) for 15 minutes at room 
temperature. Using a Dynex, MLX lumidometer and injector system, freshly prepalee Luciferase 
Assay Buffer II (LAR II) (50pl) and Stop & Glo® Reagent (50|ll) werv dispensed into each well 
with ac icteeval of 30 seconds, each taking a lueifvrase count for 10 seconds. Both firefly and 
Renilla lueiferase values were attained for each well and all lucifeease values weee analysed using 
an excel spreae sheet and a statistical analysis performed using the Mann-Whitney test.
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5.4 RESULTS
5.4.1 Cloning of the canine MMP-13 and MMP-9 promoter fragments and
deletion constructs into the pGL3-Basic luciferase reporter vector
The legions of the canine MMP-9 promoter, required for the deletion eocstluets, were successfully 
amplified from the PCR2, l®TOPO templates using the primers described in Table 5-1. All six 
camne MMP-9 promoter fragments (1984), (894), (628), (534), (176), (102) rne ernice MMP-13 
promotve (1494) werv then sub-eloced into the pGL3-Brsle luciferase eeporter vector using the kpn
1 (sticky) acd EcoRVISma 1 (bluct) restriction eczyme sites. The bacterial clones eoctnicidg thv 
MMP-9 promoter deletions weee screened using the Xhol restriction sites acd the clones cfdtrinidg 
the MMP-13 promoter were screened using PCR techniques.
One clone from each promoter construct was selected and sequenced on an automated ABI310 
genetic analyser using both forward (RV3) and revvrse (GL2) vector based primers to confirm the 
sequences acd ensure that no mutational errors had occuoeed during the cloning proeeeul•e.
Vector maps for the canine MMP promoter sequences in pGL3-Basic luciferase reeortee vector 
were drawn for pGL3/cMMP-9(l894) (Figure 5-5), pGL3/cMMP-9(984) (Figure 5-6), 
pGL3/cMMP-9(628) (Figure 5-7), pGL3MMP-9/c(534) (Figure 5-8), pGL3/cMMP-9(176) (Figure 
5-9), pGL3/eMMP-9(IG2) (Figure 5-10) and pGL3/cMMP-13(1494) (Figure 5-11).
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Figure 5-5 Vector map for pGL3/cMMP-9(1894)
Kpn\
S/naV EcoRV
Figure 5-6 Vector maps for pGL3/cMMP-9(984)
Kpn\
Smal/EcoRV
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 Figure 5-7 Vector map for pGL3/cMMP-9(628)
Figure 5-8 Vector map for pGL3/cMMP-9(534)
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Figure 5-9 Vector map for pGL3/cMMP-9(176)
Figure 5-10 Vector map for pGL3/cMMP-9(102)
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 Figure* 5-11 Vector map for pGL3/cMMP-13(1494)
Kpn I
Smal/EcoRV
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5.4.2 Characterisation of the cloned canine MMP-9(1894) and MMP- 
13 (1494) promoter fragments in MDCK and primary rat cardiocytes
The aim of this first study was to evaluate and compare the basal and induced (IL-13, TNFta and 
bFGF) activities of the largest cloned canine MMP-9 promoter fragment (1894 bp) to the MMP-13 
promoter (1494 bp); to examine their potential for driving disease-specific gene expression.
5.4.2.1 Analysis of the endogenous basal and induced MMP-13 and MMP-9 gene
transcription levels in MDCK cells and primary rat cardiocytes
To analyse the endogenous levels of MMP-13 and MMP-9 transcription in the cell lines to be used 
for the transfection of the canine MMP-13 and MMP-9 promoter fragments, relative semi­
quantitative RT-PCR was performed (Figure 5-12, 13, 14, 15). A portion of each gene was 
amplified from cDNA samples prepared from untreated (basal) and treated (IL-13, TNFa and 
bFGF) cells using species-specific primer pairs. A portion of the cyclophilin gene was also 
amplified (255 bp) as an internal control using primers designed to span an intron and control for 
the presence of contaminating gDNA (absence of a 474 bp PCR product) (Table 5-2). Samples were 
removed at three intervals, 5 cycles apart, to determine the exponential phase of amplification and 
enable the selection of one cycle number for each PCR for the semi-quantification of gene 
transcription levels. Basal transcription of the endogenous MMP-13 gene was evident in both the 
MDCK cells (Figure 5-12) and rat cardiocytes (Figure 5-13) but only the rat primary cardiocytes 
could be induced with IL-lp, TNFa and bFGF. In comparison basal levels of the canine MMP-9 
promoter could be only be enhanced by TNFa in MDCK cells (Figure 5-14), while in the primary 
rat cardiocytes the endogenous MMP-9 promoter activity was clearly up-regulated with IL-lp and 
to a lesser degree with TNFa and bFGF (Figure 5-15).
5.4.2.2 Analysis of cloned canine pGL3/MMP-911984) and pGL3/MMP-1311494)
promoter constructs using Dual^Iuciferase Reporter assays
All Dual®Luciferase assays were conducted in triplicate for statistical significance and to ensure 
reproducibility, all transfections were earned out three times. To account for differences in 
transfection efficiency the cells were co-transfected with Renilla luciferase vector (Promega) and 
the firefly luciferase values were adjusted accordingly. Renilla was expressed and shown to be 
active in cell types used. Representative Renilla values for the rat cardiocytes and MDCK cells were 
159 and 1882 respectively. The corrected luciferase activity of each construct represents the mean 
+/-SEM (n=3). The canine MMP-9 and MMP-13 luciferase reporter constructs, together with the 
promoter-less luciferase vector, pGL3-Basic vector as the negative control, were transiently 
transfected into MDCK and primary rat cardiocytes. Basal luciferase activity for each promoter was 
compared to treated samples (IL-lp, TNFa and bFGF).
Basal activity of the cloned canine MMP-13 promoter fragment was present in the MDCK cells 
but could not be induced by any of the cytokines (Figure 5-16). However, the cloned canine MMP-
166
13 promoter fragment could be significantly enhanced with IL-ip and bFGF. and to a lesser degree 
TNF, in the rat primary cardiac cells (Figure 5-17). Basal activity of the cloned canine MMP-9 
promoter fragment was significantly increased with TNFcx (Figure 5-18). In comparison, basal 
levels of activity of the in primary rat cardiocytes could be significantly increased by bFGF (Figure 
5-19).
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Figure 5-12 Basal and induced (IL-1, TNF and bFGF) levels of endogenous MMP-13
transcription in MDCK cells
A portion (365 bp) of the canine MMP-13 gene (upper band) was amplified from cDNA samples 
prepared from total RNA isolated from MDCK cells. During PCR amplification samples were 
removed within the exponential phase of the reaction (35 cycles) revealing that basal levels of 
MMP-13 transcription were not significantly up-regulated by pro-inflammatory cytokines IL-ip. 
TNFa or bFGF.
Figure 5-13: Basal and induced (IL-1, TNF and bFGF) levels of endogenous MMP-13
transcription in primary rat cardiocytes
A portion (365 bp) of the rat MMP-13 gene (upper band) was amplified from cDNA samples 
prepared from total RNA isolated from primary rat cardiocytes. During PCR amplification samples 
were removed within the exponential phase of the reaction (45 cycles) revealing that basal levels of 
MMP-13 transcription were up-regulated by pro-inflammatory cytokines IL-1 (3. TNFa or bFGF.
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Figure 5-14 Basal and induced (IL-1, TNF and bFGF) levels of endogenous MMP-9
transcription in MDCK cells
A portion (364 bp) of the canine MMP-9 gene (upper band) was amplified from cDNA samples 
prepared from total RNA isolated from MDCK cells. During PCR amplification samples were 
removed within the exponential phase of the reaction (40 cycles) revealing that basal levels of 
MMP-9 transcription were significantly up-regulated by the pro-inflammatory cytokine TNFa.
Figure 5-15 Basal and induced (IL-1, TNF and bFGF) levels of endogenous MMP-9
transcription in primary rat cardiocytes
A portion (365 bp) of the rat MMP-9 gene (upper band) was amplified from cDNA samples 
prepared from total RNA isolated from primary rat cardiocytes. During PCR amplification samples 
were removed within the exponential phase of the reaction (45 cycles) revealing that basal levels of 
MMP-9 transcription were significantly up-regulated by the pro-inflammatory cytokine IL-1 p. 
while some increase was also observed with TNFta and bFGF
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Figure 5-16: pGL3/cMMP-13(1494) promoter construct activity’ in MDCK cells 
Duallucil'erase Reporter assays were used to determine the activity of the cloned canine MMP- 
13(1494) promoter fragment in MDCK cells. Basal activity of cloned canine MMP-13 promoter 
fragment was present in the MDCK cells but could not be enhanced by any of the cytokines.
Figure 5-17 pGL3/cMMP-13(1494) promoter activity in primary rat cardiocytes
Dual Luciferase Reporter assays were used to determine the activity of the cloned canine MMP- 
13(1494) promoter fragment in primary rat cardiocytes. Basal activity of cloned canine MMP-13 
promoter fragment was evident in the primary rat cardiocytes. Statistical analysis showed that the 
basal activity could be significantly enhanced by IL-1(3 and bFGF (*P<0.05 Mann-Whitney test).
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Figure 5-18 pGL3/cMMP-9(1894) promoter construct activity in MDCK cells 
Dual '"LLiciice^rise Reporter assays were used to determine the activity of the cloned canine MMP- 
19(1494) promoter fragment in MDCK cells. Basal activity of cloned canine MMP-9 promoter 
fragment was evident in the MDCK and statistical analysis showed that the basal activity could be 
significantly enhanced by TNFa (*P<0.05 Mann-Whitney test).
Figure 5-19 pGL3/cMMP-9(1894) promoter construct activity in primary rat
cardiocytes
DualLLuciferase Reporter assays were used to determine the activity of the cloned canine MMP- 
19(1494) promoter fragment in primary rat cardiocytes. Basal activity of cloned canine MMP-9 
promoter fragment was evident and statistical analysis showed that the basal activity could be 
significantly enhanced by bFGF (*P<0.05 Mann-Whitney test).
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 5.4.3 Identification of PMA responsive elements in the canine MMP-9 
promoter sequence
The aim of the second study was to evaluate and compare the basal and induced activities of the 
cloned canine MMP-9 promoter deletion constructs pGL3/cMMP-9(1894), (984), (628), (534). 
(176), and (102), These studies aimed to identify regions of the MMP-9 promoter that may be 
responsive to PMA, mimicking the effects of cytokines and growth factors, in the disease-state.
5.4.3.1 Endogenous expression of canine MMP-9 in MDCK cells
The endogenous and PMA induced levels of canine MMP-9 gene transcription in MDCK cells was 
investigated using relative semi-quantitative RT-PCR (Figure 5-20). A portion of the canine MMP- 
9 gene (364 bp) was amplified from cDNA samples prepared from basal and PMA treated MDCK 
cells. Samples removed at 5 cycle intervals from 15 to 35 cycles showed that the exponential/linear 
phase of the MMP-9 gene amplification occurred within this range and could be used to semi­
quantify the levels of MMP-9 expression in these cells. Basal expression of endogenous MMP-9 
gene was evident in MDCK cells and treatment with PMA was shown to induce expression of this 
gene. A portion of the canine cyclophilin gene was also amplified (255 bp) as an internal control. 
The primers designed for PCR spanned an intron to control for the presence of contaminating 
genomic DNA (absence of a 474 bp PCR product).
The endogenous levels of feline MMP-9 transcription could not be analysed in the FEA cells 
since the sequence for the feline MMP-9 cDNA was not available in the Genbank sequence 
database for primer design.
5.4.3.2 Aenlysis oC cloesd cneies S'sU-lcegth MMP-9 promotse Cengmsets ned dslstioes
using luciCsenss espoetses
Dual-Luciferase®Reporter Assays were conducted as described in section 5.4.2.2. Rlnilln was 
expressed and shown to be active in cell types used. Representative RuTUln values for the MDCK 
cells and FEA cells were 1882 and 824 respectively. The six canine pGL3/MMP-9 luciferase 
reporter constructs (Figure 5-5, 6, 7, 8, 9, 10) containing motifs as illustrated in Figure 5-4 were 
transiently transfected into both the canine MDCK cells (Figure 5-21) and FEA cells (Figure 5-22). 
In these experiments the promoter-less luciferase vector, pGL3-Basic vector was used as the 
negative control and the pGL3-Control, containing the SV40 promoter and enhancer sequences was 
used as a positive control vector
In the MDCK cells basal expression of the largest promoter fragment pGL3/cMMP-9(1894) was 
found to be high, approximately one third of the value of the positive control. Comparison of the 
basal luciferase expression levels between the various promoter deletions revealed a trend of 
maximal expression with pGL3/cMMP-9(628) containing the NF-kB motif'. This trend was 
observed in three independent experiments but the difference between the promoter constructs was
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not significant. The promoter activity was not completely lost with the smallest promoter fragment 
pGL3/cMMP-9(102). Basal levels of expression from the four largest promoter eonstructs 
pGL3/cMMP-9(1894), (984), (628), (534) could be significantly enhanced by the addition of PMA, 
Comparison of the PMA luciferase expression levels between the various promoter deletions 
revealed a trend of maximal expression again with the pGL3/cMMP-9(628) construct. This trend 
was observed in three independent experiments but this time the difference between the promoter 
constructs was significant. Activity of the constructs pGL3/cMMP-9(1894), (984), (628), (534) 
were significantly higher than the smallest eonstruct pGL3/cMMP-9(102). In direct contrast there 
appeared to be very low levels of MMP-9 expression in FEA cells where basal expression of the 
MMP-9 promoter was shown to be approximately one sixth of the value of the SV40 driven 
luciferase expression. The level of basal expression could not be enhanced with PMA in these cells.
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 Figure 5-20 Basal and PMA induced levels of endogenous MMP-9 transcription in
MDCK cells
A portion (364 bp) of the canine MMP-9 gene (upper band) was amplified from cDNA samples 
prepared from total RNA isolated from MDCK cells. During PCR amplification samples were 
removed within the exponential phase of the reaction (15 to 35 cycles) revealing that basal levels of 
MMP-9 transcription were significantly up-regulated by the pro-inflammatory mediator PMA.
Basal PMA
15 20 25 30 35 -Neg I5 20 25 30 35 Cycle N
w
600
MMP-9
300 bp Cyclophilin
KXihp
174
  
Figure 5-21 pGL3/cMMP-9 promoter deletion construct activity in MDCK cells
Dual*Luciferase Reporter assays were used to determine the activity of the cloned canine MMP-9 
promoter deletion constructs in MDCK cells. Basal activity of the cloned canine MMP-9 promoter 
fragments were evident in the MDCK cells and statistical analysis showed that the basal activity 
could be significantly enhanced by PMA in the four largest constructs (*P<0.05 Mann-Whitney 
test). Comparison of the promoter deletion constructs using the Kruskal-Wallis test showed that 
there was no significant difference in promoter activity between the basal promoter deletions but 
that the PMA stimulated constructs were significantly different (P< 0.05). A follow-up comparison 
revealed that the PMA stimulated pGL3/MMP-9( 102) was significantly lower than the four largest 
promoter constructs.
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Figure 5-22 pGL3/cMMP-9 promoter deletion construct activity in FEA cells
Dual“'Luciferase Reporter assays were used to determine the activity of the cloned canine MMP-9 
promoter deletion constructs in FEA cells. Basal activity of the cloned canine MMP-9 promoter 
fragment was low in FEA cells and could not be enhanced by PMA.
■I Basal 
■ PMA
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 5.5 DISCUSSION
5.5.1 Characterisation of the cloned canine pGL3/cMMP-9(1894) and
MMP-13(1494) promoter fragments in MDCK and primary rat cardiocytes
To analyse the endogenous levels of MMP-9 and MMP-13 transcription in the cell lines to be used 
for the transfection of the canine pGL3/cMMP-9(1894) and pGL3/cMMP-13(1494) promoter 
constructs relative semi-quantitaive RT-PCR was performed. The two constructs were transiently 
transfected into the MDCK cells and primary rat cardiocytes where basal luciferase activity for each 
promoter was compared to treated samples (IL-1 (3 TNFa and bFGF) along with a promoter-less 
luciferase vector as a negative control,
5.5.1.1 Assessment of basal and induced (IL-lfi, TNFcc and bFGF) endogenous 
transcription levels of MMP-9 and MMP-13 genes in MDCK cells and rat cardiocytes. 
An immortalised rabbit synovial cell line (HlG-82) was analysed first for use in the transfection 
experiments; however, the high levels of basal transcription could not be enhanced by any of the 
stimulants used (data not shown). These results are contradictory to studies showing that cultured 
rheumatoid synovial fibroblasts responded to PMA, IL-1, TNFa, TGFP and IL-6 with increased 
collagenase-3 mRNA (Moore et al., 2000). The difference in these results may be explained by the 
phenotypic changes that have occurred during development of arthritis where the diseased cells are 
more likely to express the receptors for these cytokines and growth factors than the HIG-82 cells. 
However, MMP-13 expression can be stimulated with PMA, IL-lp and TNFa in isolated primary 
rabbit synovial fibroblasts (Vincenti et ah, 1998).
Endogenous levels of MMP gene expression were subsequently evaluated in MDCK cells and 
primary rat cardiocytes using RT-PCR techniques. Basal expression of the endogenous MMP-13 
gene was evident in both cell types but only the rat primary cardiocytes could be induced with IL- 
ip, TNFa and bFGF (Figure 5-12, 5-13). These results are in concordance with a study showing 
MMP-13 up-regulation with these cytokines in adult rat cardiac fibroblasts (Siwik, Chang et al., 
2000). In comparison basal and enhanced expression of the canine MMP-9 promoter was evident in 
both cell types (Figure 5-14, 5-15). In the MDCK cells only TNF was able to increase activity 
contradicting a previous study which demonstrated increased expression of MMP-9 in a primary rat 
mesangial cell line by IL-1 (Yokoo and Kitamura, 1996). This suggests that phenotypic changes 
may occur during immortalisation of cells and it is possible that the MDCK cells either fail to 
express IL-1 receptors or do not contain the necessary machinery for IL-1 induction. In the primary 
rat cardiocytes the endogenous MMP-9 promoter activity was clearly upregulated with IL-ip and to 
a lesser degree with TNFa and bFGF.
The results of endogenous activity of the MMP-13 and MM-9 promoters suggested that the 
cloned canine MMP-13 & 9 promoter fragments could be analysed in the primary rat cardiocytes.
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 5.5.1.2 Comparison of basal and induced (IF-lf3, TNFta and bFGF) activity of 
pGL3/MMP-9 MMP-13 promoter constructs
Activity of the canine pGL3/cMMP-13(1494) promoter construct was similar to the endogenous 
MMP-13 transcriptional activity in both cell lines. Basal activity present in the MDCK cells was 
non-responsive to any of the cytokines (IL-1 (3, TNFa and bFGF) (Figure 5-16), confirming that the 
cloned canine MMP-13 promoter could not be characterised in this cell line. The results from the rat 
primary cardiac cells revealed that basal expression of the cloned canine MMP-13 promoter 
fragment could be significantly enhanced with IL-1 p and bFGF, and to a lesser degree TNF (Figure 
5-17). However, it is thought that the level of induction seen with the cytokines may be enhanced 
by the stable transfection of the promoter constructs (Menghol et ah, 2001).
Activity of the cloned canine MMP-9 promoter fragment was also similar to the endogenous 
MMP-9 promoter activity in the MDCK cells showing significant induction with TNFa (Figure 5­
18); this suggests that the portion of the cloned canine MMP-9 promoter was functional and 
responsive to this cytokine. However, the luciferase results from the MMP-9 promoter in primary 
rat cardiocytes varied slightly from the endogenous data showing that although TNF could be used 
to increase activity only bFGF showed significant induction (Figure 5-19). Contradictory to the 
endogenous data, IL-lp showed no up-regulation at all suggesting that IL-1 responsive promoter 
elements may lie out-with the cloned fragment necessary for this cell type. The potential for 
synergistic activation of each cytokine with bFGF was also examined but no synergism was evident 
(data not shown) contradicting evidence for combined IL-1 and bFGF activation seen in rabbit 
dermal fibroblasts (Bond, Baker et ah, 1999).
It is clear that selection of cell type is important when analysing the activity of cloned promoter 
fragments. These data suggest that the region of the cloned canine MMP-13 promoter described in 
this chapter is sufficient to drive basal expression in both cell types and contains promoter elements 
responsive to IL-lp, TNFcx and bFGF signalling pathways as observed in the primary rat 
cardiocytes. However, the response of the fragments was not as large as endogenous levels and 
therefore likely to be missing some enhancer elements. The canine MMP-9 promoter fragment is 
also able to drive basal expression but only appears to contain the necessary binding motifs for TNF 
and bFGF signalling pathways in these cell types.
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5.5.2 Analysis of canine MMP-9 promoter for the identification of PMA
responsive elements using deletion constructs
To analyse the endogenous levels of MMP-9 transcription in the cell lines to be used for the 
transfection of the canine pGL3/cMMP-9(1894), (984), (628), (534), (176) and (102) promoter 
deletion constructs relative semi-quantitative RT-PCR was performed. The six constructs were 
transiently transfected into the MDCK cells and FEA cells where basal luciferase activity for each 
promoter was compared to PMA treated samples along with pGL3-Basic, a promoter-less luciferase 
vector as a negative control, and pGL3-Control a SV40 promoter driving luciferase gene 
expression.
5.52.1 Assessment of basal and PMA induced endogenous transcription levels of
MMP-9 in MDCK and FEA3 cells.
Basal and PMA induced levels of endogenous MMP-9 gene transcription in MDCK cells is shown 
in Figure 5-20. Basal and PMA induced transcription was evident over cycle range 25 to 35 
showing that samples could be compared over this exponential phase. Basal levels of transcription 
were up-regulated by PMA supporting previous documentation that PMA could be both upregulated 
and suppressed dependant on cell type (Hanemaaijer et ah, 1993). The results of the basal and PMA 
induced endogenous MM-9 transcription suggested that the cloned canine MMP-9 promoter 
deletion fragments could be analysed in the MDCK cells using PMA,
5.5.2.2 Characterisation of the canine MMP-9 promoter using deletion analysis
In MDCK cells basal expression of the largest promoter construct pGL3/cMMP-9(l 894) was found 
to be high (Figure 5-13) confirming studies showing MMP-9 is normally expressed in cells specific 
to the kidney (Yokoo and Kitamura, 1996). Comparison of the basal luciferase expression levels 
between the various promoter deletions revealed a trend of maximal expression with the 
pGL3/cMMP-9(628) construct containing the NF-kB motif indicating that it may serve to enhance 
transcription. This trend was observed in three independent experiments but the difference between 
the promoter constructs was not significant. The promoter activity was not completely lost with the 
removal of the conserved AP-1 site at position (-111 to 105) as described for the human promoter 
(Sato and Seiki, 1993). Since the canine sequence contains an additional AP-1 site (-73 to -67) not 
found in the human counterpart we speculate this extra AP-1 site may perhaps be sufficient to drive 
basal expression. Similar results have been reported in the rat promoter with mutation of the 
conserved AP-1 (-111 to -105) in the rat sequence only reducing basal expression by twenty-five 
percent (Eberhardt et ah, 2000). Up-stream repressor sites have been identified in the mouse MMP- 
9 promoter which may function to regulate basal levels of promoter activity in a tissue specific 
manner (Roach et ah, 1998) but this region of the canine promoter has not been analysed. Basal 
levels of expression from the four largest promoter constructs pGL3/cMMP-9(1894), (984), (628), 
(534) could be significantly enhanced by the addition of PMA suggesting the presence of inducible 
regions in all constructs. Comparison of the PMA luciferase expression levels between the various
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promoter deletions revealed a trend of maximal expression again with the pGL3/cMMP-9(628) 
construct. This trend was observed in three independent experiments but this time the difference 
between the promoter constructs was significant. The constructs pGL3/cMMP-9(l 894). (984), 
(628), (534) were significantly higher than the smallest construct pGL3/cMMP-9(102) suggesting 
that the latter construct does not contain any inducible regions.
In direct contrast there was very low levels of MMP-9 gene transcription in the FEA cells (Figure 
5-22). This could be due to a cell-type specificity since species-specificity could be ruled out by 
studies showing activity of human promoter in rabbit cells (He, 1996). Cell-type specific expression 
was thought to reside in the DNA sequence found upstream of -2722 bp in the mouse promoter 
(Munaut et al., 1999), and since only the 1894 bp of canine promoter DNA had been cloned it was 
not possible to assess cell type specificity in this study. The level of basal expression could not be 
enhanced with PMA in these cells.
5.5.3 Relevance of MMP promoters to gene-based therapy
The canine specific MMP-9 and MMP-13 promoters were selected to drive expression of 
therapeutic genes in preference to commonly utilised promoters such as the cytomegalovirus 
(CMV) promoter which provides high levels of constitutive gene expression. It was thought that the 
MMP promoters would provide regulated levels of gene expression, in response to pro­
inflammatory cytokines unlike viral promoters. However, although the low levels of basal 
expression observed could be up-regulated to some extent with the pro-inflammatory cytokines it is 
debatable whether these induced levels of transgenes will provide therapeutic levels of gene 
expression, equivalent to those levels observed with viral promoters. As such it is likely that these 
promoters will require manipulation to enhance activity in disease state while maintaining low 
levels of basal expression, by the incorporation of enhancer elements into the promoter sequences.
179
5.6 SUMMARY
This chapter describes the characterisation of the canine specific MMP-9 (1894 bp) and MMP-13 
(1494 bp) gene promoters in MDCK cells and primary rat cardiocytes in response to pro­
inflammatory mediators IL-1, TNF and bFGF. A series of promoter deletion constructs, based on 
the canine MMP-9 promoter sequence pGL3/cMMP-9 (1894), (984), (628), (534), (176) and (102). 
were analysed in MDCK and FEA cells in response to PMA to identify inducible elements within 
the promoter sequence. The canine MMP-9 and MMP-13 promoters were analysed to investigate 
the unique ways in which each MMP gene is regulated through pro-inflammatory mediators during 
the disease process and to enable their use in targeted structure-modifying therapies.
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 Chapter VI
Targeting therapeutic gene expression to the diseased
cell types of the canine osteoarthritic joint
6.1 ABSTRACT
The potential for undesirable systemic effects related to constitutive over-expression of certain 
therapeutic transgene products may be limited through the development of both ‘disease and cell 
type specific’ DNA targeting vectors that restricts therapeutic gene expression to diseased cell 
types of the joint through transcriptional regulation. To enable the incorporation of both disease 
and cell type specific promoter elements into one vector a novel dual-targeting vector system was 
designed. Two parameters were addressed during the development of this vector. Firstly, the 
promoters incorporated into this system for driving gene expression required strategic manipulation 
to enhance promoter activity while maintaining both disease and cell type specificity. Secondly, the 
utilisation of Cre-lox technology was necessary to enable both disease and cell type targeting 
systems to be incorporated into a single vector system. This chapter describes the analysis of the 
canine MMP-9 promoter luciferase reporter, pGL3/cMMP-9(1894) and deletion constructs, 
pGL3/cMMP-9(984), (628) and (534) in response to both pro-inflammatory cytokines, interleukin- 
1 (IL-IP) and tumour necrosis factor (TNFa) in human chondrosarcoma cells (SW1353). These 
deletion studies, in combination with mutagenesis analysis, guided the manipulation of the MMP-9 
promoter with the incorporation of multiple NF-kB sites into the 5' end to enhance activity while 
maintaining disease-specificity. This chapter also describes the cloning of the mouse collagen type 
XI (mColXl) promoter (1.2 kb) from murine genomic DNA (gDNA) and analysis of cell type 
specific promoter activity in the chondrocyte-specific cells (SW1353) and undifferentiated 
chondroprogenitor cells (ATDC5). The mColXl promoter was manipulated with the incorporation 
of S0X9 enhancer sites into the vector to increase activity while maintaining cell type specificity. 
This chapter finally describes attempts to strategically sub-clone the canine MMP-9 and mouse 
ColXl promoters, manipulated with NF-kB and S0X9 sites respectively, into one plasmid vector 
containing the gene for ‘Cre recombinase’ and loxW sites to create a novel dual-targeting system.
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6.2 INTRODUCTION
Developing gene-based therapy for osteoarthritis (OA) in both human and veterinary patients 
represents an exciting challenge. The detailed understanding of disease pathogenesis has already 
enabled the introduction of ‘structure-modifying’ therapeutic genes into arthritic joints to control 
disease progression at the molecular level by inhibiting the enzymes responsible for cartilage 
degradation while enhancing tissue repair. However, despite considerable advances in molecular 
biology several technical problems still exist, which must be solved before gene therapy can be 
considered for use in clinical practice. In the development of a gene-based therapy for OA 
appropriate therapeutic genes and vector vehicles must be selected and methods devised to 
efficiently deliver these constructs to cells of the joint where sustained therapeutic levels of gene 
expression can be provided. However, it is also necessary to minimise undesirable side-effects 
associated with most therapies by accurately targeting therapeutic gene expression to diseased joint 
cell of the osteoarthritic joint such as chondrocytes and synovial cells. To this end, regulatory 
promoter elements can be modulated to enhance therapeutic levels of gene expression whilst 
maintaining both disease and cell type specificity.
6.2.1 Transcriptional regulation of transgenes
The ultimate success of any gene-based therapy strategy will therefore rely on the efficiency and 
duration of transcription, directed by promoter DNA sequences and associated regulatory elements, 
to provide adequate levels of transgene expression. Manipulation of these regulatory sequences 
may enable the rate of transcription initiation, crucial in the achievement of modulated therapeutic 
levels of transgene expression, to be obtained in vivo. The modular nature of the promoter region 
allows a considerable degree of flexibility when deciding on the design of the promoter/enhancer 
elements to be used to control gene expression using artificial transcriptional units. For example 
enhancers isolated from one regulatory region can be incorporated into a promoter with whom they 
are not necessarily associated to produce an optimised, manipulated promoter for the regulated 
control of therapeutic gene expression. Many different methods of targeting gene expression with 
promoter manipulation have been investigated.
6.2.1.1 Manipulation of promoters for targeting gene therapy
Some eukaryotic promoters are ideally suited for gene therapy since they combine strong 
transcriptional activity with a high degree of specificity; this is true for the melanocyte-specific 
tyrosinase promoter (Siders et al., 1996), However, often the application of highly specific 
promoters results in inefficient levels of transcriptional activity. A typical example is the von 
Willebrand factor (vWF) promoter which is highly specific for endothelial cells but is a poor 
activator of transcription (Ferreira et ah, 1993). Subsequently, different methods for enhancing the 
transcriptional activity of eukaryotic promoters while maintaining their specificity have been 
developed with the incorporation of transcriptional control elements into promoter regions. One 
system has described the use of ‘self-enhancing promoters’ which incorporates a positive feedback
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 loop provided by a chimeric transcription factor consisting of the strong herpes simplex virus VP 16 
transcriptional activation domain fused to the DNA-binding domain of LexA (Nettlebeck et ah, 
1998). Disease-specific components have also been incorporated into promoter regulatory systems 
to enhance transcription in response to the disease-state. For example, therapeutic gene expression 
can be driven in response to a disease-induced hypoxic environment with the inclusion of a 
hypoxia-resonsive element (HRE) into the promoter which interacts with the transcriptional 
complex hypoxia-inducible factor-1 (HlF-1) (Dachs et ah, 1997). Other studies have utilised 
concurrent treatments to enhance promoter activity such as the radiation-inducible promoter region 
of the Egr-1 gene which can specifically direct expression of TNFa in tumour tissues in response 
to radiation treatment (Hallahan et ah. 1995). Furthermore, it is may also be desirable to switch 
gene expression on or off with the use of regulatable promoters. One of the most elegant promoter 
systems in use today is the tetracycline-switch mechanism (Gossen et ah, 1995) which involves the 
E.Coli tetracycline (tc) repressor fused with the C-terminal domain of eukaryotic transcriptional 
activator VP 16. This tetracycline-regulatable transcription factor (tTA) specifically trans-activates 
artificial minimal promoters carrying multiple tc operator sites (tc-Op). Adding tc to the system 
reversibly inhibits binding of tTA to promoter DNA and blocks gene expression. This system has 
been used in a number of systems including transgenic mice (Ghersa et ah, 1998).
6.2.1.2 Tissus spsciCic promotses Coe tnegstieggses thsenpy
The construction of vectors enabling tissue-specific gene expression, is one of the current 
challenges in the field of gene therapy now thought possible by placing therapeutic genes under the 
control of regulatory promoters that possess binding sites for tissue specific factors. However, 
correctly regulated expression may not only require promoter regions but also the distant 5' and T
elements that influence tissue specific promoter activity (Miller and Vile, 1995). Tissue-specific 
regulatory elements have already been used to target gene expression to certain cell types. For 
example, using the transgenic mouse model for muscular dystrophy, the creatine kinase promoter 
has been used to restrict dystrophin cDNA expression to skeletal and cardiac muscles to correct the 
clinical signs of disease without deleterious side-effects (Cox et ah, 1993). The promoter of the Ig 
heavy chain has also been used to direct tissue-specific expression of the diphtheria toxin A (DT- 
A) gene in lymphoid cells (Maxwell et ah, 1991). However, vector context is an important 
parameter when designing tissue-specific targeting systems. Although tissue specific promoters 
frequently retain their specificity in the context of retroviral vectors (Hatzoglou et ah, 1990) this is 
not always the case, and the design of the viral vectors may have significant effects on cell type 
specificity due to promoter interference (Vile et ah, 1994).
This cell-type specific targeting system not only applies to the treatment of systemic diseases 
but also local gene therapy, whose efficacy and safety can be improved by the use of cell-type 
specific promoters keeping the expression of therapeutic genes in non-target cells to a minimum. 
This tissue-specific promoter system can easily be applied to the gene therapy for OA by 
incorporating promoter elements that are specifically activated in cell types specific to the joint
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such as chondrocytes or synovial cells. For example the collagen types II, IX and XI are expressed 
in chondrocytes (Mendier et al., 1989) and may be used to drive cell type specific gene expression 
in joints. The discovery of synovial-specific promoter elements such as hyaluronan (although the 
expression of this gene is not entirely tissue specific) will enable the development of targeting 
systems to accompany the advanced delivery systems already established for this cell type.
6.2.1.2.1 Chondrocyte spccit'k: gene expressi on
Coliagens are expressed in a tissue-specific manner with specific types unique to the articular 
cartilage. The type XI collagen molecules co-assembles with the major type II collagen, to form 
cartilage fibrils, whereas type IX collagen is associated with the surface of the fibrils (Mendier et 
al., 1989). The type XI collagen molecule regulates the diameter of cartilage collagen fibrils 
(Mendier et al., 1989) as illustrated by a null mutation in the al(XI) gene leading to abnormally 
thick collagen fibrils in chondrodysplastic mice (Li et al., 1995). This observation suggests that the 
fidelity of the spatio-temporal expression of type XI collagen is crucial for the development and 
maintenance of the normal structure of cartilage. The type XI collagen molecule is composed of 
three distinct sub-units, a2(XI), and oc3(XI), (Morris and Bachinger 1987) each with
unique patterns of expression. The al(XI) and a3(XI) are found in a variety of non-cartilaginous 
tissues (Yoshioka et ah, 1995) whereas the expression of the collagen a2(XI) gene appears to be 
more restricted. Although low levels of alternatively spliced variants of the a2(XI) transcripts are 
found in non-cartilaginous tissues the major transcripts are pre-dominantly found in cartilage tissue 
(Tsumaki and Kitamura, 1995). The 5' flanking region of the mouse a2(XI) collagen gene 
(Collla2) was cloned and analysed to reveal that the first 742 base pairs of the promoter, 
immediately up-stream of the transcriptional start site, contained information for gene expression 
specific to the cartilage of long bones and ribs (Tsumaki et ah, 1996). Cis regulatory regions of this 
promoter, necessary for cartilage specific expression, were then identified and shown to consist of 
an enhancer site (24 bp) located within the 500 and 530 base pairs region of the promoter (Tsumaki 
et ah, 1998). This sequence was sufficient to bind nuclear proteins selectively expressed in 
chondrocytes (Lefebvre et ah, 1996) which are now specifically referred to as the SOX9 proteins. 
The SOX9 protein contains a high mobility group (HMG)-type DNA binding domain and a trans­
activation domain that has been mapped to the C terminus (Sudbeck et ah, 1996). It is expressed 
abundantly in chondrocytes and in chondroprogenitor cells (Ng et ah, 1997) and can activate the 
chondrocyte-specific enhancer in non-chondrocytic cells in transient transfection experiments 
(Lefebvre et ah, 1997). This suggests that S0X9 proteins play an important role in chondrogenesis 
perhaps by activating collagen type XI gene expression. Other HMG-like sites are present in the 
enhancer site which participate in the formation of a large chondrocyte-specific protein complex 
that includes SOX9 and other proteins which appear to belong to the HMG domain protein family 
(Zhou et ah, 1998). These enhancer sites are also present in the other sub-units of the collagen Type 
IX gene sequence, such as al(IX) (Bridgewater et ah, 1998).
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 6.2.1.3 A duaa~]proo^ootesy^stem for targetinggene therapp
Novel methods for targeting therapeutic gene delivery are now possible with the application of Cre- 
lox technology. The recombinase Cre protein (38 kDa) of bacteriophage PI (Sterberg et ah, 1978) 
is a member of the family of site-specific recombinases and integrases that catalyse inter- and intra­
molecular DNA rearrangements. Cre recombinase catalyses the excision of DNA located between 
flanking Lox sites, leaving one site behind. Lox sites are 34 base pair sequences, with two 13 base 
pair inverted repeats separated by an 8 base pair space region (Sauer and Henderson, 1990; 1989; 
1988). This technology has become widely used since its first application in mammalian cells and 
is now the universal reagent for genome tailoring (Nagy, 2000) with applications in the in vitro
manipulation of DNA without the use of restriction enzymes (Buchholz and Bishop, 2001). 
Methods of regulating Cre gene expression by linking the gene to a number of inducible promoters 
has already been described (Kuhn et ah, 1995). For example the combination of cell-type specific 
and temporal controls has enabled the expression of a chimeric protein, consisting of a fusion 
between Cre and mutated steroid ligand-binding domain of the receptor, under the control of tissue 
specific promoters. The chimeric protein becomes active upon interaction with the synthetic ligand 
tamoxifen (Schwenk et ah, 1998). A temporal, spatial and cell-type-specific control of Cre- 
mediated DNA recombination has also been developed using the tetracycline inducibility in 
transgenic mice (Utomo et ah, 1999). This self-containing Cre/lox site-specific recombination 
system has also been described to target telomerase positive/p53-negative tumour cells for bladder 
cancer (Pan and Koeneman, 1998). Furthermore, a double infection system has also been described 
for targeted treatment of hepatic carcinoma using a regulator recombinant adenovirus producing 
site specific recombinase Cre expression under the control of the hepatocarcinoma-specific a-feto- 
protein (AFP) promoter in combination with the suicide gene thymidine kinase (Sato et ah, 1998). 
Self deleting retroviral vectors using Cre gene expression have also been developed to overcome 
problems encountered with recombination into the host cell genome (Russ et ah, 1996).
Using Cre-lox technology the potential for undesirable systemic effects related to constitutive 
over-expression of certain therapeutic transgene products may be limited through the development 
of a ‘disease and cell type specific’ DNA targeting vector that restricts transgene expression to 
diseased chondrocytes (Figure 6-1). It was hypothesised that transgene expression could be tightly 
controlled at the transcriptional level through the proper assembly of the appropriate ezs-acting 
regulatory regions of DNA, Since metalloproteinase (MMP) promoters are upregulated during the 
arthritic disease process, these regulatory sequences could be utilised to direct disease-specific 
transgene expression while simultaneously avoiding undesirable expression in healthy tissues. A 
second level of targeting could be incorporated into the system using chondrocyte specific 
promoters and enhancers, such as those for the collagen type XI gene, to limit expression of 
therapeutic genes to cell types specific for the diarthrodial joint.
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Figure 6-1 Targeting therapeutic gene expression to diseased cell types of the joint 
This dual targeting vector system utilises a cell type specific promoter to drive expression of a gene 
encoding the Pl bacteriophage recombinase enzyme referred to as ‘Cre’. This enzyme is capable of 
cutting DNA at specific lox sites before recombining the two free ends of DNA. This results in the 
removal of the DNA encoding the cell type specific promoter and Cre gene bringing the disease 
specific promoter up-stream of the therapeutic gene.
Cleavane of lox sites and removal 
of DNA containing cell type specific 
promoter and Cre gene
Ligation of free DNA 
ends placing 
disease specific
promoter up-stream 
of therapeutic gene
Disease specific promoter 
e.g. MMP-9 promoter
Therapeutic gene 
e.g. II .-Ira
TNFR
TIMP
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63 MATERIALS AND METHODS
Overviews of the experimental procedures employed in this chapter are illustrated in figure 6-2. 6-3 
and 6-4. The construction of pGL3/cMMP-9(1984) and deletions pGL3/cMMP-9(984), (628) and 
(534) are described in detail in chapter V. The human chondrosarcoma cell line (SW1353) was 
analysed for basal and induced (IL-1 3 and TNFa) levels of endogenous MMP-9 gene transcription 
using reverse transcription (RT)-PCR. The canine MMP-9 promoter deletions pGL3/cMMP- 
9(1894), (984), (628) and (534) were transiently transfected into SW1353 cells and basal and 
induced (IL-1 3 and TNFa) activities were determined using Dual-Luciferase®Reporter Assays. In 
a similar fashion the mutated, pGL3/cMMP-9(628)(NF-KBmut“), and manipulated pGL3/cMMP- 
9(5NF-kB), (3NF-kB) and (1 NF-kB) constructs were analysed using the same assay system.
The human chondrosarcoma cell line (SW1353) and undifferentiated chondrosarcoma cell line 
(ATDC5) were analysed for basal and induced (IL-1 and TNF) levels of endogenous collagen type 
XI gene transcription using RT-PCR. The mouse collagen type XI promoter and intron 1 regions 
were amplified by PCR and into cloned pCR2. l®TOPO and then sub-cloned into pGL3-Basic 
luciferase reporter vector. Activity of the promoter was analysed in the two cell lines using Dual- 
Luciferase®Reporter Assays. The mouse collagen type XI promoter and intron 1 sequences were 
manipulated with the addition of S0X9 sites and activities determined using the same assay 
system.
Once the individual disease and cell type specific targeting elements had been evaluated, 
attempts were to made to eonstruct the dual-targeting vector in four steps. The mouse collagen type 
XI promoter was amplified by PCR incorporating a /oxH site into the 5" end of the sequence. This 
was sub-cloned into pGL3-Basic (Vector A). The Cre gene plus polyadenylation site was cut from 
the pCAGGS-nls Cre vector and sub-cloned into vector A to create vector B. The canine MMP-9 
promoter, containing three NF-kB sites in the 5' end of the sequence, was cut from the 
pGL3/cMMP-9(1894)(3NF-KB) vector and sub-cloned into vector B to form vector C. The mouse 
collagen type XI intronic region containing three flanking SOX9 sites was amplified, incorporating 
a /oxH site in the 3' end of the sequence, and efforts were made to sub-clone this into vector C to 
make vector D.
The final step in the construction of the dual targeting vector was not possible due to technical 
problems. Evidence for the endogenous expression of Cre during the transformation procedure was 
sought using Western blot protocols.
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Figure 6-2 Overview of experimental procedures used to manipulate and analyse the
canine MMP-9 promoter
The human chondrosarcoma cell line (SWI353) was analysed for basal and induced (IL-lp and 
TNFa) levels of endogenous MMP-9 gene transcription using RT-PCR. The activities of MMP-9 
promoter deletions pGL3/cMMP-9( 1894). (984). (628) and (534) were analysed in the SWI353 
cells using Dual-Luciferase® Reporter assays. The mutated. pGl.3/cMMP-9(628((NF-KBmut'’). and 
manipulated. pGit3/cMMP-9(5NF-K’B)f (3NF-kB) and (I NF-kB). constructs were analysed using 
the same assay system.
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Figure 6-3 Overview of the experimental procedures used to clone and analyse the
mouse collagen type XI promoter
The human chondrosarcoma cell line (SWI353) and undifferentiated chondrosarcoma cell line 
(ATDC5) were analysed for basal and induced (IL-ip and TNFa) levels of endogenous collagen 
type XI gene transcription using RT-PCR. The mouse collagen type XI promoter and intron I were 
amplified by PCR and cloned into pCR2. I bTOPO before sub-cloning into pGL3-Basic luciferase 
reporter vector. Activity of the promoter was analysed in the two cell lines using Dual- 
Luciferase"Reporter Assays. The mouse collagen type XI promoter and intronic sequences were 
manipulated with the addition of SOX9 sites and activities determined using the same assay 
system.
189
  
 
 
 
 
 
 
 
 
Figure 6-4 Overview of the experimental procedures used to clone the dual-targeting
vector
Construction of the dual-targeting vector was attempted in four steps. The mouse collagen type XI 
promoter was amplified by PCR incorporating a loxU. site into the 5' end of the sequence and sub­
cloned into pGL3-Basic (Vector A). The Cre gene containing a downstream polyadenylation site 
was cut from the pCAGGS-nls Cre vector and sub-cloned into vector A to create vector B. The 
canine MMP-9 promoter, containing three NF-kB sites in the 5' end of the sequence, was cut from 
the pGL3/cMMP-9(1894)(3NF-KB) vector and sub-cloned into vector B to form vector C. The 
mouse collagen type XI intronic region containing three flanking SOX9 sites was amplified, 
incorporating a loxH site in the 3' end of the sequence, and efforts were made to sub-clone this into 
vector C to make vector D.
Amplification of the mColXI
intron, containing flanking
SOX9 sites, with a 5' loxH site
Sub-clone into vector C Vector DI-------- ►f
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6.3.1 Cloning of all promoters into pCR2.1®TOPO vector
The cloning procedures used in this chapter were simplified, as described in chapter V, by the 
initial cloning of PCR generated inserts (containing the appropriately modified sequence) into the 
pCR2.1®TOPO vector before sub-cloning into the pGL3-Basic luciferase reporter vector. This 
intermediate cloning step, via the pCR2,l®TOPO vector, had a number of advantages. The ‘T-A’ 
cloning system is highly efficient and allows the newly generated PCR fragments to be quickly 
cloned and their sequence analysed before sub-cloning into the luciferase reporter vector. 
Restriction enzyme digestion of the insert from the pCR2.1®TOPO vector is more efficient than the 
direct digestion of PCR products (containing flanking restriction enzyme sites) since a larger area 
of DNA is available to support the enzyme. Restriction digestion of the fragment could then be 
positively controlled, since the digested insert is visibly separated from the vector backbone on 
agarose gel analysis. The pCR2.1®TOPO vector containing the PCR products can easily be grown 
in bacterial cells to repeat the sub-cloning procedure if necessary; this is preferable to repeating the 
PCR which is often variable and may introduce sequence mutations.
6.3.1.1 Primer design
Forward (sense) primers and reverse (anti-sense) primers were designed, as described in section
2.2.5.1 and supplied by Sigma-Genosys (Table 6-1), for the PCR-based cloning of the canine 
MMP-9 promoter with additional NF-kB sites, the mouse collagen type XI promoter +/- SOX9 
sites and mouse collagen type XI intron +/- SOX9 sites into pCR® 2.1-TOPO,
6.3.1.1.I Canine MMP-9 promoter manipulation \\ 'ith NF-kB sites
Forward primers were designed to incorporate five, three and one NF-kB sites (GGAATTCCC) into 
the 5' end of the MMP-9 promoter sequence (5NF-KBf, 3NF-KBf, INF-KBf). These primers, used 
for the PCR-based cloning of these constructs, contained Xho 1 (CTCGAG) restriction enzyme sites 
incorporated into the forward primers to facilitate screening for insert orientation.
6.3.1.1.2 Mouse collagen type XI promoter (+/- manipulation wiih SOX9 «ii^«^ts)
Primers pairs based on specific regions of the mouse collagen type XI gene sequence (Genbank 
Number: D84066), guided by motif location, were designed for the PCR-based cloning of the 
collagen promoter region into pCR®2.1-TOPO. Sense (mColXIpromf) and anti-sense 
(mColXIpromr) primers were designed to amplify a region of the promoter (1178 bp) immediately 
5' to the translation start site. To manipulate this promoter with the addition of chondrocyte specific 
enhancers, S0X9 sites (CTCGAAAG), into the 5' end of the promoter, two further sense 
oligonucleotide primers were designed containing three and five chondrocyte specific enhancers. 
SOX9 sites, referred to as 3SOX9promf and 5SOX9promf respectively.
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6.3.1.1.3 Mouse collagen tvpc X! intron 1 ( + /- manipulation with SOXv sites)
Primer pairs were also based on the first intronic region of the collagen type XI gene sequence 
(Genbank Number; D84066) to enable the PCR-based cloning of intron 1 into pCR"2.1-TOPO. 
Sense primer (mColXlIntronf) and anti-sense primer (mColXlIntronr) were designed to amplify 
most of intron 1 (2427bp) between exon 1 and exon 2. To manipulate the mouse collagen type XI 
intron 1 region, sense (3Sox9intronf) and anti-sense (3Sox9intronr) oligonucleotide primers were 
designed to amplify a smaller region of the intron (242 bp) both containing three chondrocyte 
specific SOX9 enhancer sites to Hank a region of intron 1.
Illustration of primer position on the mouse collagen type XI gene
►
Col(XUpiomolcr
r*
Intron 1
Table 6-1 Primer sequences for manipulating the canine MMP-9 sequence with NF-
KB sites and the cloning and manipulation of the mouse ColXI promoter and intron
with SOX9 sites
Primer
Identification
Oligonucleotide primer sequence
(5'-3')
Tm (“(2) & GC
(%) content
5NF-KBf GGCCTCGAGGGAATTCCCGGAATTCCCGGAATTCCCGG
AATTCCCGGAATTCCCGGTTCTGGGTGACTCCAACGCC
AATGCTCAT
98.1 °C:57.1 %
3NF-KBf GGCCTCGAGGGAATTCCCGGAATTCCCGGAATTCCCGG
TCTGGGTGACTCCAAAGCCAATGCTCAT
95.6 °C : 57.6 %
INF-KBf GGCCTCGAGGGAATTCCCGGTCTGGGTGACTCCAAAGC
CAATGCTCAT
91.1 °C;58.3%
mColXIpromf ACCCTGACATGTTCCCTGGATGCTGCCACG 83.0 °C : 60.0 %
mColXIpromr GGCTCAGAATGCCAGATCCCAGGCAGTCCT 80.9 °C : 60.0 %
3Sox9promf GGCCTCGAGCTCGAAAGCTCGAAAGCTCGAAAGACCCT
GACATGTTCCCTGGAT
88.5 °C : 52.9 %
5Sox9promf GGCCTCGAGCTCGAAAGCTCGAAAGCTCGAAAGCTCGA
AAGCTCGAAAGACCCTGACATGTTCCCTGGAT
90.9 V : 50.8 %
mColXIIntronf GGTGTCAGTCAGTTGGAGGTTGTAGCATCT 72.9 °C ; 50.0 %
mColXIIntronr GGCAGGGTTAGTTAGGAGTGAGAACATGTC 71.3 °C: 50.0 %
3SOX9intronf GGCGGATCCGCTAGCCTCAAAGCTCAAGCTCAAAGGTC
TCTGTGAGTCTCTGTGTCTC
89.4 °C : 54.2 %
3SOX9intronr GGCGGATCCGCTAGCCTTTGAGCTTTGAGCTTTGAGAC
CATCTCCACAGCAGAGAACTC
90.2 ‘C : 54.2 %
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6.3.1.2 PCR amptification
6.3.1.2.1 MMP-9 manipulation \sirh multiple NP'-kB sites
Manipulation of the canine MMP-9 promoter with multiple NF-kB sites was performed by PCR 
using pCR®2. l/cMMP-9 vector samples (100 ng) as template and Ready-To-Go™ PCR beads 
(Amersham, Pharmacia) in a total volume of 25pi containing 0.4 pM of sense (5NF-KBF 3NF-KBF 
INF-KBf) (Table 6-1) and anti-sense (cMMP-9r) (Table 4-2) primer pairs. Samples were subjected 
to an initial denaturation at 95"C for 5 mins followed by 30 cycles of amplification, each consisting 
of a denaturation step of 95 °C for 1 min, an annealing temperature of 66 "C for 1 min and an 
elongation step of 72 °C for 2 mins. A final extension step of 72 "C for 30 mins completed the 
reaction.
6.3.1.2.2 Mouse collagen type XI promoter am pi ification and manipulation
Using Ready-To-Go™ PCR beads (Amersham, Pharmacia) in a total volume of 25pi the mouse 
collagen type XI promoter (mCoIXI) and manipulated mColXI(3SOX9), (5SOX9) promoters were 
amplified from mouse gDNA ( 150ng) and pCR2.1/mColXI vector samples (100 ng) respectively 
with 0.4pM of both sense (mColXIpromf, 3SOX9promf, 5SOX9promf) and anti-sense 
(mColXIpromr) primer pairs (Table 6-1). Samples were subjected to an initial denaturation at 95“C 
for 5 mins followed by 30 cycles of amplification, each consisting of a denaturation step of 95 °C 
for 1 min, an annealing temperature of 60 for 1 min and an elongation step of 72 °C for 2 mins. 
A final extension step of 72 "C for 30 mins completed the reaction.
6.3.1.2.3 Mouse coiiapcn type XI intronic amplification and manipulation
Using Ready-To-Go™ PCR beads (Amersham, Pharmacia) in a total volume of 25pl the mouse 
collagen type XI intron 1 and manipulated [3SOX9(intron)3SOX9] intronic regions were amplified 
from mouse gDNA (I50ng) and pCR®2.1/mCol(XI)intron vector samples (100 ng) respectively 
with 0.4pM of both sense (ColXIIntronf and 3SOX9intronf) and anti-sense (ColXIIntronr and 
3SOX9intronr) primer pairs (Table 6-1). Samples were subjected to an initial denaturation at 95°C 
for 5 mins followed by 30 cycles of amplification, each consisting of a denaturation step of 95 °C 
for 1 min, an annealing temperature of 60°C for 1 min and an elongation step of 72 "C for 1 min. A 
final extension step of 72 °C for 30 mins completed the reaction. PCR products (8 pi) were 
visualised by gel electrophoresis on a TAB agarose gel (1%) by comparing the bands created to a 
100 bp molecular weight standard.
6.3.1.3 Cloning into pCR®2.1-TOPO vector
PCR products were cloned using methods described in section 2.2.2. Briefly, PCR products were 
purified using the QIAquick®Gel Extraction Kit (QIAGEN, UK) and eluted in 50pl of sterile water,
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4pl of which were assessed by gel electrophoresis on a TAB agarose gel (1%) by comparing the 
bands created to a 1 kb molecular weight standard. Purified PCR products were directly ligated into 
the pCR®2.1-TOPO plasmid vector following the TOPO TA® cloning protocol. The ligation 
reaction (2pi) was then transformed into One Shof™ TOP 10 competent cells and spread onto agar 
plates containing ampicillin and X-gal for incubation overnight at 37°C. White, ampicillin resistant, 
colonies were selected from the plates and cultured overnight in LB/ampicillin broth at 37°C and 
glycerol stocks of each culture were prepared for long-term storage.
The DNA constructs were isolated from overnight cultures by the alkaline lysis method of 
plasmid DNA isolation using the QIAprep® PCR Spin Miniprep Kit (QIAGEN, UK) and eluted in 
50pl of sterile water. The DNA samples were then assessed by spectrophotometry for 
quantification. All constructs were screened using PCR conditions as described above but replacing 
one of the primers with a vector primer (either M13R or MI3F) to determine orientation.
6.3.1.4 Sequence evaluation
Recombinant plasmids were sequenced and analysed as described in section 2.2.6. Briefly, Plasmid 
samples were prepared for sequencing with PCR reactions using plasmid DNA samples (400 ng) 
and the Big Dye™ Terminator Cycle Sequencing Ready Reaction (ABI Prism) with 0.5juM of both 
sense (M13R) and anti-sense (M13F) vector-based primers. Samples were amplified, and the DNA 
purified by precipitation methods before samples were loaded into the ABI 310 genetic analyser for 
generation of automated sequence data. Sequence files were downloaded from the chromas file, 
saved as Word documents using the appropriate format, and then lined up with the relevant correct 
sequence for the MMP-9 and MMP-13 sequences using ClustalW to check for the absence of 
mutational errors.
6.3.2 Sub-cloning canine manipulated MMP-9 promoter & mouse 
collagen type XI promoter/intronic fragments into pGL3-Basic luciferase
reporter vectors
6.3.2.1 HestrOetOoc eczyme dOgestooc
6.3.2.1.1 Canine MMP-9(nwltiple NF-kB sites) and mouse collagen type XI promoter
+ /- (multiple SQX9 sites)
The uni-directional sticky/blunt ended ligation reaction described in chapter V was successfully
used to sub-clone all promoter fragments into pGL3-Basic luciferase reporter vectors. This
involved ligating the Kpn I and Sma I restriction enzyme sites located in the multiple cloning site
(MCS) of the pGL3-Basic reporter vector with the Kpn I and £eoH V restriction enzyme sites
positioned either side of the promoter fragments cloned into pCR®2,1.1TOPO. To enable this
procedure it was necessary to ensure that promoter sequences did not contain Kpn I and £eoH V 
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restriction enzyme sequences. More specifically, the promoter/pCR®2.1-TOPO vectors (5pg) were 
digested for four hours with Kpn I (5 units) and EcoR V (5 units) in MULTI-CORE™ (Ix) buffer at 
37°C. The recipient pGL3-Basic luciferase reporter vector (5pg) was digested with Kpn I (5 units) 
and Sma I (5 units) at 37°C and 30°C for 2 hours with each enzyme respectively (see 2.1.7.1).
6.3.2.1.1 Mouse co)jiancntpe.'XfdSOX9{»nmon)3SOX9| sues
A non-directional sticky ended ligation reaction was successfully used to sub-clone the intronic. 
fragment containing flanking SOX9 sites into the down-stream enhancer site of the pGL3-Basic 
luciferase reporter vector. This involved ligating the BamH 1 restriction enzyme site located in the 
enhancer region of the pGL3-Basic reporter vector with the BamH restriction enzyme sites 
positioned either side of the intronic fragment cloned into pCR®2.1-TOPO. To enable this 
procedure it was necessary to ensure that intronic sequences did not contain BamHl restriction 
enzymes sites. More specifically, the pCR®2.1/[3SOX9(mtron)3SOX9] (5jlg) and recipient pGL3- 
Basic luciferase reporter vector (5|ig) were digested for 2 hours with BamHl (5 units) in MULTI­
CORE™ (Ix) buffer at 37°C (2.1.7.1), The pGL3-basic vector was dephosphorylated for 2 hours 
with CIAP as described in section 2.2.2.7.
6.3.2.2. Purification, ligation and trannfonmation
Digested DNA samples, linearised pGL3-Basic and released promoter/intronic fragments, were 
purified using QIAquick®Gel Extraction Kit (QIAGEN, UK) and eluted in 30pl of sterile water. 
The DNA was quantified (4pl) by gel electrophoresis on a TAE agarose gel (1%) by comparing the 
bands created to a Low DNA Mass™ Ladder (4pi). The quantity of vector (pGL3-Basic) and insert 
(promoter/intronic fragment) for each ligation reaction was calculated according to the equation 
shown in 2.2.2.8.1. For each calculation the vector mass (X) was 50 ng, the insert size (Y) was 
approximately 2 kb for the manipulated MMP-9 promoter, 1.2 kb for the collagen type XI promoter 
and 0.5 kb for intronic regions. The molar ratio of insert to vector used was a value of three. The 
cut ends of the inserts were then ligated to complementary ends of the cut pGL3-Basic vector using 
T4 DNA ligase over night at 16"C. The ligations (20ng) were transformed into 25pl of JM109 
competent cells, heat shocked for 45 seconds at 42°C and then grown overnight at 37 °C on 
LB/ampicillin agarose plates. Six colonies were selected from each plate and transfened to LB 
broth for overnight culture at 37°C.
6.3.2.3 Isooation trnd scceennngoofeconmh^iantplaamids
The DNA constructs were isolated from overnight cultures by the alkaline lysis method of plasmid 
DNA isolation using the QIAprep®PCR Spin Miniprep Kit (QIAGEN, UK) and eluted in 50pl of 
sterile water. The DNA samples were then assessed by spectrophotometry for quantification. All 
constructs were screened using PCR techniques as described for their original amplification. 
However, although there was no need to screen for orientation of the promoter constructs since
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they were directionally cloned into pGL3-Bcs1c but, the intronic clones were not and therefore the 
reverse primer was replaced with the vector primer (RV4) to determine orientation using PCR 
techniques.
6.3.2.4 Pluimid vaetoomaps
Using computer software plasmid vector maps were drawn from the sequence data information 
incorporating all important components of each vector including the luciferase cDNA sequence, 
relevant canine MMP or mouse collagen type XI promoter/ intronic sequences with and without 
modifications, pofyadenylction signal and ampicillin resistance gene.
6.3.3 Mutagensi is
In vitro site-directed mutagensis using the QuikChagee™ site-directed mutagenesis protocol 
(Stratgene) was applied for the site-specific mutation in supercoiled double-stranded DNA 
(dsDNA) vectors. This technique was chosen to mutate the NF-kB site from the pGL3/cMMP- 
9(628) construct as it is a rapid technique generating mutants with 80% efficiency and eliminating 
the need for sub-cloning into specialised vectors. This four step procedure (Figure 6-5) utilised 
PfuTurbo® DNA Polymerase II and a thermal cycler replicating both plasmid strands with high 
fidelity without displacing the two synthetic oligonucleotide primers containing the desired 
mutation. The oligonucleotide primers each complementary to opposite strands of the vector were 
extended during temperature cyeling by PfuTurbo DNA polymerase generating mutated plasmids 
containing staggered nicks. Following temperature cycling, the product was treated with Dpn I, an 
endonuclease (target sequence: 5'- Gm6ATC-3z) that is specific for methylated and hemi-methylated 
DNA and used to digest the parental DNA template thereby selecting for mutation-containing 
synthesised DNA (Nelson and McClelland, 1992). DNA isolated from almost all E.eoli strains is 
dam methylated and therefore susceptible to Dpn I digestion. The nieked vector DNA containing 
the desired mutation was then transformed into XL I-Blue supercompetent cells.
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Figure 6-5 Simplified diagram of mutagenesis
The in vitro QuikChange™ site-directed mutagenesis protocol (Stratgene) is a simple four step 
procedure used for the site-specific mutation in supercoiled double-stranded DNA (dsDNA) 
vectors. The mutation sequence was identified and two synthetic oligonucleotide primers containing 
the desired mutation were designed. During PCR cycling the primers annealed to the vector 
sequence and the nonstrand-displacing action of PfuTurbo*1 DNA Polymerase II extended and 
incorporated the mutagenic primers into new nicked circular DNA strands. The methylated, non- 
mutated parental DNA was then digested with Dpn 1. an endonuclease. The newly mutated vectors 
were then transformed into XI. 1-Blue supercompetent cells that repaired the nicks in the mutated 
plasmid.
Target
sequence for
mutagenesis
Primer design
containing mutated
sequence for PCR
amplification
PCR amplification
using PfuTurbo
DNA polymerase
Digestion with Dnp I
and transformation
into XLl-Blue cells
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6.3.3.1 Primer des/gn
Both primers contained the desired mutation annealing to the same sequence on opposite strands of 
the plasmid. The primers were between 25 and 45 bp in length with the desired mutation in the 
centre of the primer with approximately 10 to 15 bases of correct sequence on both sides. The 
primers contained a minimum GC content of 40% and terminating in one or more G or C bases. 
The Tm value was greater than 78°C using equation (where N is the primer length in bases and 
%GC and % mismatch are whole numbers): Tm = 81.5 + 0.41 (%GC) - 615IN- % mismatch. 
Primers were synthesised and PAGE purified by Sigma Genosys.
Conserved NF-kB sequence: GGAATTCCCC
Mutated NF-kB sequence: TTTATTTCCAA
Table 6-2 Primer sequences for NF-kB mutagenesis
Primer Primer sequence (5Z to 3Z) Tm (”C) & GC
name (%) content
NF-kBmut"f GGGCTTGCTGCGCTTTAATTCCAAAATCCCTGCCTGAGGG 86.2 °C : 55.0 % 
NF-kBmut'T CCCTCAGGCAGGGATTTTGGAATTAAAGCGCAGCAAGCCC 86.2 °C : 55.0 %
6.3.3.2 PCR amplification of mutated vectors
PCR reactions were performed using 5-50 ng pGL3/cMMP-9(628) vector as template in a total 
volume of 50pl containing both 125 ng of sense (NFkBmut"f) and anti-sense (NFkBmut'T) 
primers, 1 pi of dNTP mix, 2 mM KCl, 2 mM (NH^SC^, 4 mM Tris-HCL (pH 8.8), 0.4 mM 
MgCo, 1% Triton® X-100, 1 mg/ml nuclease-free bovine serum albumin (BSA) and 2.5 units 
PfuTurbo® DNA polymerase. Using a PE 2400 thermal cycler, samples were subjected to an initial 
denaturation at 95°C for 30 seconds, followed by 18 cycles of amplification, each cycle consisting 
of a denaturation step of 95°C for 30 seconds and annealing temperature of 55°C for 1 minute, 
followed by an elongation step of 68°C for fourteen minutes. The nonstrand-displacing action of 
PfuTurbo polymerase extended and incorporated the mutagenic primers resulting in a nicked 
circular DNA vector.
6.3.3.3 Endonuclease Digestion
All methylated, non-mutated parental dsDNA templates were digested with Dpn I (10 units) added 
directly to the reaction mix and incubated at 37°C for one hour.
6.3.3.4 Transformation and plasmid preparation
Dpn I- treated circular nicked dsDNA (1 pi) was transformed into XLl-Blue super-competent cells 
(2.2.2.9.3) (50 pi) to repair the nicks in the mutated plasmid. The DNA constructs were isolated 
from overnight cultures by the alkaline lysis method of plasmid DNA isolation using the
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 QlAprep®PCR Spin Miniprep Kit (QIAGEN, UK) and eluted in 50pl of sterile water. The DNA 
samples were then assessed by spectrophotometry for quantification.
63.3.5 Seeuennc teak-iadon
Recombinant plasmids were sequenced and analysed as described in section 2.2.6 using plasmid 
samples (400 ng) and 0.5pM of both sense (RV3) and anti-sense (GL2) vector-based primers. 
Automated sequence generated from the ABI 310 genetic analyser were downloaded as chromas 
files and saved as Word documents. The canine MMP-9 sequence was checked to ensure correct 
mutation of the NF-kB site.
6.3.3.6 Plasmid vector maps
Using computer software, a plasmid vector map was drawn from the sequence data information 
incorporating all important components of each vector including the luciferase cDNA sequence, 
mutated canine MMP-9 promoter sequence, polyadenylation signal and ampicillin resistance gene.
6.3.4 Relative semi-quantitative RT-PCR to analyse endogenous
transcription of MMP-9 and collagen type XI genes in different cell lines
To assess the suitability of different cell lines in the characterisation of the MMP-9 and collagen 
type XI gene promoter fragments relative semi-quantitative RT-PCR was once again performed. 
Both basal and induced (IE-lp and TNFa) endogenous levels of the MMP-9 and collagen type XI 
gene transcription were analysed in the human chondrosarcoma cells (SW1353) and undiffereniated 
chondroprogenitor cells (ATDC5). Care was taken when using relative, semi-quantitative RT-PCR 
to compare levels of gene transcription between cell lines since numerous reports have shown that 
the expression of internal controls such as p-actin and GAPDH can be affected by experimental 
treatments, stage of development and cell type (Spanakis et al., 1993).
6.3.4.1 Cell lines and reagents
Human chondrosarcoma cells (SW1353 cells) were maintained in Dulbecco’s MEM/F-I2 medium 
supplemented with 10% foetal calf serum (PCS) as described in section 2.2.1.2.4. Undifferentiated 
chondroprogenitor cells (ATDC5) were cultured in a mix of Dulbecco’s MEM/F-12 medium 
supplemented with 5% FCS as described in section 2.2.1.2.5. SW1353 cells and ATDC5 cells were 
seeded onto 6 well plates at a concentration of 5.5x I0° and 5x 10° cells/ml respectively and 
allowed to grow to confluence over 24 hours. SW1353 cells and ATDC5 cells used in all 
experiments were serum-starved for 24 hours prior to stimulation with IL-1 p (10 ng/ml) and TNFa 
(10 ng/ml) for a further 24 hours prior to harvesting.
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63.4.2 Isooation of purified totalf&NA
Total RNA was harvested from both untreated (basal) and treated (IL-ip and TNFa) cells using 
RNAool1M B solution (AMS Biotechnology) (500)il/well) which was added directly to the wells 
containing the adherent SW1353 cells and ATDC5 cells for lysis. Aliquots (1 ml) of the lysed cell 
solution were shaken for 15 seconds with chloroform (lOOpl) and RNA extracted as described in 
section 2.2.3. The RNA samples were re-suspended in 40pl DEPC water and the quality and 
quantity assessed using spectrophotometry and agarose gel electrophoresis. To remove 
contaminating genomic DNA from the RNA preparation the RNA was treated with DNA-free™ 
(Ambion) as described in section 2.2.3.4.
6.3.4.3 First strand cDNA synthesis
The synthesis of first strand cDNA followed the basic principles as set out in section 2.2.4. More 
specifically, total RNA samples (2|ig) in 9pl of DEPC water were heated for 5 minutes at 65°C and 
then quenched on ice. First strand synthesis reactions were performed using the heat treated RNA in 
a 25p1 reaction mix containing 5pi of reverse transcription buffer (5x), 200 units of Molony Murine 
Leukaemia Virus reverse transcriptase (MMLV-RT) (GIBCO BRL), lOmM dTT, 250pM dNTPs, 
25 units RNAse inhibitor and 25pM random primers. Using a PE 480 thermal cycler the reaction 
was incubated at 37°C for 30 minutes followed by 42°C for 60 minutes and completed with 95°C for 
5 minutes.
6.3.4.4 Primer design
In order to amplify approximately 350 bp regions of the human and mouse MMP-9 and collagen 
type XI cDNAs it was necessary to design oligonucleotide primer pairs for each gene. PCR primers 
were designed as described in section 2.2.5.1 and were synthesised and supplied by Sigma-Genosys 
(Table 6-3). Both sense and anti-sense species-specific primer pairs were designed based on the 
human (hMMP-9f and hMMP-9r) and mouse (mMMP-9f and mMMP-9r) MMP-9 gene sequences. 
Primer pairs were also designed based on the human (hColXIf and hColXIr) and mouse (mColXIf 
and mColXIr) collagen type XI gene sequences. The constitutively expressed cyclophilin gene was 
used as an internal control for the human (NMJ021130) and mouse (XM_I25205) species. Species 
specific primers were subsequently designed based on the human (hcyclophilinf and hcyclophilinf) 
and mouse (mcyclophilinf and mcyclophilinr) genes to amplify a region of 265bp from cDNA 
template. The position of the control primers were again based on the cDNA sequence to span an 
intron, to enable the identification of contaminating genomic DNA as a 450 bp fragment. Primer 
pairs (27 bp) were matched as closely as possible for Tm (70”C) and GC (40-60%) content.
200
  
Table 6-3 Primer sequences for RT-PCR (MMP-9, ColXI and cyclophilin)
Primer namc Oligonucleotide primer sequence (5' to 3 ) Tm (°C) & GC (%)
content
hMMP-9f GCTGGATAGCGCCACGCTGAAGGCCAT 81.2 °C : 63.0 %
hMMP-9r ATCGTCGAAATGGGCGTCTCCCTGAAT 77.0 "C ; 51.9 %
mMMP-9f CTGGACAGCCAGACACTAAAGGCCATT 73.0 °C :51.9 %
mMMP-9r GTCGTCGAAATGGGCATCTCCCTGAAC 76.7 "C : 55.6 %
hColXIf ATCTGTCCAGCTGATGTGGCCTACCGA 76.2 °C : 55.6 %
hColXlr TCTTCATCCAGAATACGGGCACCAAAG 73.4 °C : 48.1 %
mColXlf GTCTGTCCGGGTGATGTGGCTTACCGT 77.0 "C : 59.3 %
mColXIr TCATCGTCGAGGATGTGGGCACC 'AAAG 78.9 *C : 55.6 %
hcyc^p^H^' CGTGCTCTGAGCACTGGAGAGAAAGGA 74.9 "C : 55.6 %
hcyclophilmr CCACTCAGTCTTGGCAGTGCAGATGAA 74.7 "C : 51.9 %
mcyclophilmf CGAGCTCTGAGCACTGGAGAGAAAGGA 741 °C : 55.6 %
mcyclophilrnr CCATTCAGTCTTGGCAGTGCAGATAAA 71.2 "C : 44.-4 %
6.3.4.5 PCR amplification of MMP-9 and collagen cDNA fragments using PCR 
PCR reactions were performed using Ready-To-Go™ PCR beads (25 pi) (Amersham. Pharmacia) 
with cDNA samples (Ipg) as template and 0.4pM of spec'ies specific primer pairs for MMP-9 or 
collagen type XI each with 0,1 pM of species specific cyclophilin primers as an internal control 
(Table 6-3). Samples were subjected to an initial denaturation at 95”C for 5 min followed by a 
variable number of cycles for amplification, each cycle consisting of a denaturation step of 95 "C 
for 1 min. an annealing temperature of 67"C followed by an elongation step of 72 "C for 1 min. A 
final elongation step of 72"C for 10 min completed the reaction. Samples were removed at multiple 
(3 to 5) intervals 5 cycles apart to determine the exponential phase of the reaction where basal and 
treated samples could be semi-quantified and compared. A negative control containing a PCR bead 
with all components (dNTPs. PCR buffer and Taq polymerase) and primer pairs without template 
was performed to check for contamination of the PCR reactions with extraneous DNA that might 
serve* as a template for PCR amplification. PCR products (8|il) were analysed by TAE agarose gel 
(1%) electrophoresis by comparing the bands created to a 100 bp molecular weight standard.
6.3.5 Luciferase reporter assays to analyse the basal and induced activity
of the manipulated canine MMP-9 promoter fragments and the mouse
collagen Type XI promoter/intronic fragments
The Dual-Liiciferase Reporter assays as discussed in section 2.2.8 were chosen to analyse the 
cloned canine MMP-9 and mouse collagen type XI promoters for reasons as described in chapter V.
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 6.3.5.1 Trannfectoon of cells
SW1353 and ATDC5 cells were maintained as described in section 6.3.4.1. White, tissue culture 
treated ViewPlate™-96 (Packard) were seeded with SW1353 cells, and ATDC5 cells at 
concentrations of 5.5x104 cells/ml and 5x1 O* cells/ml respectively and incubated overnight at 37°C 
in 5% CO2. Cells should be approximately 70-80% confluent on the day of transfection for optimal 
assay conditions. Transient transfections were carried out using Trans Fast™ Reagent (Promega) at 
a 1:1 ratio with DNA according to the manufacturer's instructions as described in section 2.2.7. 
More specifically, total DNA (50-100ng) was added to pre-warmed serum free media (40pl) and 
thoroughly mixed before addition of Trans Fast™ Reagent (0.3|ll). The DNA/transfection reagent 
samples were incubated for 10-15 minutes at room temperature to allow complex formation before 
the growth medium on the 96-well plates was aspirated and replaced with the transfection samples. 
The cells were incubated with the complexes for 1 hour at 37°C in 5% COt before pre-warmed 
complete medium was added for cell recovery overnight at 37°C.
6.3.5.2 StiomuUulooot ef ceHu
To induce transcription from the promoter constructs, transfected cells were treated with different 
stimulants for the 24 hours prior to luciferase assays. SW1353 cells and ATDC5 cells were both 
serum-starved for 24 hours prior to stimulation with IL-1 (3 (10 ng/ml), and TNFta (10 ng/ml) (R&D 
Systems) for a further 24 hours prior to harvesting the cells.
6.3.3.3 Luctdceais eissps
Duaf-Luclfel■ase®Reporter assays were performed 72 hours post transfection, according to the 
manufacturer's protocol (Promega). More specifically, media was removed from the adherent cells, 
washed once with PBS and lysed with Passive Lysis Buffer (PLB) (Ix) for 15 minutes at room 
temperature. Using c Dynex, MLX luminometer and injector system, freshly prepared Luciferase 
Assay Buffer II (LAR II) (50pl) and Stop & Glo® Reagent (50pl) were dispensed into each well 
with an interval of 30 seconds, each taking a luciferase count for 10 seconds. Both firefly and 
Henilli luciferase values were obtained for each well and all luciferase values were analysed using 
an excel spread sheet.
6.3.6 Preparation of components required for the dual-targeting vector 
construction
The strategy for sub-cloning all components of the dual-targeting vector into the pGL3-Basic 
vector was designed to be as simple as possible using restriction enzyme digestion where possible 
from tested plasmids. New components, including the loxH sites and restriction enzyme sites, were 
incorporated into primer sequences for sub-cloning into the final vector by PCR methods. 
However, The dual-targeting CRE-lox vector construction was not completed due to technical 
problems in the final stages of the cloning procedure.
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6.3.6.1 The incorporation of loxH sites into the dual targeting vector
The sequence of the lox? site consists of 34 base pairs containing a 13 bp inverted repeat, separated 
by an 8 bp spacer region. The inverted repeat (underlined) may form a stem and loop structure 
which may reduce expression of the gene of interest. A variation of the lox? {loxH) was created by 
Invitrogen to eliminate the formation of stem and loop structure and potentially improve 
transcription. Mutated bases are shown in bold face.
Lox? site:
ATA ACT TCG TAT AGC ATA CAT TAT ACG AAG TTA T
LoxH site;
ATT ACC TCA TAT AGC ATA CAT TAT ACG AAG TTA T
6.3,6.2 Primer design for cloning into pCR®2.1-TOPO vector
PCR primers were designed as described in section 2.2,5.1 and were synthesised and supplied by 
Sigma-Genosys (Table 6-4). Two primer pairs were designed for the PCR-based cloning of 
intermediate products into pCR®2.1-TOPO for further sub-cloning into the dual-targeting vector. 
This enabled the incorporation of loxH sites and restriction enzyme sites, not found within pGL3- 
Basic vector multiple cloning site (MCS), into the vector system.
6.3.6.2.1 Mouse collagen hpc XI gene promoter plus /avH site:
One primer pair was based on specific regions of the mouse collagen type XI gene promoter 
sequence. Sense (mColXI/oxHf) and anti-sense (mColXI/oxHr) primers designed were designed to 
amplify a region of the promoter (1178 bp) immediately 5' to the translation start site. A loxH site 
was incorporated into the sense primer in addition to a Bgl II (AGATCT) and a Nsi 1 (ATGCAT) to 
facilitate the sub-cloning steps into pGL3-Basic. The anti-sense primer contained a Bgl II and a 
Xbal (TCTAGT) for the same reasons.
6.3.6.2.2 Mouse collagen type XI intron/sox9 sites plus /avH site
The second primer pair was based on the manipulated [3SOX9(intron)3SOX9] sequence designed 
from the mouse collagen type XI intron 1 sequence. Sense (mlntron/oxHf) and anti-sense 
(mlntron/oxHr) primers were designed to amplify a region of the intron (242 bp) with three 
flanking SOX9 sites (CTCAAAG). A loxH site was also incorporated into the anti-sense primer in 
addition to a Hind III (AAGCTT) to facilitate the sub-cloning steps into pGL3-Basic. The anti-sense 
primer also contained a Hind III site.
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 Table 6-4 Primer seqences for the cloning of the dual-targeting vector
Primer name Primer sequence (5' to 3') Tm ("C) & GC
(%) content
mColXI/avHf GGCAGATCTATGCATATTACC'
GAAGTTATACCCTGACATGTTCCCTGGAT
81.9 °C : 54.8 %
mColX I/f.vHr GGCAGATCTTCTAGTGGCTCAGAATGCCAGATCCCAGGCAG 84.3 °C : 38.6 %
mlntron/avHf GGCAAGCTTCTCAAAGCTCAAAGCTCAAAGGTCTCTAGTCT
CTGTGTC
84.7 °C : 49.0 %
mlntron/atHr GGCAAGC TTATAACTTCGTATAATGTATGCT ATA TGAGGTA
ATCTTTGAGCTTTGAGCTTTGAGACCATCTCCACAGCAGAG
AAG
85.3 °C : 80.6 %
6.3.6.3 PCR amplification
6.3.6.3.1 Mouse collagen type XI promoter/Io\i.I
PCR amplification of the mouse collagen type XI promoter with the ioxH site was performed using 
pCR®2.1/mColXI vector samples (100 ng) as template and Ready-To-Go™ PCR beads 
(Amersham. Pharmacia) in a total volume of 25pl containing 0.4 pM of sense (mColX M^cHf) and 
anti-sense (mColXI/acHr) primer pairs (Table 6-4). Samples were subjected to an initial 
denaturation at 95°C for 5 mins followed by 30 cycles of amplification, each consisting of a 
denaturation step of 95 °C for 30 secs, an annealing temperature of 60 °C for 30 secs and an 
elongation step of 72 °C for 2 mins. A final extension step of 72 °C for 10 mins completed the 
reaction.
Mouse collagen type XI intron/SOX9/7ovH 
PCR amplification of the mouse collagen type XI manipulated intron with the ioxH site was 
performed using pCR2.l/mColX1|3SOOX9(intron)3SOX9] vector samples (100 ng) as template and 
Ready-To-Go™ PCR beads (Amersham. Pharmacm) in a total volume of 25pl containing 0.4 pM 
of sense (mlntronloxHf) and anti-sense (mlntronloxHr) primer pairs (Table 6-4). Samples were 
subjected to an initial denaturation at 95°C for 5 mins followed by 30 cycles of amplification, each 
consisting of a denaturation step of 95 ”C for 30 secs, an annealing temperature of 68 °C for 30 secs 
and an elongation step of 72 °C for 1 min. A final extension step of 72 °C for 10 mins completed 
the reaction. PCR products (8 pi) were visualised by gel electrophoresis on a TAB agarose gel (1%) 
by comparing the bands created to a 100 bp molecular weight standard.
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6.3.6.4 Cloning of PCR products into p(RR" 2.1-TOPO vectors
PCR products were cloned using methods described in section 2.2.2. Briefly, PCR products were 
purified following QIAquick^Gel Extraction Kit (QIAGEN, UK) and eluted in 50pl of sterile water, 
4pl of which were assessed by gel electrophoresis on a TAE agarose gel (1%) by comparing the 
bands created with a 1 kb molecular weight standard. Purified PCR products were directly ligated 
into the pCR®2.LTOPO plasmid vector following the TOPO TA® cloning protocol. The ligation 
reaction (2pl) was then transformed into One Shot1' ' TOP 10 competent cells and spread onto agar 
plates containing ampicillin and X-gal for incubation overnight at 37°C. White, ampicillin resistant, 
colonies were selected from the plates and cultured overnight in LB/ampicillin broth at 37“C and 
glycerol stocks of each culture were prepared for long-term storage. The DNA constructs were 
isolated from overnight cultures by the alkaline lysis method of plasmid DNA isolation following 
the QlAprep® PCR Spin Miniprep Kit (QIAGEN, UK) and eluted in 50pl of sterile water. The 
DNA samples were then assessed by spectrophotometry for quantification. All constructs were 
screened using PCR conditions as described above but substituting one of the primers with a vector 
primer (either Ml3R or M13F) to determine orientation.
6.3.6.5 Sequence evaluation
Recombinant plasmids (400 ng) were sequenced as described in section 2.2.6 using 0.5pM of both 
sense (M13R) and anti-sense (M13F) vector-based primers. Sequences generated from the ABI 310 
genetic analyser were downloaded as chromas files and saved as Word documents. Sequences were 
aligned with the relevant correct sequence for the mouse collagen type XI gene sequence using 
ClustalW to check for the absence of mutational errors.
6.3.7 Construction of dual targeting- vector
6.3.7.1 Restriction enzyme (RE) digestion
See figure 6-4 for a flow chart of the cloning strategy.
6.3.7.1.1 RE digestion for the construction uf vector lAl: pGL3/mColXI/d.vII
The non-directional sticky ended ligation reaction was successfully used to sub-clone the mouse 
collagen type XI promoter containing the 5° loxH site into the MCS of pGL3-Basic luciferase 
reporter vector. This involved ligating the cut Bgl II restriction enzyme sites located in the MCS of 
the pGL3-Basic reporter vector with complementary Bgl II restriction enzymes sites positioned 
either side of the mouse collagen type XI promoter fragment cloned into pCR®2.1-TOPO. To 
enable this procedure it was necessary to ensure that promoter sequences did not contain Bgl II 
restriction enzyme sites. More specifically, the pCR®2. l/mColXio%H vector (5pg) was digested 
for two hours with Bgl II (5 units) in MULTI-CORE™ (Ix) buffer at 17°C to release the insert. The 
recipient pGL3-Basic luciferase reporter vector (5jag) was also digested with Bgl II (5 units) at
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37°C for 2 hours (see 2.1.7.1) but was also dephosphorylated for 2 hours with ClAP as described in 
section 222.1.
6.3.7.1.2 RE c4ij■ceiioi for sthe construction of vsecor SB pC^GLKVniColXI/mi^-I-Chxe 
A nni-directional sticky ended ligation reaction was then performed to sub-clone the Cre gene 
together with its nuclear localisation signal (nls) and polyadenylation signal (PolyA) into vector A: 
pGL3/mColXI/oa:H. This involved ligating the Xba I and Hind III restriction enzymes sites located 
in the MCS immediately downstream of the collagen promoter into the pGL3/mColXI/oxH vector 
with the Xba I and Hind III restriction enzymes sites positioned either side of the nls-Cre-PolyA 
sequence cloned into pCAGGS-nlsCre vector (kindly provided by Dr. Nagy, Colorado). To enable 
this procedure it was necessary to ensure that the nls-Cre-PolyA sequence did not contain Xba I or 
Hind III restriction enzymes sites. More specifically, the pCAGGS-nlsCre vector (5ftg) was 
digested for two hours with Xba I (5 units) and Hind III (5 units) in MULTI-CORE™ (Ix) buffer at 
2TC to release the insert. The recipient pGL3/mColXUi%H (5Lg) was first partially digested with 
Xba 1 (0.5 units) since a second Xba I was present in the backbone of the pGL3 vector sequence. 
The mixed population of full-length linearised DNA fragments was separated from both the uncut 
and completely digested vectors by agarose gel electrophoresis and gel extraction. To separate the 
vectors digested within the MCS from those cut within the back bone of the vector, and to produce 
the second sticky end for ligation, complete digestion with Hind III (5 units) (2.1.7.1) was 
performed. The digestion with Hind III provided a sticky end for cloning at the end of the 
linearised strand of DNA in the correctly linearised vector (in MCS), while those previously 
digested in the backbone were cut into two fragments. Agarose gel electrophoresis and gel 
extraction was then used to separate the full-length Xba I and Hind III digested vector for further 
sub-cloning.
6.3.7.13,RPi digestion for the construction of vector C: pGld/rnColXHoA'I f-Cte-
cMMP-9(3MFicB)
A uni-directional sticky ended ligation reaction was then performed to sub-clone the canine MMP- 
9(1894) promoter manipulated with three NF-kB sites into vector B; pGL3/mColXI/>xH-Cre. This 
involved ligating the kpn 1 and Nci 1 restriction enzymes sites located in the MCS immediately 
upstream of the collagen type XI promoter within the pGL3/mColXII<oo:H-Cre vector with the kpn 1 
and Nci 1 restriction enzymes sites positioned either side of the pCR2.1/eMMP-9(3NF-KB) vector. 
To enable this procedure it was necessary to ensure that the MMP-9(3NF-kB) sequence did not 
contain kpn 1 or Nci restriction enzymes sites. More specifically, the pCR2.1IeMMP-9(3NF-KB) 
vector (5[ig) and pGL3ImCoIXIIoj•H-Cre vector(5fig) were both digested for two hours with kpn 1 
(5 units) in MULTI-CORE™ (Ix) buffer at 37°C followed by Nci 1 (5 units) in buffer D (Ix) at 
37“C to release the insert and linearise the vector respectively.
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6.3.7.1.4 RE digestion for.constniction of \ector 1): pGL3/nC'^)iXIA*vH-Grc-cMMP- 
9 (3 N F kB ) [ SO X9 (i i u r<) n ) SO X91
A non-directional sticky ended ligation reaction was attempted to sub-clone the mouse collagen 
type XI intron, manipulated with six SOX9 sites, containing the second loxH site into the MCS of 
vector C: pGLd/mColXI/oxH-Cre-cMMP-dnNFKB), This involved ligating the cut Hind III 
restriction enzyme sites located in the MCS of the vector C, downstream of the Cre gene, with the 
complementary Hind III restriction enzymes sites positioned either side of the mouse collagen type 
XI intron containing six SOX9 sites in pCR®2J-TOPO. To enable this procedure it was necessary 
to ensure that the intronic sequence did not contain Hind III restriction enzymes sites. More 
specifically, the pCR®2.11mGolXI[3sox9(intron)3sox9] vector (5pg) was digested for two hours 
with Hind III (5 units) in MULTI-CORE™ (lx) buffer at 37°C to release the insert. The recipient 
pGL3/mColXIloxH-Cre-eMMP-9(3N^^KB) vector (5pg) was also digested with Hind III (5 units) at 
37°C for 2 hours (see 2.1.7.1) but was also dephosphorylated for 2 hours with CIAP as described in 
section 2.2.2.7.
6.3.7.2 Purification, ligation and trnnft^forrma^on
All digested DNA products were cloned using methods described in section 2.2.2. Briefly, digested 
DNA samples (linearised vectors and DNA inserts) were purified following QIAquick® Gel 
Extraction Kit (QIAGEN, UK) and eluted in 30pl of sterile water. The DNA was quantified (4jll) 
by gel electrophoresis on a TAE agarose gel (1 %) by comparing the bands created with a Low DNA 
Mass™ Ladder (4pl). The quantities of vectors and inserts for each ligation reaction were calculated 
according to the equation shown in 2.2.2.8. For each calculation the vector mass (X) was 50 ng, the 
insert size (Y) was approximately 1.2 for the collagen type XI promoter, 1.6 for the nls-Cre-PolyA, 
2 for the manipulated cMMP-9 promoter, and 0.5 for the intronic region. The molar ratio of insert to 
vector used was generally a value of three. The cut ends of the inserts were then ligated to 
complementary ends of the cut vector using T4 DNA ligase (Roche) over night at 16°C. The 
ligations (20ng) were transformed into 25pT of TOPIO competent cells, heat shocked for 30 seconds 
at 42‘C and then grown overnight at 37 °C on LB/ampicillin agarose plates. Six colonies were 
selected from each plate and transferred to LB broth for overnight culture at 37°C.
6.3.7.3 Isoontion anti sccrenni^g' ot'frectn^b^it^n^^tpkimtids
The DNA constructs were isolated from overnight cultures by the alkaline lysis method of plasmid 
DNA isolation following the QIAprep®PCR Spin Miniprep Kit (QIAGEN, UK) and eluted in 50pT 
of sterile water. The DNA samples were then assessed by spectrophotometry for quantification. 
Constructs were either screened using PCR techniques as described for their original amplification 
(using vector-based primers where possible) or by restriction enzyme digestion. Vector A was 
screened by PCR using primers RV3 and ColXI/oxHr, Vector B was screened by restriction
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digestion using Nsi 1 and Hind III restriction enzymes. Vector C was screened by PCR using 
primers 3NF-KBf and cMMP-9r. Vector D was screened by restriction digestion using Hind III.
6.3.7.4 Sequenee evlUultOfC
At each stage positive samples were selected and sequenced as described in section 2.2.6 to 
confirm that all sequences were correct with no mutational errors. Plasmid samples (400 ng) were 
amplified using 0.5pM of both sense both sense (RV3, mColXIpromseqf, mlntron/oxHf) and anti­
sense (GL2, Creseqr and mlntron/oxHr) primers (Table 6-5) and sequenced on the ABI 310 genetic 
analyser. Sequence files were downloaded from the chromas file, saved as Word documents using 
the appropriate format, and then lined up with the relevant correct sequence for the canine MMP-9 
promoter, mouse collagen type XI gene and Cre gene sequences using ClustalW to check for the 
absence mutational errors.
Table 6-5 Primers for sequencing the dual targeting vector
Primer name Primer sequence (S' to 3')
mcolXIpromseqf CCGTCCTCGTTCCCACCCTCACCTCCCTT
Creseqr CCCCATATCTTCCCAAACTCTAAACCA
Tm (°C) & GC (%)
content
82.3 OC ; 65.5 %
71.3 °C : 44.4 %
6.3.7.5 Phuimui vectorremps
Using computer software, plasmid vector maps were drawn from the sequence data information 
incorporating all important components of each vector including the luciferase cDNA sequence, the 
relevant canine MMP promoter sequence or mouse collagen type XI promoter and intronic 
sequences, Cre gene pofycdenyfation signals and ampicillin resistance gene.
6.3.8 Western blot analysis of Cre expression during the construction of 
the dual targeting vector
To evaluate why the cloning of vector D was not possible, investigation of Cre gene expression 
using Western blot procedures was carried out. The TOP 10 E.coli competent cells (Invitrogen) 
used for the transformation procedure were analysed for endogenous Cre gene expression and cells 
transformed with vector C were also analysed for Cre gene expression from the plasmid sequence.
6.3.8.1 Samplu preparatiooi
Vector C: pGL3/mCofXUoxH-Crc-cMMP-9(3NFKB) (20ng) and pGL3-Basic (20ng) (as a negative 
control) were transformed into 25|il of TOP 10 competent cells, heat shocked for 30 seconds at 42°C 
and then grown overnight at 37 °C on LB/ampicillin agarose plates. Untransformed bacterial cells 
were also plated on LB agarose plates. One colony was selected from each plate and transferred to
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LB broth +/- ampicillin for overnight culture at 37°C. TOP 10 bacterial cells (lOOp.l) were removed 
from each broth and spun at 13,000 rpm for 10 minutes to pellet the cells.
63.8.2 SDS-PAGE
A ready pre-cast gel (8.6 cm x 6.8 cm x 1.0 mm), comprising a 10 % resolving and 4 % stacking 
gel, with ten wells was assembled in the Mini-Protean 3 Electrophoresis cell (Biorad, Herts) as 
described in section 2.2.9. Cell pellets were resuspended in 40 pi of protein loading buffer, 
followed by incubation at 100°C for 8 minutes and loaded onto the gel with a Wide Range (6.5 to 
205 kDa) Color Markers molecular weight standard (10 pi) (Sigma). The gel was electrophoresed 
at 200 volts until the bromophenol blue dye reached the lower part of the gel and was then removed 
from the gel cast.
6.3.8.3 Blotting and blocking the membrane
Two pieces of filter paper (3MM Watmann paper) and one piece of nitrocellulose membrane 
(Biorad Transblot) were cut to size and soaked in Transfer buffer with two sponges for 30 minutes 
at room temperature. On completion of electrophoresis, the gel was carefully removed and placed 
directly on the membrane and then sandwiched between the two pieces of filter paper and sponges. 
The blotting assembly was then placed in the transfer tank, filled with transfer buffer and run at 
200V for one hour. Marker positions were highlighted on the gel in pencil before staining with 
Ponceau’s red staining for 10 minutes. After de-staining three times with distilled water, bands were 
visualised. The membrane was blocked overnight in 5% non-fat milk in TBS-Tween at 4°C. The 
membrane was rinsed with TBS-Tween (2x) and then washed three times for 10 minutes each.
6.3.8.4 Antibody binding and detection usingECL ™ techniques
The primary polyclonal antibody against Cre recombinase (crude rabbit antiserum) (Covance, CA) 
was diluted 1:1000 in 1% milk/TBS-Tween. The membrane from 6.3.8.3 was incubated in 20ml of 
the diluted antibody for one hour at room temperature with gentle rocking and then washed three 
times in 2x TBS-Tween.
Binding of the Cre antibody was evaluated using the Enhanced Chemoluminescence (ECL™) 
Western kit. This is a sensitive, rapid system for protein blotting where an antibody system coupled 
to horse radish peroxidase (HRP) catalyses the conversion of the ECL substrate, luminol into a 
light signal (maximum wavelength emmision at 430nm) that can be detected by autoradiography. 
The secondary antibody anti-rabbit HRP conjugate was diluted 1.3000 with 1%o milk/TBS-Tween 
and 20ml was added to the membrane and incubated at room temperature for one hour. The 
membrane was washed three times in 2x TBS-Tween before being completely removed. Equal 
volumes (15 ml) of ECL reagent #1 was mixed with reagent #2 and placed onto the membrane. The 
membrane was transferred to a piece of clear plastic sheet (Saran Wrap), taped to a cassette and 
exposed to film for 3 seconds.
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6.4 RESULTS
6.4.1 Cloning of the canine MMP-9 promoter deletions, NF-kB mutation
and multiple NF-kB sites into the pGL3-Basic luciferase reporter vector
The successful cloning of the four canine MMP-9 deletion constructs: pGL3/eMMP-9(/894), (984), 
(628) and (534) is described in chapter V. The pGL3/eMMP-9(628)(NFKBmutn) construct was 
made using the QuikChange™ site-directed mutagenesis protocol (Stratgene). The conserved NF- 
kB site within the canine MMP-9 promoter sequence was successfully mutated using primers 
shown in Table 6-2. The bacterial clones containing the mutated MMP-9 promoter sequence were 
confirmed by sequence analysis using both forward (RV3) and reverse (GL2) vector based primers. 
Multiple NF-kB sites were added to the 5' end of the canine MMP-9 promoter using PCR 
techniques and primers described in Table 6-3 containing one, three and five NF-kB sites and were 
immediately cloned into pCR2.1®TOPO. All three manipulated MMP-9 promoters were then sub­
cloned into the pGL3-Basic luciferase reporter vector using the kpn 1 (sticky) and EcoRYISma 1 
(blunt) restriction enzyme sites. The bacterial clones containing the manipulated MMP-9 promoters 
were screened using the described PCR techniques for their amplification and were sequenced with 
both forward (RV3) and reverse (GL2) vector based primers.
6.4.1.1 Vector maps
Vector maps for the canine MMP promoter sequences in pGL3-Basic luciferase reporter vector 
(Promega) are shown for pGL3/cMMP-9(1894) (Figure 5-4), pGL3/cMMP-9(984) (Figure 5-5), 
pGL3/cMMP-9(628) (Figure 5-6), pGL3/cMMP-9(534) (Figure 5-7). A vector map for the mutated 
canine MMP promoter construct pGI .3/cMMP-9(628)(NF-K'Bmutn) is shown in Figure 6-6. Vector 
maps for the manipulated canine MMP promoter sequences in pGL3-Basic luciferase reporter 
vector are shown accordingly: pGL3/cMMP-9(5NFKB) (Figure 6-7), pGL3/cMMP-9(3NFKB) 
(Figure 6-8), pGL3/cMMP-9(lNFKB) (Figure 6-9).
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Figure 6-6 Vector map for pGL3/cMMP-9(628)(NF-KBmutn)
Figure 6-7 Vector map for pGL3/cMMP9(1894)(5NF-KB)
Kpn\
SmallEcoVlM
21 1
Figure 6-8 Vector map for pGL3/cMMP-9(1894)(3NF-KB)
Kpn\
StnaMEcoKV
Figure 6-9 Vector map for pGL3/cMMP-9(1894)(lNF-KB)
SffwI/£coRV
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6.4.2 Characterisation of the canine pGL3/cMMP-9 promoter deletions, 
NF-kB mutation and multiple NF-kB sites in human chondrosarcoma
cells (SW1353)
The aim of this first study was to evaluate and compare the basal and induced (IL-13 and TNFa) 
activities of the four largest cloned canine MMP-9 promoter deletion constructs to identify regions 
containing cytokine responsive elements. Cytokine responsive element(s) were then to be mutated 
from the promoter sequence to confirm their involvement in cytokine induction. Multiple copies of 
these element were then to be introduced into the MMP-9 promoter sequence to enhance activity in 
response to cytokines while maintaining low basal activity.
6.4.2.1 Aln<nysCs of endogenous basO. and induccd tt'3ntncoiption of MMP-9 genes in 
SW1353 ceils
To analyse the basal and cytokine induced (IL-lp and TNFa) levels of MMP-9 gene transcription 
in the human chondrosarcoma cell line (SW1353) to be used for the transfections of all of the 
canine MMP-9 promoter constructs relative semi-quantitative RT-PCR was performed. A portion of 
the gene was amplified from cDNA samples prepared from untreated (basal) and treated (IL-lp and 
TNFa) cells using species-specific primer pairs (Table 6-2). Samples removed at three intervals, 25, 
30 and 35 cycles to enable the semi-quantification of MMP-9 gene transcription over the 
exponential phase of the PCR. A portion of the human cyclop^lm gene was also amplified (255 
bp), using species-specific primer pairs, as an internal control. The primers were designed to span 
an intron and control for the presence of contaminating genomic DNA (absence of a 474 bp PCR 
product). Basal transcription of the endogenous MMP-9 gene was evident in the human 
chondrosarcoma cells and could be upregulated by cytokines, IL-lp and TNFa (Figure 6-10). 
Subsequently this cell line was used to analyse all of the cloned MMP-9 promoter constructs.
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 Figure 6-10 Endogenous levels of MMP-9 transcription in SW1353 cells using relative
semi quantitative RT-PCR
A portion (364 bp) of the human MMP-9 gene (upper band) was amplified from cDNA samples 
prepared from total RNA isolated from human chondrosarcoma cells (SW1353). During PCR 
amplification, samples were removed within the exponential phase of the reaction (25 to 35 cycles) 
revealing that basal levels of MMP-9 transcription were significantly up-regulated by the pro­
inflammatory cytokines IL-1P and TNFa.
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 6A.2.2 Analysis of all cloned canine MMP-9 promoter constructs using Dual-
Luciferase®'Reporter assays
All Dual®Luciferase assays were conducted in triplicate for statistical significance and to ensure 
reproducibility, and all transfections were carried out three times. To account for differences in 
transfection efficiency the cells were co-transfected with Renilla luciferase vector (Promega) and 
the firefly luciferase values were adjusted accordingly. Renilla was expressed and shown to be 
active the cell type used. Representative Renilla values for SW1353 cells was 242. The corrected 
luciferase activity of each construct represents the mean +/-SEM (n=3). The canine MMP-9 deletion 
reporter constructs, together with the promoter-less luciferase vector, pGL3-Basic vector as the 
negative control, were transiently transfected into human chondrosarcoma cells (SW1353). Basal 
luciferase activities for each promoter were compared to treated samples (IL-lp and TNFaQ. The 
Mann-Whitney statistical analysis was performed on all assays.
6.4.2.2.1 Analysis of canine pGL3/cMMP-9(]L984), (984), (628). (534) luciferase reporter
constricts
Basal activities of all pGL3/cMMP-9 deletion constructs were evident in the SW1353 cell line. All 
constructs MMP-9(1894), (984), (628) and (534) could be significantly induced by TNFta to 
varying degrees (*P<0.05). Although some induction was also observed with IL-ip the results were 
not significant. The general trend of promoter activity showed that smallest construct (534) had 
significantly less activity than the three largest constructs MMP-9(1894), (984) and (628) at both 
basal and induced (IL-ipand TNFa) levels (*P<0.05) (Figure 6-11).
6.4.2.2.2 Analysis of mutated canine _ pGL3/cMMP-9(628X(NF-KBmutn) luciferase 
re p o rter co ns t uc t
Basal activity of pGL3/cMMP-9(628)(NFKBmutn) construct was evident in the SW1353 cell line 
which could be significantly enhanced by TNFa (*P<0.05), and although induction with IL-ip was 
evident this again was not significant. Basal and induced (TNFa and IL-lp) activity of the mutated 
construct was significantly lower than the MMP-9(628) promoter construct (AP<0,05). Basal and 
induced (TNFa) was also significantly lower than the MMP-9(534) construct ( P<0.05) (Figure 6­
11).
6.4.2.2.3 Analysis of manipulated canine pGLJ)/\MiMP(9(1892)(5NF-'KB), (3NF~KBj 
and (1NF-kB) luciferase re porter constncts
The canine MMP-9 promoter constmcts, manipulated with additional NF~kB sites, were directly
compared with the unmanipulated MMP-9(1894) promoter construct (Figure 6-12), The general
trend of promoter activity showed that the addition of five NF-kB sites increased basal and
cytokine-induced activity the most, followed by the addition of three three NF-kB sites while the
addition of one alone had little effect. More specifically, basal activities of the canine MMP-9 
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promoter constructs cMMP-9(1894). (5NFkB) and (3NFkB) were significantly enhanced by TNFta 
(*P<0.05 Mann Whitney test). In comparison, the MMP-9(1984) and (3NF-kB) were significantly 
enhanced by IL-lp (*P<0.05). The addition of five NF-kB sites significantly enhanced basal and 
induced (TNFa and IL-IP) promoter activity (AJP<0.05) in comparison to the unmanipulated 
cMMP-9(1894) promoter construct. The addition of three NF-kB sites only significantly enhanced 
TNFa induced activity ( P<0.05) compared to the unmanipulated MMP-9(1894) promoter 
construct. The addition of one NF-kB site had no effect on increasing promoter activity at the basal 
or induced levels.
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Figure 6-11 Deletion and mutational analysis of the canine MMP-9 promoter.
Dual-Luciferase “Reporter assays were used to determine the activity of the cloned canine MMP-9 
promoter deletion MMP-90 894). (984). (628). (534) and mutation (MMP-9NF-KBmut") constructs 
in the human chondrosarcoma (SWI353) cells. Basal activities of the canine MMP-9 promoter 
constructs were significantly enhanced by TNFa (*P<().()5 Mann-Whitney test), but not IL-ip. 
Basal and induced (TNFa and IL-IP) activities of the MMP-9(534) construct were significantly 
lower than the other MMP-9 promoter deletion constructs (•P<0.05). Basal and induced (TNFa 
and IF-1 P) activities of the MMP-9(NFKBmut") construct were significantly lower than the other 
MMP-9(638) promoter (AP<0.05). Basal and induced (TNFa) activities of the MMP-9(mut") 
construct were also significantly lower than the other MMP-9(534) promoter ( P<().()5).
□ Basal gjTNF Q IL-1
promoter constructs
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Figure 6-12 Manipulation of the canine MMP-9 promoter fragment with multiple NF­
KB sites
Dual-Luciferaae^Reporter assays were* used to determine the activity of the cloned canine MMP-9 
promoter. MM1P-9(1894) and manipulated MMP-9(5NF-k*B) (3NF-kB) ( 1NF-kB) constructs in the 
human chondrosarcoma (SWI 353) cells. Basal activities of the canine MMP-9 promoter constructs 
MMP-9( 1894). (5NF-kB) and (3NF-kB) were significantly enhanced by TNFtx (*P<0.05 Mann 
Whitney test). In comparison. the MMP-9( 1984) and (3NF-kB) were significantly enhanced by IL- 
IP (•P<0.05>. The addition of five NF-kB sites significantly enhanced basal and induced (TNHx 
and IL-lp) promoter activity (AP<0.05) over the unmanipulated MMP-9(1894) promoter construct. 
The addition of three NF-kB sites only significantly enhanced TNFta induced activity ( P<0.05) 
over the unmanipulated MMP-9( 1894) promoter construct. The addition of one NF-kB site had no 
effect on increasing promoter activity at the basal or induce'd levels.
□ Basal BTNF OIL -1
promoter constructs
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 6.4.3 Cloning of the mouse collagen Type XI promoter, 3.&5SOOX9 promoters, 
intron/SOX9 into the pGL3-Basic luciferase reporter vector
The mouse collagen type XI promoter was successfully amplified by PCR using mouse genomic 
DNA as template and primers described in Table 6-4. The promoter was cloned into 
pCR2.1®TOPO before being sub-cloned into the pGL3-Basic luciferase reporter vector using the 
kpn 1 (sticky) and EcoRWISma 1 (blunt) restriction enzyme sites. The mouse collagen type XI 
promoter was successfully amplified with three and five SOX9 sites into the 5' end of the promoter 
using the pCR2.1/mColXI construct as template and primers described in Table 6-4. The promoter 
was cloned into pCR2.1®TOPO before being sub-cloned into the pGL3-Basic luciferase reporter 
vector using the kpn 1 (sticky) and EcoRYISma 1 (blunt) restriction enzyme sites. The mouse 
collagen type XI intron was successfully amplified with three SOX9 sites flanking the sequence 
using the pCR2.1/mColXIintron construct as template and primers described in Table 6-4. The 
promoter was cloned into pCR2.1®TOPO before being sub-cloned into the pGL3-Basic luciferase 
reporter vector using the Hind III (sticky) restriction enzyme sites. All bacterial clones containing 
the promoter and intronic sequences were screened using the described PCR techniques, for their 
amplification.
6.4.3.1 Vector maps
Vector maps for the mouse collagen type XI promoter +/- S0X9 sites and intron +SOX9 sites in 
pGL3-Basic are shown for pGL3/mColXI (Figure 6-13) pGL3/mColXI(3SOX9) (Figure 6-14) 
pG3/mColXI(5SOX9) (Figure 6-15) and pGL3/mColXI[3SOX9(intron)3SOX9] (Figure 6-16).
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Figure 6-13 Vector map for pGL3/mCoXI
Kpn 1
Smal/EcoRV
Figure 6-14 Vector map for pGL3/mCoXI(3SOX9)
Kpn\ Xhol
Smal/EcoRV
Xhol
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Figure 6-15 Vector map for pGL3/mCoKI(5SOX9)
Kpn\ XZjoI
Smal/EcoRV
Xho\
Figure 6-16 Vector map for pGL3/mCoXII[3SOX9(intron)3SOX9]
SmaUEcoRV
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6.4.4 Characterisation of mouse collagen type XI promoter and intronic 
constructs manipulated with SOX9 sites in SW1353 and ATDC5 cells
6.4.4.1 Arntysio of endogenous transcription of collagen type XI genes in SW1353 ceils 
and ATDC5 eslic
To analyse endogenous activity of collagen type XI transcription in the SWI 353 and ATDC5 cell 
lines to be used for the transfection of the mouse collagen type XI promoter fragment, relative semi­
quantitative RT-PCR was once again performed. A portion of each gene was amplified from cDNA 
samples prepared from untreated (basal) and treated (IL-lp and TNFa) cells using species-specific 
primer pairs (Table 6-3). Samples were removed at three intervals, 3 cycles apart, to enable the 
semi-quantification of collagen type XI gene transcription over the exponential phase of the PCR. A 
portion of the cyclophilin gene was also amplified (255 bp) using species specific primers as an 
internal control. The primers were designed to span an intron and control for the presence of 
contaminating gDNA (absence of a 474 bp PCR product). Basal levels of endogenous transcription 
were present in both the SW1353 cells (Figure 6-17) and the ATDC5 cells (Figure 6-18) neither of 
which could be up-regulated by IL-1 and TNF. These cell lines could therefore be used to analyse 
the mouse collagen type XI promoter fragments.
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Figure 6-17 Endogenous levels of collagen type XI (mColXl) transcription in SW1353
cells using relative semi-quantitative RT-PCR.
A portion (395 bp) of the human collagen type XI gene (upper band) was amplified from cDNA 
samples prepared from total RNA isolated from human chondrosarcoma cells (SWI353). During 
PCR amplification, samples were removed within the exponential phase of the reaction (30 to 40 
cycles) revealing that basal levels of collagen type XI transcription were present which were not up­
regulated by the pro-infiammatory cytokines IL-1 (5 and TNFa.
■ Basal IL-I TNF
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Figure 6-18 Endogenous levels of collagen type XI (Col XI) transcription in ATDC5
cells using relative semi-quantitative RT-PCR.
A portion (395 bp) of the mouse collagen type XI gene (upper band) was amplified from cDNA 
samples prepared from total RNA isolated from undifferentiated chondrosarcoma cells (ATDC5). 
During PCR amplification samples were removed within the exponential phase of the reaction (25­
35 cycles) revealing that basal levels of collagen type XI transcription were present which were not 
up-regulated by the pro-inflammatory cytokines IL-1 p and TNFa.
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6.4.4.2 Analysis of moscn collagen type XI promoter and intronic isqssnenc 
manipulated with SOX9 citsc ucing Dsal-Lscoferace Reporter Accayc
Dual-Luciferase®Reporter Assays were conducted in triplicate as described for the various MMP-9 
promoter constructs using the Ren'illa luciferase vector as the internal control. Rssilln was 
expressed and shown to be active in cell types used. Representative Ren'illa values for the SWI 353 
and ATDC5 cells were 322 and 225 respectively. The different mouse collagen type XI promoter 
+/- intron luciferase reporter constructs were transiently transfected into human chondrosarcoma 
cells (SW1353) and undifferentiated chondrosarcoma cells (ATDC5). Basal luciferase activities of 
these constructs were directly compared along with a promoter-less luciferase vector (pGL3-Basic) 
as a negative control. The Mann-Whitney statistical test was used to analyse the results.
6.4.4.2.1 Mouse collagen type XI promoter +/- (3SOX9i and (5SQX9I in pGL3 
luciferase reporter vector
Activities of the cloned mouse collagen type XI promoter and manipulated (3SOX9) and (5SOX9) 
promoter constructs were significantly higher than the negative control in both the SWI 353 
(*P<0.05) and ATDC5 (»P<0.05) cell lines. However, the activities of the mouse collagen type XI 
promoter and the two manipulated promoter constmcts mColXI(3SOX9) and (5SOX9) were 
significantly higher in the SW1353 cells than the ATDC5 cells (AP<0.05). Nevertheless, the 
addition of these SOX9 sites did not enhance activity in either cell line (Figure 6-19).
6.4.4.2.2 Mouse collagen type XI promoter and QSOXPrintronQSQXV) in pGL3 
luciferase reporter vector
Activities of cloned mouse collagen type XI promoter with and without the additional intronic 
sequence flanked by three SOX9 sites were significantly higher than the negative control in both 
the SW1353 (*P<0.05) and ATDC5 (^P<0.05) cells. Activity of the promoter -h>/- the intronic 
sequence was also significantly higher in the SWI353 cells than the ATDC5 cells (AP<0.05). 
Furthermore, the addition of the intronic sequence containing flanking SOX9 sites significantly 
enhanced promoter activity in the SWI353 cells line ( P<0.05) (Figure 6-20).
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Figure 6-19 Analysis of the mouse collagen type XI promoter +/- 3 and 5 SOX9 sites.
Dual-Luciferase“'Reporter Assays were used to determine the activity of the cloned mouse collagen 
type XI promoter with additional three and five SOX9 sites in the human chondrosarcoma cells 
(SW1353) and undifferentiated chondroprogenitor cells (ATDC5). Activities of cloned mouse 
collagen type X1 promoter and manipulated promoters (3SOX9: 5SOX9) were significantly higher 
than the negative control in both the SW1 353 (*P<0.05) and AT DC 5 (•P<0.05) cells (P<0.05 using 
the Mann-Whitney test). Activity of the three promoter constructs was also significantly higher in 
the SW1353 cells than the ATDC5 cells (AP<0.()5): however the addition of the three and five 
SOX9 sites did not significantly enhance activity in either cell line.
□ SW1353 BATDC5
mouse collagen type XI promoter constructs
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Figure 6-20 Analysis of the mouse collagen type XI promoter with intronic SOX9 sites.
Dual-Luciferase “Reporter Assays were used to determine the activity of the cloned mouse collagen 
type XI promoter with and without the additional intronic sequence containing three flanking 
SOX9 sites in the human chondrosarcoma cells (SWI353) and undifferentiated chondroprogenitor 
cells (ATDC5), Activities of cloned mouse collagen type XI promoter with and without the 
additional intronic sequence were significantly higher than the negative control in both the 
SW1 353 (*P<0.05 using the Mann-Whitney test) and AT DC 5 (•F«O.()5) cells. Activity of these 
two constructs was also significantly higher in the SWI353 cells than the ATDC5 cells (AP<0.()5). 
Furthermore, the addition of the intronic sequence containing flanking SOX9 sites significantly 
enhanced promoter activity in the SWI353 cells line ( P<0.()5).
□ SW 1353 cells BATDC5 cells
construct
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6.4.5 Cloning of the dual targeting vector
Unfortunately, the construction of the dual targeting vector was not possible due to technical 
problems. The first three vectors A, B and C were all successfully constructed, confirmed by 
sequence analysis using a combination of vector-based and internal sequence-based primers (Table 
6-2,3,4). Vector A was a high copy number plasmid, but after the insertion of the second and 
subsequent DNA fragments Vectors B and C were converted to low copy number plasmids.
Problems arose during the construction of Vector D. Both Vector C and the final 400 bp insert 
were successfully digested with Hind III, visible on agarose gel analysis. On transformation into 
TOP 10 bacterial cells, several hundred colonies were produced, twenty of which were selected and 
grown overnight at 37°C. The DNA was isolated and the quantity determined by UV 
spectrophotometry which revealed that a percentage of these clones had reverted to a high copy 
number plasmid. Low copy number plasmids were selected and screened for insert with Hind III, 
irrespective of orientation. Positive clones were sent for sequencing and were all found to contain 
the final insert in inverse orientation. It was thought that the presence of Cre protein, in the bacterial 
cells used for the transformation step, could be responsible for the recombination of Vector D on 
insertion of the final insert containing the second /oxH site in the correct orientation.
Vector maps for the four intermediate plasmids produced in the constmction of the dual 
targeting vector can be found accordingly: Vector A: pGL3/mColXI/a;rH (Figure 6-21), Vector B: 
pGL3/mColXI/oxH-Cre (Figure 6-22), Vector C: pGL3/mColXI/c4:H-Cre-cMMP-9(3NFKB) 
(Figure 6-23), Vector D: pGL3/mColXI/cvHI-Cre~cMMP-9(3NFKB) (Figure 6-24)
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Figure 6-21: Vector map for Vector A construct: pGL3/mColXIIoxH
HglW
Kpn\ Nsil
Xbal
Figure 6-22: Vector map for Vector B construct: pGL3/mCoKI/AfH-Cre
Bglll
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Figure 6-23 Vector map for Vector C construct: pGL3/mColXI/oxH-Cre-cMMP- 
9(3NFkB)
Figure 6-24 Vector map for Vector D: pGL3/mCoKI/oxH-Cre-cMMP-9(3NFKB)- 
[3SOX9(intron)3SOX9]
Hindill HindiU
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6.4.6 Western blot analysis of Cre recombination during construction
It was thought that the presence of Cre protein in the bacterial cells used for the transformation step 
could be responsible for the recombination of Vector D on correct insertion of the final insert 
containing the second loxH site. A Western blot was subsequently performed to investigate both 
endogenous or plasmid mediated (under the control of the mouse collagen type XI promoter) Cre 
gene expression. Three samples were analysed for Cre protein, TOP1O bacterial cells alone, TOP 10 
bacterial cells transfected with the promoterless pGL3-Basic vector and TOPIO bacterial cells 
transfected with Vector C. All three samples, analysed for Cre gene expression, showed a 38 kDa 
band corresponding to the predicted size of the Cre protein (Figure 6-25).
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 Figure 6-25 Western blot analysis of the Cre gene expression in the TOPIO bacterial
cells
Western blot analysis of 1) TOPIO E.Coli bacterial cells. 2) pGL3-Basic in TOPIO cells and 3) 
Vector 3 in TOPIO bacterial cells. A band of 38 kDa corresponding to the Cre protein was found in 
all three lanes suggesting that the Cre gene is expressed endogenously in the TOPIO bacterial cells
Molecular
weight
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6.5 DISCUSSION
6.5.1 Can the canine MMP-9 promoter be manipulated to enhance activity
while maintaining dise as e-specificity?
6.5.1.1 Analysis of endogenous basal and induced transcription of MMP-9 genes in
SW1353 cells
Basal and cytokine stimulated endogenous levels of MMP-9 transcription were examined in the 
human chondrosarcoma cell line (SW1353) using relative semi-quantitative RT-PCR to investigate 
the potential for analysing the numerous canine MMP-9 promoter/luciferase constructs in this cell 
line. The SW1353 cell line was selected since it serves as an appropriate model for primary 
chondrocytes in OA (Vincenti and Brinckerhoff et ah, 2001). The levels of MMP-9 transcription 
were upregulated by inflammatory cytokines IL-13 and TNFa (Figure 6-10) which complements 
previous studies showing MMP-9 up-regulated by IL-ip, PMA (Cowell et ah, 1998) and TNFa 
(Hattori et al., 2001) in human chondrosarcoma cell lines.
6.5.1.2 Analysis of all cloned canine MMP-9 promoter constructs using luciferase
reporters
The MMP-9 promoter deletion constructs were transiently transfected into the SW1353 cells in an 
attempt to identify promoter elements involved in both basal and pro-inflammatory (IL-lp and 
TNFa) induced gene transcription. All of the MMP-9 promoter deletion constructs cMMP-9(1894). 
(984), (628), (534) were shown to have basal activity that could be significantly enhanced by the 
addition of TNFa, and some induction was observed with IL-lp (Figure 6-11). This suggested that 
the distal AP-1 sites (-73 to -67; -111 to 105), and other promoter elements adjacent to the TATA 
box, were sufficient for upregulating gene expression in response to both cytokines. This result 
complemented findings described in chapter V, where it was demonstrated that basal activity of 
these canine MMP-9 deletion constructs could be significantly enhanced by PMA. However, the 
actual levels of promoter activity were much greater in the three largest constructs pGL3/cMMP- 
9(1984), (984) (628) in comparison to the smallest vector pGL3/cMMP-9(534), suggesting that 
additional cytokine-responsive elements, located up-stream of position 534 bp, may co-operate with 
the distal promoter elements. This may be explained by the presence of a conserved NF-kB DNA 
binding domain (-554 to -545) that is able to cross-couple with the AP-1 site acting synergistically 
to increase promoter activity in response to pro-inflammatory cytokines (Adcock, 1997). To 
investigate this further the NF-kB binding site was mutated from the pGL3/cMMP-9(628) 
construct.
The MMP-9 promoter construct containing the mutated NF-kB site (cMMP-9/NF-KBmut") was 
also transfected into SW1353 cells and shown to have similar levels of activity to the pGL3/cMMP- 
9(534) reporter construct (Figure 6-11). Again basal levels of activity could be significantly
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enhanced by TNFcx with some increase in response to IL-ip suggesting that the NFkB was not 
essential for cytokine induction and that other elements were also important. However, actual levels 
of promoter activity were greatly reduced suggesting that the NF-kB site was probably important 
for co-operating with the AP-1 and other sites for both TNF and IL-ip induction. These results are 
similar to other studies showing the importance of the NF-kB site in the mouse MMP-9 promoter 
(He, 1996), and that the human and rabbit MMP-9 promoters both requiring the synergistic action 
of NF-kB and AP-1 sites for cytokine induction with TNF and IL-1 and growth factors (Bond et ah, 
1998). Furthermore, site-directed mutagenesis of the N-FkB site has been shown to decrease the 
TNFcx induced activity of the human E-Selectin promoter (Schindler and Baichwal, 1994) and IL-1- 
induced activity of the human MCP-1 (Martin et ah, 1997) and COX-2 (Allport et ah, 2000) 
promoters.
Further to suggestions that multiple NF-kB sites within the inducible nitric oxide synthase gene 
may co-operate to confer inducibility to both IL-lp and TNFta (Taylor et ah, 1998), it was decided 
to incorporate multiple (5, 3 and 1) NF-kB sites into the 5' end of the promoter to enhance the 
response to cytokines. Activities of the manipulated MMP-9 promoter constructs, pGL3/cMMP- 
9(5NF-kB), (3NF-kB) and (INF-kB), were analysed using the SW1353 cells (Figure 6-12). The 
addition of five NF-kB sites significantly increased both basal and cytokine (IL-lp and TNFa) 
induced promoter activity suggesting that disease-specificty had been lost. The addition of one NF- 
kB site did not increase promoter activity at the basal or induced levels, in fact promoter activity 
appeared to have decreased, the reasons for this are not apparent and further studies need to be 
performed. The addition of three NF-kB sites appeared to be optimal with a significant increase in 
promoter activity in response to TNFcx and IL-ip while basal levels remained unaffected, indicating 
that disease specificity had been maintained. The differences observed in promoter activity 
observed after the addition of five, three and one NF-kB sites into the 5' end of the MMP-9 
promoter is difficult to explain. One would think that the effect of adding NF-kB sites into a 
promoter sequence would be similar irrespective of number, but there are obviously complex 
transcriptional changes occurring that are closely associated with the number of these additional 
sites. It may be explained by the presence of the AP-1 site (-1888 to —1877) located 6 bp 
downstream of the 5' end of the MMP-9 promoter. The binding of the NF-kB transcription factor to 
one extra NF-kB site may interfere with the binding of transcription factors to this proximal AP-1 
site required for promoter activity. However, the addition of three and five extra NFkB sites may 
enable the NFkB transcription factor to bind further up-stream without interfering with the AP-1 
binding. In addition to this, there may be conformational changes in the DNA that are dependent on 
the number and type of motifs present within the sequence which not only alters the efficiency of 
the transcription factor binding but may also directly influence other sites present in the adjacent 
sequence. This may enhance transcription in the case of five and three additional sites or repress 
activity in the presence of just one site. Finally, there is an obvious discrepancy in the IL-1 response 
between experiments: this may be explained by the slight variations between batches of IL-1 (3
233
  
 
bought from the manufacturer and the stability of the recombinant protein after a number of freeze 
thaw cycles.
6.5.2 Can the mouse collagen type XI promoter be manipulated to 
enhance activity while maintaining cell-type specificity?
6.5.2.1 Analysis of endogenous transcription of collagen type XI genes In SW1353 cells
and ATDC5 cells
Endogenous levels of collagen type XI gene transcription in the two cell lines. SW1353 and 
ATDC5, were analysed using relative semi-quantitative RT-PCR. These cell lines were chosen 
since chondrosarcoma cells had previously been shown to the express the collagen type XI gene 
whilst the undifferentiated ATDC5 cells have not (Liu et al., 2000).
Basal levels of endogenous transcription were evident in the differentiated SW1353 cells (Figure 
6-17) as expected. However, the level of basal transcription could not be enhanced by the addition 
of TNFa or IL-1 (3. In contrast, studies have shown that TNFca can up-regulate collagen gene 
expression such as the collagen type II in chondrosarcoma cells (Hattori et al., 2001), while other 
groups have reported a TNF-induced decrease in the synthesis of the components of the ECM 
(Enomoto et ah, 1990). More importantly, it was clear that the undifferentiated cells (ATDC5) were 
also capable of collagen type XI transcription, contradicting reports that collagen type XI was not 
expressed in this cell line (Liu et ah, 2000). Since these authors had not analysed the endogenous 
expression of the gene in the ATDC5 cells but had shown insignificant levels of collagen XI 
promoter gene expression from a transfected construct it was decided to continue with this cell line 
using the cloned collagen type XI promoter constructs. It was hoped that there would be a large 
enough difference in the degree of gene expression between the SW1353 and ATDC5 cell lines to 
enable the cell type specific analysis of the mouse collagen type XI promoter fragments.
6.5.2.2 Analysis of all cloned mouse collagen type XI promoter fragments using
luciferase reporters in SW1353 cells and ATDC5 cells
The mouse collagen type XI promoter construct was transiently transfected into the SW1353 and 
ATDC5 cells in an attempt to show cell-type specificity. Basal levels of promoter activity were 
normalised with the negative control for each cell line and then directly compared (Figure 6-19). 
Activity of the collagen type XI promoter construct was evident in both SW1353 and ATDC5 cell 
types, which is in concordance with the endogenous data, however the promoter had significantly 
more activity in the human SW1353 cells. This suggested that the collagen type XI promoter 
contained cell-type specific binding elements within its sequence enabling higher levels of promoter 
activity in the differentiated chondrocytes. These results are in agreement with a series of 
transfection studies demonstrating that the collagen type XI promoter had comparable activity in 
similar cell lines (Liu et al., 2000). However, DNA sequences containing minimal promoter
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elements may serve as a promoter if placed upstream of a gene containing all the necessary 
elements required for transcription. In gDNA, cell type specificity is not only determined by the 
primary structure of a gene, such as the promoter and enhancer sequences, but also by the secondary 
and tertiary structural elements in the region of that gene. The 3-dimensional folded arrangement of 
the DNA in combination with the presence of histone acetylation and DNA methylation (Ng and 
Bird, 1999) maintains cell-type specificity of a promoter by regulating the binding of transcription 
factors and thus to the recruitment of RNA polymerase to the transcription initiation site. As such it 
is very difficult to attain a high level of cell type specific regulation when evaluating the level of 
gene transcription from a promoter positioned in a plasmid vector which contains minimal 
secondary and tertiary structure. In this situation, the promoter under analysis is easily accessible to 
the transcriptional machinery of the cell and therefore will not necessarily reflect the action of the 
promoter in vivo.
The size of the promoter fragment under analysis is also important for cell type specificity. In this 
study a relatively small portion of the mouse collagen type XI promoter (1.2 kb) was analysed. 
Although studies have shown this region to contain cartilage specific elements (Tsumaki et al., 
1998), such elements are often located hundreds of kilo bases upstream of the transcription start 
site. For example an up-stream repressor site in the mouse MMP-9 promoter has been identified and 
shown to regulate basal levels of promoter activity in a tissue specific manner (Roach et al., 1998). 
However, until vector technology advances for example with the development of mammalian 
artificial chromosomes which can deliver the entire genomic fragment containing the promoter and 
other elements, it is necessary to try and design the best cell-type targeting vector possible within 
the constraints of available DNA plasmid vectors. To this end, the collagen type XI promoter 
sequence was manipulated with chondrocyte specific enhancers (SOX9 sites), in an attempt to 
incorporate enhanced promoter activity and maintain cell type specificity.
The first attempt to modify the collagen type XI promoter involved the introduction of three and 
five SOX9 sites into the 5f end of the promoter sequence as described for the manipulation of the 
canine MMP-9 promoter with NF-kB sites. The two constructs pGL3/mColXI(3SOX9) and 
(5SOX9) were transiently transfected into the SW1353 and ATDC5 cell lines as described before 
and compared to the unmanipulated pGL3/mCOLXI construct (Figure 6-19). Although activities of 
the two manipulated promoter constructs were again significantly higher in the SW1353 cells 
compared to the ATDC5 cells the addition of SOX9 sites did not enhance activity in either cell line 
(Figure 6-19). This contradicted evidence that SOX9 proteins bind to the collagen type XI gene to 
up-regulate promoter activity in chondrocytes (Lefebvre et ah, 1997). However, further studies to 
investigate the role of SOX9 in cartilage specific expression identified enhancer sites in the first 
intron of the collagen type XI gene (Liu et al., 2000). This suggested that $0X9 sites downstream 
of the transcription start site were important for enhancing chondrocyte specific expression of the 
gene. As a result it was decided to clone a 300 bp region of the mouse collagen type XI intron 1, 
containing two S0X9 sites within its sequence, and flanking it with a further six S0X9 sites. The 
manipulated intron was then cloned down-stream of the luciferase reporter gene into the
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pGL3/mC0LXI vector luciferase reporter construct. The modified vector, 
pGL3/mColXI[3SOX9(intron)3SOX9], was transiently transfected into the SW1353 and ATDC5 
cell lines and compared to the unmanipulated mColXI construct (Figure 6-20). Activity of the 
modified construct was again significantly higher in the SW1353 cells compared to the ATDC5 
cells. However, this time the incorporation of the intronic sequence, containing flanking SOX9 
sites, into the promoter sequence significantly enhanced the mouse collagen type XI promoter 
activity in the SW1353 cell line while maintaining low levels in the ATDC5 cells. This is in 
agreement with studies showing that SOX9 expression is considerably higher in chondrosarcoma 
cells than undifferentiated ATDC5 cells (Morishita et ah, 2001).
6.5.3 Can a dual-targeting vector system be developed to restrict 
therapeutic gene expression to diseased cell types of the canine
os te o arthritic joint?
Once the disease and cell-type specific transcriptional control systems had been evaluated 
separately, attempts were made to incorporate both components into one system using Cre-lox 
technology for the development of a dual-targeting vector.
6.5.3.1 Construction of thee dual targeting vector
Technical problems were associated with the constmction of the final vector (Vector D). The clones 
selected from the final ligation step contained a mixture of high and low copy number plasmids. 
The low copy number plasmids were screened with Hind III for the presence of the insert and then 
sequenced: however all constructs contained the final insert in reverse orientation. This suggested 
that on correct orientation of the insert, the DNA sequence would encode a toxic gene. This was not 
likely since the final insert containing the intronic sequence flanked by SOX9 enhancer sites had 
already been successfully cloned into the pGL3/mColXI construct. It was therefore suggested that 
on ligation of the insert into the vector, in the correct orientation, the presence of Cre recombinase 
protein within the bacterial cells used for the transformation step, may be responsible for 
recombining Vector D. This would result in the removal of the collagen promoter and Cre gene 
from the vector with the joining of the two /oxH sites (leaving one site behind) to produce the high 
copy number plasmid corresponding to the unique vector pGL3MMP-9(3NF-KB)/oxH. A selection 
of the high copy number plasmids was therefore sequenced from both the 5' and 3' ends of the 
region using vector primers (RV3 and GL2). The forward primer (RV3) confirmed that the new 
construct contained the manipulated MMP-9(3NF-kB) promoter fragment. However, the reverse 
primer (GL2) would not generate any sequence data suggesting that unpredictable recombination 
events may have occurred between constructs and possibly with the gDNA. After several attempts 
at sequencing this region it was decided to simply confirm the presence of Cre protein in the cells 
used for transformation, using Western blot analysis. However, it was not known whether the
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 endogenous expression of Cre protein or expression from the vector under construction was 
responsible for the recombination event.
6.5.3.2 Wesstm blot anafyssi of Cre recombination during construction
Western blot analysis for Cre gene expression was subsequently investigated in TOPIO bacterial 
cells alone and cells transfected with Vector C and pGL3-Basic. A band corresponding to a protein 
of 38 kDa was observed in all samples suggesting the endogenous expression of the Cre gene in the 
TOPIO cells was responsible for the problems associated with the cloning procedure. A web-based 
search led to the discovery of a cell line (*PIR1, Invitrogen) with gDNA containing a mutation in 
the sequence encoding the Cre gene, for use in the Echo™ Cloning System (Invitrogen). The 
genotype of the cells used for this procedure has the cysteine at position 510 in the Cre gene 
mutated to prevent the formation of functional Cre enzyme. However, this Western blot can not rule 
out expression of the Cre gene from the plasmid vector which may also occur.
6.5,4Futon dirretion for the duu! targeting vecMr
To enable the construction of the dual targeting vector new technology needs to be developed. If 
endogenous Cre gene expression is responsible for the recombination event then the use of the Cre 
knockout (PIR') cells will enable the final constmction of the vector. However, if the Cre gene is 
also expressed from the plasmid, complex cloning techniques will be required. One method would 
be to develop a cell-free cloning system. To date, there is no efficient method for amplifying DNA 
without the use of bacterial cells although a combination of the Site Directed Mutagenesis kit 
(Stratgene) and the Amplitaq (Amersham) offers a potentially unique method. Two complementary 
primers (with 5' phosphate modification) can be designed, based on the overlapping sequence 
between the insert and vector to eliminate all incorrectly orientated inserts. PCR can then be 
performed using a high fidelity Pfx polymerase and the ligation sample as a template to selectively 
amplify correct vectors. The linearised DNA can then be ligated to form circular vectors to be used 
as template in the Amplitaq rolling circle protocol. Since this results in linearised concatamers of 
the vector sequence the DNA must then be digested using a single cutting restriction enzyme, 
ensuring that the recognition sequence is located in an unimportant region of the vector. The vector 
must then be dephosphorylated (to prevent the concatameric DNA reforming) and finally ligated 
with small filler fragments also digested with the same restriction enzyme. Although this technique 
may be theoretically possible, it was attempted and found to be technically impossible.
An easier alternative may be to re-design the vector incorporating regions of DNA that prevent 
Cre expression from the vector in bacterial cells without hindering expression in mammalian cells. 
One way in which this can be done is to clone the binding region for Lacl protein (seven base pairs) 
into the immediate 5" region of the Cre recombinase gene sequence. On transformation into 
bacterial cells, which specifically express high levels of the Lacl protein from a plasmid vector, the
PIR1;F Alacl69 rpoS(Am) robAl creC510 hsdR514 endA recAl uidA (AMlu I)::pir-116
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Lacl protein will bind to its recognition site and prevent the recruited RNA polymerase from 
reaching the 5' end of the Cre gene thus blocking transcription. However, this system must 100% 
efficient at blocking Cre transcription since the expression of a single molecule of Cre the enzyme 
will prevent cloning.
Even if the problems associated with the cloning of the dual targeting vector are solved there are 
still several concerns with the ultimate application of such a vector system in vivo. Cre recombinase 
is a bacterial protein and although on expression in mammalian cells it will be directed to the 
nucleus small protein fragments will be expressed in the major histocompatibility complex (MHC) 
of the cell. As such the expression of this protein will be immunogenic and therefore abrogate all 
potentially therapeutic properties of the delivered therapeutic gene. However, this problem may 
ultimately be circumvented with the identification and application of mammalian species-specific 
recombination systems. For example mature B lymphocytes are able to specifically alter their Ig 
isotype expression in response to extra-cellular stimuli through a regulated recombination process 
called isotype switch recombination. An endonuclease, EndoSR (32 kDa) has been shown to 
preferentially cleave at highly repetitive, G-rich switch regions containing variable numbers of 
pentameric motifs TGGGN and TGAGC located directly upstream of the immunoglobulin heavy- 
chain constant region genes (Lyon et ah, 1996; Lyon and Aguilera, 1997). However, further 
research is necessary to characterise these mammalian enzymes before they can be applied to such a 
targeting system.
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6.6 SUMMARY
This chapter describes the modification of the canine MMP-9 promoter with multiple NF-kB sites 
to enhance activity while maintaining disease specificity. This was guided by a series of promoter 
deletion constructs, pGL3/MMP-9(984). (628), (534), and mutagenesis using human
chondrosarcoma cells (SW1353), A second level of cell type specific targeting was investigated 
using the mouse collagen type XI promoter to restrict gene expression to chondrocytes. Activity of 
this promoter was enhanced while maintaining cell type specificity by the incorporation of intronic 
sequence containing flanking S0X9 enhancer sites. Finally, attempts were made to incorporate the 
two promoter systems into one vector utilising Cyq-Iox technology. Both disease and cell type 
specific promoters can be utilised individually to target therapeutic gene expression to diseased cell 
types of the joint. However, incorporating the two promoter systems into one vector is not possible 
at present but may be a possibility in the future with advances in molecular biology.
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Chapter VII
Delivery of genes to synovial cells using
particle-mediated bombardment transfection techniques
7.1 ABSTRACT
The introduction of DNA into target cells both in vitro and in vivo is a challenge in the 
development of efficient gene-based therapeutics. Therefore many chemical, biological and 
physical transfection techniques methods have been developed. Although these delivery systems 
are routinely used for the study of gene regulation and function, problems associated with cell type 
specificity, transfection efficiency and safety have encouraged the development of new transfer 
technologies. A relatively new physical approach for mammalian gene transfer is particle mediated 
bombardment using a gene gun where microscopic particles, coated with the gene of interest, are 
accelerated into cells by a motive force such as helium pressure discharge. This chapter evaluates 
the use of the gene gun (BioRad) for the in vitro delivery of DNA to cells in tissue culture. Two 
reporter genes, (-Galactosidase ((^^Gal) and Enhanced Green Fluorescent Protein (EGFP), were 
delivered to Mxdin-Darby canine kidney (MDCK) cells and rabbit synovial fibroblasts (HIG-82) 
respectively using gold particle (1.0 pm) bombardment to evaluate transfection efficiency at 
different helium pressures (100 and 150 psi). Transfection of both cell types was evident at these 
pressures despite some cell death. This chapter also describes the in vitro delivery of gold particles 
into synovial tissue samples tissues taken from a freshly euthanatised dog at post-mortem
examination (PME) to evaluate the penetration depth of gold particles (1.0 pm) at helium pressures 
of 250 and 500 psi. Darkfield microscopy, used to evaluate histopathologic synovial specimens, 
demonstrated that particle-mediated bombardment could potentially be used to transfect the lining 
cells of the synovial membrane.
240
7.2 INTRODUCTION
7.2.1 Gene delivery systems
Different methods of gene delivery are currently being used to transfer and express therapeutic 
DNA in many types of mammalian cells. These include agents that deliver DNA by chemical means 
and include calcium phosphate (Wigler et ah, 1977), DEAE dextran (Ishikawa and Homey, 1992). 
polylysine conjugates (Wu and Wu, 1987; Wagner et ah, 1990), polybrene-dimethyl sulfoxide 
(Kawai and Nishizawa, 1984) and liposmes (Strauss et ah, 1996). Another method uses biological 
agents such as viral vectors to deliver DNA (Robbins and Ghivizzani, 1998) and finally there are 
agents that deliver DNA by physical means including microinjection (Capecchi, 1980), 
electroporation (Lurquin et ah, 1997) and particle bombardment (Yang et ah, 1990).
7.2.1.1 Liposome-mediated gene delivery
The liposome-mediated gene delivery system has been of particular use in the efficient transfer of 
genes in vitro, and depending on the cell type, can result in higher transfection rates than calcium 
phosphate or DAEA-dextran (Feigner et ah, 1987). Cationic liposomes form complexes with 
negatively charged molecules. Since DNA is highly negatively charged it can be held within the 
positively charged liposomes, to make a compact and stable complex, small enough for cellular 
entry (Kabanov and Kabanov 1995; Labat-Moleur et ah, 1996). The liposome-DNA complex has 
been used for both transient and stable transfections of various cell lines. These include T 
lymphoblastoid and macrophage cell lines in suspension culture (Dorman and Yong, 1989), 
primary cultures of rat pituitary cells (Maurer, 1989), pancreatic islet cells (Welsh et ah, 1990;) 
fibroblasts and hepatocytes (Legendre and Szoka, 1992). Liposomes have also been used to deliver 
RNA (Malone et ah, 1989) and proteins to cells (Debs et ah, 1990). However, the significant 
toxicities observed in various cells has limited its use as a general carrier for DNA in vivo (Feigner 
et ah, 1987).
7.2.1.2 Viral vector mediated gene delivery
Viral vectors, which often give a high level of transduction have received a considerable amount of 
interest for gene-based therapeutics. Details of this biological delivery system are described in 
chapter 1.
7.2.1.2 Particle bombardment mediated gene delivery
Particle bombardment has many technical advantages over standard gene transfer methods 
including the delivery of a high concentration of large DNA molecules such as cosmids or MACs to 
individual cells (Yang, 1992). Also, since DNA-coated micro-projectiles can penetrate multiple cell 
layers of a target tissue, particle bombardment may enhance the simultaneous use of other gene 
transfer methods. The creation of millions of microscopic paths through the tissue will enhance the 
deeper penetration of a transducing virus or lipofectin methods used concurrently (Yang et ah,
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 1994). In addition, since the gene gun uses inert gold particles to physically carry the DNA into the
cell, the culture is not contaminated with bioactive substances such as calcium phosphate (CaPO4),
lipids or resins. Furthermore, particle mediated gene transfer is essentially instantaneous.
Particle bombardment (Biolistlc transfection) is a physical method of cell transformation in 
which high density, sub-cellular-sized particles are accelerated to high velocity to carry DNA into 
cells. This gene delivery system does not depend on specific ligand receptors and/or biochemical 
features of the structural components present on the surface of cells and can be applied in a variety 
of biological systems for both in vitro and in vivo transfection of recombinant genes. Biolistic 
transfection methods were originally developed to introduce genetic material into plants, whose 
walls presented a physical barrier to conventional techniques (Klein et ah, 1987). However, they 
have since been used to transfect bacteria (Smith et ah, 1992), yeast (Johnston et ah, 1988), fungi 
(Armaleo et al 1990) and are now available for many mammalian experimental systems.
7.2.1.2.1 In vitro and ex i eo feme transfer
Particle bombardment is suited for the introduction of recombinant genes into many cell types, but 
is particularly useful for those that are difficult to transfect by conventional means. Particle 
bombardment has been successfully used to transfect primary cultures of macrophages (Burkholder 
et ah, 1993), dorsal root ganglion cells (Usachev et ah, 2000) and foetal rat brain cells (Jiao et al 
1993). Particle bombardment has also been successfully used to transfect organotypic tissue 
explants such as the cerebellum (Arnold et ah, 1997), hippocampus and hypothalamus (Thomas et 
ah, 1998), mammary ductal organoids (Yang et ah, 1990), liver and kidney tissues (Zelenin et ah, 
1991). However, there is limited information concerning the use of the gene gun for in vitro
delivery to the tissue types, specific for the joint.
7.2.1.2.2 In r/iYand in siiugenc transfer
Particle bombardment has also been used successfully for in situ and in vivo gene transfer in a 
variety of mammalian species (Williams et ah, 1991). In vertebrates, the accessible epidermal cells 
of the skin are the most obvious targets for particle bombardment with in vivo experimental 
systems targeting this tissue type for vaccination studies (Tang et ah, 1992; Fynan et ah, 1993; 
Eisenbraun et ah, 1993). In addition to skin, muscle and internal organs such as the liver, pancreas, 
spleen, kidney and central nervous system (CNS) have also be targeted in vivo after appropriate 
surgical exposure (Yang et ah, 1990, Williams et ah, 1991; Cheng et ah, 1993; Zhang and Selzer, 
2001). Particle bombardment has also been used to transfer genes encoding IL-6, TNFa, IFNy, IL- 
2 and lL-12 into neoplastic tissues for the regression of tumours in mice (Sun et ah, 1995; 
Rakhmilevich et ah, 1996). Reporter genes, (^--^[dlK^l^tositdase and luciferase, and granulocyte 
macrophage-colony stimulating factor have also been successfully delivered to the oral mucosa and 
epidermis of dogs (Keller et ah, 1996). However, there is limited literature reporting the use of the 
gene gun for in vivo delivery to tissue types of the joint.
242
7.2.1.2.3 Mechanical and functional parameters of particle bombardment
In all systems of particle bombardment microscopic particles are coated with the gene of interest 
and accelerated by a motive force to penetrate cells and deliver the DNA coated particles (Sanford, 
1988). The motive force can be generated by a high-voltage electrical discharge (McCabe et ah. 
1988) or helium pressure discharge (Williams et ah, 1991). In either of these systems the 
parameters for efficient gene delivery can be modified to enhance expression in specific tissues or 
cell types (Yang et ah, 1994). The first important parameter is the particle acceleration rate that is 
varied by the discharge voltage or pressure to give optimal penetration of monolayer cells or multi­
layered tissues and organs. A low particle acceleration rate is generally sufficient to transfect 
samples in tissue culture (Yang et ah, 1990): a higher acceleration rate is usually required for 
optimal particle bombardment of somatic tissues in vivo (Cheng et ah, 1993). The material used for 
this raicroprojectile system is another very important parameter. Gold has been selected for 
mammalian gene transfer due to its inert and non-toxic nature: its high density permits greater 
momentum and deeper penetration. A range of gold particles is commercially available for particle 
bombardment ranging from 0.6 to 15 pm diameter. The 1 pm particles are suitable for most cell 
culture studies where 1 -3 pm sized particles are generally used for in vivo somatic tissue delivery. 
The larger beads can be used when much deeper penetration is required but greater destruction is 
observed which, thus limits their use (Yang et ah, 1994). The gold particle loading rate also has to 
be adjusted to optimise cell transfection efficiency which will vary between cell types. However, 
cells bombarded with an optimised concentration of particles generally results in the sealing of cell 
membranes in ten minutes. Greater than 90% of adherent tissue culture cells are viable after this 
period, when optimised concentrations are used: whereas a higher gold particle density causes 
extensive cell and tissue damage (Jiao et ah, 1993).
7.2.1.2.4 Limitations of particle bombardment
As an emerging technology, the gene gun method of gene transfer has certain technical limitations. 
Unlike integrating viral vectors, in vivo gene transfer to most somatic tissues using particle 
bombardment results in only transient expression lasting a few days to two weeks this probably 
results from the lack of stable integration into the bombarded target cells. However, strategies for 
long-term transgene expression may include the repeated bombardment of tissues to provide a 
continuous therapeutic level of transgene expression or combining particle bombardment with 
artificial chromosome technology to maintain stable expression levels for adequate periods of time 
(Yang et ah, 1994). Another current limitation of particle bombardment for in vivo use is the low 
level of transgene expression despite deep tissue penetration. This is thought to be related to the 
high levels of cell damage observed in bombarded tissues (Yang et ah, 1994). However, 
modification of particle forms, acceleration hardware designs and the optimisation of bombardment 
parameters are continually under revision to reduce this problem. Safety is also a key issue when 
using this technique and the fate of the gold particles will have to be thoroughly addressed before 
particle bombardment is used in clinical practice.
243
  
 
7.2.2 Therapeutic gene delivery to cell types of the joint
Delivery of therapeutic genes to tissue-types specific for the joint using intravenous, intramuscular 
and oral routes of delivery is not only inefficient but results in the undesirable systemic exposure to 
the therapeutic agents. An intra-articular approach however, provides higher levels of therapeutic 
gene transfection in target cells within the localised joint compartment without exposing other 
tissues and is therefore the technique generally used for gene transfer to the joint.
Hyaline cartilage is the tissue primarily involved in the osteoarthritic processes and would be 
the obvious tissue to target in gene based therapeutics. However, hyaline cartilage consists of a 
dense extra-cellular matrix (ECM) containing type II collagen and proteoglycan which may be 
responsible for the low transfection efficiency of chondrocytes. Furthermore, despite the presence 
of a few immature chondrocytes at the periphery of hyaline cartilage most are located deep in the 
tissue appearing in groups where they are difficult to access for efficient transfection using in vivo
methods of gene delivery. However, one study has demonstrated that the IL-lRa gene can be 
transduced directly in vivo using non-viral plasmid technology for delivery to chondrocytes to 
reduce progression of experimental osteoarthritis (Fernandes et al., 1999). Although articular 
chondrocytes can be transfected in tissue culture using adenoviral vectors (Brower-Toland et ah, 
2001) there are significant difficulties in using these cells to re-surface hyaline cartilage (Brittberg 
et ah, 1994) which currently excludes this for ex-vivo gene delivery technique.
Synovial tissue however can be easily targeted for transfection using both in vivo (direct) and in
vitro (indirect) delivery systems. The synovium is particularly applicable in the direct approach 
since the synovium lacks a basement membrane and therefore presents no physical or chemical 
barrier between itself and the joint space. Any type of particle introduced into the joint is quickly 
captured by the synovium which consists of loose a connective tissue into which particles may 
penetrate freely (Figure 7-1). The synovium lines all the non-cartilaginous internal surfaces of the 
joint and therefore possesses a huge surface area for gene transfer. Viral vectors, in particular 
retroviruses, have been used for this approach even though they require cell division for infection 
and integration. The normally quiescent synovial lining is induced by inflammation in OA and 
shows hyperplasia, encouraging transduction by viruses in situ. This has been demonstrated with 
the transduction of synovial cells in vivo by the intra-articular injection of retroviral vectors 
containing the human IL-lRa to reduce the progression of experimental OA in the dog (Pelletier et 
ah, 1997). The indirect approach is also possible since the type B synovial fibroblasts readily divide 
in culture and can be easily transduced before re-introduction into the joint. Intra-articular injection 
of suspensions of these synoviocytes should result in the attachment and maintenance of 
transplanted cells in the host synovial lining since synovial fibroblasts appear to possess specific 
homing receptors that help restrict them to the synovial lining (Galea-lauri et ah, 1991). The ex vivo
transfer of human IL-lRa genes has been shown to suppress collagen-induced arthritis in mice 
(Bakker et al, 1997) and this approach has been recently used in a human clinical trial (Evans et ah, 
1996).
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Figure 7-1 Histological structure of the synovial membrane
The synovial Layer is arranged in folds that occasionally penetrate into the interior of the articular 
cavity. The internal surface of the synovial membrane is lined by a layer of squamous or cuboidal 
cells with a layer of loose or dense connective tissue underneath. The lining cells ol the synovial 
membrane are separated from each other by a small amount of connective tissue ground substance. 
The synovium originates from the mesenchye and thus there is no basal lamina between the lining 
cells and the underlying connective tissue and the entire tissue is rich in blood capillaries with 
variable amounts of adipose tissue (AD). The supporting layer may consist of areolar, fibrous and 
adipose connective tissue or a mixture of all three.
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7.3 MATERIALS AND METHODS
Overviews of the experimental procedures employed in this chapter are illustrated in figure 7-2. 
Particle mediated transfection, using the gene gun (BioRad) apparatus, was evaluated for gene 
transfer and gold penetration into the synovial tissues of the joint. Briefly, in vitro tissue culture 
studies were performed to analyse the transfection ability of the gene gun. Vectors containing 
reporter genes, Enhanced Green Fluorescent protein (EGFP) and [^--^nll^c^tt^.sidase (p-Gal), were 
transiently transfected into rabbit synovial (HIG-82) and Madin Darby canine kidney (MDCK) 
cells respectively using cationic liposome and gene gun methods. Fluorescence microscopy and X- 
gal staining assays were used to visualise transfected cells. Particle mediated bombardment was 
then evaluated for the penetration depth of gold particles into explant synovial tissues taken from a 
10 year old dog at post-mortem examination (PME). Samples were fixed in formalin, stained with 
hematoxylin and eosin (H/E) and visualised using light microscopy to identify synovial tissue 
structure. Dark field microscopy was than used to identify the position of gold particles in the 
lining cells of the synovium.
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 Figure 7-2 Overview of experimental procedures for particle-mediated bombardment
transfection of cells
The Enhanced Green Fluorescent protein (EGFP) and P-galactosidase (p-Gal) reporter vectors 
were transiently transfected into rabbit synovial (Hig-82) and Madin Darby canie kidney (MDCK) 
cells respectively using cationic liposome and gene gun methods. Fluorescence microscopy and X- 
gal staining assays were used to determine transfection efficiency. Particle bombardment of gold 
particles into synovial tissues was performed to determine penetration efficiency analysed by 
histopathological techniques.
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7.3.1 Preparation of components for gene gun system
7.3.1.1 Preparation of cartridges
Bullets used in this study were made of Tefzel tubing coated with gold particles (1.0 pm) carrying 
plasmid DNA encoding Enhanced Green Fluorescent Protein (EGFP, Clontech) or (5-galactosidase 
(pCMVp, Clontech) and made following the manufacturer’s instructions. Ethanol (100%), from a 
previously unopened bottle, was first divided into 10 ml aliquots. A fresh aliquot was opened each 
time cartridges were prepared since opened bottles of ethanol absorb water and may result in the 
production of poor quality cartridges during the drying step with streaking, clumping and uneven 
coating of micro-carriers over the inner surface of the Gold-Coat (Tefzel) tubing.
7.3.1.1.1 Precipitation of DNA onto micocarriers (gold particles)
A fresh stock solution of Polyvinylpyrrolidine (PVP), in ethanol (20 mg/ml) was prepared as an 
adhesive during the cartridge preparation. This PVP stock solution was diluted with ethanol to 0.1 
mg/ml (3.5 ml of this dilute solution was required for each 30" length of Gold-Coat tubing in the 
tubing Prep Station). The following procedure refers to a Micro-carrier Loading Quantity (MLQ) of 
0.5 and a DNA Loading Ratio (DLR) of 2. Gold micro-carriers (25 mg of 0.1pm) were mixed with 
lOOjal spermidine (0.05M), briefly vortexed, then sonicated for 3-5 seconds using an ultrasonic 
cleaner to break up gold clumps. DNA (50 pg) samples were added and the contents mixed 
thoroughly by vortexing for 5 seconds. While vortexing at a moderate rate on a variable speed 
vortexer, 100 pi of CaCL was added drop-wise to the mixture to allow the DNA to associate with 
the gold micro-carriers. The mixture was incubated at room temperature for 10 minutes and flash 
spun to pellet the precipitate enabling the transparent supernatant to be discarded. The pellet was 
then re-suspended in the remaining supernatant by briefly vortexing and then washed three times 
with fresh 100% ethanol (1 ml), flash spinning between each wash and discarding all supernatants. 
After the final ethanol wash, the pellet was re-suspended in 200 pi of PVP/ethanol solution (0.1 
mg/ml) and transferred to a polyproplene centrifuge tube (15 ml). The microfuge tube was washed 
with 200 pi of PVP/ethanol solution (0.1 mg/ml) and added to the same centrifuge tube to produce 
a DNA/micro-carrier solution corresponding to a MLQ of 0.5.
7.3.1.1.2 Loading the DNA/Micro-carrier suspension into Gold-Coat Tubing
The Tubing Prep Station, as shown in figure 7-3, was connected to the nitrogen tank and the Gold- 
Coat tubing was completely dried by purging with nitrogen (0.3-0.4 LPM) for at least 15 minutes. 
Once ready to prepare the cartridges, the tubing was removed from the Prep Station and the flow of 
nitrogen stopped. A 30" length of dried Tefzel tubing was cut and one end inserted into the adaptor 
tubing fitted to the lOcc syringe. The micro-carrier suspension was briefly vortexed, sonicated and 
inverted several times to achieve an even suspension of gold. The micro-carrier suspension was 
immediately and quickly drawn into the Tefzel tubing for approximately 22-24" after which the
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tubing was withdrawn from the suspension while continuing to draw in air to leave some space at 
each end; care was taken to ensure that no bubbles were drawn into the tubing. The Gold-Coat 
tubing was immediately brought to a horizontal position and loaded into the Tubing Prep Station. 
The micro-carriers were allowed to settle for 3-5 minutes before the ethanol was removed using the 
10 cc syringe at a rate of 0.5 to 1.0"/sec (taking approximately 40 seconds). A delay in the removal 
of the ethanol may cause the gold to adhere too strongly to the tubing and coat unevenly, however, 
it has been shown that a reduction in PVP concentration does not overcome this problem (O’Brien 
et al., 2001). The syringe was then detached from the tubing which was immediately rotated I8O° 
to allow the gold to begin coating the inside surface of the tubing for 3-4 seconds. The Tubing prep 
Station was automatically rotated to allow the gold to evenly coat the inside of the tube for 25 
seconds; nitrogen was then passed through the tube at 0.35-0.4 LPM for 3 to 5 minutes to dry the 
inside of the tubing while it continued to rotate. Once complete the tubing was removed from the 
Tubing Prep Station and examined to ensure that the micro-carriers were evenly distributed over 
the length of the tubing. Using scissors, sparsely coated regions were discarded and the remaining 
usable tubing was cut into cartridge sized portions (0.5") using the Tubing Cutter. All cartridges 
were stored in a tightly sealed container, wrapped in parafilm and stored at 4°C.
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Figure 7-3 The Tubing Prep Station
The Tubing Prep Station was connected to the nitrogen tank and the Gold-Coat tubing was 
completely dried by purging with nitrogen. The tubing was then removed from the Prep Station and 
the flow of nitrogen stopped before the tubing was loaded with the gold/DNA preparation and then 
reloaded into the Tubing Prep Station. The ethanol was removed and the tubing prep apparatus 
immediately rotated 180° before being allowed to automatically rotate with nitrogen passing 
through the tube.
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7.3.1.2 Preparation of gene gun
The BioRad Gene Gun, as illustrated in figure 7-4 and 7-5, uses a pulse of helium fired through the 
apparatus to strip gold microcarriers coated with DNA from the inner surface of a cartridge 
constructed of Gold-Coat tubing. The accelerator channel fits against the cartridge carrying the 
gold/DNA microparticles with a tight seal produced by two ‘O’ rings. This tight seal directs the 
flow of helium down the channel towards the outer barrel. The expanding gas stream propels the 
particles forwards down the accelerator channel to the coned shaped outer barrel at the distal end. 
As the helium leaves this coned surface it follows the contour thereby dispersing the gold/DNA 
particles in a continuing outward motion that defines the extent of the target area. The standard 
configuration of the cone is optimised to project particles over a relatively wide area and the spacer 
that is attached distal to the cone barrel determines the radius of this area. This spacer also defines 
the minimum distance between the cone barrel and the target tissue. There is a decreased likelihood 
that gold/DNA particles will penetrate the target if the distance from the barrel to the tissue is too 
great (Wellmann et al., 1999), but if the distance is to short there will be an increased risk of tissue 
damage from the pressure wave. The performance of the Gene Gun in terms of target area, tissue 
penetration and tissue damage is determined by the balance between gas pressure, the area of 
dispersion over the target, and the proximity of the outer barrel to the tissue. The major feature that 
affects these factors is the profile of the aceelerator channel, which causes the microcarriers to 
spread out from their original 2mm diameter of up to 1.5 cm at the target site (Yoshida et al., 
1997).
To activate the Helios Gene Gun an empty cartridge holder was inserted into the barrel liner, 
before connection to the helium source where the flow of helium into the gun was adjusted to the 
required setting (100-500 psi). A 70 )fm nylon mesh was placed directly over the barrel to reduce 
cellular damage. Hearing and eye protection was then worn for the remainder of the procedure. The 
gene gun device was pointed away from any by-standers and the trigger depressed 2-3 times to 
discharge the device and equilibrate the pressure. The cartridge holder was then removed and 
replaced with a fully loaded cartridge. Six well plates were used for the cell culture as the diameter 
of the wells enabled the gene gun’s plastic spacer to fit inside the well and reduce the distance 
between the end barrel and the cells/tissue samples.
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Figure 7-4 The gene gun
The gene gun (BioRad) is considered a convenient, hand-held device that provides rapid and direct 
gene transfer into a range of targets both in vitro and in vivo. The unit uses an adjustable low- 
pressure helium pulse to sweep DNA-coated gold microcarriers from the inner wall of a small 
plastic cartridge directly into the target. Up to twelve DNA-coated gold cartridges can be loaded 
into the holder, which is inserted into the device and fired.
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Figure 7-5 Mechanics of the gene gun
The BioRad gene gun produces a helium pulse to sweep the DNA-coated gold micro-carriers from 
the inside wall of the sample cartridge. The micro-carriers accelerate for maximum penetration as 
they move through the barrel, while the helium pulse diffuses outward. The accelerator channel fits 
against the cartridge with a tight seal produced by two ‘O’ rings. This tight seal directs the flow of 
helium down the channel towards the outer barrel and out of the coned surface. The standard 
configuration of the cone is optimised to project particles over a relatively wide area and the spacer 
that is attached distal to the cone barrel determines the radius of this area. The spacer maintains the 
optimal target distance for most applications and vents the helium gas away from the target to 
minimise cell surface impact.
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 7.3.2 Delivery of reporter plasmid vectors to cells in tissue culture using 
particle bombardment and liposome-mediated techniques
7.3.2.1 Cell lines and reagents
MDCK cells were maintained in Dulbecco’s MEM with gluatamax-1 medium supplemented with 
10% foetal calf serum (PCS) as described in section 2.2.1.2.1 Rabbit synovial fibroblasts (HIG-82) 
were maintained in Hams F-12 medium supplemented with 10% PCS as described in section 
2.2.2.1.6. Both MDCK and HIG-82 cells were seeded onto 6 well plates at concentrations of 6x104 
cells/ml and incubated overnight at 37°C, 5% CG?.
7.3.2.2 Reporter plasmid vectors
7.3.2.2.1 Bc^a-Gakiciosidasetp-Gal) reporter plasmid
The pCMVP-Galactosidase DNA plasmid (Clontech) is a mammalian reporter vector designed to 
express beta-galactosidase in mammalian cells driven by the human cytomegalovims immediate 
early gene promoter (MacGregor and Caskey, 1989). pCMVp contains a polyadenylation signal 
from SV40 and the full length E.coli beta-galactosidase gene with eukaryotic translation initiation 
signals (MacGregor et al., 1987).
7.3.2.2.2 Enhanced Green Fluorescent Protein reporter plasmid (EGPPl
The Enhanced Green Fluorescent Protein (EGPP) mammalian reporter vector (Clontech) contains a 
unique EGPP variant which has a chromophore that is 35 times brighter than wild-type GPP (wt 
GPP). The EGPP vector encodes the GFPmutl variant, consisting of the double substitution of the 
Phe-64 to Leucine and Serine 65 to Threonine. (Cormak et al., 1996). The EGPP has a single 
strong red-shifted excitation peak at 488 nm in filter sets used in fluorescence microscopy. This 
vector contains the kanamycin resistance gene.
7.3.2,3 Trmsscnt transfection of tissue cultuir monolayer cells with reporter constructs
7.3.2.3.1 Particle bombardment method of transfection
The CMVP-Galactosidase (Clontech) and Enhanced Green Fluorescent protein (EGPP) (Clontech) 
reporter plasmid vectors were transiently transfected into cells using the Helios Gene Gun system 
(Figure 7-6). After aspiration of the media, the gene gun was held perpendicular to the tissue culture 
plates with the plastic spacer held as close to the target as possible. The gene gun was then 
discharged at different pressures (100 and 150 psi) once (or twice at low pressures) before 5 ml of 
media was added to each well and the tissue culture plates were returned to the incubator for cell 
recovery at 37°C and 5% CO2.
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Figure 7-6: Transfection using the gene gun apparatus
After aspiration of the media, the gene gun was held perpendicular to tissue culture plates with the 
plastic spacer held as close to the target as possible. The gene gun was then discharged once, or 
twice at low helium pressures, before 5 ml of media was added to each well and the tissue culture 
plates returned to the incubator for cell recovery at 37"C and 5% COi.
255
7.3.2.3.2 Liposome-mediated tirwstection
The CMVP-Galactosidase (Clontech) and the Enhanced Green Fluorescent protein (EGFP) 
(Clontech) reporter plasmid vectors were transiently transfected into cells using the cationic 
liposome mediated transfection system. TransFast™ Transfection Reagent (see 2.2.7). Briefly, 
transient transfections were carried out using DNA (2 pg per well) in a 1:1 ratio with the 
Trans Fast™ Reagent, in a total volume of 1 ml of serum free media per well. After one hour of 
incubation at 37°C cells were allowed to recover overnight in supplemented media and 48 hours 
later all cells were harvested.
7.3.2.4 Reporter Assays
7.3.2.4.1 X-gal staining aaaay
The X-Gal Staining Assay was used to detect in sieu levels of p-galactosidase activity from cells 
transfected with plasmids expressing lacZ. LacZ is a bacterial gene used as a reporter construct in 
eukaryotic transfection experiments because the gene product, (S-galactosidase is very stable, 
resistant to proteolysis in cellular lysates, and its activity is easily assayed. The X-gal staining 
system provides a rapid and simple method to analyse cells transfected with p-aalactosidase- 
expressing plasmid. The [-gglactosidase enzyme catalyses the hydrolysis of X-gal (5-bromo-3- 
indole-b-d-gatactopyranoaide), a p-galactoside. Following fixation and incubation with the X-gal 
substrate, transfected cells appeared blue and could be easily visualised by light microscopy.
More specifically, forty-eight hours post transfection the media was aspirated from the cells and 
washed in PBS (O.1M, pH. 7.4) before the cell fixing solution was added for 15 minutes at room 
temperature. The cells were then washed three times with PBS (0.1 M), each for five minutes, 
before being permeabilised for five minutes with 0.1% v/v Triton/PBS. The cells were washed for a 
second time in PBS (0.1 M) as before, the X-Gal assay solution was added to each well (just enough 
to cover the cells) and then incubated at 37°C for three hours. The cell monolayer was observed 
under a light microscope and blue cells observed. An empty plasmid vector was used as a negative 
control for determining the level of background activity caused by endogenous p-galactosidase 
activity. Photographs were taken for a permanent record of the results and then digitalised using 
Coolscan apparatus (Nikon)
7.3.2.4.2 Enhanced Green Fluorescent Protein (EG F Pi Assay
Green fluorescent protein (GFP) was discovered as a companion protein to aequorin, a 
chemiluminescent protein from Aequorea jellyfish (Shimomura et al., 1962), the emission spectrum 
of which peaked at 508 nm (Johnson et al., 1962). However, the emission spectmm of purified 
aequorin was blue and peaked near 470 nm, the approximate value of one of the excitation peaks of 
GFP. These data implied that the GFP converted the blue light emitted from aequorin into green 
fluorescence in intact cells. The GFP chromophore was later identified (Shimomura et al., 1979)
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 and the GFP gene cloned (Prasher et ah, 1992) and subsequently shown to retain its fluorescent 
properties when expressed in other organisms (Chalfie 1994).
Briefly, forty-eight hours post transfection, the cells (in media) were observed under fluorescent 
microscopy for GFP expression. The EGFP fluorescence was excited and collected through 480+/- 
10 and 540 +/- nm bandpass filters on a fluorescent microscope (Olympus Ix 70). Images were 
captured using Image Pro-plus software (assisted by Lynn Stevenson).
7.3.3 Delivery of gold particles to tissue samples taken at post mortem
examination using particle bombardment
7.3.3.1 Sample preparation
A Labrador-cross dog, ten years of age, with no history of OA was humanely euthanatised for 
clinical reasons. At post-mortem examination (PME), both stifle joints appeared grossly normal and 
were dissected to remove synovium from both joints. Sections (approximately 0.5 cm4) were 
immediately trimmed and placed into wells of a six-well tissue culture plate.
7.3.3.2 Particle bombardment of tissues
The plastic spacer of the gene gun was held as close to the target tissue as possible and the gene gun 
discharged at 250 and 500 psi. Samples were immediately placed in formalin (10%) for 24 hours for 
fixation and then sent for histopathological H/E staining. Untransfected cells were used as negative 
controls. Samples were analysed for gold particle penetration into tissue samples using darkfield 
microscopy (Zeiss A xloskop 2). This particular method of microscopy allowed the gold particles to 
reflect incident light and so become visible as bright granules (De Waele and Beesley, 1989). The 
same part of the section was observed in light microscopy and all images were digitally recorded 
using Zeiss KS 300 3-0 software.
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 7.4 RESULTS
7.4.1 Comparison of liposome-mediated and particle-bombardment- 
mediated transfection of monolayer cells in tissue culture
7.4.1.1 The j3-galactosidase assay
MDCK cells were transfected with the reporter vectors containing the P-galactosidase gene using 
both liposome-mediated and particle bombardment methods and then analysed using the X-gal 
staining assay to observe for the presence of blue-stained cells under light microscopy. The 
liposome-mediated method of transfection resulted in efficient transfection of cells, evenly 
distributed throughout the well, with little cell death (Figure 7-7). The particle bombardment 
method of transfection also resulted in the transfection of cells with both 100 psi (Figure 7-8a) and 
150 psi (Figure 7-8b). In both particle-mediated deliveries the transfection distribution was uneven, 
determined by the position of the gene gun barrel during bombardment. There was some cell death 
in the centre where the main focus of the gene gun barrel had been positioned, providing the 
greatest helium pressure. Surrounding the small area of cell death a ring of efficiently transfected 
cells was evident. The higher the pressure, the greater the cell death but the larger the area of 
transfected cells. Untransfected cells did not stain blue with the X-gal stain (Figure 7-9).
7.4.1.1 The EGFP assay
Rabbit synovial fibroblast cells (HIG-82) were transfected with the reporter vector containing the 
EGFP gene using both liposome-mediated and particle bombardment methods then analysed using 
fluorescent microscopy to observe the presence of green fluorescent cells. The liposome-mediated 
method of transfection resulted in efficient transfection of cells, evenly distributed throughout the 
well, with little cell death (Figure 7-10). The particle bombardment method of transfection also 
resulted in the transfection of cells with both 100 psi (Figure 7-1 la) and 150 psi (Figure 7-1 Ib). 
Again, at both pressures the distribution of transfection was uneven, determined by the position of 
the gene gun barrel during bombardment. There was considerably more cell death observed with the 
rabbit fibroblasts as compared to the MDCK cells. Again, the cell death was present in the centre 
consistent with the main focus of the gene gun barrel. Surrounding the small area of cell death was 
a ring of efficiently transfected cells seen by a large number of fluorescent cells. The higher the 
pressure, the greater the cell death but the larger the area of transfected cells. Untransfected cells 
were not fluorescent (data not shown).
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Figure 7-7: Liposome-mediated method of gene delivery
MDCK cells were transfected with the ((-galactosidase reporter gene using liposome-mediated 
transfection methods. Light microscopy of X-gal stained cells revealed that the transfected cells 
were evenly distributed throughout the well, with little cell death
Magnification xlO
Figure 7-8: Particle bombardment-mediated method of gene delivery
MDCK cells were transfected with the (-gaaactosidase reporter gene using a particle bombardment 
method of transfection at helium pressures of a) 100 and b) 150 psi. Light microscopy of X-gal 
stained cells revealed that transfection of' cells was possible, however their distribution was uneven, 
with some evidence of cell death.
a) b)
Figure 7-9: Untransfected MDCK cells
There was no evidence of blue cell staining in the untransfected samples
Magnification xlO
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Figure 7-10: Liposome-mediated gene delivery
Rabbit synovial fibroblasts (HIG-82 cells) were transfected with the BGbP reporter vector using 
liposome-mediated delivery and analysed using fluorescent microscopy to observe the presence of 
green fluorescent cells. The liposome-mediated method of transfection resulted in efficient 
transfection of cells, evenly distributed throughout the well, with little cell death.
Magnification x20
Figure 7-11: Particle bombardment-mediated gene delivery
Rabbit synovial fibroblasts (HIG-82 cells) were transfected with the EGFP reporter vector using the 
particle bombardment method of transfection at helium pressures of a) 100 psi and b) 150 psi. and 
analysed using fluorescent microscopy. The particle-bombardment method of transfection resulted 
in transfection of cells although unevenly distributed throughout the well, with some cell death.
a) b)
Magnification x20 Magnification x20
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7.4.2 Gold particle delivery to cell types of the canine joint
The efficiency of gold particle bombardment was assessed using the Gene Gun system (BioRad) for 
penetration into canine synovial tissue dissected from the stifle joint. Using six-well tissue culture 
plates the plastic spacer of the gene gun was held as close to the target tissue as possible and the 
gene gun discharged at 250 and 500 psi before samples were immediately fixed in formalin and sent 
for histopathological H/E staining. Using darkfield microscopy samples were analysed for gold 
particle penetration into the tissue samples, the gold particles were easily visible through their 
ability to reflect light. All gold particles were distinguished from dust contaminants by their 
uniformly circular shape.
H/E stained synovial tissue samples were observed by light microscopy and divided into sub­
types referred to as fibrous (Figures 7-12b, 13b, 14b), fibroareolar (Figure 7-15b, 16b) and adipose 
(Figure 7-17b) synovium. The same samples were then analysed by dark-field microscopy to 
identify the position of gold particles within the tissue structure. Gold particles were found to 
penetrate the lining cells of the fibrous synovium at helium pressures of 500 psi (Figure 7-12a) and 
250 psi (Figure 7-13b). Gold particles could also penetrate the fibroareolar synovium at a helium 
pressure 250 psi (Figure 7-15a). Finally, gold particles could easily penetrate the adipose synovium 
at a pressure of 250 psi (Figure 7-17a). Untransfected tissues did not contain any gold particles 
(Figure 7-14a, 16a).
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Figure 7-12: Gold particle penetration of canine fibrous synovium with particle 
bombardment pressures of 500 psi observed using a) darkfield and b) light microscopy 
(H&E)
b)
Magnifiaction x 10 Magnification x l O
Figure 7-13: Gold particle penetration of canine fibrous synovium tissue with particle
bombardment pressure of 250 psi observed using a) darkfield and b) light microscopy
(H&E)
a)
Magnification xlO Magnification xlO
a)
Figure 7-14: Untransfected canine fibrous synovium observed using a) darkfield and b)
light microscopy (H&E)
Magnification xlO
b)
Magnification xlO
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 Figure 7-15: Gold particle penetration of canine fibroareolar synovium with particle 
bombardment pressure of 250 psi observed using a) darkfield and b) light microscopy 
(H&E)
a) b)
Magnification x l O Magnification x 10
Figure 7-16: Untransfected canine fibroareolar synovium observed using a) darkfield and b)
light microscopy (H&E)
a) b)
Magnification x 10 Magnification x 10
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Figure 7-17: Gold particle penetration of canine adipose synovial tissue at particle
bombardment pressure of 250 psi observed using a) darkfield and b) light microscopy
(H&E)
a) b)
Magnification xlO Magnification xlO
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 7.5 DISCUSSION
The BioRad Gene Gun is considered a convenient and effective means of transfecting a wide range 
of tissue and cell types (Pecorino et al., 1992), particularly for DNA-based immunisation (Fynan. 
1993) and has now been adopted for cancer therapy (Rakhmilevich et al., 1996; Sun et al., 1995; 
Mahvi et al., 1996). This chapter assesses the potential application of the gene gun in the delivery of 
therapeutic genes to the synovial tissues of the joint for arthritis gene therapy.
7.5.1 Liposome-mediated and particle bombardment-mediated methods of 
gene transfection into monolayer cells in tissue culture
Particle-mediated gene transfer represents a useful approach for the transfection of cells in tissue 
culture systems. First of all it was necessary to establish that the gene gun could be used to 
successfully deliver reporter eonstructs to different cells lines in tissue culture with the cationic 
liposome-mediated method used as a positive control. Confluent cultures of MDCK and rabbit 
synovial cells (HIG-82) were bombarded with the gene gun apparatus at different pressures (100 
and 150 psi) with the spacer against the cell monolayer (i.e target 40 mm from the distal cone of the 
accelerator channel). Successful transfection was identified by the expression of {-galaatosidase 
and EGFP reporter genes in MDCK cells and rabbit synovial fibroblasts respectively.
When used at 100 psi the gene gun produced diffuse areas of transfected cells in the MDCK 
cells (Figure 7-8a) and rabbit synovial cells (Figures 7-1 la) with little cell death. This is consistent 
with experiments using 100 psi to transfect neurons in tissue culture (Wellman et ah, 1999) and a 
primary culture of rat neonatal cardiomyocytes (Eizema et ah, 2000). However, contradictory 
studies have shown that pressures of 100 psi and below may not result in efficient delivery of genes 
to Hela or HEK293 cells (O’Brien et ah, 2001). The difference in these results may be related to the 
preparation of the gold/DNA tubing, since very adherent gold particles, due to a high PVP 
concentration, would require a higher pressure to displace them from the cartridge. It may also be 
due to using a double firing process adopted to remove all micro-earriers from the inner tube and 
maximise transfection efficiency (Gan et ah, 2000), although it could just be due to cell-type 
specificity. When used at 150 psi, the gene gun produced areas of transfected cells in both MDCK 
(Figure 7-8b) and rabbit synovial cells (Figure 7-1 lb) at the periphery of the well which is 
consistent with experiments using 150 psi to transfect COS ceils (Yoshida et ah, 1997). 
Contradictory studies showed that monocyte-derived dendritic cells could not be transfected with a 
reporter gene at 150 psi (Smith et ah, 2001) or HeLa and HEK cells (O’Brien et ah, 2001). Despite 
the reasonable transfection rates there was considerable cell death in the centre of the well, 
attributed to the gas impact and heavy gold particle loading. A similar ‘dead zone’ has been 
reported with pressures of 175 psi that could destroy HeLa and HEK293 cells in the centre of a 
cover slip (O’Brien et ah, 2001; Yoshida et ah, 1997). A pattern of transfection was evident with a 
radial increase in transfection frequency with increasing distance from the centre (Wellman et at,
1999). This peaked and then tended to fall away again as the distance increased from the target
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centre. At even higher pressures cell transfection is still possible with considerable cell viability as 
shown with the transfection of islet cells in vitro at a pressure of 250 psi (Guo et al., 1997).
Variability in cell death was observed between the two cell types, with the rabbit synovial cells 
more susceptible to cell death than the MDCK cells. This may simply be due to an ability of the 
MDCK cells to firmly adhere to the matrix provided by the tissue culture base unlike the synovial 
cells which are more easily displaced on cell splitting (authors observations). Variation in cell death 
between different cell types has previously been described when comparing the particle-mediated 
delivery of reporter genes to rat dorsal root ganglion and hippocampal neurons in primary culture. 
Few toxic effects were observed with the peripheral neurons but this delivery system was 
detrimental to the integrity of the synaptic network in cells isolated form the CNS (Usachev et al,
2000) . It has subsequently been suggested that the pressure of the helium pulse will affect cell 
survival because higher pressures cause shock-waves across cultured cells, detaching them from the 
matrix (O’Brien et al. 2001).
The standard configuration of the Gene Gun is known to induce appreciable cell death when used 
at the higher gas pressures required for effective transfection (Yoshida et al., 1997; Zang and Selzer,
2001) . Therefore modifications to this Gene Gun system are necessary to reduce the potential for 
cell damage. The use of a 70 jam mesh between the Gene Gun and target is essential for effective 
transfection with the use of a finer mesh (3 pm pore size) to cover the end of the accelerator channel 
recommended to further reduce tissue damage (Gan et al., 2000). Another method to reduce cell 
death is to limit the amount of gold micro-carriers per shot (Eizema et al,, 2000).
7.5,2 Gold psarttcle delivery to cell types of t3he canine joint
Particle-mediated gene transfer also represents a useful approach for the transfection of 
organotypic/explant cultures as shown by several groups with the successful transfection of 
neuronal cells in short-term slice-explant cultures of the cerebellum and cortex (Arnold et al, 1994; 
Lo et al., 1994). However, the efficiency of particle bombardment has not been assessed in explant 
tissues specific to the joint. First of all it is necessary to establish the penetration power of the gold 
particles using the gene gun system for delivery to the synovial tisues of the joint before gene 
transfection studies using explants can be performed. To this end gold particle bombardment was 
performed on canine synovial tissue dissected from the stifle joint at PME. Two different helium 
pressures were analysed (250 and 500 psi) for efficiency in projecting gold particles through the 
tissue samples. Gold particles were easily visible using darkfield microscopy with their ability to 
reflect light and distinguished by their uniformly circular shape.
Analysis of the bombarded synovial samples revealed that particle bombardment could be used to 
deliver gold particles to the lining cells of the fibrous, fibroareolar and adipose synovium at a 
helium pressure of 250 psi. This is consistent with studies demonstrating that the hand-held Gene 
Gun is optimised to transfect superficial tissues or dispersed cells in culture, propelling 
microparticles superficially over a wide area (O’Brien et al., 2001). This also corresponds to data 
showing that the particle bombardment-mediated delivery has been useful for the in situ
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transfection of external cells in mammalian skin (Johnston and Tang, 1993). However, gold particle 
penetration did not extend beyond the outer lining which is consistent with previous reports 
suggesting that deeper penetration into tissues is limited (O’Brien et ah, 2001). Nevertheless, one 
report has demonstrated penetration of some 30 to 50 cells layers in various tissues types (Yang et 
al., 1995). The discrepancy in these results is probably due to the difference in composition and 
structure between different tissue samples. However modifications to this system are already being 
developed to enable the accelerator channel to achieve a more compact, focused shot of gold 
particles and increased penetration depth (O’ Brien et ah, 2001). It is true that the lining layer is the 
most relevant part of the synovium for introducing genes and thus the pattern of penetration 
recorded here would be satisfactory.
7.5.3 Optiimissatton of transfection parameters
The success of the particle-mediated bombardment transfection technique depends on the 
optimisation of several variables, most of which balance cell death, as observed in the cell 
monolayer studies against tissue penetration as shown in the tissue explant study. One of the most 
important parameters is the velocity of the particles which in turn is dependent on the helium 
pressure, the distance of the particle source from the target tissue and the particle size. The pressure 
of the helium gas must be finely balanced between the high pressures that result in excessive 
cellular death and the low pressures that restrict penetration of microcarriers to the outer layers of 
the tissue. The helium pressure regulator used in these experiments did not permit accurate control 
of pressures at intervals smaller than 25 psi; therefore a more accurate regulator may be required for 
future studies in order to refine the pressure conditions. The distance of the particle source from the 
target tissue is also important since particle acceleration is dependent on atmospheric effects. To 
reduce this slowing effect, the gene gun spacer was kept as close to the target as possible. However, 
modification of spacer attachments are also possible with shortening of the stem to reduce the 
particle flight distance (Eizema et al., 2000). Particle size is also an important variable (Tanner et 
al., 1997) with gold particles available in a range of sizes from 0.6 to 1.6 jtm (supplied with Gene 
Gun Kit, BioRad). Small particles are more susceptible to the slowing effects of the atmosphere, 
whereas larger particles may inflict greater cellular injury during bombardment. In the present 
study, 1.0 jam gold particles were used but optimisation with other sizes will be necessary for future 
studies.
However, the ultimate levels of transfection efficiency are determined by many additional factors 
including the concentration of particles delivered to the tissue. The more particles that enter a tissue, 
the greater the chance that cells will express the transgene, but smaller the chance that cells will 
survive membrane damage (Klein et al., 1987). In fact, in several mammalian cell lines, increasing 
the concentration of gold particles to more than 1 mg per cartridge load reduced transfection 
efficiency (Heiser et al., 1994). DNA concentration is another important consideration and several 
studies have shown that increasing the concentration of DNA coating the gold particles results in 
higher expression levels of the transfected gene (Burkholder et ah, 1993, Thompson et ah, 1993).
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Contamination of DNA samples with protein and higher DNA loading concentrations are believed 
to enhance clumping which results in the uneven coating of the inner surface of the tubing. This and 
the coating state of the DNA on the gold micro-particles results in uneven particle penetration, 
increased tissue damage and variable transfection efficiencies. Another problem is the uneven 
distribution of microcarriers in the well, since the area of the gun barrel is smaller than the area of 
the well; however a special delivery device has now been developed in order to evenly bombard all 
cells present in the well (Eizema et al.. 2000).
Many of these factors are difficult to standardise and are responsible for considerable variability in 
biolistic transfection (Biewenga et al., 1997). As a result it is difficult to reliably reproduce particle- 
mediated bombardment transfection between cultures. To adjust for this variability a standard must 
be used when attempting to quantify biolistic transfections. One quantitative method that has been 
used is based on evidence that when two DNA constructs are added to the gold particles, both 
constructs are virtually always expressed in the same cell (Arnold et al., 1994; Arnold and Heintz. 
1997). Therefore two plasmids can be co-transfected, and the plasmid under evaluation can be 
corrected by the second internal control. This observation that several DNA constructs mixed with 
gold particles are expressed in the same cell has been adopted for multi-gene based therapies for 
cancer. The simultaneous delivery of lL-12, pro-IL-18 and IL-l- converting enzyme (ICE) using 
the gene gun has been shown to significantly augment anti-tumour effects (Oshikawa et ah, 1999). 
The co-expression of two plasmids can be accomplished by simply mixing the plasmids, rather than 
constructing a vector encoding both genes (Usachev et al., 2000). Many of these parameters need to 
optimised before the gene gun apparatus can be used to efficiently deliver genes to the lining cells 
of the synovium for gene-based therapeutics.
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 7.6 SUMMARY
This chapter describes the preliminary evaluation of particle mediated bombardment for the 
delivery of therapeutic genes into synovial cells for future use in therapeutic gene delivery systems 
to the joint. Rabbit synovial fibroblasts and MDCK cells were successfully transfected with reporter 
genes, EGFP and (-Gal, respectively in tissue culture using this delivery system. Synovial tissue 
samples, collected at PME were also bombarded with gold particles to demonstrate that the gene 
gun could be used to penetrate the lining cells of the synovium. Particle bombardment-mediated 
gene delivery is a simple, fast and versatile technique for gene transfer and may be applicable for 
gene therapy research in the delivery of candidate therapeutic genes to somatic tissues. This 
technique has been shown to be effective under various experimental conditions within ex vivo, in
vivo and in vitro mammalian gene transfer systems. With future modification and optimisation, this 
evolving technology may serve as a suitable approach for gene transfer in osteoarthritic disease.
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 Chapter VIII
General Discussion
8.1 ABSTRACT
Osteoarthritis (OA) is a chronic, painful condition and is of major concern to both human and 
veterinary medicine. To date, treatment modalities in both species are generally limited to 
‘symptom-modifying’ therapies that only address joint pain. The primary aim of this project was to 
develop a targeted, ‘structure-modifying’ gene based therapy for the future treatment of OA in the 
dog, with the prospect of developing an animal model for human disease. Candidate canine- 
specific therapeutic genes, based on their ability to regulate the levels of matrix metalloproteinase 
(MMP) activity within arthritic joints, were cloned and expressed. Pro-inflammatory cytokine- 
inducible MMP promoters were subsequently cloned and characterised to evaluate their potential 
for driving disease-specific expression of therapeutic genes in joints. Targeting therapeutic gene 
expression to diseased cell types of the osteoarthritic joint was attempted with the development of a 
novel dual-targeting vector incorporating both disease-inducible and cell-type specific regulatory 
elements, with both components modulated to enhance activity whilst maintaining specificity. 
Finally, particle-mediated bombardment methods of synovial tissue transfection were evaluated as 
a method of gene delivery to the joint.
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8.2 DISCUSSION
8.2.1 Work described in this thesis
Recent research has identified several proteins that have promising chondroprotective and anti­
inflammatory properties which offer the prospect of establishing ‘structure-modifying’ therapies. 
However, recombinant proteins have limited half-lives in vivo: thus, it is difficult to deliver and 
maintain therapeutic concentrations of these agents for sustained intervals. By delivering cDNAs 
that encode these proteins to the diseased joints and providing for their expression in a relevant 
manner, it may now be possible to devise an effective treatment strategy for arthritic disease. The 
design of a gene delivery strategy for osteoarthritis (OA) should include mediators for cortrollira 
the synthesis and activity of the matrix metalloproteinases (MMPs) at either or both the 
transcriptional and post-translational levels using therapeutic inhibitory proteins. This is the first 
step in controlling the disease at the molecular level using gene therapy by inhibiting the enzymes 
responsible for cartilage degradation while enhancing tissue repair. Subsequently canine specific 
cDNAs for IL-lRa, sTNFRI, TIMP-2 (Campbell et al., 2001b) and TIMP-1 (Zeiss et al., 1998) 
have been isolated for gene-based therapeutics for canine OA.
Developing an effective yet safe gene based therapy for OA in both human and veterinary 
patients is an exciting challenge, yet several technical problems must be overcome before it can be 
considered for use in clinical practice. Methods can be devised to regulate therapeutic gene 
expression, at the transcriptional level, in a disease-specif-ic manner. Since MMPs are up-regulated 
during the arthritic disease process it is hypothesised that these regulatory sequences could be 
utilised to direct disease-specific transgene expression while simultaneously avoiding undesirable 
expression in healthy tissues. The canine MMP-9 promoter (Campbell et al., 2001a) and canine 
MMP-13 promoter (Campbell et al., 2002) were cloned and characterised for driving disease 
specific therapeutic gene expression. Using computer-based analysis, inducible elements were 
identified in both promoter sequences corresponding to the conserved regions found in sequence 
alignments with the promoters published for other species. Both promoters were characterised in 
various cell lines using a luciferase reporter gene to determine promoter activity in response to pro­
inflammatory mediators, Interleukin-1 (IL-1 (), tumour necrosis factor (TNFa) an basic fibroblastic 
factor (bFGF). A series of promoter deletion contracts were also made, based on the canine MMP- 
9 promoter sequence, to evaluate phorbol myristate acetate (PMAUresponsive elements within the 
promoter sequence.
The potential for undesirable systemic effects related to constitutive over-expression of certain 
therapeutic transgene products may be limited through the development of both ‘disease and cell 
type specific’ DNA targeting vectors that restricts transgene expression to diseased cell types of the 
joint. Therefore, in addition to the development of MMP promoters for driving disease-specific 
expression, it was necessary to investigate a second level of targeting using cartilage specific 
promoters and enhancers, such as those for the collagen type XI gene to limit expression of
therapeutic genes to chondrocytes. It was thought that these two targeting elements could be 
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 combined into one plasmid vector utilising ‘Cre Recombinase’ technology, an enzyme system 
which affects DNA recombination between lox recognition sequences to develop a dual targeting 
vector.
First of all it was necessary to modulate the two components of the dual targeting vector to 
enhance activity while maintaining specificity. It was demonstrated that the canine MMP-9 
promoter could be manipulated to increase activity while maintaining disease specificity through 
the introduction of multiple NF-kB sites at the 5' end, guided by a series of promoter deletion 
studies and mutational analysis. The mouse cell-type specific collagen type XI promoter, had 
selectively higher activity in the chondrosarcoma cell line (SW1353) compared to the 
undifferentiated chondroprogenitor cell line (ATDC5). However, this promoter activity could be 
modulated to enhance activity while maintaining cell type specificity with the incorporation of a 
region of the collagen type XI intron 1 sequence, containing three flanking S0X9 enhancer sites in 
the vector. Attempts were finally made to combine these two modulated promoter sequences into 
one plasmid vector containing the gene for Cre Recombinase and loxH sites to restrict therapeutic 
gene expression to diseased chondrocytes in tissue culture. Although the analysis of the individual 
components of the targeting system was successful, the incorporation of each of these components 
into one vector, to demonstrate that a simple recombination-based system can produce a functional 
targeting vector, was not technically possible. Nevertheless, considerable experience and 
knowledge was gained during the construction steps and it is now apparent that further studies are 
required to develop this technology for in vivo application. It is possible that this specific system 
may not have provided sufficient levels of transgene expression in vivo and the potential for an 
immunogenic response to the bacterial Cre protein may have prohibited its use. Therefore, before 
novel targeting vectors such as this are delivered and analysed in vivo, methodical steps need to be 
taken to evaluate the overall feasibility and efficacy of using gene therapy to treat a canine model 
ofOA.
Methods must also be devised to efficiently deliver therapeutic genes to cells of the joint. 
Synovial cells are the most promising cell-type for targeting gene-based therapeutics in OA since 
they can be directly transfected in vivo, due to their location lining the joint cavity but can also be 
used for ex vivo gene delivery methods (Bandara et al., 1992). Furthermore, synovial cells are more 
abundant than chondrocytes and line the joint space for efficient secretion of soluble therapeutic 
gene products into the joint fluid. Synovial cells were therefore selected to analyse particle- 
mediated methods of gene delivery. Two reporter genes p-galactosidase (P-Gal) and enhnaced 
green fluorescent protein (EGFP) were successfully transfected into monolayer cells in tissue 
culture using the gene gun apparatus. Synovial tissue samples, collected at post-mortem
examination PME, were also successfully bombarded with gold particles to the lining cells of the 
synovial tissue.
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8.2.2 Future studies
Future studies need to build on this in vitro work directed towards the development of an in vivo
homologous gene-based therapy for canine OA, as a model for treating human disease. The long­
term goal is to establish a method for delivering species-specific therapeutic cDNAs directly to the 
synovial lining of joints, whose subsequent expression is regulated by the amplitude of disease.
Fundamental tissue-explant studies should first be performed to characterise and quantify the 
expression and chondroprotective capacity of canine-specific therapeutic genes for in vivo
application. Then viral vectors, such as recombinant Adeno Associated Virus (AAV) vectors 
incorporating the disease inducible promoters, should be generated and evaluated for levels of in
vivo gene expression in the joints of standard laboratory animal models such as the rat. AAV 
mediated, intra-articular gene transfer of cDNAs encoding homologous therapeutic proteins can 
finally be evaluated for feasibility and therapeutic efficacy using an in vivo homologous canine 
study such as the experimental Pond-Nuki canine model of OA (Pond and Nuki, 1973).
Developing gene based therapies using the canine model of OA not only has veterinary 
importance but also represents an ideal in vivo model of human disease from both a bio-mechanical 
and biological perspective. More specifically, section of the cranial cruciate ligament (CCL) in the 
canine Pond-Nuki Model of OA mimics the naturally occurring failure of the CCL (Pond and Nuki, 
1973) the single most common cause of OA in the dog. A recent report has revealed that many 
cases of so-called primary OA of the human knee are in fact secondary to failure of the anterior 
cruciate ligament (ACL) (Wada et al., 1996) reinforcing the relevance of the dog model to the 
human patient. Alternative animal models, such as the rat, have evolutionary diverged from the 
human species and therefore have several disadvantages. Not only are the effects of locomotion 
and weight bearing on the joint different, but there is also a disparity in collagenase gene 
expression within articular cartilage. Rodents have two rather than the three functional collagenases 
so far identified in the human and canine species (Cawston et al., 1996). The size of the canine 
joint compared to other smaller laboratory species is also of distinct benefit allowing easy sampling 
and gene delivery.
8.2.2.1 Details ofpropooedfuture research project
8.2.2.1.1 Expression and. biological characterisation of the canine specific therapcutic 
proteins using a tissue culture explant system
A biological assay for the evaluation of the canine therapeutic proteins can be developed using an 
in vitro tissue culture explant system where portions of bovine nasal septum cartilage tissue are co­
cultured with adherent rabbit synovial fibroblasts (HIG-82 cells). Constitutive expression (CMV 
promoter) of the respective therapeutic gene (IL-lra, TNFR, TIMP-1, -2), or gene combination 
from simple mammalian expression plasmids can then be analysed after stable transfection into the 
synovial cell monolayer and incubation with inflammatory cytokines (lL-1, TNF). The relative 
chondroprotective capacity of the secreted soluble therapeutic proteins can then be measured by
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 their ability to inhibit the cytokine-indnced changes within the cartilage explains by analysing the 
harvested supernatants and cartilage tissue samples for established markers of OA.
8.2.2.1.2 Local and systemic assessment of inducible disease specific promoters in vivo
using Adcno Associated Viral (AAV) \ectors in rats.
Activity of the inducible disease specific promoters (MMP-9, MMP-13), which have already been 
assessed in vitro can be evaluated in vivo using viral vector technology. The MMP-9 and MMP-13 
disease-specific promoters can be inserted into recombinant AAV vectors using the cDNA for 
human interleukin-1 receptor antagonist (hIL-lRa) as a surrogate reporter gene. The AAV 
constructs can be analysed in rats using the adjuvant-induced arthritis system to determine the 
levels of intra-articular hlL-lra expression in response to the disease-state. The tissues of the knee 
joints can be assayed for hlL-lRa concentrations using a commercially available ELISA kit, that 
does not cross-react with the rat homologue of IL-lRa, and the bio-distribution of the hlL-lRa 
transgene product and vector can be evaluated in selected tissues using a combination of ELISA 
and RT-PCR techniques.
8.2.2.1.3 hi riVo study, using the canine model of osteoarthritis
The previous studies will determine the appropriate combination of canine therapeutic cDNA(s) 
and MMP promoter for use in gene transfer/efficacy studies in the canine model of OA. A 
recombinant AAV vector containing this cDNA/promoter combination can then be generated and 
characterised for functional expression and titre, and the biological effects of therapeutic gene 
expression at the gross and microscopic level in the canine model can then be deteiunined. Dogs 
should be divided into three groups, one group to include untreated naive animals, the other two 
groups to undergo surgical section of the cranial cruciate ligament for induction of OA. Following 
an appropriate interval, one group of diseased animals should be treated with an empty AAV vector 
and the other group with the therapeutic AAV vector via intra-articular injection. Clinical 
evaluation and radiographic analysis of joints should occur on a daily and weekly basis, 
respectively. Joint biopsies and synovial samples can be taken at intervals for evaluation at the 
microscopic and molecular level. More specifically, cartilage and synovial tissue samples can be 
evaluated for differential protein expression using proteomic techniques (Pandey and Mann, 2000). 
At PME tissue samples can be taken from selected tissues and studied at the gross and microscopic 
levels for pathological changes and for the bio-distribution of the IL-IRa transgene product using 
RT-PCR.
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 8.3 SUMMARY
These studies are essential for the development of a canine-specific animal model to analyse a 
homologous gene transfer system for OA. Once the biological effects of the most effective 
therapeutic protein (IL-lra, sTNFRI, TIMP-1, TIMP-2) combinations have been shown and the 
efficacy of disease-specific (MMP-9 & -13) promoter constructs demonstrated in vivo, the first in
vivo targeted homologous gene transfer study using the cruciate transection experimental canine 
model of OA can be performed. These data will enable the implemention of a Phase II clinical trial 
in dogs which is an essential step to take in the promotion of gene-based therapeutics for the human 
disease.
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GLOSSARY
A Adenosine
AAV Adeno associated virus
ADAM A Disintegrin and metalloproteinase Thrombospondin motif
AMV-RT Avian myeloblastosis virus RT
AP-1 Activator protein-1
APMA Aminophenylmercuric acetate
ATDC5 Undifferentiated chondroprogenitor cells
ATCC American Type Tissue Culture
AV Adeno virus
bFGF Basic Fibroblastic growth factor
(-Gal (--Galactosidase
bp Base pair(s)
BSA Bovine serum albumin
C Cytosine
CDNA Complementary DNA
cIL-lRa Cytoplasmic IL-lRa
COX Cyclooxygenase
CMV Cytomegalovirus
CNS Central nervous sysstem
cs Chondroitin sulphate
DEPC Diethylpyrocarbonate
dHoO distilled water
DLR DNA loading ratio
ECM Extra-cellular matrix
E.Coli Escherichia coli
BGF Epidermal growth factor
EGFP Enhanced green fluorescent protein
ELISA Enzyme linked immunosorbant assay
ERK Extra-cellular stimulus-regulated kinases
EST Esculetin
FEA Feline embryonic fibroblasts
FGF-2 Fibroblast growth factor-2
FCS Foetal calf serum
G Guanine
G/C Guanine/Cytosine ratio
GCG Genetics Computer Group
GCSF Granulocyte colony stimulating factor
gDNA Genomic DNA
HA Hyaluronan
H/E Hematoxylin and eosin dye
HIG-82 Rabbit synovial fibroblasts
HMG High mobility group
HOCl Hypochlorous acid
HSV Herpes simplex virus
IFNy Interferon y
IGD Interglobular domain
IGF-1 Insulin-like growth factor-1
IkB Inhibitory kB
IKK IkB
IL Interleukin
IL-lRa Interleukin-1 receptor antagonist
JNK c-Jun N-terminal kinase
Kb Kilobase(s)
KDa Kilodalton
KS Keratan sulphate
LCR Locus control region
LIF Leukaemia inhibitory factor
EPS Lipopolysaccharide
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MAC Mammalian artificial chromosome
MAPK Mitogen-activated protein kinase
MAPKK MAPK kinase
MBq Mega Beqerels
MCS Multiple cloning site
MDCK Madin Darby canine kidney cells
MEK MAPK kinase
MLQ Micro-carrier loading quantity
MMLV Molony murine leukaemia virus
MMP Matrix metalloproteinase
mRNA Messenger RNA
MT-MMP Membrane Type MMP
mut" Mutation
NF-kB Nuclear factor-KB
NIK NF-kB inducing kinase
NO Nitric oxide
NOS Nitric oxide synthase
NSAID Non-steroidal anti-inflammatory drug
OA Osteoarthritis
OD Optical density
OPGL Osteoprotegerin ligand
OSM Oncostatin M
PAGE Poly acrylamide gel electrophoresis
PBMC Peripheral blood mononuclear cells
PCR Polymerase chain reaction
PE 480, 2400 Perkin-Elmer 490, 2400
PDGF Platelet derived growth factor
PG Prostaglandin
PKC Protein kinase C
PLC Phosholipase C
PMA Phorbol myristate acetate
PME Post-mortem examination
PVP Polyvinylpyrrolidine
R Receptor
RA Rheumatoid arthritis
RACE Rapid amplification of cDNA ends
RANKE Receptor activator of NF-kB ligand
RE Restriction enzyme
ROS Reactive oxygen species
RT-PCR Reverse transcription PCR
SAPK Stress-activated protein kinases
sIL-IR Soluble IL-1 receptors
sIL-IRa Soluble IL-lRa
sTNRI Soluble TNFRI
SV 40 Simian virus-40
SW1353 Human chondrosarcoma cells
TACE TNFta converting enzyme
TAFs TBP-Associated Factors
TBP TATA-binding protein
TF Transcription factor
TGF Transforming growth factor
TIMPs Tissue inhibitor of MMP
Tm Temperature of primer melting point
TNF Tumour necrosis factor
UAS Upstream activator sequence
UTR Untranslated region
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